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Observed differences in practices, outcomes and quality.
The common denominator in the chapters of this thesis is the observation of the 
application of different methods in cardio-thoracic surgery, multicenter registries, 
tissue banking, quality improvement by comparison of clinical outcomes data, and 
(international) benchmarking. All studies and publications are aimed at analysing 
these differences, and to compare outcomes. Consequently, the outcomes are valued in 
terms of differences in quality. Obviously, quality is what everyone, specifically medical 
professionals and patients righteously strive for and desire. However,  considering the 
definition of quality in scientific management literature, one is confronted with a large 
range of interpretations about what quality encompasses. In industry the term Zero 
Defects was introduced in the 1960’s and focuses on eliminating all defects in industrial 
production. (1) Already hard to apply in industry, where incoming basic materials 
must comply with standardised quality characteristics, the principle is hardly applicable 
in health care or more specifically in cardio-thoracic surgery where medical history, 
congenital conditions, morbidity, age and related factors are a predominant pre-existent 
risk with respect to a default outcome. 
Another definition, that is congruent to application in health care is the belief that 
products should be designed to reflect customers’ desires and tastes. (2) Although the 
primary desire to be healed may be assumed to be any patient’s rightful mindset before 
entering a hospital, other considerations play a role as well. (3) Management literature as 
well as studies in medicine, specifically if they originate from the United States, include 
value for money in their definitions (4). In Europe such considerations are scarce when 
it comes to assess what quality in health care should encompass. “To meet justified 
customer expectations and demands”, derived form an EU Parliament study is perhaps 
most consistent with the purpose of the EuroSCORE. (5,6) However, specifically 
because the terminology “desired” and “consistent professional knowledge” is included, 
we consider “quality of care is the degree to which health services for individuals and 
populations increase the likelihood of desired health outcomes and are consistent with 
current professional knowledge” as the most suitable. (7)
Current challenges
Instruments and platforms to benchmark by comparing objective outcomes, have 
been developed during the past 15-20 years. The aforementioned instruments consist 
of databases and registries, the reach of which has tremendously grown as a result of 
the possibilities offered by the Internet and by the innovative statistical and imaging 
software development. Platforms are offered by professional societies, peer-organisations 
in focus-meetings, through workshops, by organising joint projects and the like.
Studies concerning the observed differences in outcomes, whether it be in the use of 
allografts, in mechanical circulatory support or in cardio-thoracic surgery in general, 
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have demonstrated that the use of benchmarking instruments and platforms provides 
benefits (8,9,10). When checking local outcomes against risk-assessed data of peer 
organisations strengths and weaknesses can be identified. The search for best practice is 
called benchmarking. (11) In doing so, those who are responsible to oversee the level of 
performance, should not only analyse weaknesses in the core activity but consider the 
entire structure, process and outcome of the sequence of treatment. (12)
The next step will then be to focus on the observed performance gap with similar units, 
the result of which should be the initiation and implementation of an improvement 
project. At the closure of such an improvement project the new outcomes are to be 
compared with those from the pre-improvement period to determine whether the 
desired improvements have been realised. Once consolidated in renewed procedures 
or in adapted structures, the plan-do-check-act circle leads to a new check to reveal the 
next performance gap and area for improvement. (14) Over time the number of process-
constraints will be reduced to an absolute minimum, though there will always be room 
for improvement. (15)
For those for whom this method is new it will be hard to comply with this consistent and 
continuous approach of their own processes. However, once results become tangible, the 
culture of continuous quality improvement has been realised.
The platforms where professionals meet should ideally offer an atmosphere in which 
differences in methods, insights and outcomes can be openly communicated with 
peers. Thus, the objectivity of the organization is of great importance for the success of 
registries and the resulting improvement initiatives. This is preferably carried out by an 
association of professionals from the field who practice principles of good governance. 
So, when organised in a setting of objectivity, trust among participants will gradually 
grow. Examples from practice show that growing trust, using anonymous data at first, 
leads to the ‘uncovering of the veil’, thus adding to the power of the benchmarking 
process.
Taking all of this into account, registry reports show that patient morbidity and survival 
of therapies have improved over time. Registries are constructed with overall results and 
defined outcomes and do not make a difference between the different professionals or 
circumstances involved.  For instance, registries don’t measure is the positive influence 
of the resilience of theatre nurses. (16) Neither do they register improvements as a result 
of technological innovation. When it comes to cardio-thoracic surgery in general, the 
introduction of new diagnostic possibilities such as magnetic resonance imaging (MRI), 
innovation in professional areas such as perfusion and anaestesiology have had, and will 
have, positive effects on the process of care. More specifically in mechanical circulatory 
support, the changes that were instigated by technological renewal have led to the new 
era in advanced heart failure therapy. (17). Additionally, the application of statistical 
methods have enabled scientists to derive and validate risk-scores. (18) The challenge is 
not only in the adoption of new therapeutic insights, but also in setting up the structure 
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from diagnosis and patient selection to surgical therapy, and from out-patient care to 
long-term follow-up. Technological renewal combined with checking and benchmarking 
outcomes amplify the cycle of continuous improvement. This should ultimately lead to 
a situation in which professionals in health care reach a situation in which the likelihood 
of desired health outcomes has increased for individuals as well as for populations and in 
are in consistency with current professional knowledge.
Aims and outline of this thesis
As we investigated applied methodologies and outcomes in several areas of cardio-
thoracic surgery in Europe, differences have become evident. The aim of this thesis 
is therefore to assess these differences, the methods that are used, to define areas for 
improvement, as well as approaches toward harmonisation and improvement of 
outcomes. Harmonisation and improvement lead to best practices and improved 
quality. As the objective assessment of quality takes place by comparison with external 
sources, the chapters in this thesis are all characterised by this adagium. Formal scientific 
comparison between organisations, measuring quantitative results, lead to insights in 
the causes of quality differences in critical operational data.
The studies, presented in this thesis demonstrate that diversity of methods and systems 
is large; particularly in Europe. In order to provide the desired insights in the diversity 
of European practices, we aim to demonstrate where there is room for improvement in 
order to pave the way for future quality advancement projects.
Starting with the hypothesis that benchmarking leads to quality improvement, a selection 
of literature is presented in Chapter 2. By executing a systematic review of hundreds of 
publications in the cardio-thoracic surgery domain, only a limited number of 6 studies 
remained, showing quantitative improvements by using databases of registries for 
benchmarking. In addition to providing tangible evidence of benchmarking results, all 
studies provided additional instruments to come to best practices. Five out of 6 papers 
originated from the United States and Australia, and only one from Europe.
Chapters 3 and 4 are the results of 2 studies providing reports on the application of 
Mechanical Circulatory Support (MCS) in respectively adult and paediatric patients. 
EUROMACS, an EACTS registry for patients with MCS, provides a platform to 
accumulate baseline and follow-up data of these patients’ therapy. Since it is the only 
European international registry of its kind, outcomes are provided on an international 
level and represents a comprehensive representation of European data.
In Chapter 5 the Interagency (IMACS) report, a large worldwide database for patients 
receiving durable Mechanical Circulatory Support (MCS) devices is being presented. 
IMACS collects data from three major registries: EUROMACS, JMACS (Japan) and 
InterMACS (United States) as well as from individual hospitals in Australia and in 
16
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the Far-East (Australia, Singapore). By accumulating data from a growing number of 
countries, trends with respect to global developments such as use of axial, centrifugal 
and pulsating devices become apparent. The relevance of the IMACS report is that it 
offers multiple benchmarks with respect to device strategies, risk factors, adverse events 
and predictors of mortality for the worldwide “MCS-community”.
In Chapter 6 gender differences in indications, haemodynamics and outcomes are 
examined. The observed differences are evaluated. Gender-specific predictors for survival 
of women and men, undergoing MCS implantation are identified.
In Chapter 7 we investigate the impact of a phenomenon that was unforeseen at the 
onset of MCS therapy: the rare occurrence of sufficient myocardial recovery resulting 
in explantation of the mechanical circulatory assist device. In this study we focus on the 
incidence of explantation and the long-term outcomes post explantation. 
In Chapter 8 we aimed to determine the association between concomitant tricuspid 
surgery and clinical outcomes. As tricuspid regurgitation is common after the 
implantation of a left ventricular assist device (LVAD), the controversy exists as to 
whether tricuspid valve surgery improves clinical outcomes in the early and late period 
after LVAD implantation.   
In Chapter 9 factors having an impact on the availability to patients of safe tissue and 
cell therapies are being investigated. To satisfy the clinical demands for human tissue 
allografts in cardio-thoracic surgery, as well as in other applications tissue establishments 
in general have a complex serious of tasks: to correctly estimate the demand for tissue 
transplants; plan the number of donations needed accordingly; purchase procurement 
and processing materials; and finally, produce transplantable allografts. The tissue and 
cell “market” is not subject to economic market dynamics given the fact that these are 
not typical commercial products. The tissue of donors is donated for altruistic reasons, 
and free of charge, while several process steps must ensure freedom of transmittable 
diseases as well as the compliance of the final “product” with clinical quality standards. 
In Chapter 10 we provide current and future perspectives and conclusions on the most 
common replacement tissues: cardiovascular, ocular, musculoskeletal tissue and skin. 
Different structures as well as incidence of donations and applications for tissue grafts 
are analysed. 
Chapter 11 describes a conducted European survey to establish the level of cardiovascular 
tissue banking activities and the demand for allografts. For the first time different 
methodologies with respect to the use of decontamination protocols became discernible. 
These methods, as well as the de-selection of donors and discard of already donated 
cardiac tissues are determinants for the quality of the implanted allograft.
17
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Thereafter, in Chapter 12, triggered by the observed differences in Chapter 12, we first 
conducted a quality round trial. In the trial tissue establishments received heart valve 
samples that were purposely contaminated with known micro-organisms. They were 
asked to carry out microbiology tests and decontamination protocols using their local 
methods. The applied methodologies should prove their effectiveness to decontaminate 
tissue allograft processes.
Following the data generated in the earlier chapters, and considering the fact that human 
cardiovascular tissues may be lifesaving and in high demand when it comes to patients 
with urgent etiologies such as endocarditis, it felt important to follow-up on a wide 
range of methodologies in Chapter 13. 
Based on the previously published validations and publications it was decided to 
investigate in more detail the microbiological and decontamination protocols used in 
Chapter 14. The aims were to isolate and identify the micro-organisms present and to 
successfully decontaminate heart valve tissue.
Finally, in Chapter 15, we provide a general overview and discuss the most important 
findings of this thesis. In addition, the clinical implications and future perspectives will 
be discussed.
18
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INTRODUCTION
The notion of measuring clinical outcomes in order to improve the results of the 
treatment provided is accepted as standard practice. Initiatives of data collections in 
clinical registries are available in many specialties around the world. The three main 
scopes for clinical registries are performance monitoring, quality improvement and 
clinical research.
Software-technology innovations have enabled health care organisations, authorities, 
professional societies, national or regional hospital groups to set up databases registering 
outcomes of cardiothoracic surgery procedures. The analyses of the data from these 
registries often revealed large differences in results, measured in parameters such as 
length of stay (LOS), morbidity and mortality between hospitals. The outcomes, being 
discussed at peer meetings and symposia prompted active discussions about techniques, 
patient selection and care approaches [1].
These days, it is widely recognised that registries are important tools for defining areas 
for improvement [2-9]. While this positive influence of registries is widely accepted as 
being evident, differences in quality continue to exist.
In this study we examined the causal relation between the use of cardiothoracic surgery-
oriented registries, implementation and improvement of clinical outcomes. A systematic 
literature review was set up to identify studies providing evidence that benchmarking 
leads to consolidated quality improvement in cardiothoracic surgery units. The selected 
studies provide insight in how data was used to change processes, structures and 
outcomes in the organisations that were the subject of quality improvement initiatives.
METHODS
Definition
The following definitions were used. Firstly, a registry was defined as a clinical database 
in which cardio- thoracic centers systematically register some data on all patients 
with the purpose to use the data for the improvement of clinical outcomes. In the 
registry data are collected using standardised methods and data definitions, and patient 
intervention data are anonymised.[10].  As a result, the registry represents baseline data 
as well as outcomes of interventions, and is accessible for its contributors. Secondly, 
benchmarking was defined as a method of directly accessible, online quality assessment 
based on best practices, on which informed decisions can be made through the use of 
outcome related, validated statistics and trends from the registry.
Study outcome
The primary outcome of this review was the impact of cardiothoracic surgery registries 
on quality improvement in clinical practice. This impact had to be exhibited by data 
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before and after benchmarking, to prove the causal effect of the use of the registry. 
Such data includes improvement of outcome (survival, complications, surgery time, and 
morbidity) or health care utilisation (duration of stay, ICU stay, and re-hospitalisation). 
Secondary outcomes included any improvement of protocols or organisational processes.
Search strategy
In October 2018 a systematic literature search according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA) guidelines was conducted [11,12]. 
Embase, MEDLINE, Web of Science, Cochrane and Google Scholar were searched for 
articles published after 1990 (search terms are provided in the supplementary Table 1.) 
[13]. Inclusion and exclusion criteria were defined a priori (Supplementary Table 2). The 
search was restricted to English language publications.
Studies were included if the study population consisted of cardiovascular patients in 
hospital care or community care setting. Furthermore, a registry needed to be used 
as a tool to produce changes in quality. This included: either assessments of changes 
in processes in the organisation as a result of benchmarking by means of registry 
data; validated scoring systems developed to predict outcomes based on registry 
data; identification or development of risk factors based on registry data and their 
quantification and application in clinical organisation practice.
Proposals, reviews, letters, case-reports, single center studies, and cost analyses were 
excluded. Studies were excluded if benchmarking by means of a registry data were not 
used to demonstrate tangible changes in outcome or quality with data from multi-center 
registries. Likewise, studies including quality improvement based on other interventions 
than registry data e.g. diagnostic tools, pharmaceuticals, surgery techniques were 
excluded. Also, studies limited to a specific population, technique, device, disease, or 
center were as well as studies and registries or databases, including data of a small number 
of centers (<5) were excluded. Two researchers (TdB and RM) independently extracted 
and reviewed abstracts and full texts in a blinded standardised manner. In case of a 
disagreement regarding the inclusion of a study an agreement was jointly negotiated. 
Finally, references were cross-checked for relevant studies.
Data extraction and statistical analysis
The data was extracted through a standardised form. The extracted data included year of 
publication, study design, population, data source used as registry, reporting technique 
and reporting mechanism, and feedback process. Additionally, the study outcome, 
intervention, impact of the registry on the processes of care, health service use and 
on clinical outcomes, and the study limitations were extracted. The individual study 
definitions were used to define the outcomes. Microsoft Office Excel 2011 (Microsoft 
Corp., Redmond, WA, USA) was used for data extraction. The ROBINS-I tool was 
used to assess bias in the individual study outcomes (Supplementary Table 3). A meta-
analysis or pooling of the data was not possible due to the heterogeneity between studies 
and the use of words and text to summarize the findings. Therefore, a narrative synthesis 
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of studies meeting the inclusion criteria was conducted, and the authors made an 
inventory of the outcomes.
Figure 1: Literature search and inclusion flow chart.Figure 1. Literature search and inclusion fl owchart
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RESULTS
Search outcome
A total of 2990 records corresponded with the described search criteria. After removal of 
210 duplicates, 2780 titles and abstracts were screened. Subsequently, 2725 studies did 
not match the inclusion criteria and 55 studies were selected for full text screening. Of 
these, another 50 full text articles were excluded for failing to match the definitions for 
inclusion. By means of cross-referencing, 1 additional article was selected, which made 
the total number for the narrative synthesis 6 studies (Fig. 1).
Six studies demonstrated that a registry was used for benchmarking at a local level, 
alleging that the results led to a change in improvement of outcomes [2,3, 14-17]. Three 
studies describe the method for the improvement of outcomes from the perspective 
of the cardiothoracic care unit and three studies describe the methodology from the 
perspective of the registry. Overall, there was a low risk of bias due to confounding 
according the ROBINS-I tool (supplementary material Table 1).
The included studies are summarised in Table 1 and broken down into demographics. 
Studies were mainly established in the USA (4), in addition to Sweden (1) and Australia 
(1). All included studies had a prospective design and were conducted between 2009 
and 2018. One study was an internationally orientated registry, 3 studies were national 
registries, and 2 studies were regional registries. The median number of hospitals per study 
was 40 [minimum 30 - maximum 1150]. The median number of patients per study was 
115500 [minimum 6720 – maximum 475000]. The main reporting mechanism was 
web-based (83%). Furthermore, the majority of the registries performed multiple audits 
(67%), logic checks (83%), error-checks (100%), and organised meetings to discuss 
subjects such as: registry outcomes, benchmarking of anonymous or unblinded data, 
and collaborative improvement initiatives (83%) (Table 2).
Impact of the individual registries on clinical result
An overview of consolidated outcomes, the impact of the selected registries on processes 
of care, health service use and clinical outcomes is depicted in Table 3.
Nayar et al.[14], conducted a quality improvement initiative linking the Society of 
Thoracic Surgeons Congenital Heart Surgery Database (STS-CHSD) and Infection 
Surveillance Database (ISD) with the local administrative data system. The combination 
of registry and in-house administrative data improved reporting and reduced the 
incidence of Surgical Site Infection (SSI). During a 24-month study period, the authors 
ascertained 1715 surgical cases. Through quality improvement initiatives, including: 
standardised clinical protocol changes; ameliorated communications, and reporting, 
corrective interventions were initiated in a rapid-cycle manner. By means of wound 
alert reports, focused actions were developed.
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Table 1. Demographics of included studies
Reference Year 
published
Scope Design Population Number of 
hospitals 
(units)
Number of 
patients
D. Eccleston et al.16 2017 Australia Prospective Adult Cardiac 
population
40 6,720
R.S. D’Agostino et al.17 2018 USA, Canada & 
7 other countries
Prospective Adult Cardiac 
Surgery
1,150 224,724
T. Jernberg et al.15 2010 Sweden Prospective Cardiac Surgery 74 80,000
E.L. Hannan et al.3 2012 New York State Prospective CABG 30 57,187
V. Nayar et al.14 2016 USA Prospective Paediatric 
cardiac Surgery
1,061 475,000
R. Prager et al.1 2009 Michigan State Prospective CABG 33 151,000*
*151,000 is the annual average reported by Likosky et al.
CABG; Coronary arterial bypass grafting
Table 2. Data sources, characteristics and control mechanisms
Control mechanisms
Reference
Data 
source
Reporting 
region
Reporting 
mechanism Audits
Logic 
checks
Error- 
checks Meetings
D. Eccleston et al.16 Registry in
real-time National Web-based multiple yes yes yes
R.S. D’Agostino 
et al.17
registry in
real-time International Web-based multiple yes yes yes
T. Jernberg et al.15 Registry National Web-based on site yes yes yes
E.L. Hannan et al.3 Registry Regional Reports on site unknown yes yes
V. Nayar et al.14 Registry National Web-based multiple yes yes yes
R. Prager et al.1 Registry Regional Web-based multiple yes yes yes
Following the wound alert, a collaborative bedside review would take place, and in 
a multi-disciplinary manner a consensus decision would be made regarding the 
underlying cause. Through this method, compliance with the current guidelines and 
protocols would be assessed in order to determine the status of potential causes for 
the SSI development. This systematic approach resulted in a 59% SSI reduction in the 
Children’s Hospital of Philadelphia over a year. 
Jernberg et al. [15], described the functioning of the SWEDEHEART Registry as an 
online interactive reporting system functioning as a tool for continuous collaborative 
quality improvement projects in which all Swedish hospitals are engaged. Annual 
reports are openly published and outcomes of each hospital can be directly compared 
with others. All users are provided with online interactive reports concerning changes of 
processes of care. SWEDEHEART openly publishes quality comparisons and indexes 
reflecting the whole chain of patient care. 30-days mortality decreased from 1.9% to 
1.1% between 1995 and 2008. Additionally, one year and in-hospital mortality after 
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an acute myocardial infarction decreased as well, while later reports show a continuous 
trend of decreased mortality in all cardiothoracic procedures [20].
Hannan et al. [3], studied the development of the New York State program to increase 
quality and improve outcomes in a historical perspective. Annual feedback reports, 
in which key performance indicators [30-day (risk adjusted) expected and observed 
mortality] were tools that were used to make cardiac surgeons, as well as interventional 
cardiologists, aware of their relative performance. Negative outliers received a letter from 
the NY State Department of Health (DOH).
This method and its impact on quality improvement in specific hospitals has been 
described by Chassin [2], who elaborated on the large influence of publicly disseminating 
cardiac surgery outcomes 2. As in the study of Nayar et al. [14], administrative data 
suffered issues of data quality and were not appropriate for use for calculating necessary 
ratios to measure quality in New York State hospitals. For this reason, a patient-level 
clinical database was created to assess clinical outcomes for CABG surgery.
In all 3 hospitals, referred to by Hannan et al. [3], major changes in processes and 
structures were implemented. As a result, the 30-day mortality rate decreased from 
26% to 0% (emergency cases only), from 9.2% to 2.3% and from 7.31% to 2.57% 
respectively over a 3- to 4-year period. After 5 years, the risk adjusted odds for short-
time mortality was only 0.66 times the odds in the remainder of the country. Eccleston 
et al. [16], set up a registry to benchmark local practice against international standards. 
The feedback of the registry to the health care providers, either as individuals or as a 
group, is aimed at appropriate use of guidelines in cardiac therapy and to assess long-
term medication compliance. Between the first and latest year of data collection there 
was significant improvement in the rates of statin therapy at discharge (92.1 vs. 94.4% 
p<0.03) and 12 months post-PCI (87.0 vs 92.2% p<0.001) and of antiplatelet therapy 
at 12 months (90.7 vs 94.3% p<0.001).
The Society of Thoracic Surgeons Adult Cardiac Surgery Database 2018 report goes 
beyond explaining the methodology of the registry in detail [4,17]. The 2018 publication 
reports on data quality improvement, reports to sites as well as voluntarily to the public 
and offers linking with other databases. Still, after 3 decades the 2016 outcomes show 
an overall decrease of in hospital mortality for the majority of procedures [17]. One of 
the additional instruments for quality improvement, on top of site-reports and other 
feedback is a task force on quality initiatives e.g. on the use of blood products resulting 
in 18% reduction of exposure to blood products in patients undergoing CABG, while 
similar trends are observed in aortic valve repair and mitral valve repair [17].
Prager et al. [1], report that parallel to the STS database, the Michigan State Collaborative 
Approach uses STS data, based on which quality meetings are organised in the state. 
From the onset in 2005, the provided data from state hospitals were anonymous. 
Practices were shared, sites visits and reverse site visits took place. Anonymous data were 
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gradually unblinded and peer to peer discussions took place in which an atmosphere of 
openness and trust prevailed. Th e initial results of this Collaborative Approach included: 
improvement of risk adjusted mortality rates; reduction of ventilation time; and an 
increase of the use of internal mammary arteries (IMA) as compared to the other STS 
national average. In its most recent study the Michigan State Collaborative proved that 
their methodology resulted in better outcomes in a project aimed at the reduction of 
pneumonia: a 3.23% reduction for Michigan State Collaborative hospitals versus a 
1.96% reduction in STS hospitals [19].
Figure 2: The Deming Circle, method of continuous quality improvement by Plan-Do-Check-Act with the application of registry data to benchmark 
local outcomes against registry data.Figure 2. Th e Deming Circle, method of continuous quality improvement by Plan-Do-Check-Act with the 
application of registry data to benchmark local outcomes against registry data.
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DISCUSSION
In this systematic review of the literature, the analysis of 2990 abstracts, the selection of 
many in-depth articles about databases, and about the importance, influence and use of 
registries, concluded that the number of publications regarding the use of registries runs 
into the thousands. Using the methodological limitations and inclusion criteria, of the 
systematic search-strategy, a very small quantity of six studies could be selected -though 
with an enormous number of patients- providing evidence that the use of a registry leads 
to quantifiable and consolidated improvements. Moreover, the selected studies deliver 
additional insights, and confirm what has elsewhere in research been published.
Several studies discuss the preferable sources of such data. While Siregar et al. stress 
that great caution is needed when using administrative data to measure cardiovascular 
events, Pagano and Gale state that both clinical as well as administrative sources of data 
have a qualitative restriction when considered separately [20,21]. Thus, the use of a 
combination of data sources is preferable.
The study of Nayar et al. demonstrates that the reliability of registry data is essential. 
Their applied methodology of using data from 2 robust clinical registries (STS and 
ISD) and an additional local administrative database to benchmark the level of Surgical 
Site Infection (SSI), enabled the researchers to obtain better insights. The execution of 
quality improvement initiatives at the Children’s Hospital of Philadelphia (CHOP) is 
an example of the use of both internal databases and registries to benchmark outcomes 
and use these outcomes to improve patient care in the local hospital organisation. 
This resulted in changing infection incidences as a rolling 12-month rate for each data 
source. As expected, the in-house administrative data were sub-standard; using them in 
isolation would have resulted in limited insights and uncalibrated conclusions.
By means of a visualisation software tool, using statistical process control charts, the 
variations in trends were made visible and staff could concentrate on addressing the 
most influential causes for SSI through targeted quality improvement projects. As a 
logical spin-off process-flows were mapped and medical records were standardised from 
all perspectives, resulting in a 59% SSI reduction in the CHOP over a 2-year period of 
time. Additionally, the execution of the CHOP quality improvement initiatives shows 
all core characteristics of the innovation process that Deming described as “Plan, Do, 
Check, Act (PDCA)”, and is shown in Fig. 2 [23]. According to Nayar et al. [14], 
the methodology can be applied to other disciplines within cardiac surgery: systematic 
continuous quality improvement based on observed differences between registry data 
and statistical deviation of the administrative in-house data must be the basis of every 
hospital’s quality-strategy. The SWEDEHEART Registry encompasses all relevant 
baseline and follow-up data from all hospitals. 
Several publications about the situation in Sweden appeared during the process of 
data analysis and selection in this study [15,20]. The report by Jernberg et al. was 
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selected because of meeting the criteria, yet it offers a ’tour d’horizon’ with respect to 
structure, functioning and outcomes of the SWEDEHEART Registry. SWEDEHEART 
distinguishes itself by ‘comparing not only the performance of participating hospitals 
but also different treatment modalities and medical devices’. 
The proof that there’s a causal relationship between the use of the registry and measurable 
quality improvement can be found in the additional features consisting of an array 
of interactive reports in which physicians, nurses and decision-makers can structurally 
follow the outcomes of their local processes of care in trend-analyses.
The public availability of outcome, and the aforementioned trends, have been correlated 
with wider professional attention. Subsequently, many hospitals have undertaken co-
operative quality-improvement projects.
Although not similar to SWEDEHEART the New York State Cardiac Registries were 
initiated as an audit-oriented data collection to address inter-hospital variations in 
mortality and complications, and offer some comparable features. One of the earliest 
publications on the use of data to identify areas for improvement is the study of Chassin 
[2], on the New York State Cardiac Surgery
Reporting System (CSRS). Chassin describes the localised approach of several hospitals 
as well as individual surgeons and the publication of specifically negative outcomes and 
the publicity that followed [2, 24]. Ten years later Chassin questions whether “naming 
and shaming” is the preferable professional method of choice.
Hannan et al. [3] describe the further development of the New York State CSRS as a 
patient-level clinical database that was created to assess clinical outcomes for CABG 
surgery. Annual feedback reports in which key performance indicators [30-day (risk 
adjusted) expected and observed mortality] were tools that New York State Registries made 
available to cardiac surgeons as well as to interventional cardiologists. This demonstrates 
that through their life-cycle registries may develop into a multi-purpose tool from audit-
oriented to the use for quality improvement or research and vice versa [25].
In the early 1990’s, the New York State Cardiac Surgery Reporting System (CSRS) was 
a database, it wasn’t a registry that functioned as a modern near real-time web-based 
tool though. Therefore, Chassin’s publication wasn’t selected for our study. However, 
the wider impact on health care of disclosing data for the public at large appears to 
be a necessity to induce quality improvement implementations. As surgeons were 
provided with trustworthy data concerning their performance, they, as well as hospital 
administrators, are stimulated to create effective quality improvement programs [3]. 
Hannan confirms that feedback reports to the general public are a trigger for hospital 
organisations and medical professionals to stimulate them to focus on how to minimize 
mortality in their institutions.
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The selection method also excluded the study of the improvement project of the 
American College of Surgeons, described by Ingraham et al. [26]. Though the field of 
study is general surgery, rather than cardiothoracic surgery, the method recognises that 
data alone doesn’t translate into improvement of outcomes. The authors identified 12 
critical steps for implementing quality improvement on a local level. Measures through 
the entire care-process were taken, changing one or more of the steps in the pre-, peri- 
and post-operative working method(s) was evidence based, controlled and quantified. 
Moreover, the involvement of surgeons-champions, multi-area leadership support and 
a quality improvement team including trained and audited data abstractors, or Surgical 
Clinical Reviewers (SCRs), ensured the collection of consistent, robust and high-quality 
clinical data using precise definitions. Over a period of 15 years post-operative morbidity 
was reduced by 43% and mortality by 47%, though this may partially be attributed to 
the evolution of surgical techniques.
All publications that were selected for this study, and all that are considered relevant 
for the discussion concerning the best method to apply benchmarking to identify areas 
for improvement and to implement the results of quality enhancement initiatives, seem 
to follow a common pattern that consists of three components: structure, process and 
outcome: the ‘Donabedian Model’ [27]. Ingraham et al. [26] refer to this Model, in 
which health care is approached as being a system with processes that can be re-designed 
in order to improve quality. In the study of Ingraham et al. the Donabedian model is 
applied, overlapping with Deming’s PDCA method, which results in a better:
1. Structure: consistent, reliable and uniform data collection. Assignment of roles of 
medical professionals in the quality-improvement projects (plan, do).
2. Process: evidence-based improvement in the working methods (check).
3. Outcomes facilitate the identification of process measures that are highly 
correlated with quality improvement resources (act).
As proof that the methodology can serve as an effective tool for achieving significant 
gains in surgical quality, the authors report a sharp decrease in morbidity and mortality.
While the availability of studies that demonstrate the relation between the use of 
registries in the cardiothoracic domain is very limited, the modest attainability of such 
evidence-based studies seems to be similar in other areas of medicine in which registries 
are used [28,29].
Our literature search resulted in a selection of registries in which the North American and 
Australian continents emerged predominantly. The limitation of our search to English 
language publications may have overlooked the existence of well-functioning national or 
regional registries in other geographical areas. With the exception of SWEDEHEART 
no other registries met the criteria set for this review. An early version of a European 
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Adult Cardiac Database (ACD) was abandoned because data were inaccessible online 
and did not offer the tools for multilayer comparison of data from individual hospitals 
with the database [30]. The comprehensiveness of the STS database and its ability to 
offer an adequate benchmarking tool led to the initiative of the European Association 
for Cardio- Thoracic Surgery EACTS) to accumulate data on a European level.
An incoming first report will present the first results and is expected to encourage 
Europeans to catch up participate in a European registry. It can be expected that 
aggregating and comparing outcomes on a larger than just national scale, and learning 
from successfully applied methods elsewhere, will lead to further quality improvement 
at an international level.
Limitations
This systematic review has limitations. consisting of the following elements: quality 
improvement methods and strategies are usually poorly indexed within bibliographical 
databases. Further, the selected studies show differences in size, in heterogeneity of 
the study cohorts, time frame, time-period, continuance and outcomes of interest in 
different quantification methods. These make it impossible to pool results. We found 
variation in follow-up, reporting mechanism, data management, quality assurance, and 
audit of data within the registry. In Table 3 (last column) we provided a breakdown of 
limitations per included papers.
A limitation of our review concerns the search strategy. The broadness of the search 
increased the number of irrelevant articles (we excluded more than 98% of all articles 
reviewed). However, it decreased the risk of systematically missing relevant studies. We 
believe that our findings haven’t missed potentially relevant studies. 
CONCLUSION
The perceived impact of the large quantity of medical registries is not denied, though 
often they’re merely used as a reference. For a one-on-one relation between the use 
of registry data, measurements of outcomes of quality improvement is the key for 
determining the success of the quality improvement intervention. Registries do have 
limitations and clinicians who undertake quality improvement projects should seek 
to extract data from multiple resources if they provide reliable essential information. 
Feedback of outcomes does influence registry participants. However, several studies 
substantiate that providing data and feedback alone, contributes less to change processes 
focused on the improvement of outcomes. The application of additional tools such as 
collaborative meetings are provided and used. Subsequently, these tools result in the 
improvement of clinical outcomes.
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This study demonstrates that the instruments to develop quality initiatives and 
methodologies can be supplied, and that a benchmarking platform can be created by 
the registry or by peer-associations, leading to quality improvement throughout the 
collaborative of cardiothoracic surgery units. Furthermore, this study shows that the 
comparison of consolidated results before and after quality improvement initiatives 
provide the tangible evidence that the use of registry data leads to clinical outcomes 
with decreased morbidity and mortality.
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ABSTRACT
Objectives: The European Registry for Patients with Mechanical Circulatory Support 
(EUROMACS) was founded in Berlin, Germany. EUROMACS is supported fully by 
the European Association for Cardio-Thoracic Surgery (EACTS) and, since 2014, has 
functioned as a committee of the EACTS. The purpose of having the EUROMACS 
as a part of the EACTS is to accumulate clinical data related to long-term mechanical 
circulatory support for scientific purposes and to publish annual reports.
Methods: Participating hospitals contributed surgical and cardiological pre-, peri- 
and long-term postoperative data of mechanical circulatory support implants to the 
registry. Data for all implants performed from 1 January 2011 to 31 December 2016 
were analysed. Several auditing methods were used to monitor the quality of the data. 
Data could be provided for in-depth studies, and custom data could be provided at the 
request of clinicians and scientists. This report includes updates of patient characteristics, 
implant frequency, mortality rates and adverse events.
Results: Fifty-two hospitals participated in the registry. This report is based on 2947 
registered implants in 2681 patients. Survival of adult patients (>17 years of age) with 
continuous-flow left ventricular assist devices with a mean follow-up of 391 days was 
69% (95% confidence interval 66–71%) 1 year after implantation. On average, patients 
were observed for 12 months (median 7 months, range 0–70 months). When we 
investigated for adverse events, we found an overall event rate per 100 patient-months 
of 3.56 for device malfunction, 6.45 for major bleeding, 6.18 for major infection and 
3.03 for neurological events within the first 3 months after implantation.
Conclusions: Compared to the first EUROMACS report, the number of participating 
hospitals increased from 21 to 52 (+148%), whereas the number of registered implants 
more than tripled from 825 to 2947 (+257%). The increase in the number of participating 
hospitals led us to increase the quality control measures through data input control, on-
site audits and statistical analyses.
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INTRODUCTION
The purpose of the European Registry for Patients with Mechanical Circulatory Support 
(EUROMACS) registry of the European Association for Cardio-Thoracic Surgery 
(EACTS) is to accumulate clinical data on long-term mechanical circulatory support 
(MCS) and to enable scientific research to improve this method of treatment for patients 
with end-stage heart failure. The registry permits the retrieval of data on survival and 
morbidity rates so that clinicians and industry representatives can identify and learn 
from the factors that influence the results of MCS therapy. Various measures were taken 
to safeguard the completeness and correctness of the data that have been submitted by 
the participating centres to improve data quality. These methods include data input 
control, on- site audits and statistical analyses.
Data have been made available for several studies that resulted in publications [1, 2] or 
abstracts [3]. Upon the request of the participating centres, custom analyses of data could 
be provided. Of special interest, a paediatric study group has been established among the 
EUROMACS members to carry out studies on the treatment of children with MCS. 
The first article containing paediatric data from the EUROMACS will be submitted in 
2017 to the European Journal of Cardio-Thoracic Surgery (EJCTS). Several joint projects 
with other national and international registries to exchange or to accumulate data were 
initiated. Finally, a course for ventricular assist device (VAD) coordinators, including 
the EUROMACS registration modalities, has been conducted annually since 2015 [4].
The EUROMACS and the International Society for Heart and Lung Transplantation 
(ISHLT) have an agreement whereby the ISHLT participates in the Interagency Registry 
for Mechanically Assisted Circulatory Support (IMACS). IMACS enrolls and follows 
patients receiving durable MCS devices on a global basis. The first IMACS annual 
report, including data from EUROMACS, was published in the spring of 2016 [5].
METHODS
Hospitals that contribute baseline and follow-up clinical data from their consenting 
patients to EUROMACS agree to do so within 6 weeks after the patient receives an 
MCS device. Similarly, events are to be registered within 6 weeks after their occurrence. 
Hospitals register their patients with MCS online via a secured Internet connection, 
using an individual password, in an ongoing prospective manner, but also retrospectively 
to 1 January 2011. Although some centres have chosen to submit earlier records, only 
implants from 1 January 2011 are included in this analysis, which is consistent with the 
data included in the first annual report [6].
All paediatric and adult patients who received a long-term MCS device, designed for  >_6 
months support, were eligible for registration in the EUROMACS database (Table 1). A 
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provision has been made for devices that were implanted concomitantly (as a temporary 
right ventricular assist device) with a long-term device (see Table 1, ‘Short-term devices’).
QUALITY CONTROL
To safeguard the correctness and completeness of the data sub- mitted by the contributing 
hospitals, a set of tools and protocols has been developed. Primarily, the hospitals sign 
an agreement in which they consent to submit data from every patient who receives 
MCS on a long-term basis (support duration >_6 months), unless the patient refuses 
consent to participate. The procedure to obtain consent is based on national legislation, 
which varies in the different nations in which hospitals submitting data are situated. 
The hospitals agree to communicate data records to the registry in accordance with the 
structure of the EUROMACS data- base and ensure that all data have been correctly 
acquired, in accordance with the state of the art of medical procedures.
In addition, checks on data completeness and data consistency are carried out on a 
structural basis. Data managers are approached directly in case of specific issues. The 
participating hos- pitals are requested to confirm the completeness of their data on 30 
June and 31 December each year. Thus, the consolidated data can be used for analyses 
and the annual report. For more details, see Supplementary Material.
On-site audits are conducted by the EUROMACS management team and comprise an 
overview of possible non-compliance re- ports using a random selection of patient files 
that are compared with the respective data files from the local hospitals.
Statistical analysis
In preparing the analysis for this report, we involved on-site data managers to achieve 
complete data with respect to the most important variables. Our goal was to increase 
the completeness of the survival data by assuming a patient’s death if a date of death or 
a cause of death had been entered or if the patient’s death was mentioned as an adverse 
event or as a type of discharge. We used the brand of the device to derive the type of 
pump in case this information was missing. No multiple data imputations were done. 
We checked for the chronological plausibility of the follow-up records and eliminated 
or corrected implausible re- cords by queries to on-site data managers. 
The Kaplan–Meier estimates of cumulative probabilities were calculated for mortality, 
including 95% confidence intervals (CIs) as a measure of certainty, where we did not 
truncate the curves. A patient is considered at risk up to the date of his or her individual 
last follow-up information saying that the patient has received a transplant, has been 
weaned from the device, has died or is alive. For major adverse events other than death, 
we calculated event rates per 100 patient-months and constructed corresponding CIs 
that accounted for the Poisson distribution of event counts. Competing outcomes 
(ongoing device support or death or heart  transplant or weaning) are  presented for the 
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first 6 months after device implant. Percentages are calculated as the ratio of the number 
of subjects who experienced the mentioned outcomes divided by the total number of 
subjects in the data set multiplied by 100. To avoid any censored individuals, only 
patients with a follow-up period of at least 6 months were considered for the competing 
outcome analysis. All CIs and P-values were 2-sided. All calculations were made using 
Stata 12 (Stata Corporation LLC, College Station, TX, USA).
RESULTS
Since the publication of the first EUROMACS annual report, the enrolment of hospitals 
increased by 148%, from 21 to 52, and patients in the registry more than tripled from 
741 to 2681 (262%) [6].
Table 1
MCS type  
Long term devices
Continuous flow Berlin Heart INCOR
CircuLite Synergy*
Heart Assist 5
HeartWare HVAD
Jarvik 2000
MicroMed DeBakey
Thoratec HeartMate II
Thoratec HeartMate 3
Pulsatile extracorpreal Berlin Heart EXCOR
Thoratec pVAD
Abiomed AB5000
Total artificial heart SynCardia Cardiowest
Short-term devices
DeltaStream Medos**
Levitronix CentriMag**
    Maquet CardioHelp**
*Withdrawn from the market in 2014.** These short-term devices can be used with an oxygenator as ECLS/
ECMO. A provision has been made for devices which were implanted concomitantly (as a temporary 
RVAD) with a long term device.
CE: European conformity; MCS: mechanical circulatory support.
Centres
Table 2 presents the 52 hospitals in 18 countries (in 2013, 21 hos- pitals in 12 countries) 
[6] contributing data to the EUROMACS as of 31 December 2016. On the same date, 
the agreement in which the rules of engagement were defined was under consideration 
in 4 hospitals in 2 additional countries. In addition, the Spanish Registry for Mechanical 
Circulatory Support (ESPAMACS), which includes the collective data from almost all 
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Spanish hospitals that implant MCS devices, agreed to provide data to EUROMACS 
on a regular basis, whereas 1 hospital contributes its data separately [7]. At the end of 
2015, an agreement was reached with the Societé Française de Chirurgie Thoracique et 
Cardio-Vasculaire (SFCTCV) [8] whereby the 18 hospitals in France that implant MSC 
devices will start contributing data in 2017.
Table 2. Participating institutions as of December 31, 2016.
Country City, Hospital
Austria Innsbruck, Universitätskliniken
Azerbaijan Baku, Central Clinic Hospital 
Belarus Minsk, National Institute “Cardiology”
Belgium Aalst, Onze Lieve Vrouwenziekenhuis
Gent, Universitair Ziekenhuis Gent
Leuven, Katholieke Universiteit Leuven
Czech Republic IKEM (Institute for Experimental Cardiac Surgery)
Brno, Center for Cardiovascular and Transplant Surgery
Denmark Århus, Århus University Hospital Skejby, Copenhagen, Rigshospitalet
France Le Plessis-Robinson, Centre Chirurgical Marie Lannelongue
Germany Berlin, Deutsches Herzzentrum Berlin
Lübeck, Universitätsklinikum Schleswig Holstein
Bad Oeynhausen, Herz- und Diabeteszentrum Nordrhein-Westfalen
Hamburg, Universitätsklinikum Eppendorf
Freiburg, Universitäts Herzzentrum Freiburg - Bad Krozingen
Jena, Universitäts-Herzzentrum Thüringen
Karlsburg, Klinikum Karlsburg
Köln, Universitätsklinikum Köln, AöR
Greece Athens, Onassis Cardiac Surgery Center
Thessaloniki, Aristotle University of Thessaloniki
Hungary Budapest, Heart Center of the Semmelweis University
Budapest, Gottsegen György Hungarian Institute of Cardiology
Italy Bologna, Ospedale S. Orsola
Rome, Ospedale San Camillo
Milan, Ospedale Niguarda Ca’Granda
Bergamo, Ospedale Papa Giovanni XXIII
Naples, Ospedale dei Colli
Palermo, ISMETT
Rome, Ospedale Pediatrico Bambino Gesù
Torino, Regina Margherita Children’s Hospital
Kazakhstan Astana, National Research Cardiac Surgery Center
Netherlands Groningen, Universitair Medisch Centrum Groningen
Rotterdam, Erasmus Medisch Centrum
Utrecht, Universitair Medisch Centrum Utrecht
Norway Oslo, Rikshospitalet
Poland Warsaw, Childrens Memorial Hospital
Zabrze, Silesian Heart Center
Spain Pamplona, Clínica Universidad de Navarra
ESPAMACS, collective of 7 hospitals
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Country City, Hospital
Switzerland Bern, University Hospital Bern (Inselspital)
Zürich, Kinderspital Zürich
Turkey Izmir, Ege University School of Medicine
Istanbul, Florence Nightingale Hospital
Ankara, Bashkent University Hospital
Ankara, Yüksek Ihtisas Hospital
EUROMACS, in turn, has come to an understanding with the ISHLT concerning its 
participation in IMACS.
Update per 31 December 2016 
The analyses in this annual report are based on the data for implantation of MCS devices 
beginning 1 January 2011. Between 1 January 2011 and 31 December 2016, 2681 
patients (mean age 51.7 years, median 55 years, range 0–86 years) were registered in 
the EUROMACS database (Table 3). The increase in the number of devices implanted, 
compared with the number in the first annual report, is 1856 (+225%).
Table 3. Demographic profile of 2681 patients
Patient characteristics  
Mean age ± SD (median, range), years 51.7 ± 15.3 (55, 0-86)
Gender (male/female) 2200 / 481
Ethnic origin
Asian 217
Caucasian 2117
Other or unknown 347
 Primary Diagnosis 
Idiopathic cardiomyopathy 926
Ischemic cardiomyopathy 1091
Restrictive cardiomyopathy 17
Hypertrophic cardiomyopathy 22
Toxin-induced cardiomyopathy 40
Postpartal cardiomyopathy 16
Myocarditis 136
Endstage valvular heart disease 45
Congenital heart disease 56
Neoplasia 7
Unkown 325
The aetiology of heart failure was primarily ischaemic cardiomyopathy (n = 1091, 
40.7%) and idiopathic cardiomyopathy (n = 926, 34.5%) (Table 3). The distribution 
by ABO blood group type and gender is given in Table 4. Table 5 presents the types of 
VADs implanted stratified ac- cording to age in 2681 patients for whom exact data were 
available.
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Table 4. Patient characteristics according to gender and blood groups
Blood Group Male Female Total, N (%)
A 985 196 1181 (44.05%)
AB 119 30 149 (5.56%)
B 292 56 348 (12.98%)
O 803 199 1002 (37.37%)
Unspecified 1 0 1 (0.04%)
Total, N (%) 2200 481 2681 (100%)
Table 5. Type of VADs per age group in the 2695 implants of which data were available. 
<17 17-65 >65 Total
LVAD alone        
Continuous 37 1897 324 2258
Pulsatile 48 29 3 80
Unspecified 1 120 24 145
LVAD + RVAD
Continuous 1 102 18 121
Continuous LVAD, pulsatile RVAD 0 4 0 4
Pulsatile LVAD, continuous RVAD 2 0 0 2
Continuous LVAD, unspecified RVAD 0 3 0 3
Unspecified LVAD, unspecified RVAD 0 1 0 1
BIVAD
Continuous 2 20 4 26
Continuous LVAD, pulsatile RVAD 0 1 0 1
Continuous LVAD, unspecified RVAD 0 6 1 7
Pulsatile LVAD, continuous RVAD 0 1 0 1
Pulsatile 16 16 1 33
Pulsatile LVAD, unspecified RVAD 2 9 0 11
Unspecified LVAD, unspecified RVAD 0 2 0 2
All implants 109 2211 375 2695
An isolated left ventricular assist device (LVAD) was implanted in 2366 (88.3%) 
patients as a first implant. An LVAD with a temporary right ventricular assist device 
was implanted in 126 (4.7%) patients. Isolated right ventricular assist device s were 
implanted in 28 (1.0%) patients and total artificial hearts in 27 (1.0%) patients. Table 
6 presents that, after the first implantation of MCS, 218 patients underwent a second 
device implantation and 37 patients received a third implantation, 9 patients a fourth 
implantation and 2 patients a fifth implantation.
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Table 6. Primary and subsequently implanted devices (n=2947). (SVAD = VAD placement in single 
ventricle anatomy)
  Sequence of operation
1st 2nd 3rd 4th 5th Total
BiVAD 80 1 0 0 0 81
LVAD 2366 122 22 5 0 2515
LVAD,RVAD 126 4 1 0 0 131
RVAD 28 72 10 3 1 114
SVAD 3 0 1 0 0 4
Total artificial heart 27 4 0 0 0 31
Unknown 51 15 3 1 1 71
Total 2681 218 37 9 2 2947
Strategy for ventricular assist device implantations
Table 7 presents the strategy for VAD implantations in 2947 implantations. VADs were 
implanted primarily as bridge to candidacy (possible bridge to transplant, n = 1052, 
36%) or bridge to transplant (n = 813, 28%). VADs as a destination or a permanent 
therapy were implanted in 458 (16%) patients. We expected that, given the large 
numbers of patients on the heart transplant waiting lists in several countries, a relative 
increase would be seen in the number of patients older than 65 years on destination 
therapy compared to the numbers in other age categories [9].
Table 7. Device strategy at time of implantation, stratified by age categories, N (%)
  <50 50-64 65-70 >70 Total
Bridge to recovery 24 (2) 28 (2) 3 (1) 2 (1) 57 (2)
Bridge to candidacy 402 (42) 568 (39) 60 (18) 22 (12) 1052 (36)
Bridge to transplant 332 (34) 414 (28) 48 (14) 19 (10) 813 (28)
Destination therapy 22 (2) 170 (12) 157 (47) 109 (60) 458 (16)
Rescue therapy 68 (7) 105 (7) 19 (6) 18 (10) 210 (7)
Other 4 (0) 5 (0) 2 (1) 0 (0) 11 (0)
Unknown 112 (12) 176 (12) 45 (13) 13 (7) 346 (12)
Total 964 1466 334 183 2947
INTERMACS LEVELS
VAD implantation was performed primarily in Interagency Registry for Mechanically 
Assisted Circulatory Support (INTERMACS) Levels 2 and 3 as presented in Table 8.
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Table 8. INTERMACS levels of 2947 VAD implantations in 2681 patients
INTERMACS Patient Profile N (%)
1 - Critical cardiogenic shock 424 (14)
2 - Progressive decline 896 (30)
3 - Stable but inotrope dependent 733 (25)
4 - Resting symptoms 472 (16)
5 - Exertion intolerant 104 (4)
6 - Exertion limited 49 (2)
7 - Advanced NYHA class 3 43 (1)
Unknown 226 (8)
Total 2947
OUTCOME OF VENTRICULAR ASSIST DEVICE IMPLANTATION
Types of ventricular assist devices implanted Figure 1 shows the types of VADs implanted 
in both paediatric and adult patients from 1 January 2011 to 31 December 2016, 
entered into the EUROMACS database.
Figure 1. Types of Mechanical Circulatory Support Systems implanted from January 1, 2011 to 31 
December 2015
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Survival
The overall survival of 2268 adult patients (aged >17 years) with a continuous LVAD or 
a biventricular assist device (BiVAD) and a mean follow-up period of 379 days (median 
236 days, range 1– 2098 days) was 86% (CI 85–88), 66% (CI 64–68), 53% (CI 51–56) 
and 42% (CI 39–45) at 30 days, 1 year, 2 years and 3 years, respectively (Fig. 2).
Figure 2: Survival of adult patients after primary LVAD or BiVAD implantation with 
continuous flow LVAD 
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Figure 2. Survival of adult patients after primary LVAD or BiVAD implantation with continuous flow 
LVAD
Stratified according to the site of VAD implantation, the survival rate of 2113 patients 
with continuous-flow LVAD, either as a destination therapy or as a bridge to transplant, 
was 88% (CI 87–90), 69% (CI 66–71), 55% (CI 52–58) and 44% (CI 40–47) at 30 
days, 1 year, 2 years and 3 years, respectively (Fig. 3). The survival rate of 141 patients 
with BiVAD was 61% (CI 52–68), 32% (CI 23–40), 27% (CI 19–35) and 21% (CI 
13–30) at 30 days, 1 year, 2 years and 3 years, respectively (Fig. 3).
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Chapter 3 Figure 3: Survival of adult patients having continuous flow LVAD stratified by primary 
LVAD or primary BiVAD implantation  
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Figure 3. Survival of adult patient having continuous flow LVAD stratified by primary LVAD or primary 
BiVAD implantation
Figure 4: Survival of adult patients after primary LVAD or BiVAD implantation, stratified by 
age category with continuous flow LVAD 
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Figure 4. Survival of adult patient having primary LVAD or BiVAD implantation stratified by age cathegory 
with continuous flow LVAD
Figure 4 shows the age group-based survival rates of patients with primary LVAD and 
BiVAD support. At 2 years, the survival rate was 64% (CI 59–68), 53% (CI 49–56), 
42% (CI 35–49) and 27% (CI 18–37) in patients aged <50, 50–64, 65–70 and >70 
years, respectively. Figure 5 depicts the actuarial survival depending on device strategy. 
Bridge-to-transplant strategy revealed the best survival. Table 9 shows the causes of 
death of 1027 patients with VAD who were registered as deceased. The 2 main causes 
of death were multiorgan failure in 186 (18%) patients and infections and sepsis in 208 
(20%) patients.
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Figure 5: Survival of adult patients after primary LVAD or BiVAD implantation with 
continuous flow LVAD, stratified by strategy pursued with the device implantation. 
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Figure 5. Survival of adult patients after primary LVAD or BiVAD implantation with continuous flow 
LVAD, stratified by strategy pursued with the device implantation
Table 9. causes of death
Causes of death N (%)
Infection 208 (20)
Cerebro-vascular accident 132 (13)
Cardio-pulmonary failure 48 (5)
Multi-organ failure 186 (18)
Bleeding 50 (5)
Other cause of death 403 (39)
Total 1027
Adverse events (morbidity)
Major adverse events (Table 10) related to device malfunctions, such as accidental 
disconnection, wear or breaking of the driveline and pump thrombosis, were 
observed 454 times  within the entire follow-up period, which corresponds to 0.037 
malfunctions per patient year. For definitions of adverse events, we refer the reader 
to the corresponding INTERMACS definitions [10]. As other groups have reported, 
patients with continuous-flow assist devices had a higher risk for major bleeding [11]. 
In the EUROMACS database, major bleeding (requesting at least 1 unit of blood for 
transfusion) was reported 433 times, whereas 845 major infections caused by either the 
driveline or the assist device were observed. Neurological dysfunction (stroke) occurred 
in 319 of the adverse events, whereas 52 of the adverse events were a combination of 
one or more events. All major adverse events occurred more frequently within the first 
3 months after implantation than later during the patients’ course. The rate of device 
malfunctions and infections reached a stable state 1 year after implantation, whereas 
the rates of bleeding and neurological events decreased for the entire follow-up period.
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Competing outcomes
Within 6 months after device implantation, 5.4% of the patients received a heart 
transplant and 27.9% died. Only 1.5% could be weaned from the device, and 65.2% 
had ongoing device support during this period (Fig. 6).
Figure 6. Competing risks of patients after assist implant who have been followed-up at Competing 
Outcomes in Patients with Assist Device Implants
DISCUSSION
Compared to the first EUROMACS report, the number of participating hospitals has 
increased from 21 to 52 (+148%), whereas the number of registered implantations 
more than tripled from 825 to 2947 (+257%). The 3-year survival rate of patients with 
continuous-flow LVAD and BiVAD implants, 44% and 21%, respectively, was far less 
favourable than the results of the seventh NTERMACS annual report (fig. 6 of that 
report), which was 58% and 40%, respectively [12].
There are major differences between the rate of morbidity in our current EUROMACS 
report and recent INTERMACS results, such as the occurrence of major infections, 
which is far higher in the INTERMACS cohort within the first 3 months after 
implantation (15.19 vs 6.18 events per 100 patient-months) but lower during the later 
course (4.03 vs 5.49) [6]. The same pattern can be seen with respect to neurological 
events (4.18 vs 3.03 events per 100 patient-months within 3 months after implant, 1.21 
vs 1.87 in the later course).
What are the possible explanations for differences? (i) One rea- son might be differences in 
the quality of the data with respect to the completeness of reported events. INTERMACS 
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has a high level of completeness of collected data, mandated by the National Institutes 
of Health, though, similar to EUROMACS, INTERMACS has also periodic site visits, 
confirmation of case counts and frequent contact with sites to review adverse events 
(J.K. Kirklin, personal communication). On the other hand, EUROMACS, being an 
EACTS Committee, follows the same strategy of quality control as INTERMACS (see 
section ‘Quality Control’). (ii) There might be some differences in definitions of events 
and different periods of observation times. (iii) There may be some real differences in 
outcomes related to different devices and management strategies or patient selection 
practices. These differences were discussed with IMACS before the 2 registries agreed to 
analyse aggregated anonymous EUROMACS data. An incoming study proposal intends 
to investigate the details of these differences. The growth in the number of participating 
hospitals precipitated the increase in quality control by means of statistical analyses.
Limitations
The registry continues recruiting to increase the numbers of contributing centres, the 
goal being to include as many European centres as possible. In contrast to the situation 
in the USA, participation in EUROMACS is not mandatory in Europe. Therefore, 
surveillance and improvement of data quality are ongoing efforts.
CONCLUSION
Because EUROMACS became an official committee of EACTS, the registry experienced 
an increase in the number of participating hospitals (+148%) and more than tripled the 
number of implants, representing European MCS data at the best achievable level and 
reached a unique comprehensive representation of European MCS baseline and follow-
up data. In addition, the productive co- operation with IMACS permits the inclusion 
of worldwide data and important comparisons. Mortality and morbidity outcome data 
differ between the registries. It is of high importance to investigate the reasons for these 
differences.
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Abstract
Objectives: EUROMACS is a registry of the European Association for Cardio-Thoracic 
Surgery (EACTS) whose purpose is to gather clinical data related to durable mechanical 
circulatory support for scientific purposes and to publish annual reports. Because the 
treatment of children with end-stage heart failure has several significantly different 
characteristics than the treatment of adults, data and outcomes of interventions are 
analysed in this dedicated paediatric report.
Methods: Participating hospitals contributed pre-, peri- and long-term postoperative 
data on mechanical circulatory support implants to the registry. Data for all implants in 
paediatric patients (<_19 years of age) performed from 1 January 2000 to 31 December 
2017 were analysed. This report includes updates of patient characteristics, implant 
frequency, outcome (including mortality rates, transplants and recovery rates) as well as 
adverse events.
Results: Twenty-five hospitals contributed 237 registered implants in 210 patients (81 $, 
129 #) to the registry. The most frequent diagnosis was any form of cardiomyopathy 
(71.4%) followed by congenital heart disease (18.6%). Overall mean support time on 
a device was 11.6 months (±16.5 standard deviation). A total of 173 children (82.4%) 
survived to transplant, recovery or are ongoing; 37 patients (17.6%) died while on 
support within the observed follow-up time. At 12 months 38% of patients received 
transplants, 7% were weaned from their device and 15% died. At 24 months, 51% 
of patients received transplants, 17% died while on support, 22% were on a device 
and 9% were explanted due to myocardial recovery. The adverse events rate per 100 
patient-months was 0.2 for device malfunction, 0.05 for major bleeding, 0.06 for major 
infection and 0.03 for neurological events within the first 3 months after implantation.
Conclusions: The first paediatric EUROMACS report reveals a low transplant rate 
in European countries within the first 2 years of implantation compared to US data. 
The 1-year survival rate seems to be satisfactory. Device malfunction including pump 
chamber changes due to thrombosis was the most frequent adverse event.
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INTRODUCTION
The use of durable mechanical circulatory support (MCS) in children in the form of 
a ventricular assist device (VAD)  has increased dramatically over the years and has 
improved survival for paediatric patients on the waiting list for a heart transplant [1]. 
Paediatric patients receiving MCS is a unique area of study due to the physical size of 
the recipient, which not only requires careful selection of an appropriately sized device 
but also different management techniques than those used in adults. Children require 
specially adapted pharmacological treatment and the prevention of adverse events 
requires a very different clinical management from that in adults.
The EUROMACS Committee of the European Association for Cardio-Thoracic Surgery 
(EACTS) governs the registry, which was launched in 2009 and became operational  in 
2012. EUROMACS  is the only European-based durable MCS registry for all devices 
with the CE Marking implanted in children and adults (Table 1). The purpose of the 
registry is to gather clinical data related to durable MCS for scientific purposes and to 
publish  annual reports. From the outset, all possible options in MCS  strategy with 
respect to devices on the market and to data on patients of every age and geographic 
area were included [2]. This approach enables the registry not only to select paediatric 
patients as a distinguished patient cohort for analyses of baseline data but also to follow 
them up even after they have passed the age of 19 years. EUROMACS collects data 
continuing through the period of VAD support; there are 3 end points: transplantation, 
weaning and death. The EUROMACS database has been designed in such a way that the 
patient and the device outcomes will be comparable with the Pedimacs and Interagency 
Registry for Mechanically Assisted Circulatory Support (INTERMACS) databases.
So far, 2 EUROMACS reports have been published [2, 3] analysing the adult population. 
This EUROMACS report is the first to focus on patients <_19 years of age. Its goal is to 
report outcomes of children supported with MCS from a European perspective.
METHODS
As per 31 December 2017, 25 centres from 14 different countries (Table 2) submitted to 
EUROMACS data on patients <_19 years  of age. The participating centres are advised 
to enter data (of the patients or of the parents who have given consent in writing) of 
the patients who received an MCS device since 1 January 2011. Thus, newly enrolled 
centres will retrospectively enter data through that date. Some centres have chosen to 
submit data from an earlier date, and 35 patients were registered before 1 January 2011.
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Data quality checks and audits
To ensure the best quality of data and to exclude the under- reporting of suboptimal 
outcomes, the EUROMACS Registry applies several methods. Incoming data are 
analysed on a regular basis. Individual hospitals are approached, and guidance  is offered 
to complete or correct their data. Entries are adapted to adhere to the standard. Twice 
a year, each centre receives a file  in which an overview of patients whose statuses need 
to be updated and whose changes/answers have to be monitored is presented. Statistical 
consistency and plausibility checks are per- formed, and the records containing the 
inconsistent data of the participating centres are identified. Data that are not plausible 
re- quire checking and confirmation by the participating centres.
Table 1. Present CE-marked mechanical circulatory support systems registered in the EUROMACS database
MCS type
Durable devices
Continuous flow Berlin Heart INCOR
CircuLite SYNERGYa 
HeartAssist 5 
HeartWare HVAD 
Jarvik 2000 
MicroMed DeBakey 
Thoratec HeartMate II
Thoratec HeartMate 3
Pulsatile extracorporeal Berlin Heart EXCOR
Thoratec PVAD
Abiomed AB5000
Total artificial heart SynCardia Cardiowest
Short-term devices Medos DeltaStreamb 
Levitronix CentriMagb 
Maquet CARDIOHELPb
aWithdrawn from the market in 2014.
bThese short-term devices can be used with an oxygenator for ECLS/ECMO. A provision has been made 
for devices that were implanted concomitantly (as a temporary right ventricular assist device) with a long-
term device.
CE: European conformity; ECLS/ECMO: extracorporeal life support/extracorporeal membrane 
oxygenation; EUROMACS: European Registry for Patients with Mechanical Circulatory Support; 
HVAD: HeartWare ventricular assist device; MCS: mechanical circulatory sup-port; PVAD: paracorporeal 
ventricular assist device; VAD: ventricular assist device.
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Table 2. Participating paediatric units providing data for this report
Country City, hospital
Austria Innsbruck, Innsbruck University Clinics
Belarus Minsk, Republican Scientific and Practical Center Cardiology
Belgium Gent, Universitair Ziekenhuis Gent
Leuven, Universitair Ziekenhuis UZ Leuven
Czech Brno, Center for Cardiovascular and Transplant Surgery Republic
Prague, Institute for Clinical and Experimental Medicine
France Le Plessis Robinson, Centre Chirurgical Marie- Lannelongue
Germany Bad Oeynhausen, Herz und Diabeteszentrum Nordrhein-Westfalen
Berlin, Deutsches Herzzentrum Berlin
Freiburg, University Heart Center Freiburg Bad Krozingen
Hungary Budapest, Gottsegen Hungarian Institute of Cardiology
Italy Rome, Ospedale Pediatrico Bambino Gesù
Bergamo, Ospedale Papa Giovanni XIII
Bologna, San Orsola Hospital
Torino, Regina Margherita Children’s Hospital
Kazakhstan Astana, National Research Cardiac Surgery Center
Netherlands Rotterdam, Erasmus Medisch Center
Utrecht,Universitair Medisch Centrum Utrecht
Poland Warsaw, Childrens Memorial Hospital
Spain Madrid, Hospital La Paz
Switzerland Zürich, Kinderspital Zürich
Bern, University Hospital Bern (Inselspital)
Turkey Ankara, Baskent University Hospital
Izmir, Ege University Hospital
Istanbul, Florence Nightingale University Hospital
The average number of follow-up records per patient is calculated on a per centre basis 
and serves as an indicator for homogeneity and completeness of recording. In addition, 
random on-site audits of participating centres are carried out.
Statistical analysis 
We checked for the chronological plausibility of the records and eliminated or corrected 
implausible records by queries to on-site data managers. Data are presented as the mean 
± deviation (SD) or frequency with percentage. To examine mortality after implant, 
Kaplan–Meier estimates of cumulative probabilities were calculated, including 95% 
confidence intervals as a measure of certainty, because we did not truncate the curves. 
Kaplan–Meier curves were censored at explantation due to trans- plant or recovery. A 
patient is considered at risk until explantation because the patient received a transplant, 
has been weaned from the device, has died or is alive. To determine these values, 
cumulative incidences were calculated using competing out- comes methods and are 
presented for the first 2 years after the device is implanted. To avoid any censored 
individuals, only patients with a follow-up period of 2 years were considered for the 
competing outcome analysis. The user-written programme ‘STCOMPET’ in STATA 
was used to calculate the cumulative incidence [4]. Statistical analyses and figures were 
constructed using Stata 15.0 (StataCorp, College Station, TX, USA).
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RESULTS
Patient population
Between January 2000 and December 2017, 237 implants in 210 patients were registered 
(Fig. 1), 129 (61.4%) of which were male and 81 (38.6%) of which were female. Th e 
mean age was 9.3 years (±7.0 SD), and it ranged from 0 weeks to 19 years. Almost 
one-fi fth of the patients were below 1 year of age, and half of the population was above 
10 years of age. Baseline characteristics can be seen in Table 3. Primary diagnoses at 
admission included cardiomyopathy (including myocarditis) in 150 (71.4%), congenital 
heart disease in 39 (18.6%) and other in 21 (10%) (Table 4). VAD implantation was 
performed primarily in patients with INTERMACS levels 1, 2 and 3 with 44 (21.0%) 
patients at INTERMACS profi le 1.
A total of 70.5% of all children were on inotropic support prior to VAD implantation. 
Extracardiac life support was used in 17.6% of the patients prior to VAD implantation. 
Twenty-two patients received a 2nd VAD implant after the 1st one, 3 patients a 3rd 
and 2 patients a 4th implant (Table 5). Th e majority of the patients (73.8%) were 
treated with the intention to transplant (i.e. bridge to transplant or possible bridge to 
transplant),  and this was true for all age groups (Table 6).
A total of 46.8% of the patients were supported with the Berlin Heart Excor (Berlin 
Heart, Berlin, Germany), 5.9% with the Heart Mate II (Th oratec Corp., Pleasanton, 
CA, USA), 0.8% with HeartAssist5 (MicroMed, Houston, TX, USA) and 27.0% 
with HeartWare HVAD (HeartWare Ltd., Framingham, MA, USA) (Table 7). In 67 
patients, a concomitant cardiac procedure (21 congenital and valve procedures and 46 
other procedures) was performed.
Figure 1: Paediatric patients registered in the EUROMACS Registry. LVAD: left ventricular assist device; RVAD: right ventricular assist device; 
TAH: total artificial heart.Figure 1. Paediatric patients registered in the EUROMACS Registry. LVAD: left ventricular assist device; 
RVAD: right ventricular assist device; TAH: total artifi cial heart.
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Figure 2: Survival of paediatric patients after primary left or biventricular assist device implantation.Figure 2. Survival of paediatric atients after primary left r biventricular assist device implantation.
Outcomes
Th e mean support time on a device was 11.6 months (±16.5 SD). Th e mean stay in 
the intensive care unit was 37.0 days (±54.5 SD). Ninety-three (44.3%) patients were 
discharged either to their homes or to a rehabilitation facility. A total of 173 children 
(82.4%) survived to transplant, recovery, or are on ongoing treatment until the last 
follow-up. At 6 months, 33% of the patients and at the 1st year 38% of the children 
received a transplant. Th is percentage climbed to 51% at 2 years post VAD implantation. 
Th irty-seven patients (17.6%) died while on support within the observed follow-up 
time (Table 8).
A total of 37 patients (17.6%) died, of which 24.3% died of cerebrovascular accidents. 
Five patients (13.5%) died of multiorgan failure. Th e primary cause of death was not 
specifi ed for 14 patients (Table 9).
Survival
Event-free survival of all paediatric patients on MCS was 81% at 6 months, 78% at 
12 months and 66% at 2 years with censoring at time of explantation for transplant 
or recovery (Fig. 2). When stratifi ed by device type, i.e. left ventricular assist device 
(LVAD) or a biventricular assist device, 81% survival was observed in the 1st year for 
LVADs and 63% for biventricular assist devices (P = 0.06) (Fig. 3).
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Figure 3: Survival of paediatric patients after primary implantation of a left ventricular assist device or a biventricular assist device, stratified by age. 
Figure 3. Survival of paediatric patients after primary implantation of a left ventricular assist device or a 
biventricular assist device, stratifi ed by age.
When stratifi ed by age, the oldest age group (11–19 years) had an 86% survival rate at 
the end of the 1st year and 76% at the end of the 2nd year; the age group 6–10 years 
had an 86% 1-year and 72% 2-year survival rate and the age group 1–5 years had a 69% 
survival rate at the end of the 1st year and 55% at the end of the 2nd year. Patients <_1 
year old showed the poorest outcome: 54% had a 1-year and 43%, a 2-year survival rate 
(Fig. 4). However, the latter survival rates showed poor statistical signifi cance (P = 0.22). 
Figure 5 shows the survival rate stratifi ed by device strategy.
Table 3. Patient characteristics preimplant
Characteristics Total (n = 210)
Age (years), mean ± SD (median, range) 9.3 ± 7.0 (10.5, 0–19)
Preoperative creatinine level (mg/dl),
mean ± SD (median, range)
0.83 ± 0.51 (0.70, 0.19 – 3.74)
Preoperative total bilirubin level (mg/dl),
mean ± SD (median, range)
0.1 ± 0.1 (0.06, 0.001–0.9)
Body mass index (kg/m2), mean ± SD (median, range) 17.87 ± 5.08 (16.4, 9.78–37.65)
Age categories, n (%)
<1 year 38 (18.1)
1–5 years 45 (21.4)
6–10 years 22 (10.5)
>10 years 105 (50.0)
Total 210
Gender, n (%)
Male 129 (61.4)
Female 81 (38.6)
SD: standard deviation.
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Figure 4: Survival of paediatric patients after primary implantation of a left ventricular assist device or a biventricular assist device, stratified by the 
device implant
strategy used. HTX: heart transplant.
Figure 4. Survival of paediatric after primary implantation of a left ventricular assist device or a biventricular 
assist device, stratifi ed by the device implant.
HTX: heart transplant.
Figure 5: Survival of paediatric patients after primary implantation of a left ventricular assist device or a biventricular assist device, stratified by 
Interagency Registry
for Mechanically Assisted Circulatory Support (INTERMACS) level.
Figure 5. Survival of pa diatric after primary implantation of a left ventricular assist device or a biventricular 
assist device, stratifi ed by Interagency Registry.
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Table 4. Primary diagnosis
Diagnosis n %
Cardiomyopathy 117 55.7
Myocarditis 33 15.7
Congenital heart disease 39 18.6
Coronary artery disease 1 0.5
Valvular heart disease 3 1.4
Cancer 1 0.5
Unknown/missing 16 7.6
210
Table 5. Primary and subsequently implanted devices
Devices 1st 2nd 3rd 4th Total
BiVAD 36 2 38
LVAD 163 12 1 176
LVAD and RVAD 8 1 9
RVAD 1 6 2 2 11
Total artificial heart 1 1 2
Unknown 1 1
Total 210 22 3 2 237
Table 6. Device strategy at time of implantation, stratified by age categories
<1 1–5 6–10 >10 Total
n (%) n (%) n (%) n (%) n (%)
Bridge to recovery 4 (8.9) 4 (8.0) 2 (7.1) 7 (6.1) 17 (7.2)
Bridge to transplant 18 (40.0) 23 (46.0) 9 (32.1) 51 (44.7) 101 (42.6)
Destination therapy 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9) 1 (0.4)
Possible bridge to transplant 14 (31.1) 13 (26.0) 11 (39.3) 36 (31.6) 74 (31.2)
Rescue therapy 3 (6.7) 7 (14.0) 2 (7.1) 7 (6.1) 19 (8.0)
Unknown 6 (13.3) 3 (6.0) 4 (14.3) 12 (10.5) 25 (10.5)
Total 45 (100) 50 (100) 28 (100) 114 (100.0) 237 (100)
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Table 7. Type of ventricular assist devices per age group
Lvad alone 1 1-5 6-10 10 Total
Pulsatile 32 30 7 14 83
Continuous 2 2 9 68 81
Unspecifi ed 1 1 10 12
LVAD, temporary RVAD
Continuous LVAD, continuous RVAD 6 6
Pulsatile LVAD, continuous RVAD 2 1 3
BiVAD
Pulsatile 6 11 5 13 35
Continuous 3 3
Total artifi cial heart
Pulsatile 2 2
Unknown 1 1
237
BiVAD: biventricular assist device; 
LVAD: left ventricular assist device; RVAD: right ventricular assist device.
Competing outcomes
Within 2 years after an implant, 51% of the patients  received a heart transplant and 
17% died. Only 9% c ould be weaned from the device and 22% had ongoing device 
support (Fig. 6).
Figure 6: Competing outcomes.Figure 6. Competing outcomes.
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Figure 7: Freedom from infection.Figure 7. Freedom from infection.
Adverse events
Overall, 151 major adverse events were reported during VAD support. Major adverse 
events are defi ned using the INTERMACS defi nitions [5]. Th ese included infection, 
device malfunction, bleeding and neurological events (Table 10). Within the fi rst  3 
months after VAD implantation, 38 events occurred whereas 113 occurred after 3 
months.
Th e most frequent major adverse event was device malfunction, which included as 
per defi nition pump exchanges from extracorporeal devices due to pump thrombosis. 
Device mal- function occurred 20 times in the fi rst 3 months. In the same period, 
the device malfunction rate was 0.2 per 100 person- months and 4.2 per 100 person-
months after 3 months.
Infections were the 2nd most frequent adverse event (n = 31; event rate: 20.5%). 
Infections were divided into VAD-specifi c, VAD-related and non-VAD-related.
Major infection in paediatric patients occurred more frequently after the fi rst 3 months 
post implantation (n = 23), i.e. 1.3 events per 100 patients. During the fi rst 3 months, 
8 cases, or 0.06 per 100 patients, were reported.
Major bleeding, defi ned as an episode of suspected internal or external bleeding that 
resulted in death, reoperation, hospitalization or major transfusion, but not including 
cerebral haemorrhage, occurred in 15 patients (event rate, 9.9%) with 0.05 events per 
100 patients in the fi rst 3 months and 0.5 events per 100 patients after 3 months. Two 
patients died (0.95%) of a bleeding event.
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Neurological events were defined by the occurrence of an ischaemic or a haemorrhagic 
stroke. Eleven patients had a neuro- logical event (event rate: 7.3%). Whereas only 
0.03 events per 100 patients occurred within the first 3 months after implantation, 
the majority occurred later (0.8 events per 100 patients after 3 months). Nine patients 
(24.3%) died of neurological events, making this the primary cause of death within the 
whole cohort (see also Table 9). Six patients had heart transplants or sere successfully 
weaned from the device after a neurological event.
DISCUSSION
This report is the first of children supported with durable MCS that has emerged 
from the EUROMACS database. The EUROMACS registry is the largest database 
monitoring children supported with VADs in Europe, and enrolment of centres and 
patients continues. The authors believe it is crucial to add information about the 
European cohort to the other paediatric MCS database of similar size, Pedimacs, which 
is restricted to North American data.
One of the most striking differences between the EUROMACS and the Pedimacs 
cohorts is the waiting time for a heart trans- plant. Whereas permanent support has long 
become a reality for adults, bridge to transplantation or transplantability still remains 
the highest percentage in intention to treat within the paediatric population. Whereas 
almost 50% [6] of the paediatric patients in North America had a transplant within the 
first 6 months after a VAD implant, in Europe, only 33% at 6 months had a transplant 
and 38% patients at 12 months. These numbers reflect the lack of suitable donor 
organs in Europe, which leads to significantly longer support times. Especially in small 
countries or in patients under 5 years of age [7, 8], times on the heart transplant waiting 
list have increased. In the registry of the Eurotransplant International Foundation, the 
percentage of paediatric patients who receive transplants is 48% at 6 months and 57% 
at 12 months (personal communication, J. Smits, Eurotransplant). In Switzerland, the 
number of paediatric heart transplant candidates between 2009 and 2013 increased by 
a factor of 4 compared to the previous period [9]. In Italy, the mean time on the waiting 
list is more than 11 months, and in Poland (all patients), the mean waiting time is 12 
months. Especially for small countries, inter- national organ exchange among organ 
procurement organizations is essential. It has a direct positive impact on the possibility 
of patients receiving a timely, often life-saving, transplant [8]. The longer support times 
in Europe enable us to provide outcome data beyond 12 months of support.
One important finding of this report is that the cumulative competing incidence of 
death is 15% by the end of year 1 and 17% by the end of year 2. This result indicates a 
low mortality rate in the 2nd year of support and makes permanent support in children 
more feasible.
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A total of 44.3% of the patients were discharged on the device. The methods used for 
quality checks do not indicate that serious infections are under-reported; in fact, the 
opposite is true. The percentage is high (20.5%), though the specificity with respect to 
the severity and location is low, which leads to the suspicion that different definitions 
may have been used.
The implantation strategy of bridge to recovery is low at 7.3%, which is relatively similar 
to the percentage published in  the  Pedimacs report (6.3%). In the group categorized as 
bridge to recovery (n = 16), 11 patients underwent successful explantation (69%). The 
others are either still on support (n = 2), have died (n = 2) or received a transplant (n = 1). 
For the whole cohort, 24 patients out of 210 had the device explanted due to weaning 
(see Table  8). The percentage  of devices implanted with the intention to treat for 
bridge to recovery almost equals the number of devices explanted due to recovery. One 
reason why this number is so low might be the current lack of standardized guidelines 
for echocardiographic and haemodynamic criteria for LVAD removal in children [10], 
although children may have a greater potential for recovery [11] compared to adults.
Adverse events
Neurological events were the leading cause of death in our cohort as well in the North 
American cohort (24% vs 30%). Blume et al. [6] reported a higher stroke rate of 13 
early events per 100 patient months and 2 late events per 100 patient months with 
paracorporeal devices compared to continuous flow devices (3 and 1 events per 100 
patient months, respectively). Almond et al. [12] showed comparably high stroke rates 
for children on EXCOR VADs during the investigational device exemption trial of 15 
events per 100 patient years with 29% of children affected. Although the stroke rate 
was not investigated within this 1st EUROMACS Paediatric Report, a recent study 
from the paediatric EUROMACS cohort reported low early and late stroke rates with 
intracorporeal continuous flow devices (0.03 and 0.4 events per 100 patient months, 
respectively), independent of body surface area [13]. The stroke rates in children on 
EXCOR and on continuous flow VADs reported in the EUROMACS registry are 
remarkably low. However, a recent survey addressing the antithrombotic protocols for 
children on EXCOR VADs in European centres revealed many modifications of the 
recommended Edmonton protocol with a trend towards more aggressive antithrombotic 
therapy [14]. Whether these modifications have contributed to lower stroke rates 
compared to the investigational device exemption trial is under investigation.
Another frequent adverse event was infection in 20.5%, which is clearly high (Fig. 7). 
One explanation could be that the definition of infection in the EUROMACS registry 
includes VAD- specific, VAD-related and non-VAD-related infections. The authors 
found that the major infection rate 3 months post implant was 1.3 per 100 person-
months compared to 0.06 per 100 person-months within the first 3 months of implant. 
This result suggests that many of these infections are less likely to be related to implant 
surgery and occur while patients remain for pro- longed stays in the intensive care unit 
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or during hospitalization post implant. This result could be another effect of the lower 
transplantation rate and the longer support times in Europe.
Limitations
The present study does not include all European centres that are implanting MCS 
devices. Besides the contributing centres, 14 additional hospitals were invited to join 
EUROMACS and submit data. Considering their positive feedback, it is expected 
that, in a 2nd EUROMACS Paediatric report, the data from most of these ‘additional’ 
hospitals will be in the registry. Data collection by means of a registry has per se an 
important limitation: as in every database, despite all efforts to guarantee data quality 
and the implementation of audits, under-reporting of adverse events cannot be ruled 
out.
CONCLUSION
Because EUROMACS is supported by the EACTS, the registry can reach out to an 
increasing number of participating hospitals to collect baseline and follow-up data on 
MCS  from  both  adults  and children, thus representing European data at the best 
achievable level. The ability to specify the different factors contributing to the outcomes 
of MCS in patients enables paediatric medical professionals to benchmark their data 
against the results of this study. Many questions remain to be addressed, i.e. discharge, 
additional specifics in anticoagulation  management, focus on congenital heart disease 
and much more, which were beyond the scope of this 1st paediatric EUROMACS 
report. Further, a comparison with the 2nd Pedimacs report shows that outcome 
data differ between the registries. Investigating the rea- sons for these differences may 
contribute to insights with respect to treatment modalities and thus provide leads to 
possible improvements both in Europe and elsewhere.
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Table 8. Current device strategy stratified by the end point
End point On Dead Received Weaned Total device 
transplant
Missing 1 3 1 11
Bridge to recovery 2 2 1 11 16
Bridge to transplant 22 12 60 2 96
Possible bridge to transplant 10 16 38 6 70
Rescue therapy 2 6 5 4 17
Total 42 37 107 24 210
Table 9. Primary cause of death
Primary cause of death n %
Bleeding 2 5.4
Cardiopulmonary failure 2 5.4
Cerebrovascular accident 9 24.3
Device failure 1 2.7
Multiorgan failure 5 13.5
Other cause of death 1 2.7
Right heart failure 1 2.7
Sepsis 2 5.4
Unknown/missing 14
37
37.8
Table 10. Major adverse event rates 
Within 3 months after implant More than 3 months after implant
Event counts Events per 100 
patient months (CI)
Event counts Events per 100 
patient months (CI)
Device malfunction 20 0.2 (0.1–0.3) 74 4.2 (3.4–5.3)
Major bleeding 6 0.05 (0.02–0.1) 9 0.5 (0.3–1.0)
Major infection 8 0.06 (0.03–0.1) 23 1.3 (0.9–2.0)
Neurological event 4 0.03 (0.01–0.09) 7 0.4 (0.2–0.8)
Total events 38 113
CI: confidence interval
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The second annual International Society for Heart and Lung Transplantation 
Mechanically Assisted Circulatory Support (IMACS) Registry report includes over 
14,000 patients from 35 countries. Survival, adverse events, and an updated risk model 
are presented. Continuous-flow pumps continue to dominate the world’s  experience. 
One- and 2-year survival remains at 80% and 70%, respectively. Congenital heart 
disease and biventricular support are the most prominent risk factors. The database is 
poised for major novel analyses.
The International Society for Heart and Lung Trans- plantation (ISHLT) Mechanically 
Assisted Circulatory Support  (IMACS) Registry represents a  global  database for 
patients receiving durable mechanical circulatory sup- port (MCS) devices. The stated 
mission focuses on acquisition of international MCS patient data and generation of 
analyses and publications that benefit the field.1,2 This second annual report focuses on 
an updated survival analysis, adverse events, and risk modeling.
Since the initiation of patient enrollment in January 2013, 14,062 patients have been 
enrolled through December 31, 2016, representing 35 countries (Table 1). Data sources 
include individual hospitals and the following collectives (large databases that have 
collected MCS data for entire countries or regions): the European Registry for Patients 
with Mechanical Circulatory Support (EURO- MACS, Europe)3; the Interagency 
Registry for Mechanically Assisted Circulatory Support (INTERMACS, USA)1; the 
Japanese Registry for Mechanically Assisted Circulatory Support (J-MACS, Japan)4; and 
the UK Registry (UK). Collective data downloads occur in December of each year and 
are merged into one comprehensive IMACS data set for analysis.
Table 1. IMACS Participating Countries, January 1, 2013 to December 31, 2016 (n ¼ 14,062)
Australia Finland Japan Spain Belarus
Austria France Kazakhstan Sweden
Azerbaijan Germany Netherlands Switzerland
Belgium Greece New Zealand Turkey Canada
Brazil Hong Kong Norway UK
Colombia Hungary Poland USA
Czech Republic Ireland Saudi Arabia
Denmark Israel Singapore
Egypt Italy Slovakia
IMACS; International Society for Heart and Lung Transplantation Mechanical Circulatory Support 
Registry
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Patients’ demographics and device types
Among device types represented in this database, left ventricular assist devices (LVADs) 
accounted for 13,102 (93%) implants, of which 99% were continuous-flow (CF) 
pumps. Total artificial hearts (TAHs) represented 2% (279 devices) of the experience 
and biventricular support 5% (refer to Supplementary Material Figure S1, available 
online at www.jhltonline.org/).
Patients’ demographics indicate 79% males, with 60% of patients between 50 and 60 
years of age (Table 2). At the time of implant, 51% of patients were in rapid decline or 
cardiogenic shock (Table 3). Only 16% of patients had ambulatory heart failure (Patient 
Profile 4 to 7). Nearly 60% of patients were actively listed or considered candidates for 
heart transplantation, whereas 41% received devices as long-term destination therapy 
(Table 4). The device strategies among various patient profiles1  at implant are listed in 
Table 5.
Table 2. Age Distribution at Implant, IMACS, January 1, 2013 to December 31, 2016 (n ¼ 14,062)
Age at implant Number Percent
19 to 29 years 713 5%
30 to 49 years 3,248 23%
50 to 60 years 8,447 60%
70þ years 1,654 12%
Total 14,062 100%
IMACS, International Society  for Heart and Lung Transplantation Mechanically Assisted Circulatory 
Support.
Survival
Among all patients, survival at 1 and 2 years continued to be 79% and 70%, respectively 
(Supplementary Material Figure S2 online).5 The 3-year survival with CF durable devices 
(Figure 1) was just over 60%. Figure 1 shows hazard function6 had a rapidly decreasing 
risk, which merged with a constant phase at about 3 months. Survival was clearly superior 
for patients receiving isolated left ventricular support compared with biventricular 
support (Figure 2). The 1-year survival for isolated CF LVAD support was 81% vs 
53% for biventricular support and about 48% for TAH. The rate of transplantation 
was rather low, 28% at 1 year, among patients with a CF LVAD listed for transplant 
(Supplementary Material Figure S3 online). The transplant rate was higher for listed 
patients requiring biventricular support (36% at 1 year), and highest for TAH patients 
(50% at 1 year) (Supplementary Material Figures S4 and S5 online). Patients implanted 
with a strategy of destination therapy continued to show worse survival compared with 
a strategy of bridge to transplant or transplant candidacy (Figure 3).
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Causes of death
The most frequent primary causes of death were multi- system organ failure (21% of 
mortality), cardiovascular causes (primarily right heart failure) (20%), and stroke (19%) 
(Supplementary Material Table S1 online).
Table 3. Patient Profile Distribution at  Implant, IMACS, January 1, 2013 to December 31, 2016 (n ¼ 14,062)
Patient profile at time of implant Number Percent
1. Critical cardiogenic shock 2,405 17%
2. Progressive decline 4,714 34%
3. Stable but inotrope dependent 4,558 32%
4. Resting symptoms 1,817 13%
5. Exertion intolerant 298 2%
6. Exertion limited 87 0.6%
7. Advanced NYHA Class III 66 0.5% 
Unspecified 117 0.8% 
Total 14,062 100%
IMACS, International Society for Heart and Lung Transplantation Mechanically  Assisted Circulatory 
Support; NYHA, New York Heart Association.
Table 4. Device Strategy, IMACS, January 1, 2013 to December 31, 2016 (n ¼ 14,062)
Device strategy N %
Listed for transplant 3,984 28%
Bridge to candidacy 4,072 29% 
Destination therapy 5,724 41% 
Other 282 2%
Total 14,062 100%
IMACS, International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory 
Support.
Adverse events
Infection and bleeding affected the most patients, occurring in 40% and 35% of patients, 
respectively; 19% had neurologic events (Table 6). Bleeding was the most frequent 
adverse event during the first 3 months post-implant, followed by infection (Table 7). 
During the later phase (beyond 3 months), infection and internal bleeding had the 
highest incidence. Among patients with CF devices, freedom from first infection was 
68% at 6 months (Supplementary Material Figure S6). The likelihood of stroke (ischemic 
or hemorrhagic) was 14% at 6 months and 19% at 12 months (Supplementary Material 
Figure S7 online). The risk of respiratory failure was highest during the first month 
(Supplementary Material Figure S8 online).
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Risk factors for mortality
A detailed multivariable analysis identified risk factors for early and midterm mortality 
for patients receiving CF devices (Table 8). The 2 most dominant risk factors for early 
mortality were a diagnosis of congenital heart disease (hazard ratio [HR] 5.2) and the 
need for biventricular support (HR 3.4). The adverse effect of congenital heart disease 
was only evident during the first 2 months, after which patients with congenital heart 
disease did as well as those with other diagnoses (Figure 4).
Older age was a risk factor both in the early and constant phases, particularly in patients 
450 years old (Figure 5). Among patients 30 to 50 years old, the 2-year survival was 79% 
compared with 58% for patients 470 years old (p o 0.0001). The increased vulnerability 
of elderly patients is especially magnified when they are critically ill at implant or require 
biventricular support (Figures 6 and 7).
This global analysis quantifies the importance of. increased risk among patients who are 
critically ill (Profile 1 or 2) at the time of implant (Figure 8). Compared with stable but 
inotrope-dependent patients (Patient Profile 3) those presenting in cardiogenic shock 
had a 1-year survival of 71% vs 84% (p o 0.0001), respectively. The stratified Kaplan–
Meier depiction in Figure 8 also shows the midterm survival benefit of patients who 
were less ill (Levels 5 to 7) at the time of implant. If this trend continues, and depending 
on associated post-implant morbidity in less ill patients, this may have implications 
regarding patient selection. A strategy of destination therapy was only a risk factor in 
the constant phase, with HR 1.14 (Figure 3 and Table 8). Concomitant surgeries also 
increased risk (Table 8, and Supplementary Material Figure S9 online).
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Summary
1. The IMACS database now includes 14,000  patients with global representation.
2. CF pumps currently constitute 97% of device implants.
3. Patients with ambulatory heart failure account for only 16% of durable device 
implants.
4. Overall 1- and 2-year survival have continued at 80% and 70%, respectively, in this 
international database.
5. For the first time, we have identified a more favorable midterm survival among 
patients with ambulatory heart failure.
6. Among the elderly, survival is particularly poor among patients critically ill at implant 
or if biventricular support is required.
7. Bleeding and infection remain the most common adverse events.
8. The most dominant risk factors early after implant are a diagnosis of congenital heart 
disease and the need for biventricular support.
9. Peripheral vascular disease is a major predictor of midterm mortality.
10. The IMACS database is poised to generate impactful analyses in the international 
MCS arena.
Table 6. Major Adverse Events, Continuous-flow LVAD/BiVAD, IMACS, January  1, 2013 to December 
31, 2016 (n ¼ 13,618)
Adverse event type Patient Experiencing event Percentage of of all patients
Infection 5,439 40%
Bleeding 4,745 35%
Neurologic dysfunction 2,638 19%
Respiratory failure 2,205 16%
Device malfunction 233 2%
Arterial non-CNS thromboembolism 159 1%
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Pre-implant renal function had a dominant effect on survival (Table 8). Patients requiring 
dialysis within 2 days before implant had a high early mortality (Supplementary Material 
Figures S10 and S11 online), and higher blood urea nitrogen (BUN) (Supplementary 
Material Figure S12 online) and creatinine impacted early and later survival. Signs of 
hepatic dysfunction and tricuspid regurgitation as risk factors likely reflect worsening 
right heart failure. Poor nutritional status (lower albumin) impacted both early and 
longer term survival (Table 8).
Summary
1. The IMACS database now includes 414,000  patients with global representation.
2. CF pumps currently constitute 97% of device implants.
3. Patients with ambulatory heart failure account for only 16% of durable device implants.
Causes of death
The most frequent primary causes of death were multi- system organ failure (21% of 
mortality), cardiovascular causes (primarily right heart failure) (20%), and stroke (19%) 
(Supplementary Material Table S1 online).
Table 3. Patient Profile Distribution at  Implant, IMACS, January 1, 2013 to December 31, 2016 (n ¼ 14,062)
Patient profile at time of implant Number Percent
1. Critical cardiogenic shock 2,405 17%
2. Progressive decline 4,714 34%
3. Stable but inotrope dependent 4,558 32%
4. Resting symptoms 1,817 13%
5. Exertion intolerant 298 2%
6. Exertion limited 87 0.6%
7. Advanced  NYHA Class III 66 0.5%
Unspecified 117 0.8%
Total 14,062 100%
IMACS, International Society  for Heart and Lung Transplantation Mechanically  Assisted  Circulatory 
Support; NYHA, New York Heart Association.
Table 4. Device Strategy, IMACS, January 1, 2013 to December 31, 2016 (n ¼ 14,062)
Device strategy N %
Listed for transplant 3,984 28%
Bridge to candidacy 4,072 29%
Destination therapy 5,724 41%
Other 282 2%
Total 14,062 100%
IMACS, International Society  for Heart and Lung Transplantation Mechanically Assisted Circulatory 
Support.
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Adverse events
Infection and bleeding affected the most patients, occurring in 40% and 35% of 
patients, respectively; 19% had neurologic events (Table 6). Bleeding was the most 
frequent adverse event during the first 3 months post-implant, followed by infection 
(Table 7). During the later phase (beyond 3 months), infection and internal bleeding 
had the highest incidence. Among patients with CF devices, free- dom from first 
infection was 68% at 6 months (Supplementary Material Figure S6). The likelihood 
of stroke (ischemic or hemorrhagic) was 14% at 6 months and 19% at 12 months 
(Supplementary Material Figure S7 online). The risk of respiratory failure was highest 
during the first month (Supplementary Material Figure S8 online).
Risk factors for mortality
A detailed multivariable analysis identified risk factors for early and midterm mortality 
for patients receiving CF devices (Table 8). The 2 most dominant risk factors for early 
mortality were a diagnosis of congenital heart disease (hazard ratio [HR] 5.2) and the 
need for biventricular support (HR 3.4). The adverse effect of congenital heart disease 
was only evident during the first 2 months, after which patients with congenital heart 
disease did as well as those with other diagnoses (Figure 4).
Figure 1. Parametric survival curve and associated hazard function with 70% confidence limit for survival 
after implantation of a continuous-flow left ventricular assist device (LVAD) or biventricular assist device 
(BiVAD), January 1, 2013 to December 31, 2016 (n ¼ 13,618). The number of patients at risk during each 
time interval is indicated below the diagram.
Older age was a risk factor both in the early and constant phases, particularly in patients 
450 years old (Figure 5). Among patients 30 to 50 years old, the 2-year survival was 79% 
compared with 58% for patients 470 years old (p o 0.0001). The increased vulnerability 
of elderly patients is especially magnified when they are critically ill at implant or require 
biventricular support (Figures 6 and 7).
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This global analysis quantifies the importance of increased risk among patients who are 
critically ill (Profile 1 or 2) at the time of implant (Figure 8). Compared with stable but 
inotrope-dependent patients (Patient Profile 3) those presenting in cardiogenic shock 
had a 1-year survival of 71% vs 84% (p o 0.0001), respectively. The stratified Kaplan–
Meier depiction in Figure 8 also shows the midterm survival benefit of patients who 
were less ill (Levels 5 to 7) at the time of implant. If this trend continues, and depending 
on associated post-implant morbidity in less ill patients, this may have implications 
regarding patient selection. A strategy of destination therapy was only a risk factor in 
the constant phase, with HR 1.14 (Figure 3 and Table 8). Concomitant surgeries also 
increased risk (Table 8, and Supplementary Material Figure S9 online).
Table 5. Device Strategy by Patient Profile, IMACS, January 1, 2013 to December 31, 2016 (n ¼ 14,062)
Device strategy at time of implant
Listed for 
transplant
Candidacy to 
transplant
Destination 
therapy
Other
Patient profile at time of implant n % n % n % n %
1. Critical cardiogenic shock 526 13.2% 865 21.2% 885 15.4% 129 45.7%
2. Progressive decline 1,478 37.0% 1,315 32.2% 1,828 31.9% 93 32.9%
3. Stable but inotrope dependent 1,313 32.9% 1,212 29.7% 2,005 35.0% 28 9.9%
4. Resting symptoms 468 11.7% 534 13.1% 799 13.9% 16 5.6%
5. Exertion intolerant 107 2.6% 71 1.7% 115 2.0% 5 1.7%
6. Exertion limited 32 0.8% 23 0.5% 28 0.4% 4 1.4%
7. Advanced NYHA Class III 22 0.5% 20 0.4% 23 0.4% 1 0.3%
Unknown 38 0.9% 32 0.7% 41 0.7% 6 2.1%
Total 3,984 100.0% 4,072 100.0% 5,724 100.0% 282 100.0%
IMACS, International Society for Heart and Lung Transplantation Mechanically Assisted Circulatory 
Support; NYHA, New York Heart Association.
Figure 2. Actuarial survival curve for primary implants, stratified by flow type and device type, January 
1, 2013 to December 31, 2016 (n ¼ 14,062). The shaded areas indicate ±1 standard error. BiVAD, 
biventricular assist device; LVAD, left ventricular assist device; TAH, total artificial heart.
88
Chapter 5
Pre-implant renal function had a dominant effect on survival (Table 8). Patients requiring 
dialysis within 2 days before implant had a high early mortality (Supplementary Material 
Figures S10 and S11 online), and higher blood urea nitrogen (BUN) (Supplementary 
Material Figure S12 online) and creatinine impacted early and later survival. Signs of 
hepatic dysfunction and tricuspid regurgitation as risk factors likely reflect worsening 
right heart failure. Poor nutritional status (lower albumin) impacted both early and 
longer term survival (Table 8).
Summary
1. The IMACS database now includes 414,000  patients with global representation.
2. CF pumps currently constitute 97% of device implants.
3. Patients with ambulatory heart failure account for only 16% of durable device 
implants.
4. Overall 1- and 2-year survival have continued at 80% and 70%, respectively, in this 
international database.
5. For the first time, we have identified a more favorable midterm survival among 
patients with ambulatory heart failure.
6. Among the elderly, survival is particularly poor among patients critically ill at implant 
or if biventricular support is required.
7. Bleeding and infection remain the most common adverse events.
8. The most dominant risk factors early after implant are a diagnosis of congenital heart 
disease and the need for biventricular support.
9. Peripheral vascular disease is a major predictor of midterm mortality.
10. The IMACS database is poised to generate impactful analyses in the international 
MCS arena.
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strategy, January 1, 2013 to December 31, 2016 (n ¼ 13,618). The shaded areas indicate ±1 standard error. 
BiVAD, biventricular assist device; LVAD, left ventricular assist device.
Table 6. Major Adverse Events, Continuous-flow LVAD/BiVAD, IMACS, January 1, 2013 to December 
31, 2016 (n ¼ 13,618)
Adverse event type Patient experiencing event Percentage of all patients
Infection 5,439 40% 
Bleeding 4,745 35% 
Neurologic dysfunction 2,638 19% 
Respiratory failure 2,205 16% 
Device malfunction 233 2%
BiVAD, biventricular assist device; CNS, central nervous system; IMACS, International Society for Heart 
and Lung Transplantation Mechanically Assisted Circulatory Support; LVAD, left ventricular assist device.
Table 7. Adverse Event Rates, Continuous-flow LVAD/BiVAD, IMACS, January 1, 2013 to December 31, 
2016 (n ¼ 13,618)
Adverse event 
type
Early event (o3 
months) count (n)
Early event 
(o3 months) 
rate (per 100 
patient-months)
Late event 
(≥3 months)
count (n)
Late event 
(≥3 months) 
rate (per 100 
patient-months)
p-value
Bleeding 5,074 13.78 4,845 2.88 o0.0001
Infection 4,664 12.66 5,891 3.51 o0.0001
Respiratory failure 2,242 6.09 641 0.38 o0.0001
Neurologic 
dysfunction
1,536 4.17 1,943 1.16 o0.0001
Device malfunction 99 0.27 241 0.14 o0.0001
Arterial non-CNS 
thromboembolism
112 0.30 54 0.03 o0.0001
BiVAD, biventricular  assist device; CNS, central nervous system; IMACS, International Society for Heart 
and Lung Transplantation Mechanically Assisted Circulatory Support;  LVAD, left ventricular assist device.
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Table 8. Continuous-flow LVAD/BiVAD, IMACS, January 1, 2013 to December 31, 2016 (n ¼ 13,618)
Early hazard Constant hazard
Pre-implant risk factors for death Hazard ratio p-value Hazard ratio p-value
Demographics
Older age (unit: 10 years) 1.44 o0.0001 1.23 o0.0001
Female 1.28 0.003 1.18 0.008
Higher BMI (unit: 5 kg/m2) 1.12 o0.0001 1.04 0.021
Destination therapy strategy at time of implant 1.14 0.014
Not blood type O 0.89 0.013
Surgical complexities
History of CABG 1.31 0.002 1.20 0.004
Concomitant surgery 1.34 o0.0001
BiVAD 3.42 o0.0001
Clinical status
Patient Profile 1 1.77 o0.0001
Patient Profile 2 1.51 o0.0001
Not patient Profile 4 to 7 0.85 0.014
Primary diagnosis—congenital 5.23 0.002
Peripheral vascular disease 1.41 o0.01
Intervention 48 hours pre-implant—ventilator 1.32 0.003
BUN (unit: 10 mg/dl) higher 1.06 o0.0001 1.04 o0.0001
Creatinine (unit: 1 mg/dl) higher 1.08 0.004
Intervention with 48 hours pre-implant—dialysis 1.92 o0.0001
Albumin (unit: 1 g/dl) lower 0.85 0.001 0.86 o0.0001
Sodium (unit: 10 mEq/liter) lower 0.86 0.004
AST (unit: 10 U/liter) higher 1.13 o0.0001
ALT (unit: 10 U/liter) lower 0.94 o0.01
Total bilirubin (unit: 5 mg/dl) higher 1.18 o0.0001
Tricuspid regurgitation: moderate/severe 1.37 o0.0001
Implantable cardioverter-defibrillator 1.21 0.004
CNS-Central Nervous System; LVAD-left ventricular assist device; BiVAD-biventricular assist device; 
CABG-Coronary Artery  Bypass Graft; ALT, alanine aminotransferase; AST, aspartate aminotransferase; 
Bi-VAD, biventricular  assist device; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronoary 
bypass artery graft; IMACS, International Society for Heart and Lung Transplantation Mechanically 
Assisted Circulatory Support; LVAD, left ventricular assist device.
• Age: calculated risk factor for 10 year range
• BMI-Body  Mass Index (kg/m2): 5 unit increase
• Total Bilirubin (mg/dL): 5 unit increase
• Sodium (mEq/L): 10 unit decrease
• BUN-Blood Urea Nitrogen (mg/dL): 10 unit increase
• Aspartate Aminotransferase/AST (u/L): 10 unit increase
• Alanine Aminotransferase/ALT (u/L): 10 unit decrease
aNone.
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indicate ±1 standard error. BiVAD, biventricular assist device; LVAD, left ventricular assist device.
Figure 5. Actuarial survival curve for continuous-flow LVADs and BiVADs, stratified by pre-implant age 
group, January 1, 2013 to December 31, 2016 (n ¼ 13,618). The shaded areas indicate ±1 standard error. 
BiVAD, biventricular assist device; LVAD, left ventricular assist device.
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Figure 6. Nomogram showing the solution to the multivariable equation for death by 1 year, depicting 
the interaction between patient age and patient profile level at implant for continuous-flow LVADs and 
BiVADs, January 1, 2013 to December 31, 2016 (n ¼ 13,618).
Figure 7. Nomogram showing the solution to the multivariable equation for death by 1 year, depicting 
the interaction between patient age and device type at implant for continuous-flow LVADs and BiVADs, 
January 1, 2013 to December 31, 2016 (n ¼ 13,618).
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Figure 8. Actuarial survival curve for continuous-flow LVADs and BiVADs, stratified by pre-implant 
patient profile, January 1, 2013 to December 31, 2016 (n ¼ 13,618). The shaded areas indicate ±1 standard 
error. BiVAD, biventricular assist device; LVAD, left ventricular assist device.
Appendix A. Supplementary material
Supplementary data associated with this article can be found online version at 
www.jhltonline.org.
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ABSTRACT
Background: In contrast to the increasing use of ventricular assist devices (VAD), gender 
differences in indications, haemodynamics and outcome are not well understood. We 
examined gender differences and gender-specific predictors for perioperative outcome 
on ventricular support.
Methods: Multi-centre data of 966 patients (median age 55 years, 151 women) from the 
EUROMACS (European Registry for Patients with Mechanical Circulatory Support) 
registry were analysed. The median follow-up was 1.26 years. 
Results: At the time of VAD implantation, women were more often in unstable condition 
(INTERMACS profile 1 and 2) (51.7% vs. 41.6% in men), suffered significantly more 
often from major bleeding (P=0.0012), arrhythmias (P=0.022) and right ventricular 
(RV) failure (P<0.001) with need for additional RV support. The survival of women on 
isolated LVAD support was significantly worse (1-year survival 69.3% vs. 78.3% in men). 
Age-adjusted Cox regression analyses showed significant associations with mortality 
for pre-operative inotropic therapy, percutaneous mechanical support, INTERMACS 
profile 1 and 2, RV dysfunction, major bleeding, cerebral bleeding, ischemic stroke, 
and RV failure. In women, pump thrombosis was more strongly related with mortality 
compared to men, while the direction of the association of renal dysfunction with 
mortality was different for women and men (P-Value interaction 0.028 and 0.023, 
respectively).
Conclusions: Women and men differ in peri-operative haemodynamics, adverse events 
and mortality after VAD implantation. A gender-dependent association of pump 
thrombosis with mortality was seen. The impact on treatment practice needs to be 
shown.
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INTRODUCTION
Due to the growing organ shortage and technical progress, ventricular assist devices 
(VAD) are gaining importance in the therapy of end-stage heart failure (HF). Women 
and men differ in terms of HF aetiology, diagnosis, prognosis, and treatment.(1) Women 
have a higher HF incidence than men.(2) Women are hospitalised more frequently 
and die more often than men from the consequences of HF.(3) Although women are 
hospitalised in more advanced states of decompensated HF(4), VAD placement is far 
less likely.(5),(6) At time of implantation, women are more frequently in cardiogenic 
shock (INTERMACS level 1) (7) and receive devices with smaller pump sizes.(8) After 
VAD implantation, women require longer ventilatory and inotropic support resulting 
in prolonged intensive care stays.(7) Furthermore, women have a higher risk for 
neurological complications and perioperative right ventricular (RV) failure requiring 
additional RV support.(9),(6),(7) However, there is contradictory evidence regarding 
gender-specific outcome.(4),(7),(5),(6)
Therefore, in the largest European study sample of patients undergoing mechanical 
circulatory support to date, the EUROMACS registry (European Registry for Patients 
with Mechanical Circulatory Support), we aimed to further evaluate gender differences 
in adverse events. Additionally, we tried to identify gender-specific predictors for survival 
of women and men undergoing VAD implantation.
METHODS
Study population
Between January 2011 and June 2014, 966 patients were prospectively enrolled into the 
EUROMACS registry, an online database collecting anonymised data of demographics, 
device implantation and long-term follow-up of patients with ventricular support.
(10) At present, more than 50 European and non-European centres from 15 countries 
are involved. Pre-implantation data regarding patient characteristics, social situation, 
HF medication at admission, pre-operative blood values, primary cardiac diagnosis 
and INTERMACS profile are recorded. Data on the following device strategies are 
available: bridge to recovery, bridge to transplantation (possibly bridged, currently 
listed), destination therapy, rescue therapy and others. Hemodynamic data from 
echocardiography and right heart catheter, intraoperative and procedural characteristics 
are stored. Adverse events including ischemic strokes, cerebral bleeding, arrhythmias, 
pump thrombosis, major bleedings, major infections, RV failure, renal and hepatic 
dysfunction are indicated. The definition of adverse events in the EUROMACS registry 
corresponds to the INTERMACS definition.(11),(10) Every follow-up visit and adverse 
events including death of a patient are reported. All contributing centres were contacted 
to confirm correctness of data by the end of follow-up. Paediatric patients were excluded.
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Statistical methods
After exclusion of paediatric patients and one patient with missing device information, 
the dataset consisted of 966 patients undergoing long-term ventricular assist device 
support. Patients receiving an RVAD, BIVAD, total artificial heart, a CircuLite® 
Synergy™, HeartWare® MVAD® or not specified device brands were excluded from all 
survival analyses (including survival and incidence estimation, and Cox regression 
analyses).
Available-case analyses, also known as pairwise deletion, were used. That means that for 
each computation, only those without missing values on the variables involved in that 
particular analysis were used. For continuous variables, median, 25th and 75th percentile 
is given and the Mann-Whitney test is performed. For categorical variables absolute and 
relative frequencies and Fisher Exact test is computed. Gender-specific survival curves 
on LVAD and temporary RVAD therapy were drawn using the Kaplan-Meier method. 
The equality of the survival curves was tested using the Log-rank test. Cumulative 
incidence functions were computed for the outcomes transplanted, death and recovery 
for each gender using a competing risks approach. Equality of these functions was tested 
by Gray’s test. Incident gender-specific adverse event rates are given. We performed Cox 
regression analyses to examine the extent to which selected hemodynamic parameters 
(analyses shown for pre-operative inotropic therapy, percutaneous mechanical circulatory 
support, INTERMACS profile 1 and 2 and RV function) and adverse events (analyses 
shown for major bleeding, cerebral bleeding, pump thrombosis, RV failure) associate 
with survival for each gender. All Cox models were adjusted for age, gender and LVAD 
device brand. Each adverse event was used as time dependent covariate in the respective 
Cox model. Besides the predictor of interest (hemodynamic parameter, adverse event) 
the models include age, device type, gender and an interaction term for gender and the 
predictor of interest. Cox models that do not include the aforementioned interaction 
term were also computed. Confidence intervals (CI) and P-values for the variable of 
interest were computed using the methods described in Figueiras et al.(12) 
Analyses were performed using R version 3.3.3 (R Core Team (2016). R: A language 
and environment for statistical computing. R Foundation for Statistical Computing, 
Vienna, Austria. URL http://www.R-project.org/). 
RESULTS
Gender-specific pre-operative characteristics 
Selected baseline characteristics of the study sample are presented in Table 1 (for 
further baseline characteristics please see Supplementary Table 1a). N=966 patients 
(median age 55 years, 151 [15.6%] women, 84% European origin) underwent primary 
ventricular support (LVAD N=790; BIVAD N=52; LVAD with temporary RVAD 
N=99; isolated RVAD N=10; total artificial heart N=15). Ischemic cardiomyopathy 
was less frequent in women than in men with women exceeding men in prevalence of 
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dilated cardiomyopathy (Table 1). At the time of VAD implantation, women were more 
often in unstable condition (INTERMACS profile 1 or 2), although, preoperatively, no 
differences were seen in need for renal replacement therapy, ventilation or percutaneous 
mechanical circulatory support. 
Gender-specific intra- and post-operative characteristics
More women had moderate or severe mitral and tricuspid regurgitation, but less 
aortic regurgitation resulting in less concomitant aortic valve replacement (Table 2 
and 3; additional hemodynamic parameters and procedural characteristics are given in 
Supplementary Table 2 and 3). Choice of device brands was different in both genders 
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(Table 3). The HeartWare® HVAD® was significantly more often implanted in women. 
Women needed more additional RV support. In women, a longer post-operative 
ventilatory support and a trend towards a longer stay at intensive care unit was reported.
Gender differences in adverse events 
After a median follow-up of 1.3 years (range 0.03-50.73 months; median follow-up 1.3 
years in men vs. 1.2 years in women) and 987 patient-years, 309 deaths (247 among 
men and 62 among women) were reported. In women, more major bleedings (events per 
patient year [PY] in women: 0.3 vs. 0.14 in men, P=0.0012) (Figure 1) were reported. 
Women had a higher incidence of arrhythmias (events per PY in women: 0.08 vs. 0.03 
in men, P=0.022) and RV failure (events per PY in women: 0.11 vs. 0.03 in men, 
P<0.001). No differences in ischemic stroke (events per PY in women: 0.08 vs. 0.06 in 
men, P=0.36) and cerebral bleeding (events per PY in women: 0.03 vs. 0.03 in men, 
P=0.84) were observed (Figure 1). 
Survival and predictors for mortality
Women undergoing isolated LV support showed a significantly worse overall survival 
(Figure 2). On LVAD with temporary RVAD support, survival of women was even worse, 
but did not differ significantly from men (Figure 2). No gender differences in transplant 
rates were seen (Figure 3). Parameters mirroring hemodynamic compromise were shown 
to predict survival on VAD support. Pre-operative inotropic therapy, percutaneous 
mechanical support, INTERMACS profile 1 and 2, and highly reduced RV function, 
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respectively, were related to mortality (Supplementary Table 4) with a significant gender 
interaction for the association of percutaneous mechanical circulatory support and 
mortality (Table 4). In a refining analysis, which included these variables in a single 
model, INTERMACS profile 1 and 2 in women and preoperatively highly reduced 
RV function in both genders were no longer associated with mortality (Supplementary 
Table 5).
Furthermore, several VAD-related adverse events were significantly related to mortality. 
After adjustment for age, gender and device brand, major bleeding, cerebral bleeding, 
ischemic stroke, pump thrombosis, RV failure, and renal dysfunction were significantly 
associated with mortality in the overall cohort (Supplementary Table 6). In a refining 
analysis with gender interaction (Table 5), the associations persisted in women and 
men, with the exception of renal function in women. A significant gender interaction in 
the association of pump thrombosis with mortality was observed indicating a stronger 
association in women (Table 5). The associations remained statistically significant after 
further adjustment for body mass index, diabetes, systolic blood pressure, chronic 
obstructive pulmonary disease, and symptomatic peripheral and carotid artery disease 
(analyses not shown). 
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Figure 1. Gender-specifi c adverse event rates.
Events per patient year are given for women and men. N=739 men, N=136 women.
Patients with RVAD, BIVAD, total artifi cial heart, CircuLite® Synergy™ and HeartWare® MVAD®, and not 
specifi ed device brands were excluded from analysis.
Red: women. Blue: men.
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Figure 2. Kaplan-Meier survival curves by gender and assist types (with mortality as the endpoint). Patients 
who died or were censored in the fi rst 30 days after surgery were excluded from analysis. Th e follow-up is 
censored at transplant or recovery.
Results of Log-rank test (men vs. women): LVAD: P=0.046; LVAD, temporary RVAD: P=0.50. Numbers at 
risk are given below the Kaplan-Meier curves. Patients with RVAD, BIVAD, total artifi cial heart, CircuLite® 
Synergy™ and HeartWare® MVAD®, and not specifi ed device brands were excluded from analysis.
Abbreviations: LVAD: left ventricular assist device, RVAD: right ventricular assist device.
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Figure 3. Cumulative incidence functions for both genders with the outcomes transplanted, death and 
recovery. Th e probability of being alive without being transplanted nor recovering is also shown.
Results of Gray’s-Test (men vs. women): P=0.33; dead: P=0.004; recovery: P=0.81. Numbers at risk are 
shown below the curves. Patients with RVAD, BIVAD, total artifi cial heart, CircuLite® Synergy™ and 
HeartWare® MVAD®, and not specifi ed device brands were excluded from analysis.
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DISCUSSION
We could demonstrate signifi cant gender diff erences not only in the peri-operative but 
also in the long-term course after VAD implantation. Women were shown to receive less 
VAD support despite a more critical HF state at admission. Both genders diff ered for 
implanted device types with implantation of smaller device pumps in women. Women 
required temporary or permanent RV support more often due to a higher incidence of 
RV failure. Th e overall survival in women was signifi cantly worse. 
In contrast to prior smaller studies with a comparatively low number of women (6),(4), 
our sample represents the largest European registry and one of the largest cohorts 
worldwide that permits the investigation of gender diff erences in long-term mechanical 
support. In comparison to the earlier report on gender diff erences by Hsich et al. in the 
INTERMACS registry (13), our study is characterized by a longer follow-up time post 
VAD implantation and by a higher rate of continuous-fl ow devices (Heart Mate II® and 
HeartWare HVAD®). Th e latter have almost completely replaced pulsatile systems. Th us 
our study mirrors current daily clinical practice with a state-of-the-art technology. 
Gender-specifi c peri-procedural characteristics 
Despite a higher probability of hemodynamic compromise,(4),(7) women still are less 
likely to undergo assist device support.(4, 5) Women are underrepresented in large 
multi-center trials as stated by the ACC/AHA 2005 Guideline Update for the Diagnosis 
and Management of Chronic Heart Failure in the Adult.(14) Accordingly, only a small 
part of 15.6% in our study population were women, which is slightly lower than in 
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comparable international registries like the INTERMACS registry. If this is due to 
European referral strategies or preferred device types cannot be answered by our data. 
Women presented significantly more often in INTERMACS level 1 and 2. This may 
be explained by two reasons: First, women are more likely to be transferred for VAD 
implantation in a later and more critical clinical state. Second, the smaller intrathoracic 
volume of women is not suited for larger pump sizes. We and others have shown, that the 
smaller HVAD® pump was preferred in women.(8) Despite the more unstable condition 
at admission in women, there were no differences in inotropic therapy or percutaneous 
mechanical support. Consistent with prior reports,(7) women needed longer ventilatory 
support. They showed a trend towards a longer stay at intensive care unit. Additionally, 
women and men differed in HF aetiology. Ischemic cardiomyopathy is less frequent in 
women undergoing VAD support,(6) explained by the fact that women have coronary 
artery disease less often than men(15).
Gender-specific adverse events 
In line with the report by Boyle et al., who could show that women have a higher risk 
for bleeding complications on continuous-flow assist devices(16), women had a higher 
rate of major bleeding after VAD implantation in our cohort. The assumption that 
differences in blood coagulation or gender-specific pharmacokinetics and -dynamics 
of anticoagulant medication are driving the bleeding risk, is pathophysiologically 
plausible, but cannot be answered by our current data. In addition, women and men 
differed in RV haemodynamics. In line with prior studies(6),(7), we could show that 
women had a higher incidence of peri-operative RV failure requiring more additional 
RV support, although no difference in pre-operative RV function was seen. With respect 
to the observed higher incidence of arrhythmias in women, RV failure may partly be 
explained by the occurrence of arrhythmias. In particular ventricular arrhythmias have 
the potential to induce RV failure under LVAD support.(17)
A possible relation of device type and specific adverse events has to be considered. The 
HeartWare® HVAD®, which was significantly more often implanted in women, has been 
related to a higher rate of cerebrovascular events.(18) The centrifugal flow of the HVAD® 
pump was associated with a hypercoagulable state,(19) which renders thromboembolic 
events more plausible. Prior investigations could show, that anticoagulation, antiplatelet 
therapy and blood pressure management affected stroke rate after HVAD® implantation.
(20) In our study, after adjustment for LVAD device brands, the association of cerebral 
bleeding, ischemic stroke and pump thrombosis with mortality did not change markedly. 
Therefore, the association of these adverse events with mortality cannot be explained by 
the device choice.
Survival and predictors for mortality
There is conflicting evidence for survival differences between genders undergoing VAD 
therapy across heterogeneous studies with mostly smaller numbers of participants and 
different device types. In studies performed with several device types, continuous-flow 
systems were shown to be related to better survival rates.(21) Morgan et al. found a 
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significantly worse survival for women undergoing pulsatile-flow support.(4) In contrast 
to other studies, which did not see differences in short-term survival,(9, 13),(6),(7) 
women had a significantly worse 1- to 3-year survival in our study population. Our data 
provide evidence for three possible reasons for our findings: First, women were shown 
to present to hospital in more advanced heart failure states.(4) Second, women suffered 
significantly more often from peri-operative RV failure. Third, women are more likely to 
suffer from arrhythmias and major bleeding complications. In line with Shah et al.(22), 
we could show that need for percutaneous mechanical support was associated with peri-
operative mortality in both genders. INTERMACS profile 1 and 2, which represent a 
clinically unstable condition, were identified to predict survival. We could directly link 
RV haemodynamics with mortality in both genders. In women with need for LVAD and 
temporary RVAD support, the probability of death was 81% at 1 year compared to 31% 
for women undergoing isolated LVAD support. That means, once temporary RVAD 
support is needed, the survival is significantly worse. But as soon as women undergo 
additional RV support, no differences in outcome were seen compared to men under 
biventricular support. If a better pre-operative evaluation of the right ventricle and a 
stricter determining of indication will improve the outcome on mechanical circulatory 
support needs to be further investigated.
In addition, the significant association of pump thrombosis with mortality was stronger 
in women. Prior studies could show that women suffer more often from thromboembolic 
events under VAD support and may therefore need more intensive anticoagulation.
(9),(23) Prospective studies are needed to verify if gender-specific anticoagulation 
regimens will reduce thromboembolic complications and improve survival of women 
on long-term assist device support.
Limitations
Data quality of a large registry relies on the data input of the participating centers. 
Therefore, the possibility exists that not all adverse events were reported. Furthermore, the 
very nature of a registry allows no analyses on center-specific trends and device choices.
CONCLUSIONS
In summary, we were able to demonstrate in a large European sample that women and men 
undergoing VAD support differ in pre-operative condition, peri-operative haemodynamics, 
adverse events and survival. Women were shown to have a higher incidence of major 
bleeding, arrhythmias, perioperative RV failure and a worse early and long-term survival. 
Several hemodynamic parameters and adverse events predicted survival in both, women 
and men. The association of pump thrombosis with mortality was stronger in women. 
Whether changes in referral strategies, implant timing and gender-specific out-patient 
aftercare may improve outcome for women on VAD support needs to be investigated.
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Abstract
Aims: Sufficient myocardial recovery with the subsequent explantation of a left 
ventricular assist device (LVAD) occurs in approximately 1-2% of the cases. However, 
follow-up data about this condition is scarcely available in the literature. This study 
aimed to report the long-term outcomes and clinical management following LVAD 
explantation.
Methods: An analysis of the European Registry for Patients with Mechanical Circulatory 
Support (EUROMACS) was performed to identify all adult patients with myocardial 
recovery and successful explantation. Pre-implant characteristics were retrieved and 
compared with the non-recovery patients. The follow-up data after explantation were 
collected via a questionnaire. A Kaplan-Meier analysis for freedom of the composite 
end-point of death, heart transplantation (HTx), LVAD-reimplantion or heart failure 
(HF) relapse was conducted.
Results: A total of 45 (1.4%) cases with myocardial recovery resulting in successful 
LVAD explantation were identified. Compared with those who did not experience 
myocardial recovery, the explanted patients were younger (44 vs. 56 years, p<0.001), 
had a shorter duration of cardiac disease (p<0.001) and were less likely to have ischemic 
cardiomyopathy (9% vs 41.8%, p <0.001). Follow-up after explantation could be 
acquired in 28 (62%) cases. The median age at LVAD implantation was 43 years 
(IQR: 29-52) and 23 (82%) were male. Baseline left ventricular ejection fraction was 
18% (IQR: 10-20%), and 60.7% of the patients had INTERMACS profile 1 or 2. 
Aetiologies of HF were dilated cardiomyopathy in 36%, myocarditis in 32%, ischemic 
in 14% of the patients, and 18% had miscellaneous aetiologies. The devices implanted 
were: HeartMate II in 14 (50%), HVAD in 11 (39%), Heartmate 3 in 2 (7%), and 
one unknown with a median duration of support of 464 days (range: 59–1286). The 
median follow-up after explantation was 26 months (range 0.3 –73 months) and 82% 
of the patients were in NYHA class I or II. β-blockers were prescribed to 85%, ACE-
inhibitors to 71% and loop-diuretics to 50% of the patients, respectively. Freedom from 
the composite end-point was 100% after 30 days and 88% after two years.  
Conclusions: The survival after LVAD explantation is excellent without the need for 
HTx or LVAD reimplantation. Only a minority of the patients suffer from a relapse of 
significant HF. 
115
Long-term outcome of patients after successful LVAD explant: A EUROMACS Study
7
INTRODUCTION 
Continuous flow left ventricular assist devices (cf-LVADs) have become an important 
modality in the treatment of end-stage heart failure (HF) as a bridge to transplantation 
(BTT), bridge to candidacy (BTC) or as destination therapy (DT). This has led to a 
significant improvement of the quality of life and overall survival of patients once all 
other therapeutic options have been exhausted[1]. 
A small percentage of these patients experience significant myocardial recovery under 
LVAD support and can therefore undergo LVAD explantation, defined as actual bridge-
to-recovery (BTR)[1]. The eighth Interagency Registry for Mechanically Assisted 
Circulatory Support (INTERMACS) annual report and the second European Registry 
for Patients with Mechanical Circulatory Support (EUROMACS) report, reported that 
1-2% of the patients implanted with cf-LVADs recovered, allowing successful LVAD 
explantation[1, 2]. Similarly, in a pooled Heartmate II cohort with 1.108 patients 
enrolled, the rate of myocardial recovery was 1,8%[3].  
Several case series and small cohort studies report patients having sufficient recovery of 
left ventricle (LV) function that allowed LVAD explantation. These studies show higher 
rates of myocardial recovery after LVAD explantation and survival ranging from 78.3-
100%, with varying rates of HF recurrence[4-8].
These studies report encouraging survival outcomes, however, much remains unknown 
concerning adverse events (AEs) and HF management after explantation and most 
studies are based on single centre experiences. Little is known about long-term outcomes 
and AEs, such as ventricular tachycardia or thromboembolic complications, given the 
fact that the inflow cannula is not (always) extracted and data about its management is 
usually lacking. Furthermore, the follow-up of these patients is limited, details on specific 
medication are lacking and not consistent due to a small number of patients. There is 
no evidence-based knowledge regarding the long-term treatment of these patients in 
case of recurrence of HF or other complications. Such inconsistencies prompt a need 
for a complete long-term follow-up in these patients, with a special emphasis on chronic 
medication, AEs and longer-term survival after successful LVAD explantation
Objectives
The aim of the study is to evaluate long-term outcomes and patient management after 
a successful LVAD termination due to the recovery, including survival, complications, 
relapse of HF and specific medical treatments.
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METHODS
Study design
A retrospective study was conducted in all patients in whom a LVAD was successfully 
explanted after myocardial recovery as registered in the European Registry of Mechanically 
Assisted Mechanical Circulatory Support (EUROMACS)[2, 9]. Inclusion criteria were: 
successful explantation of an cf-LVAD (as a stand-alone VAD system, not RVAD) as 
captured in the follow-up of EUROMACS. Exclusion criteria included an explantation 
due to any other reason than myocardial recovery (e.g. infection, device malfunction) or 
patients aged <18 years.
Data collection
From January 2011 until March 2018, a total of 45 patients in the EUROMACS registry 
were identified as being successfully explanted after myocardial recovery, from now on 
named recovery patients. Baseline characteristics before LVAD implantation including 
age, sex, aetiology of HF, preoperative condition and comorbidities, electrocardiogram 
(ECG), echocardiogram and blood chemistry values were collected for adult patients 
in EUROMACS. Furthermore, perioperative data on device strategy, device type, 
concomitant surgical procedures and cardiopulmonary bypass (CPB) time, time in 
operating theatre (OR), intensive care unit (ICU) and hospital stay were retrieved. 
Finally, time on LVAD, type and number of AEs and hospitalizations were collected 
from the follow-up.
Subsequently, a detailed questionnaire was sent to involved centres to attain the follow-
up of these patients after LVAD explantation. These data are currently not captured 
in the EUROMACS registry. Since data entry into EUROMACS is anonymized for 
external reviewers, the executive director (TdB) approached the centres asking to provide 
the follow-up of these patients. Data collected included the primary outcome: survival, 
HTx, reimplantation of LVAD and data on re-hospitalizations due to HF. Secondary 
outcomes consisted of the following parameters: presence of the inflow cannula, the 
occurrence of cerebrovascular accidents (CVAs), New York Heart Association (NYHA) 
class at last follow-up, oral anticoagulation and HF medication. Finally, data of ECG, 
echocardiography and blood chemistry values were requested. 
Statistical Analysis 
Continuous parameters are expressed as mean and confidence interval or median and 
range or interquartile range(IQR). Categorical parameters are expressed as number and 
percentage. For categorical parameters Chi-square test or Fischer’s exact test were applied 
as appropriate. For continuous parameters Student’s t-test or Wilcoxon rank sum test 
were used. A comparison of baseline characteristics was performed to assess differences 
in patients with VAD-explantation and without VAD explantation. Furthermore, 
baseline characteristics of patients whose LVAD was explanted with and without follow 
up were compared to assess a potential reporting bias. Finally, a Kaplan-Meier curve 
was constructed to evaluate freedom of the composite end-point of death, HTx, LVAD 
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reimplantation or relapse of HF to ≥NYHA III after LVAD explantation. Statistical 
analysis was performed using SPSS, version 25.0 for Windows (IBM Inc, Armonk, NY, 
USA). 
RESULTS
Baseline characteristics
A total of 45 patients in whom the LVAD was explanted due to myocardial recovery were 
identified in the EUROMACS registry, representing 1.4% of the patients registered at 
the time. A complete follow-up of 28 (62.2%) recovery patients post-explantation was 
obtained. In these patients, median age at implantation was 43 years (range 29-52) and 23 
patients (82.1%) were male (Table 1A). Predominant aetiologies of HF were myocarditis 
in 9 (32.1%) patients and dilated cardiomyopathy in 10 (35.7%) patients. Most patients 
had a short history of cardiac disease, with 14 (50%) patients having had their first 
cardiac diagnosis less than one month prior to the LVAD implantation and 20 (71.4%) 
within one year prior to the implantation. Patients were almost evenly distributed over 
INTERMACS patient profiles I to III, only 3 patients had INTERMACS patient profile 
IV-V. Median LVEF was 18% (IQR: 10-20%),whereas 5 patients exhibited ≥moderate 
mitral regurgitation. At the time of implant, 23 (82.1%) patients had inotropic support 
and 14 patients (50%) experienced any form of mechanical circulatory support by either 
extra-corporeal life support (ECLS) or an intra-aortic balloon pump (IABP). There were 
no significant differences between patients with or without an obtained follow-up after 
LVAD explantation (Table 1A). 
A comparison between patients whose LVAD was explanted and patients with another 
outcome (ongoing, heart transplantation or death) reveals that recovery patients were 
significantly younger (45 vs. 53.5 years (p < 0.001), had a shorter duration of cardiac 
disease (p <0.001), less ICD’s implanted (8.9% versus 61.4% (p < 0.001) and were 
more often in INTERMACS patient profile 1 (p = 0.01; (Table 1B). Furthermore, the 
predominant aetiologies of heart failure were myocarditis and dilated cardiomyopathy 
for recovery patients, while ischemic cardiomyopathy was the main cause of heart failure 
in the non-recovery group. 
Perioperative characteristics
The indication designation was BTT in 22 (78.5%), DT in 2 (7.1%) and rescue therapy 
in 4 (14.3%) (Table 2). Implanted devices included the HeartMate II (n=14) (Abbott, 
Lake Bluff, IL, USA), HeartWare HVAD (n=11) (Medtronic, Minneapolis, MN, 
USA), HeartMate 3 (n=2) (Abbott, Lake Bluff, IL, USA) and one unknown device. 
Concomitant cardiac surgery was performed in 5 patients: 3 patent foramen ovale 
repairs, 1 tricuspid valve repair and 1 aortic valve replacement. Two patients received 
a temporary right ventricular assist device. Median time in the operating room was 
208 minutes (range:130-683), with a median CPB time of 75 minutes (95-147). Post-
operative ICU stay ranged from 4 to 147 days with a median of 17 days and a median 
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hospital stay of 30 days (17-165). Patients with a follow-up after LVAD explantation had 
significantly different device strategies (p <0.001) (less BTR and more BTT patients) 
and a shorter duration of CPB (p = 0.034) compared to patients without a follow-up. 
Table 1A. Baseline characteristics of all patients with LVAD explantation due to myocardial recovery with 
and without follow-up after explantation
With follow-up (28) No follow-up (17) p-value
Age (y) 43 (29-52) 53 (41-65) 0.053
Male 23 (82.1) 13 (76.5) 0.711
BMI 26.9 [25.1-28.6] 25.7 [23.2-28.2] 0.182
BSA 2.02 [1.92-2.12] 1.98 [1.87-2.10] 0.395
Aetiology 0.579
Myocarditis 9 (32.1) 3 (17.6)
Dilated cardiomyopathy 10 (35.7) 4 (23.5)
Ischemic cardiomyopathy 4 (14.3) 5 (27.1)
Peripartum 1 (3.6) 1 (5.9)
Valvular heart disease 2 (7.1) 2 (11.8)
Hypertrophic cardiomyopathy 0 (0) 1 (5.9)
Toxic 1 (3.6) 0 (0)
Restrictive cardiomyopathy 0 (0) 0 (0)
Congenital heart disease 0 (0) 0 (0)
Other/Unknown 1 (3.6) 1 (5.9)
Time since first cardiac diagnosis 0.453
<1 month 14 (50) 6 (35.3)
1 month-1 year 6 (21.4) 5 (29.4)
1 year or more 4 (14.3) 5 (29.4)
Unknown 4 (14.3) 1 (5.9)
Current ICD in place 2 (7.1) 2 (11.8) 1.000
INTERMACS profiles 0.918
INTERMACS 1 8 (28.6) 6 (35.3)
INTERMACS 2 9 (32.1) 6 (35.3)
INTERMACS 3 8 (28.6) 3 (17.6)
INTERMACS 4 – 5  3 (10.7) 2 (11.8)
INTERMACS 6 – 7 0 (0) 0 (0)
Echocardiography
LVEF 18 (10-20) 15 (15-20) 0.612
LVEDD(mm) 68 (63-70) 66 (62-73) 0.771
Aortic regurgitation ≥moderate 1 0 1.000
Mitral regurgitation ≥moderate 4 9 0.038
ECG rhythm 0.389
Sinus 18 (64.3) 14 (82.4)
Atrial fibrillation/flutter 5 (17.9) 3 (17.6)
Paced 1 (3.6) 0 (0)
Other/Unknown 4 (14.3) 0 (0)
Heart rate (bpm) 97 (89-121) 98 (74-111) 0.455
Blood pressure
Systolic 105 (92 – 115) 106 (94-114) 0.919
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With follow-up (28) No follow-up (17) p-value
Diastolic 61 (60-70) 67 (50-70) 0.942
Mean arterial pressure 74 (72-84) 78 (70-82) 0.965
Diabetes 2 (7.1) 0 (0) 0.519
Inotropic support
Intravenous Inotropes 23 (82.1) 14 (82.4) 0.333
1-2 inotropes 18 (64.3) 8 (47.1)
≥3 inotropes 5 (17.9) 6 (35.3)
IABP 4 (14.3) 3 (17.6) 1.000
ECLS 10 (35.7) 7 (41.2) 0.715
Mechanical ventilation 8 (28.6) 6 (35.3) 0.637
Blood chemistry
Creatinine (µmol/L) 105 (79-114) 114 (91-141) 0.142
ALAT (U/L) 76 (39-177) 46 (34-520) 0.892
ASAT (U/L) 180 (42-592) 73 (27-184) 0.147
LDH (U/L) 469 (308-1189) 407 (338-992) 0.859
Total Bilirubin (mg/dL) 1.5 (0.8-2.5) 1.5 (0.8-2.1) 0.525
Haemoglobin (g/dL) 11.8 (10.2-13.4) 10.9 (10.4-13.7) 0.971
White blood cell count (x 109/L) 10.6 (9.3-14.3) 10.7 (8.7-13.4) 0.819
Thrombocytes (x 109/L) 164 (75-241) 191 (104-266) 0.479
Values are median(IQR), mean[confidence interval] or, n(%) BMI: body mass index; BSA: body surface 
area; ICD: implantable cardioverter-defibrillator; INTERMACS: Interagency Registry for Mechanically 
Assisted Circulatory Support); LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-
diastolic diameter; ECG: electrocardiogram; IABP: intra-aortic balloon-pump; ECLS: extra-corporeal life-
support.
Table 1B. Baseline characteristics of all patients with and without LVAD explantation due to myocardial 
recovery.
Explanted Not explanted p-value
Age (y) 44 (32 – 54) 56 (47 – 62) <0.001
Male 36 (80.0) 2568 (83.6) 0.542
BMI 26.4 [25.0 – 27.8] 26.1 [26.0 – 26.3] 0.691
BSA 2.00 [1.93 – 2.08] 1.97 [1.96 – 1.98] 0.313
Aetiology <0.001
Myocarditis 12 (26.7) 125 (4.1)
Dilated cardiomyopathy 14 (31.1) 995 (32.4)
Ischemic cardiomyopathy 9 (20) 1285 (41.8)
Peripartum 2 (4.4) 14 (0.5)
Valvular heart disease 4 (8.9) 45 (1.5)
Hypertrophic cardiomyopathy 1 (2.2) 30 (1.0)
Toxic 1 (2.2) 51 (1.7)
Restrictive cardiomyopathy 0 (0) 20 (0.7)
Congenital heart disease 0 (0) 28 (0.9)
Other/Unknown 2 (4.4) 480 (15.6)
Time since first cardiac diagnosis <0.001
<1 month 20 (44.4) 302 (11.1)
1 month-1 year 11 (24.4) 356 (13.1)
1 year or more 9 (20) 1857 (68.4)
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Explanted Not explanted p-value
Unknown 5 (11.1) 198 (7.3)
Current ICD in place 1633 (61.4) 4 (8.9) <0.001
INTERMACS profiles 0.01
INTERMACS 1 14 (31.1) 412 (13.4)
INTERMACS 2 15 (33.3) 996 (32.4)
INTERMACS 3 11 (24.4) 781 (25.4)
INTERMACS 4 – 5  5 (11.1) 637 (21.6)
INTERMACS 6 – 7 0 (0.0) 123 (4.2)
Echocardiography
LVEF 17 (15 – 19) 19 (19 – 19) 0.125
LVEDD(mm) 65.6 (62.2 – 69.0) 71.3 (70.1 – 72.6) 0.270
Aortic regurgitation ≥moderate 1 (3.4) 92 (3.8) 1.000
Mitral regurgitation ≥moderate 13 (38.2) 1221 (50.9) 0.141
ECG rhythm 0.005
Sinus 32 (71.1) 1359 (51.5)
Atrial fibrillation/flutter 8 (17.8) 424 (16.1)
Paced 1 (2.2) 663 (25.1)
Other/Unknown 4 (8.9) 192 (7.3)
Heart rate (bpm) 100 (92 – 107) 87 (86-87) <0.001
Blood pressure
Systolic 106 (100 – 112) 100 (100 – 102) 0.048
Diastolic 64 (59 – 69) 65 (64 – 65) 0.725
Mean arterial pressure 78 (73 – 83) 77 (76 – 77) 0.519
Diabetes 2 (4.4) 2105 (73.5) 0.001
Inotropic support
Intravenous Inotropes 37 (82.2) 2495 (89) 0.547
1-2 inotropes 26 (57.8) 2149 (76.7)
≥3 inotropes 11 (24.4) 346 (12.3)
IABP 7 (15.9) 297 (11.3) 0.342
ECLS 17 (37.8) 303 (10.5) <0.001
Mechanical ventilation 14 (31.1) 406 (15.4) 0.004
Blood chemistry
Creatinine (µmol/L) 111 (83 – 123) 111 (85 – 150) 0.465
ALAT (U/L) 29 (54 – 177) 29 (18 – 70) 0.001
ASAT (U/L) 135 (31 – 410) 33 (23 – 74) <0.001
LDH (U/L) 434 (314 – 1173) 308 (238 – 452) <0.001
Total Bilirubin (mg/dL) 1.78 (0.78 – 2.26) 1.29 (0.80 – 2.10) 0.591
Haemoglobin (g/dL) 11.9 (10.3 – 13.6) 11.8 (10.2 – 13.5) 0.844
White blood cell count (x 109/L) 10.7 (8.9 – 14.0) 8.4 (6.7 – 11.0) <0.001
Thrombocytes (x 109/L) 173 (80 – 247) 199 (150 – 250) 0.030
Values are median(IQR), mean[confidence interval] or, n(%) BMI: body mass index; BSA: body surface 
area; ICD: implantable cardioverter-defibrillator; INTERMACS: Interagency Registry for Mechanically 
Assisted Circulatory Support); LVEF: left ventricular ejection fraction; LVEDD: left ventricular end-
diastolic diameter; ECG: electrocardiogram; IABP: intra-aortic balloon-pump; ECLS: extra-corporeal life-
support.
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Table 2. Implantation and post-implantation characteristics for recovery patients
With follow-up (28) No follow-up (17) p-value
Device strategy <0.001
BTT 22 (78.5%) 7 (36.9%)
DT 2 (7.1%) 2 (10.5%)
Rescue Therapy 4 (14.3%) 2 (10.5%)
Bridge to recovery 0 (0%) 8 (42.1%)
Device type 0.204
HeartMate II 14 (50%) 6 (31.6%)
HVAD 11 (39.3%) 9 (47.4%)
HeartMate 3 2 (7.1%) 0 (0%)
PVAD 0 (0%) 2 (10.5%)
Other/Unknown 1 (3.6%) 2 (10.5%)
Concomitant cardiac procedures
PFO/ASD closure 3 (10.7%) 2 (10.5%)
Tricuspid repair 1 (3.6%) 4 (21.1%)
Tricuspid replacement 1 (5.3%)
Aortic repair 1 (5.3%)
Aortic valve replacement 1 (3.6%)
Mitral repair 1 (5.3%)
CABG 1 (5.3%)
Concomitant temporary RVAD implantation 2 (7.1%) 2 (10.5%) 1.000
Time in OR(minutes) 208 (130-683) 276 (95-375) 0.600
Cardiopulmonary bypass time(minutes) 75 (95-147) 124 (50-235) 0.034
ICU stay(days) 17 (4-147) 27 (2-66) 0.377
Hospital stay(days) 30 (17-165) 39 (14-144) 0.328
Values are median(range) or, n(%)
ASD: atrial septal defect; BTT: bridge to transplantation; CABG: Coronary artery bypass grafting; DT: 
destination therapy; ICU: intensive care unit; RVAD; right ventricular assist device; OR: operating room; 
PFO: patent foramen ovale.
Outcomes during VAD support
The median support time of the patients was 465 days (59-1286). Within this time 
frame the following key AEs were captured: major infection, major bleeding and 
device malfunction and haemolysis (Table 3). 8 (28.6%) patients remained free of any 
AEs during LVAD support, while 10 patients (35.7%) encountered 3 or more AEs. 
Forty-eight (73.8%) captured AEs required a hospitalization. There were no significant 
differences to the patients with missing follow-up after explantation.
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Table 3. Time on support and adverse events during mechanical circulatory support for recovery patients
With follow-up (28) No follow-up (17) p-value
Time on support(days) 410 (59-1286) 231 (10-1425) 0.06 
Type of adverse events
Major Infection 21 (32.3%) 4 (14.3%)
Major Bleeding 8 (12.3%) 1 (3.6%)
Device malfunction 6 (9.2%) 5 (17.9%)
Haemolysis 4 (6.2%) 2 (7.1%)
Cardiac Arrhythmia 3 (4.6%) 1 (3.6%)
Stroke 2 (3.1%) 3 (10.7%)
Renal Dysfunction 2 (3.1%) 4 (14.3%)
Right heart failure 0 (0%) 1 (3.6%)
Other 19 (29.2%) 7 (25%)
Number of AEs per patient 0.889
0 8 (28.6%) 5 (29.4%)
1-2 10 (35.7%) 8 (47.1%)
3-4 7 (25.0%) 3 (17.6%)
≥5 3 (10.7%) 1 (5.9%)
Hospitalizations required for AE 48 (73.8%) 26 (92.9%)
Hospitalizations per patient 1.000
0 10 (35.7%) 6 (35.3%)
1-2 11 (39.3%) 7 (41.2%)
3-4 5 (17.9%) 3 (17.6%)
≥5 2 (7.1%) 1 (5.9%)
Values are median(range) or, n(%)
AE: adverse event
Outcomes after LVAD explantation
Median follow-up time after LVAD explantation is 26 months (0.3-73). Freedom 
from death, LVAD reimplantation, HTx and relapse of HF ≥NYHA III was 100% 
at 30 days and 88% at 24 months after explantation (Figure 1, Table 4). Two patients 
encountered a HF relapse, which is in part attributable to new onset of degenerative 
mitral regurgitation in 1 patient. One patient required reimplantation of an LVAD after 
32 days. Finally, one patient died 302 days after LVAD explantation due to sepsis. Until 
48 months this percentage remained unchanged (88%), however follow-up was only 
available for six patients for this duration of follow-up 
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Months 0 12 24
Number at risk 28 18 14
Figure 1. Freedom of death, LVAD reimplantation, heart transplantation and signifi cant heart failure 
relapse after LVAD explantation.
Th e infl ow cannula remained in situ after explantation in 3 patients (11%). Of these 
patients, 2 were on both warfarin and aspirin, one patient only used warfarin. Th e infl ow 
cannula was not in situ in the 25 other patients, 2 of them used both warfarin and 
aspirin. Long-term anticoagulation treatment was aspirin in 43% of the patients, while 
in 39% warfarin was used. Four patients were prescribed both aspirin and warfarin. 
In 8 (29%) patients no antiplatelet or anticoagulation therapy was used. No CVA was 
reported in any patient.
Table 4. Long-term outcome post-LVAD explant for recovery patients
Follow-up time(months) 26 (0.3-73)
Primary outcome
Ongoing after explant 26 (92.8%)
HF recurrence 3 (10.7%)
LVAD reimplantation 1 (3.6%)
Death 1 (3.6%)
BMI 27.6 [25.4-29.7]
Blood pressure
Systolic 113 (88-160)
Diastolic 77 (51-98)
Mean arterial pressure 90 (68-113)
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Follow-up time(months) 26 (0.3-73)
Echocardiography data
LVEF 40 (15-60)
LVEDD(mm) 54 (41-74)
LVESD(mm) 43 (27-63)
MR grade≥3 2
ECG
Heart rate 73 (48-105)
Rhythm
Sinus 21 (75%)
Atrial fibrillation/flutter 3 (10.7%)
Other 4 (14.3%)
QRS width (ms) 98 (74-188)
QTc duration (ms) 435 (374-593)
Blood chemistry
Creatinine (µmol/L) 97 (62-248)
Bilirubin (mg/dL) 0.6 (0.3-2.8)
Functional status at last FU
NYHA class I 7 (25%)
NYHA class II 16 (57.2%)
NYHA class III 3 (10.7%)
Unknown 2 (7.1%)
HF medication
β-blockers 24 (85.7%)
ACE inhibitors 20 (71.4%)
Loop diuretics 14 (50%)
Inflow cannula in situ 3 (10.7%)
Anticoagulation/antiplatelet therapy 20 (71.4%)
Acetylsalicylic acid 12 (42.9%)
Vitamin K antagonist 11 (39.3%)
Both 4 (14.3%)
None 8 (29%)
Number of patients with CVA 0 (0%)
Values are median (range), mean [standard deviation] or, n (%) ACE; angiotensin converting enzyme; 
BMI: body mass index; BSA: body surface area; CVA: cerebrovascular accident; ECG: electrocardiogram; 
ECLS: extra-corporeal life support; HF: heart failure; IABP: intra-aortic balloon pump; ICD: implantable 
cardioverter-defibrillator; INTERMACS: Interagency Registry for Mechanically Assisted Circulatory 
Support); LVAD: left ventricular assist device; LVEF: left ventricular ejection fraction; LVEDD: left 
ventricular end-diastolic diameter; LVESD: left ventricular end systolic diameter; MR: mitral regurgitation; 
NYHA: New York Heart Association, 
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DISCUSSION
This study provides a multi-centre, mid- to long-term follow-up of patients whose LVAD 
was explanted due to myocardial recovery. The mid- to long-term outcomes appear to 
be encouraging with 88% of the patients surviving without HTx, LVAD reimplantation 
or relapse of HF at 24 months of follow-up. Furthermore, the majority of patients 
suffered from mild HF-symptoms only (NYHA class I-II). The number of patients with 
sufficient myocardial recovery for LVAD explantation is comparable to other registries 
such as INTERMACS, which reported a successful weaning rate of approximately 1% 
in the latest annual report[10, 11].
A comprehensive review of single-centre studies reporting on myocardial recovery 
allowing LVAD explantation found weaning rates ranging from 4.5% to 63% and thus 
contrasts with lower recovery rates reported in the INTERMACS or EUROMACS 
registries[12]. Some of these studies have reported higher rates of successful weaning. 
Interestingly, some showed a successful explantation rate of 12 in 19 (63%) patients 
supported by a HeartMate II[13]. However, this population was young (mean age 35.2 
years) and patients with ischemic heart disease were excluded. Moreover, they received 
aggressive pharmacotherapy with maximum HF medication combined with clenbuterol 
(β2-agonist).  
These high rates of recovery may partly be explained due to the commitment of some 
centres resulting in specific clinical and scientific focus on the recovery. This might 
result in advanced, aggressive strategies to identify potential patients eligible for LVAD 
explantation and thus treating those patients with targeted and strictly regulated HF 
medication. Furthermore, studies that included patients with non-ischemic heart 
disease as aetiology of HF and patients with recent onset of HF tend to have higher 
rates of successful myocardial recovery. These observations correspond well with our 
study in which the majority of patients had their first cardiac disease diagnosis less 
than 1 year ago and ischemic cardiomyopathy represented an uncommon aetiology of 
HF. Indeed, the baseline characteristics that are significantly different in patients with 
LVAD explantation are very similar to the variables used in the INTERMACS Cardiac 
Recovery Score (I-CARS) of Wever-Pinzon et al.[11].
In the literature, several case series and small cohort studies report on patients having 
recovery of left ventricle (LV) function that allowed LVAD explantation. Studies such 
as Dandel et al. report that LVAD (Novacor) explantation was successful in 32 of 131 
patients with idiopathic dilated cardiomyopathy, with a 5-year survival of 78,3% and 
31,1% HF recurrence rate in 3 years, after being supported with a LVAD for a mean 
duration of 4,6 months (SD ± 4,4)[4]. Birks et al. reported that out of 15 patients with 
severe HF due to non-ischemic cardiomyopathy, 11 had LVAD explantation after a 
mean of 320 days LVAD support. 88,9% of the surviving patients were free from HF 
at 4 years after explantation[5]. Another study showed survival after explantation of 
HeartMate II was 83.3% after 3-year follow-up[13]. A study of 14 patients revealed 
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that after a mean follow-up time of 3.6 years (± 1.9) after explantation, no patient had 
died and had a functional NYHA class of I[6]. Frazier et al. achieved explantation in 
27 patients out 657 patients supported by a LVAD, with 25 of them surviving after 
a mean follow-up of 3.2 years (± 2.6)  all of them with NYHA class I with medical 
therapy[7]. In comparison, we showed a similar excellent survival of 88% without HTx, 
LVAD reimplantation or significant HF relapse in a European multi-centre registry, 
with the majority of patients only suffering from mild HF symptoms after explantation. 
This highlights that, in carefully selected patients, excellent results can be achieved after 
LVAD explantation and are not restricted to one centre.
Pathophysiology and clinical implications of LV recovery
The pathophysiology of HF is complex and multifactorial. Systolic HF is accompanied 
by left ventricular (LV) remodelling, which  is characterized by three categories of 
changes in the heart: myocyte defects, myocardial defects and abnormal LV geometry 
[14]. In contrast, to achieve myocardial recovery, the heart has to undergo cardiac 
reverse remodelling. Support by cf-LVADs results in left ventricular pressure and volume 
unloading as well as increased cardiac output[15, 16] and has shown to promote certain 
forms of reverse remodelling[17]: reduction of cardiac myocyte hypertrophy[18, 19], 
changes in gene expression[20, 21] and normalization of β-adrenergic receptor and 
inotropic responsiveness[22]. Concerning restoration of the ECM, conflicting studies 
exist, with some studies reporting an increase in total ECM collagen[23, 24], while others 
report a decrease[25]. Finally, studies have shown an improvement in cardiac myocyte 
contractility after LVAD implantation[26, 27]. There are some excellent reviews covering 
this topic in much more detail[14, 28]. On the clinical side, the criteria used for the 
decision of LVAD explantation differ between centres[8, 13, 29]. Clinical parameters 
that indicate LV remodelling and might indicate myocardial recovery often include an 
increase in LVEF, decreases in end-diastolic left ventricular diameter,  (partial) reversal 
of functional mitral regurgitation, normalization of cardiac filling pressures and cardiac 
sinus rhythm with a normal heart rate. Unfortunately, studies linking pathophysiological 
findings with these clinical outcomes are scarce. 
Future perspectives
A combination of data on clinical and biological findings for patients undergoing LVAD 
implantation is currently lacking robust data with both studies conducted separately of 
each other. Preferably, one would collect histological/biological data and clinical data 
before LVAD implantation, during LVAD support and after explantation (if applicable). 
This holistic approach would provide much needed insight in the changes that are 
induced by VAD therapy and would enable us to link and understand pathophysiological 
changes to clinical changes and vice versa. 
Finally, because the number of patients that have sufficient myocardial recovery to enable 
LVAD explantation is limited, it is critical that researchers and clinicians cooperate in 
large registries such as EUROMACS and INTERMACS, by adding data fields for 
centres willing to capture data on the follow-up of these patients. As a consequence, the 
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EUROMACS board set out the goal that follow-up of after explantation of VAD devices 
due to recovery should also be captured in the near future. 
Limitations
This study has certain limitations that should be considered while interpreting the 
results. Data were gathered retrospectively and the number of data fields captured is 
limited. Furthermore, it is possible that not all patients whose LVAD was explanted 
due to recovery were captured in the EUROMACS registry. It is also possible that 
the follow-up of patients who actually have been explanted due to recovery, has not 
been registered yet. This might result in a relative underestimation of the number of 
patients with myocardial recovery, however the EUROMACS registry regularly checks 
and audits participating centres for data quality and completion. Finally, we only 
received follow-up data on 62% of those patients weaned from LVAD support which 
may constitute a potential selection bias resulting in favourable outcomes. However, 
the baseline characteristics and follow-up during LVAD support of patients with and 
without follow-up were, apart from two variables, not significantly different (Table 1A). 
CONCLUSION
To our knowledge this is one of the first multi-centre studies to review mid- to long-
term follow-up after LVAD explantation due to myocardial recovery. Although LVAD 
explantation remains rare, outcomes after explantation are excellent with a majority 
of patients ongoing without HTx or LVAD reimplantation while having limited HF 
symptoms only. Large, prospective registries and/or studies are required to generate 
pertinent data in order to better understand this challenging population.
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ABSTRACT
Objective: Tricuspid regurgitation (TR) is common in patients receiving a left 
ventricular assist device (LVAD) and controversy exists whether concomitant is tricuspid 
valve surgery (TVS) is beneficial in currently treated patients. Therefore, we aimed to 
investigate the effect of concomitant TVS during LVAD implant.
Methods: The European Registry for Patients with Mechanical circulatory Support 
(EUROMACS) was used to identify adult patients. Matched patients with and without 
concomitant TVS were compared by using a propensity score matching strategy. 
Results: In total, 3323 patients underwent LVAD implantation of which 299(9%) 
with TVS). After matching 258 patients without TVS were matched to 258 patients 
with TVS. In the matched population hospital mortality, days on inotropic support, 
temporary right ventricular assist device implant and hospital stay were comparable, 
whereas intensive care stay was higher in the TVS cohort (11 vs. 15 days, P=0.026). Late 
mortality (P=0.17), cumulative incidence of unexpected hospital readmission (P=0.15) 
and right heart failure (P=0.55) were comparable between patients with and without 
concomitant TVS. In the matched population probability of moderate-to-severe TR 
immediately after surgery was lower in patients with concomitant TVS compared to 
patients without TVS (33%vs70%, P=0.001). Nevertheless, the probability of moderate-
to-severe TR decreased more quickly in patients without TVS (P=0.030), resulting in 
comparable probabilities of moderate-to-severe TR within 1.5 year of follow-up. 
Conclusion: In matched patients concomitant TVS during LVAD implant does not seem 
be associated with better clinical outcomes.  Concomitant TVS reduced TR significantly 
early after LVAD implant, however, differences in probability of TR disappear during 
follow-up.
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INTRODUCTION
Implantation of a left ventricular assist device (LVAD) improves survival, functional 
status and quality of life in patients with end-stage heart failure (1, 2). In these patients 
tricuspid regurgitation is common (3) and current guidelines recommend consideration 
of tricuspid valve surgery when moderate to severe tricuspid regurgitation is present 
(4). Nevertheless, controversy exists whether concomitant tricuspid valve surgery 
is associated with better outcomes, as contemporary  studies are hampered by small 
sample size and biased due to baseline differences (5). In this study, we investigate the 
clinical outcomes after concomitant tricuspid valve surgery during LVAD implantation 
compared to a propensity score matched controls using the European Registry for 
Patients with Mechanical Circulatory Support (EUROMACS). Furthermore, we aimed 
to assess the postoperative course of tricuspid regurgitation in patients with and without 
concomitant tricuspid valve surgery (TVS).
METHODS
Study design
The EUROMACS is a registry of the European association for Cardio-Thoracic Surgery. 
In this registry all relevant clinical, echocardiographic hemodynamic and laboratory 
parameters of patients who require mechanical circulatory support are collected 
prospectively since January 2011. Participating centers were allowed to enter data 
before 2011 retrospectively, making this study an ambispective cohort study. A detailed 
description of the database and collection procedure are described previously (6).
Patients
All patients operated between 1995 and 2018 were identified. Patients <18 years old 
and with planned right ventricular -, biventricular- and assist device were excluded 
from analysis. Additionally, patients with single ventricle physiology were excluded 
(Supplementary Figure 1).
Study outcome
The main outcomes that were assessed were early (both 30-day and hospital mortality 
separately) and late mortality. Late mortality was defined as mortality after 30 days, 
regardless of hospital admission status. Furthermore, unplanned hospital readmission 
and right heart failure were assessed. Right heart failure was defined according to the 
INTERMACS adverse event definitions (7). Patients were censored at heart transplant, 
death and lost to follow-up. Lastly, the course of the probability of moderate-to-severe 
tricuspid regurgitation was evaluated in patient with and without TVS.
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Missing values
Multiple imputation by chained equations using the statistical “MICE” package in R was 
used to impute missing values (8). Selected baseline variables with <55% missing, were 
imputed, above 55% missing was considered excessive missingness (Supplementary Table 
1). Nevertheless, 51 out of the 67 imputed variables (76%) had less than 30% missings. 
An exception was made for the variable Tricuspid annular plane systolic excursion 
(TAPSE) (62% missing), since this variable is highly important in the setting of TVS, 
and it was reasonable to assume it could be imputed based on observed variables, such as 
right ventricle ejection fraction (missing mechanism: missing at random). Imputations 
were done based upon the other baseline variables. In case of highly correlated variables 
the variable with highest clinical value was chosen as predictor (Supplementary Table 2). 
Correlation was tested with Pearson R or Spearman rho, as appropriate. Five imputed 
datasets were generated using this method using 5 iterations each. The imputations were 
visually checked by strip plots and density plots, and no major deviations are noted 
between imputed data and complete data (Example TAPSE: Supplementary Figure 2). 
Analyses was done on each dataset separately and pooled according to Rubin’s rules (9). 
In baseline comparisons of the matched groups, continuous data was transformed to 
approximate Gaussian distribution and was pooled according to Rubin’s rules.
Statistical analysis 
Continuous data is presented as mean ± standard deviation (Gaussian distribution) or 
median (interquartile range[IQR]) (non-Gaussian distribution). Categorical data is 
presented as frequencies (percentage). Comparisons among continuous variables were 
made with the Student T-test or Mann-Whitney test, as appropriate. Continuous data 
outside 3 standard deviations was considered erroneous and removed (Supplementary 
Table 3). Comparisons of categorical variables were made with the Chi-squared test 
or with the Fisher exact test, as appropriate. Propensity score matching was used to 
balance baseline differences, since the main interest of this study is the treatment effect 
in a typical treated patient instead of a population level treatment effect (10). The 
parsimonious propensity score model was developed using least absolute shrinkage and 
selection operator (LASSO) regression (11). This machine learning analysis technique 
shrinks unimportant covariates to zero. The parsimonious model consisted out of 
all non-zero covariates. In total, 62 variables were offered to the Lasso model, which 
selected 15 variables (Supplementary Table 4). Thereafter, 9 variables were added due 
clinical significance and to achieve satisfactory balance (Supplementary table 5). The 
final propensity score model contained 24 variables (Supplementary table 5/6). One-
on-one matching without replacement was performed and the caliper was set at 0.15. 
For the main outcome a sensitivity analyses was performed with caliper set at 0.001. 
Standard mean difference prior and after matching was used to assess covariate balance. 
Late survival was calculated and visualized with the Kaplan-Meier method and both 
cohorts were compared with log-rank test. Since some patients had no recorded follow-
up, a sensitivity analyses was performed to test the robustness of the log-rank test under 
different missing mechanisms. Unplanned hospital readmission and right heart failure 
was considered a competing risk with mortality and Fine and Gray competing risk 
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models were used to calculate cumulative incidences. Gray’s tests were used to quantify 
significant differences among cohorts. Generalized mixed-models were used to analyze 
repeated echocardiograms. Further details regarding the mixed-models are provided in 
Supplementary Text 1 Follow-up completeness was calculated using the modified Clark 
C (C*) (12). All analyses were done in R (R core team 2017, Austria, Vienna) with 
the use of statistical packages “glmnet”, “Matching”, “survival”, “cmprsk”, “splines” and 
“lme4”.
RESULTS
In total, 3323 procedures were included (3024 [91%] without TVS and 299 [9%] 
with TVS). In the TVS cohort 292 (97%) patients had a tricuspid valve repair and 
7 (3%) patients had a tricuspid valve replacement (6 mechanical and 1 biological). 
After propensity score matching, 258 procedures without TVS surgery were matched 
to 258 procedures with additional TVS. Density plots of the propensity score in the 
unmatched and matched cohorts are presented in Figure 1. In patients that survived 30-
days and had recorded late follow-up the mean follow-up time was 1.7 ± 1.5 years with 
a completeness of 86% (*C).
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Figure 1. Density of propensity score in the unmatched and the matched cohorts.
Patient characteristics
Patient characteristics are presented in Table 1. In the unmatched cohort, patients who 
did not undergo TVS had, among others, significantly less tricuspid regurgitation, more 
ischemic cardiomyopathy and better kidney and liver function. In the matched cohort, 
patients no significant differences in baseline characteristics were noted. In addition, 
overall absolute standard mean difference before matching was 18.7 and after matching 
4.9 (Supplementary Table 7).
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Table 1. Patient characteristics of  patients with or without concomitant tricuspid valve surgery in matched 
and unmatched cohorts. 1Data and tests on complete cases. 2Data from first imputed dataset , and p-values 
from tests are derived from the pooled analyses. 
Unmatched groups1 Matched groups2
No TVS TVS p-value No TVS TVS P-value
n 3024 299 258 258
Age, y  56.00 [47.00, 
62.00]
57.00 [47.50, 
63.00]
0.044 56.00 [47.00, 
64.00]
57.00 [47.25, 
63.00]
0.74
Male sex, n (%) 2519 (83.3) 235 (78.6) 0.048 205 (79.5) 202 (78.3) 0.83
Body surface area, 
m2 
1.96 [1.81, 
2.12]
1.96 [1.85, 
2.12]
0.80 1.94 [1.79, 
2.11]
1.96 [1.84, 
2.11]
0.75
Caucasian, n (%) 2271 (87.4) 248 (95.8) 0.003 247 (95.7) 245 (95.0) >0.99
Etiology (%) <0.001 0.77
Coronary artery 
disease 
252 (10.0) 24 (9.3) 20 (7.8) 26 (10.1)
Ideopatic 614 (24.5) 100 (38.8) 95 (36.8) 97 (37.6)
Ischemic 1011 (40.3) 62 (24.0) 66 (25.6) 65 (25.2)
Other 632 (25.2) 72 (27.9) 77 (29.8) 70 (27.1)
≥2 years since first 
diagnosis  
1546 (63.5) 188 (75.5) 0.001 190 (73.6) 192 (74.4) 0.90
Destination therapy 467 (16.9) 47 (15.9) 0.72 42 (16.9) 43 (16.8) >0.99
Ascites 198 (10.3) 36 (18.0) <0.001 55 (21.3) 56 (21.7) 0.90
Rhythm, n (%) 0.084 0.99
   Sinus 1337 (55.4) 119 (47.8) 128 (49.6) 120 (46.5)
   Atrial fibrillation 397 (16.4) 44 (17.7) 45 (17.4) 49 (19.0)
   Paced 613 (25.4) 80 (32.1) 82 (31.8) 82 (31.8)
   Other 68 (2.8) 6 (2.4) 3 (1.2) 7 (2.7)
INTERMACS class, 
n (%) 
<0.001 0.90
1 427 (15.0) 19 (6.4) 17 (6.6) 20 (7.8)
2  942 (33.2) 118 (40.0) 101 (39.1) 93 (36.0)
3 738 (26.0) 92 (31.2) 80 (31.0) 80 (31.0)
≥4 733 (25.8) 66 (22.4) 60 (23.3) 65 (25.2)
IABP, n (%) 287 (11.3) 17 (6.6) 0.030 24 (9.3) 15 (5.8) 0.34
ECMO, n (%) 306 (10.9) 22 (7.5) 0.097 18 (7.0) 19 (7.4) >0.99
Ventilator (%) 377 (14.8) 19 (7.5) 0.002 18 (7.0) 26 (10.1) >0.99
Medication, n (%) 
Loopdiuretics, n (%) 1886 (80.5) 218 (86.9) 0.018 213 (82.6) 224 (86.8) 0.82
Use of ≥3 inotropes, 
n (%)
198 (10.5) 23 (11.2) 0.87 51 (19.8) 33 (12.8) 0.79
Laboratory values 
Serum creatinine, 
mg/dL 1 
107.00 [83.00, 
150.00]
115.00 [90.50, 
150.00]
0.035 109.50 [84.00, 
152.75]
114.00 [88.00, 
150.00]
0.51
ASAT, U/L 33.00 [23.00, 
75.00]
35.00 [25.00, 
57.00]
0.41 34.00 [24.00, 
67.75]
34.00 [25.00, 
55.00]
>0.99
Total bilirubin, 
mg/dL 
1.20 [0.78, 
2.00]
1.69 [1.14, 
2.50]
<0.001 1.50 [0.90, 
2.55]
1.53 [1.05, 
2.28]
0.92
Albumin, g/dL 507.15 [420.21, 
579.60]
507.15 [449.91, 
574.16]
0.54 507.15 [405.72, 
579.60]
507.15 [434.70, 
579.60]
0.82
Hemoglobin, g/dL 1 11.80 [10.20, 
13.60]
11.40 [10.07, 
13.03]
0.11 11.70 [9.83, 
13.20]
11.40 [10.00, 
13.28]
0.65
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Unmatched groups1 Matched groups2
No TVS TVS p-value No TVS TVS P-value
n 3024 299 258 258
Hemodynamic 
RA pressure, mmHg 10.00 [7.00, 
15.00]
13.00 [9.50, 
17.00]
<0.001 12.00 [8.00, 
16.00]
13.00 [9.00, 
16.00]
0.63
PCWP, mmHg 24.00 [18.00, 
30.00]
25.00 [20.75, 
29.25]
0.085 24.00 [18.00, 
30.00]
24.50 [20.00, 
29.00]
0.21
PVR 231.50 [137.00, 
354.75]
267.00 [166.75, 
372.50]
0.11 262.00 [177.00, 
368.00]
276.50 [160.00, 
372.50]
0.71
SVR 1262.00 
[896.25, 
1676.50]
1446.50 
[1102.75, 
1908.00]
0.001 1317.00 
[1021.00, 
1590.00]
1300.00 
[1062.50, 
1858.00]
0.38
PAP, systolic, mmHg 51.00 [39.00, 
64.00]
49.50 [40.00, 
63.00]
0.71 52.00 [40.00, 
63.00]
52.00 [40.00, 
65.00]
0.66
Echocardiographic 
TAPSE, mm  14.00 [12.00, 
17.00]
15.00 [12.00, 
18.00]
0.28 14.00 [11.00, 
17.00]
14.00 [12.00, 
17.00]
0.63
No aortic 
regurgitation, n (%)  
1469 (63.5) 151 (55.7) 0.060 146 (56.6) 148 (57.4) 0.98
Severe mitral 
regurgitation, n (%)  
392 (17.4) 77 (30.4) <0.001 76 (29.5) 66 (25.6) 0.83
Tricuspid 
regurgitation
<0.001 0.79
   None 286 (11.4) 4 (1.4) 8 (3.1) 4 (1.6)
   Trivial 504 (20.1) 14 (4.8) 15 (5.8) 15 (5.8)
   Mild 907 (36.2) 34 (11.7) 39 (15.1) 37 (14.3)
   Moderate 564 (22.5) 113 (38.8) 96 (37.2) 112 (43.4)
   Severe 243 (9.7) 126 (43.3) 100 (38.8) 90 (34.9)
LVEF (%) 19.00 [15.00, 
23.00]
20.00 [15.00, 
25.00]
0.029 20.00 [15.00, 
24.00]
20.00 [15.00, 
23.00]
0.85
RVF <0.001 0.89
Normal 400 (22.1) 21 (10.7) 37 (14.3) 31 (12.0)
Mild 460 (25.4) 44 (22.3) 45 (17.4) 52 (20.2)
Moderate 700 (38.6) 96 (48.7) 124 (48.1) 114 (44.2)
Severe 252 (13.9) 36 (18.3) 52 (20.2) 61 (23.6)
IABP: intra atrial balloon pump, ECMO: Extracorporeal membrane oxygenation. ASAT: Aspartate 
Aminotransferase, RA: Right atrium, PCWP: pulmonary capillary wedge pressure, PVR: pulmonary 
vascular resistance, SVR: systemic vascular resistance, PAP: pulmonary atrial pressure, TAPSE: Tricuspid 
annular plane systolic excursion, LVEF: left ventricular ejection fraction, RVF: Right ventricle function.
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Figure 2. Kaplan-Meier curve of patients that survived 30-days in the unmatched cohort and the matched 
cohort. 
Hospital outcome
Hospital outcomes are presented in Table 2. In the unmatched cohort, cardiopulmonary 
bypass time (80 vs 118 minutes, p<0.001), ICU stay (10 vs 15 days, P<0.001) hospital 
stay (30 vs 34, p=0.001) and days on inotropic support (>14 days: 24.7% vs 32.4%) 
were longer in the patients that underwent TVS. In the matched cohorts these were all 
comparable, except for cardiopulmonary bypass time (85 vs 116 minutes, p<0.001) and 
ICU stay (11 vs 15 days, p=0.026) (Table 2). Additionally, in the matched groups, the 
30-day mortality (13.6%, 95%CI [9.5–18.6] vs 10.0%, 95%CI [6.5–14.4], p=0.27) 
and hospital mortality (20.2% 95%CI[14.7–24.7] vs 16.5% 95%CI[13.0–22.6], 
p=0.41) was comparable between the patients with and without concomitant TVS. 
Sensitivity analyses with caliper at 0.001 did not change point estimates considerably 
(Supplementary Table 8).
Table 2. Hospital outcomes of  patients with or without concomitant tricuspid valve surgery in matched 
and unmatched cohorts.
Unmatched groups Matched groups
No TVS TVS p-value No TVS TVS P-value
n 3024 299 258 258
CPB time (min) 80 [58, 111.5] 118 [94, 157] <0.001 84.50 [61.00, 
114.50]
115.50 [92.25, 
157.75]
<0.001
Device brand <0.001 0.93
   HeartMate II 776 (27.4) 120 (40.4) 102 (39.5) 96 (37.2)
   HeartWare HVAD 1481 (52.3) 117 (39.4) 112 (43.4) 113 (43.8)
   HeartMate III 414 (14.6) 58 (19.5) 42 (16.3) 47 (18.2)
   Other 160 (5.7) 2 (0.7) 2 (0.8) 2 (0.8)
Hospital death n (%) 452 (15.2) 55 (18.8) 0.58 50 (20.2) 45 (16.5) 0.41
30 – day death 306 (11.9) 32 (11.0) 0.72 32 (13.6) 25 (10.0) 0.27
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Unmatched groups Matched groups
No TVS TVS p-value No TVS TVS P-value
n 3024 299 258 258
Temporary RVAD 
support
138 (4.5) 23 (7.7) 0.024 22 16 0.40
Days of intropic 
support
0.013 0.29
   1 -7 days 993 (56.6) 92 (48.2) 11 (7.0) 13 (7.7)
   8 - 13 days 321 (18.3) 37 (19.4) 85 (53.8) 85 (50.6)
   14 - 27 days 276 (15.7) 48 (25.1) 27 (17.1) 41 (24.4)
   >27 days 158 (9.0) 14 (7.3) 33 (20.9) 29 (17.3)
   Ongoing 6 (0.3) 0 (0.0) 2 (1.3) 0 (0.0)
ICU-CCU stay 10 [5, 23] 15 [6, 53] <0.001 11.00 [5.00, 
24.00]
15.00 [6.00, 
31.00]
0.026
Hospital stay 30 [21, 46] 34 [25, 53] 0.001 33.00 [22.00, 
54.00]
34.50 [24.75, 
52.25]
0.38
RVAD: Right ventricular assist device, ICU: Intensive care unit, CCU: Cardiac care unit. 
Late outcome
In total, 2522 patients had recorded late follow-up and did not die within 30 days (no 
TVS: 2263 and TVS: 259 patients), of which 819 patients died during follow-up (no 
TVS: 736 and TVS: 73) (Supplementary Figure 3). Kaplan-Meier curves of survival 
are shown in Figure 2a. Unmatched patients with and without concomitant TVS had 
comparable late survival (p=0.41). Additionally, cumulative incidence of unplanned 
hospital re-admission from any cause (No TVS: 764 and TVS: 102) and cumulative 
incidence of right heart failure (No TVS: 138 and TVS: 25) was higher in the TVS 
cohort (Figure 3a and 4a), p=0.006 and p=0.011, respectively.
In the matched cohort, 226 TVS patients survived 30 days and had recorded late follow-
up versus 204 matched controls, of which 128 died during follow-up (no TVS: 62 
and TVS: 66). Late survival was comparable between patients with and without TVS 
(p=0.17) (Figure 2b). Notably, the curves diverged after approximately 1 year of follow-
up with 2-year survival estimates of 75.6% (95% CI[69.3 – 82.5]) in the no TVS cohort 
and   63.2% (95% CI[55.3 – 72.2]) in the TVS cohort, but still with overlapping 
confidence intervals. In total 22 patients in the matched control group and 7 patients 
in the TVS cohort, did not have recorded follow-up. Sensitivity analyses revealed that 
only in the scenario that all missing patients in the no TVS cohort survived and in the 
TVS cohort all died the log-rank test was significantly differed (Supplementary Table 9). 
Sensitivity analyses with caliper set at 0.001 did not change point estimates considerably 
(Supplementary Table 8).. In the matched cohorts, cumulative incidence of unplanned 
hospital re-admission (No TVS: 80 and TVS: 92 patients, p=0.15) and right heart 
failure (No TVS: 16 and TVS: 20 patients, p=0.55) were comparable between patients 
with and without concomitant TVS (Figure 3b and 4b). 
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Figure 3. Cumulative incidence estimated by Fine and Gray model with death as competing risk of 
unexpected hospital readmission in the unmatched and the matched cohort.
Evolution of tricuspid regurgitation
In total, 1219 patients had 3956 recorded echocardiograms during follow-up (mean: 
3.2 echocardiograms, range: 1 – 28). Figure 5a presents the probability of moderate-
to-severe tricuspid regurgitation over time in the unmatched cohorts. In the matched 
cohorts 224 patients had 725 recorded echocardiograms (mean 3.2, range: 1 – 21), which 
could be used in the mixed models. Immediately after LVAD implantation, patients 
that underwent TVS had significantly lower probability of moderate-to-severe tricuspid 
regurgitation (33% vs 70%, p=0.001). Nevertheless, during follow-up probability 
of moderate-to-severe tricuspid regurgitation decreased more quickly in the no TVS 
cohort compared to the TVS cohort (p=0.030), resulting in comparable probabilities 
within one year of follow-up.
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Figure 4. Cumulative incidence estimated by Fine and Gray model with death as competing risk of right 
heart failure in the unmachted and matched cohort
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Figure 5. Course of the probability of moderate-to-severe tricuspid regurgitation over time in the unmatched 
and matched cohort estimated by the mixed model. 
DISCUSSION
In this study we evaluated outcomes of concomitant TVS during LVAD implantation in 
the largest European LVAD registry. In a matched cohort comparable risks and rates of 
mortality, days on inotropic support, cumulative incidence of unexpected readmission 
and right heart failure were noted. Not surprisingly, cardiopulmonary bypass time 
was longer in the TVS cohort. Furthermore, patients that underwent concomitant 
TVS stayed longer in the ICU compared to patients that did not underwent TVS. 
Immediately after surgery the probability of moderate-to-severe TVS is significantly 
lower in the TVS cohort, however, this difference disappeared to during follow-up.
Patients undergoing TVS are significantly different compared to patients without 
concomitant TVS. Patients undergoing TVS presented as less acute patients with a 
longer history of cardiac diagnosis and less ischemic etiology (among others), which 
is also illustrated by different densities in propensity scores (Figure 1). Hence, patients 
undergoing TVS seem to be a select subgroup in the overall LVAD population. It has 
to be noted that conclusions regarding treatment effect in this study only apply this 
subgroup and may not apply in other subgroups within the LVAD population.
Prior analyses of the society of Thoracic surgeons (STS) database and the INTERMACS 
database noted comparable results compared to this study (13, 14). Patients receiving 
TVS that were recorded in the STS database stayed longer in the ICU. RVAD implant 
and hospital mortality was comparable in this cohort (13).
The investigators of the INTERMACS database noted comparable late survival in 
patients with preoperative moderate-to-severe TR with and without concomitant TVS 
(14). Moreover, a recent systematic review, pooling mostly small retrospective studies, 
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found no differences early and late survival (5). Interestingly, both in retrospective 
studies and INTERMACS database it was noted that pre-LVAD moderate-to-severe TR 
was associated with a poorer late survival (3, 14, 15). Regarding the latter observation, 
it seems peculiar that eliminating TR does not result in better outcome. Two hypotheses 
may explain these paradoxical results. Firstly, TVS may not sustainably reduce post-
LVAD TR. Song et al. found a relatively high rate of recurrent TR in patients that 
received concomitant TR. Additionally, there are reports that observe that LVAD support 
exacerbates TR due to a leftwards shift of the interventricular septum and increased 
venous return (16, 17). Nevertheless, our results support that TVS does reduce TR from 
early on postoperatively, but that in patients with patients without concomitant TVS TR 
does also decrease in the following months. Secondly, it may be possible that TR is not 
a causing factor of mortality in most cases. It is known that TR is frequently caused by 
right ventricular dilatation in response of elevated pulmonary pressures (18). Therefore, 
TR may merely be a symptom, or a marker of, RV damage secondary to longstanding 
pulmonary hypertension  or primary damaged RV due the underlying ischemic or 
cardiomyopathic diseases. By treating TR one may be treating the symptom rather than 
the causing factor of mortality and morbidity (e.g. right ventricle dysfunction). To some 
extent our findings do support this theory, since favorable right ventricular remodeling 
is observed in patients with a LVAD implantation without concomitant TVS (19, 20). 
This would inherently be paired with a reduction of TR, even without an intervention, 
assuming the TR is functional in nature.
In this respect, the cause of TR (primary or secondary) is important. Primary TR, 
caused by structural valve damage or interfering pacemaker/ICD leads will certainly not 
reduce by itself and may even cause right ventricular dysfunction (21). Therefore, we 
propose this aspect be taken into account in the decision process whether to perform 
concomitant TVS. Roberston et al. suggested that the decision to perform concomitant 
TVS should not be solely based on pre-LVAD TR grade (13). Our data and current 
literature support this suggestion, as our results and multiple other studies were unable 
to show any benefit from concomitant TVS with current guidelines suggesting TVS in 
all patients with pre-LVAD moderate-to-severe TR may not be necessary. Nevertheless, 
following the trends in concomitant TVS for functional TR during left sided valve 
surgery it has become clear that TR in some cases does not reduce, or even worsens (22, 
23). The remaining challenge is now to adequately identify these patients in the LVAD 
population.
Strengths and Limitations
The strength of this study is the relatively large sample size compared to current 
literature. Additionally, the EUROMACS registry records serial echocardiograms which 
made it possible to analyze the change of TR over time. In contrast to previous studies, 
we accounted for the within-patient correlations in our analyses of postoperative course 
of TR over time using advanced statistical modelling.  This study has several important 
limitations. First of all, this database is not designed to specifically address concomitant 
TVS in patients with LVAD implantation. Therefore, important factors, such as the 
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cause of TR or reasons for intervention are not collected. This may introduce selection 
bias, as these could not be captured in the propensity model. Furthermore, surgeon and 
institutional preferences can introduce selection bias.  Although the majority of variables 
of interest had below 30% missing, we accepted up to 55% missingness. On the other side, 
the EUROMACS database collects many variables, making it more plausible missing data 
could be predicted on other observed variables and, therefore, strengthening the missing 
at random assumption. Additionally, since last year the EUROMACS investigators 
intensified their quality control measures to reduce missingness in the future (24). 
Furthermore, assessing TR remains challenging and TR is subject to loading conditions, 
which means TR severity is highly dynamic (25). Unfortunately, it was impossible to 
analyze patients receiving a tricuspid valve replacement compared to a tricuspid valve 
repair due to small numbers.  Due to multiple testing some differences could be due to 
chance. Propensity score matching reduces the sample size, and therefore may reduce 
power of tests. Nevertheless, we utilized a matching technique because the main interest 
of this study was the effect if treatment in a typical treated patient. Some patients in the 
matched population had no recorded follow-up. Notwithstanding, sensitivity analyses 
did not change the direction of conclusions in most hypothetic missing scenarios. 
CONCLUSIONS
Patients undergoing concomitant TVS differ significantly from patients without TVS. In 
matched patients concomitant TVS during LVAD implant does not seem be associated 
with better clinical outcomes. Concomitant TVS reduced TR significantly early after 
LVAD implant, however, differences in probability of TR disappear during follow-up. 
Using current selection criteria, TVS does not seem beneficial 
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HORIZONTAL ASPECTS OF ECONOMIC FACTORS IN TISSUE AND CELL 
BANKING
Tissue establishments, regardless of whether they focus on replacement tissues, assisted 
reproductive tissues and cells, or hematopoietic stem cells, share some common, 
horizontal economic aspects.
It is widely accepted and encouraged in the EU Member States that donation of human 
tissues and cells for transplantation is unpaid. According to the EU Directive on quality 
and safety of human tissues and cells (2004/23/EC), the philosophy of voluntary unpaid 
donation (VUD) should be a guiding principle, and Member States are urged to take 
steps to encourage a strong public and non-profit sector involvement in the provision of 
tissue and cell application services (2004/23/EC:18).
However, it is important to note that economic factors do have an impact on the broad 
range of tissue banking activities. Every activity undertaken comes with a cost, regardless 
whether they are undertaken within a public or private setting. As such these factors 
have an impact on the availability to patients of safe tissue and cell therapies.
This section focuses on costs and incomes for tissues and cells produced and delivered 
by tissue establishments.
If tissues or cells are needed for a patient in a hospital or clinic, either that organisation 
or the appropriate health (insurance) institution1 is charged by a tissue establishment.2 
Although tissue was donated altruistically and free of charge, costs of labour and services 
necessary to transform the donor material into a usable and safe transplant add up, 
and need to be covered. For tissues aimed at autologous treatments after processing or 
storage in the tissue establishment, costs are equally applicable.
Throughout the European Union, the process of establishing the fees necessary to cover 
the costs incurred in tissue and cell banks is regulated and influenced in many ways. This 
chapter provides an indication of which costs are generated in the different steps of the 
process from donation to transplantation.
INVESTMENT AND FUNDING OF TISSUE ESTABLISHMENTS
Investment
The demand for tissue or cellular allografts can be intermittent (incidental) or structural. 
For example, if a hospital or clinic uses donor tissue only a few times per year, it may 
not be feasible to invest in the construction of a tissue bank. If the demand is structural 
(e.g. daily use in orthopaedics or ophthalmology), setting up a tissue or cell bank can 
guarantee a continuous flow of tissue, of which the specifications should correspond 
with the demand from one or more hospitals. Many tissue and cell banks have been set 
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up to cover a specific local demand. The bone/musculoskeletal sector is a good example 
of this. In the EU, there are hundreds of local tissue establishments providing femoral 
heads, procured in the OR, for the benefit of recipients in the same hospital. However, 
in parallel larger tissue establishments supply bone (and other multiple tissues) on a 
regional or national level or even across borders.
Initiating a tissue establishment compliant with the requirements of EU Directives 
(Directive 2003/94/EC), particularly with relation to the processing facility requirements, 
requires investment. Not only for the construction of a cleanroom and adjacent service 
rooms, but also for special instruments, education and training of personnel, quality 
system and certification, as well as for putting in place the appropriate ICT solutions. 
The table below shows the following range of costs per m2 of a GMP laboratory.
Table 1. Classification of cleanroom levels
Maximum permitted number of particles/m3 
equal to or above
Recommended limits for microbial 
contamination
Grade At rest** In operation Air 
sample 
cfu/m3
Settle 
plates 
cfu/4 
hours
Contact 
plates 
cfu/plate
Glove 
print 
5bfingers 
cfu/glove
0.5µm 5µm 0.5µm 5µm
A 3,500 0 3,500 0 <1 <1 <1 <1
B* 3,500 0 350,000 2,000 10 5 5 5
C* 350,000 2,000 3,500,000 20,000 100 50 25 -
D* 3,500,000 20,000 not defined not defined 200 100 50 -
Source: Camfil Farr (via Advantage Business Media, Controlled Environments, 2013)
*(a) In order to reach the B, C and D air grades, the number of air changes (i.e. a measure of how many 
times the air within a defined space per hour is replaced) should be related to the size of the room and the 
equipment and personnel present in the room. The air system should be provided with appropriate filters 
such as HEPA for grades A, B and C.
**(b) The guidance given for the maximum permitted number of particles in the “at rest” condition 
corresponds approximately to the US Federal Standard 209E and the ISO classifications as follows: grades 
A and B correspond with class 100, M 3.5, ISO 5; grade C with class 10 000, M 5.5, ISO 7 and grade D 
with class 100 000, M 6.5, ISO 8.
Indeed, one of the main drivers for initial investment relates to the level of environmental 
air quality and related cleanroom conditions required to process tissues and cells. 
Depending on the tissue grafts that will be processed, different levels of airborne 
particulate classification can be defined, based on the EU guide to GMP, which is also 
used by the Directive 2006/86/EC to define the requirements of the environment during 
processing of tissues and cells in a tissue establishment.3 These so called cleanrooms 
are necessary to prevent microbial contamination of the tissues during processing. The 
requirements for a certain level also depend on the processing steps (debridement, 
cutting, sizing) after the work in the clean room has been completed. To achieve this, a 
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certain level of absence of particles in the air must be maintained (see table below). For 
a Class A clean room, a level of maximal 3 500 particles of a size of 0.5 µm and 0 (zero) 
particles of 5 µm is permitted (Commission Regulation (EC) No 1234/2008).4 A Class 
A environment requires continuous monitoring of particle counts (FDA 2004; 91/356/
EEC Annex 1 Revised 2008). Under Class D these values are 3 500 000 and 20 000 per 
m3 respectively.
Although legislation, guidelines and standards exist, in general best practice translates 
into aseptic tissue processing within environmentally controlled facilities, as it is up 
to each establishment to determine and establish the qualification of their facility in 
relation to cleaning and sanitation (AATB, 12th Edition; Nair et al, 2012). As such, 
musculoskeletal and cardiovascular tissues may be processed in Grade A clean rooms 
(A laminar Flow Cabinet against in a grade B environment), but a lower grade (A with 
C or D background) is also still common practice. Skin and corneal grafts, depending 
on the final graft that is to be produced, may be processed in a Grade A Laminar Flow 
Cabinet, with an environment of Grade C or D. HPC processing usually takes places 
in Grade C or D environment in a Grade A Laminar Flow Cabinet. If the grafts are 
not processed in a Grade A clean room, and the tissue allows it, terminal sterilisation is 
applied or required by local authorities. The investment for a clean room facility can be 
considerable as shown in the table below.
Table 2. Investment cost of GMP cleanrooms
€ price m2 € price m2
Minimum Maximum
Class A 12,331 14,061
Class B 9,730 11,178
Class C 7,452 8,746
Source: Advantage Business Media 2013
As indicated, since facilities with Grade A clean rooms must be entered from Grade 
B,  and assuming that the minimum Grade A surface area is 16m2, and the Grade 
B room is 8m2, the minimum investment in this facility (without service and office 
space) would be about €275 000. Assuming a ten-year depreciation period, the annual 
costs would be €27 500. If the tissue establishment in this example were to distribute 
1,000 tissue grafts per year, a cost of €27.50 per graft could be included (in addition 
to other costs, see below) in the calculation of the final fee to the end user, in order 
to recover this investment. It might be assumed therefore, that it is in the interest of 
tissue establishments with high investment costs to process as many grafts as possible to 
achieve an economy of scale in which these costs per tissue are as low as possible.
In a typical processing unit, multiple environmental Grades are required. For instance, 
a clean room complex can consist of 20 m² Grade A, 100 m² Grade B, 20 m² Grade C 
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and 800 m² Grade D. A typical investment in a cleanroom facility therefore costs easily 
over €1 million.
Maintaining and running clean rooms also incur high operational costs, including:
• Electricity to provide clean air and temperature control
• Regular change of hepa-filters
• Sterile personnel suits
• Microbiological control and environmental monitoring
• Sterile materials and agents
• Cleaning after each donor
Additionally, before the tissue establishment can start using its clean rooms for 
processing tissues, there will be a non-productive, preparatory, testing and validation 
period required for the qualification of the facility. The cost of this non-productive 
period and the investment in construction of the tissue establishment during a phase 
without income should be taken into account.
Funding
There are multiple options for financing a new, state of the art tissue establishment:
• Donation such as a subsidy by a government, a charity or the general public
• Grant or financial injection by the hospital or the university, primarily to create a 
solution for the demand for tissues or cells in that specific clinic/hospital
• Bank loans (from financial institutions)
• Private party investment
• A combination of two or more of the above.
The source of investment may very well influence the fees that tissue establishments ask 
for their services, either within or outside the location where they are situated.
In the case of subsidies, grants or injections by public actors, charities or governments, 
there is usually no necessity for a return on investment. So it may very well be that the 
investment and operational costs are not reflected in the fee or price. When banks or 
private investors have contributed, standalone or in a combination with other modalities, 
there is a necessity for a return on investments through interests, and/or a dividend to 
the investor(s) and eventually return of the investment itself.
The modality of investment also influences the legal entity under which the tissue 
establishment is operating. The nature of the legal entity may influence the fees tissue 
establishments are charging. Tissue establishments are set-up in different ways. As a 
result, the following broad funding models can be observed in tissue establishments in 
the EU.
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1. Public sector: centrally allocated operating budget; tissues and cells provided to the 
user without charge
This was the typical model for a hospital based tissue bank, supplying only to users in 
its own hospital, and fully hosted and financially supported by the hospital. Although 
common in the past, this model is now much less frequently seen. It does however still 
exist in a number of Member States for some tissue and cell types. It avoids any kind 
of competitive market, any disincentive for hospitals to use tissues and cells, and any 
pressure on tissue establishments to distribute a particular volume of tissues or cells for 
clinical use. However, it is often challenging for centrally-funded tissue establishments 
to obtain the funding needed for investment in new or improved facilities or for 
preparation process developments (depending on who is the centrally funding entity, 
e.g., a hospital or government). In this model, many essential internal steps are carried 
out by public sector players also without charging, e.g. donor testing or microbiological 
testing of tissues or cells, and total service costs are often not well defined, which can be 
performed by other horizontal hospital services. Salaries and benefits of employees are 
tightly controlled as in all public sector health service units.
2. Public Sector: cost recovery from user hospitals, clinics, patients or health insurance 
schemes
This health service ‘internal market’ model is increasingly common in the field of tissue 
and cell services, as is it is in the entire public health sector. It requires a full costing 
activity that includes identification and quantification of fixed and variable costs, 
including capital depreciation and the costs of all third party contracts. The fee charged 
for each unit of tissues or cells distributed should equal the total unit cost so that income 
from tissues or cells supplied provides adequate funds for a sustainable service. The fee 
charged might include a small percentage for service development and for contingency 
planning in the event of emergency. Salaries and benefits of employees are also controlled 
in this model, as in all public sector health service units.
In this model, there is a ‘break-even’ point when the tissue establishment is supplying 
a sufficient number of finished tissues or cells to cover all costs; a so-called critical 
mass. The need to achieve a ‘break-even’ point could be seen as putting pressure on 
the tissue establishment to compete with other (private or public) tissue establishments 
for orders; their service might not be economically sustainable otherwise and hospitals 
might become dependent on commercial providers. However, in this model, there 
is usually more opportunity for leading tissue establishments to carry out thorough 
cost- assessments and to obtain adequate funds for service developments and facility 
improvements. Commonly, this model exists in the context of tissue establishments that 
are established within other public sector health organisations such as blood transfusion 
services. In some cases, tissue establishments operating in this funding model might 
obtain an injection of ‘start-up’ funding from the central health service or cross- 
subsidisation from the parent organisation for an initial period until well established.
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3. Independent: non-profit; cost recovery from user hospitals, clinics, patients or 
health insurance schemes
The establishment of independent foundations or other types of non-profit organisations 
has been observed in this sector over a number of years. This model is characterised by 
cost-recovery based on a full-cost analysis as in the previous model and the same pressure 
exists to achieve a threshold level of supply activity to ensure adequate income to cover 
all costs. The independence of these organisations, however, means that there is less 
(or no) health service financial governance and aspects such as employee salaries, and 
benefits and the margins included for developments or other contingencies, can be much 
higher. The greater flexibility provided in this model often allows a tissue establishment 
to achieve a high level of efficiency and rapid development but the model raises concerns 
regarding the sustainability of services if the owners choose to move to another activity. 
Many independent non-profit organisations achieve success through supplementing 
their income by achieving charity status and organising fund-raising programmes; this 
applies notably to a number of independent bone marrow donor registries.
4. Independent: for profit companies
This purely commercial model involves accurate costing of activities but no requirement 
to ensure that fees or prices equal costs. In the EU, this model exists in the field of 
assisted reproduction (private ART establishments), private cord blood banks for family 
use and some replacement tissues, particularly bone. In the case of commercial bone 
banking and supply, most commercial actors are subsidiaries of US companies.
Traditionally, tissue banking in the EU has been organised under one of the models 
described above. Some commercial players are quoted on the stock exchange, bringing 
the added feature that their strategy for tissue and cell processing and supply can be 
determined by shareholders, not in any way involved in the field. The levels or sources 
of the investments were not studied for this report.
Operational costs
In order to understand how tissue establishments have calculated their costs, four main 
activities (processes) are recognised in any tissue establishment. In terms of micro- 
economics, these may be indicated as cost-centres. This division in four major activities 
doesn’t differ from similar structures in any productive organisation:
• Donor recruitment and selection; tissue procurement or cell collection (acquisition 
of raw materials)
• Testing and quality control (quality management)
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• Processing and storage of tissues or cells (production into end products)
• Distribution (customer relations and physical distribution to end users - hospitals, 
health professionals or recipients directly).
Overhead costs such as management costs, public relations, software, etc. are allocated 
over the four main activities by means of ‘activity-based costing’. This means that these 
costs are divided according to a factor representing the level of activity (work) taking 
place in these four activities.
Figure 1. Core processes and cost in tissue establishments
Source: Theo de By (2013)
The costs, generated in these four main processes, add up to the total costs of the tissue 
establishment. The tissue establishment management needs to recover these costs from 
the revenue for the number of finalised tissue/cell grafts that are distributed during one 
year, in order to financially break-even. Also, the investment costs might also need to be 
recovered from these revenues, over a period of years of depreciation, depending on the 
funding model.
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It is therefore important that tissue establishments have a good understanding of their 
cost-structure. Cardiovascular and ocular tissue establishments were asked in research 
for this report whether they have cost calculation information, specified for the four 
main processes. Replies are summarised in the table below.
Table 3. Number of tissue establishments with cost calculation
Cost calculation 
made
No cost calculation 
made
No answer Total
Cornea Banks* 12 3 15
Cardiovascular Banks** 6 5 1 12
Total 18 8 1 27
Sources: * Survey to ocular tissue establishments (2015), data from 2012 ** Survey to cardiovascular tissue 
establishments (2014), data from 2012
Respondents who did not calculate the costs, were mostly tissue establishments where 
the price is determined by either the government or by another authority. Only three 
cornea banks, and no cardiovascular tissue establishments, specified the costs in line 
with the core processes.
Donor recruitment and selection, and tissue procurement costs
Direct and indirect costs occur when a tissue establishment recruits donors and 
donations. The direct costs are the costs of the procurement that can vary significantly 
in complexity. Obtaining sperm cells from a living donor is relatively simple, while 
obtaining heart valves from a deceased donor requires invasive surgery. Appropriately-
trained staff, sterile instruments and materials for tissue retrieval, and transportation of 
tissues and/or retrieval teams are the main direct costs.
Frequently, tissue has to be discarded after procurement due to quality and safety reasons 
such as medical contraindications to transplantation, microbiological contamination, 
and tissue quality. For example, in cornea banking the percentage of discarded tissues 
is approximately 40% on donor related, serological, microbiological or morphological 
grounds (EEBA Annual Directory, 22nd edition). In cardiovascular tissue banking, 
many valves are rejected because of calcification, fenestrations or other anatomical 
abnormalities.
Thorough donor selection based on the donor history, professional procurement 
techniques, as well as donor testing (see Chapter 2) is therefore essential. Obviously these 
are easier with living donors. A set of well thought-out questions, with cross references 
and an assessment by qualified and trained healthcare professionals is therefore of 
upmost importance in order to pre-select donors well and minimize later discard rates. 
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The donor retrievals that result in discarding of tissue grafts are still a direct cost burden 
that contributes to the overall running cost of a tissue establishment.
The indirect costs include maintenance of an infrastructure for recruitment and initial 
selection of donors. In the case of regional post-mortem donation, the infrastructure 
includes such necessities as: maintenance of a stock of materials, trained staff and a 24/7 
duty desk.
Tissue establishments providing bone marrow, Peripheral Blood Stem Cells (PBSC) or 
sperm present a specific situation of donor recruitment and banking. These activities 
are based on an inventory of potential donors. Having a register of potential donors is 
an essential asset for providing an adequate number of donations for medical purposes. 
The effort that goes into recruiting donors, but also in retaining and keeping track of 
them, is a substantial part of the costs in these establishments. For stem cell registries, it 
also means that because of the unique HLA typing, an enormous number of potential 
donors is needed to provide for a limited number of effective donations and eventual 
grafts (0.01-0.1% of the registered donors actually donate per year) (WMDA report, 
2012).
Costs of testing for safety
To minimise the risk of serious adverse reactions (SARE) due to the infection of the 
recipient with contaminated material from the donor, various tests are carried out in all 
tissue establishments. EU legislation lays down a set of minimum testing requirements 
(Directive 2006/17/EC Annex II), while in several countries, there are additional tests 
designed to address the local epidemiological situation.
The composition of the test regimen may therefore be different from country to country 
and from bank to bank, however a minimum set of tests to be performed is mandatory. 
In addition to blood tests for markers of transmissible diseases, tissue establishments 
sometimes include blood cultures or the determination of absence of malignancies by a 
pathologist. Emerging infectious diseases or changes in the prevalence or incidence of 
existing viruses require that new tests be added to the existing regimen.
Testing techniques are continually developing. Contaminant micro-organisms that 
could not previously be detected may be detectable in the future; e.g. nucleic acid 
technology (NAT) tests, which enable tissue establishments to determine the presence 
of specific donor-related viruses, and/or to confirm the negative outcome of other tests. 
The existing regimen and the necessity to add additional tests can influence the final fee 
for the tissues.
Costs of processing and storage
Processing is the activity in which the donated tissue is prepared as a graft for storage 
and subsequent transplantation. Processing can be more or less intensive, depending on 
the kind of tissue as well as on the chosen decontamination method. For example, the 
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preparation of corneas involves cleaning and disinfection of the whole eye, dissection of 
the cornea, placement in storage medium (with or without subsequent microbiological 
testing) and an assessment of tissue quality. On the other hand, the processing of bone 
may involve different steps, including terminal sterilisation by gamma-irradiation. 
Many tissue establishments perform microbiological testing during processing and and/
or apply methods aimed at eliminating any micro-organism. These activities generate 
high costs. Processing requires trained personnel with appropriate expertise who process 
the tissue in cleanrooms.
Depending on the kind of tissue and the packaging and storage method, the storage 
time after processing can vary from a few days to many years. Short-term storage has the 
risk that tissue or cell grafts expire more quickly, while long-term storage has the risk 
that revenues may be obtained years after the costs have been incurred, possibly leading 
to financial liquidity problems.
The costs for equipment and organisation of storage also depend on how the tissue 
is stored; e.g. by room temperature on shelves (glycerol-preserved skin); in incubators 
(cornea); at -80oC (musculoskeletal tissue); or in liquid or vapour phase nitrogen (heart 
valves). Monitoring storage temperatures by continuous logging and alarm systems add 
to the cost of storage.
Costs of distribution
In the distribution process, which aims to provide finalised tissue/cell grafts to the 
end- user (surgeon, patient or hospital) of the tissue establishment, there are direct and 
indirect costs. The direct costs include packaging and transportation. The indirect costs 
consist of the administration of logistics in relation to final destination, recipient data 
and costs to be charged.
Distribution costs vary significantly. There are tissue establishments which process 
tissue/cells mainly for local use, for example, tissue establishments related to a hospital. 
At the other end of the scale are tissue establishments that ship tissues/cells to clinics/
healthcare professionals across borders, as is often the case in the HPC sector.
Allocation of financial surpluses
In order to guarantee long-term continuity, all organisations, both for-profit and non- 
profit, must at least generate sufficient income to cover their costs. Financial surpluses 
occur when there is more income than costs.
Whereas for-profit organisations focus at maximising profits and will use (part of ) these 
surpluses to compensate shareholders or other providers of risk capital, organisations 
that are not aimed at making profit might allocate any financial surplus as ‘reservations’ 
to the financial balance, or might transfer them to the centrally funding entity. 
Where reservations are made, these can be earmarked to compensate future losses, 
or investments, for example. As in tissue banking, donations fluctuate from year to 
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year, and therefore income fluctuates accordingly, such reservations are important to 
guarantee the continuity of the services provided.
MANAGING VOLUMES AND THE RELATED COST FOR TISSUE 
ESTABLISHMENTS
The main purpose of banking human materials for transplantation is to satisfy the 
clinical demand for tissues and cells. In many cases, a tissue/cell transplant is the best 
or only therapeutic option for patients. Tissue establishments in general have a complex 
serious of tasks: to correctly estimate the demand for tissue transplants; plan the number 
of donations needed accordingly; purchase procurement and processing materials; and 
finally, produce transplantable allografts.
Tissue establishments have an additional challenge: they depend on the willingness 
of the general public to donate tissues and cells before or after death. The return on 
investment of donor recruitment is uncertain. Donor shortage is frequently reported 
(WHO, 2014); NTS, 2014), and can be absolute or relative (insufficient donors of a 
specific type of tissue). In a situation of absolute donor shortage, the tissue establishment 
cannot satisfy the medical demand, nor can it cover its projected costs. The nationally 
defined donor consent system plays a role in this, and is often related to organ donation, 
although consent systems fall outside the scope of this report.
A different scenario is when tissue establishments are very successful in recruiting 
donors. In such situations the stock of grafts, for which no recipients can be found (yet), 
becomes a financial burden. For the management of the tissue or cell bank, it might 
be difficult to explain why, after many years of publicity about the need to donate, 
donations from the public are refused because there is a surplus.
In situations where tissue establishments distribute relatively few tissues, it may be that 
the total financial proceeds received by distributing tissues to the end-users (hospitals 
or surgeons) is not enough to compensate exploitation and investment costs. In such 
cases, without other financial resources, the tissue establishment may have insufficient 
‘critical mass’ for innovation and investments for improvements and ultimately, the 
continuity and sustainability of the tissue establishment may become uncertain (as was 
demonstrated in the case of Bayerische Gewebebank and Bislife in the Netherlands). The 
‘critical mass’ is difficult to estimate however, since tissue establishments are organised 
in different ways, as described above.
In conclusion, the supply and demand in banking of human materials is a management 
task in which medical, financial and additional social aspects must be constantly balanced 
in order to strive for the continuity of the organisation and its acceptance in society.
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VALUE AND FEES CHARGED FOR TISSUES AND CELLS
There is a great variety in the way prices or fees of tissues are calculated. Moreover, in 
many instances the fee charged to the end-user is determined on grounds other than the 
costs generated in the tissue establishment. Referring to the ‘fee’ for tissues rather than 
to the ‘price’ is therefore more appropriate.
EU Directive 2004/23/EC states: “As a matter of principle, tissue and cell application 
programmes should be founded on the philosophy of voluntary and unpaid donation, 
anonymity of both donor and recipient, altruism of the donor and solidarity between 
donor and recipient. Member States are urged to take steps to encourage a strong public 
and non-profit sector involvement in the provision of tissue and cell application services 
and the related research and development”.
Since the tissue of donors is donated for altruistic reasons, and free of charge, some state 
that the tissue has a socio-medical value before it gets a financial value. Some speak of 
the production of bio-value in this respect (Waldby, 2002). The value of altruism is the 
result of people being concerned for the welfare of others (Rodriguez and Leon, 2002). 
The socio-medical value cannot be expressed in monetary terms, since it is literally the 
value of life. If only the economic value of donated tissue or cells is appraised, serious 
concerns can be raised that, through the creation of a market for body parts, there is the 
potential to devalue human life. It would imply that an individual’s worth is based on 
the material value of their body rather than that of a human being (Boo et al, 2011).
Donation of tissue and cells is estimated to be cost-effective and potentially cost saving, 
since the final resulting therapies are often live-saving and/or enabling patients to return 
to work and therefore reduce the reliance on social or medical support (Committee 
on Increasing Rates of Organ Donation Board on Health Sciences Policy, 2006). In 
other areas of healthcare, for example, pharmaceuticals, this value is often estimated 
through dedicated bodies working on health technology assessments (HTA). Such 
value-based pricing-mechanisms do not explain how the prices or fees for tissues and 
cells are determined, however. Tissue and cell therapies are relatively low priced on a 
cost-basis, or sometimes even below costs in a public funding model. It is said that 
fees just ‘cover the costs’, but this does not entirely explain the differences between the 
fees charged by tissue establishments. Fees partly depend on the cost of procurement, 
and take into account the additional tests required to safeguard the potential recipient 
(Epstein, 2009). These fees may differ per laboratory (Hoeyer, 2013).
In order to protect the system of altruistic donation and the socio-medical value of the 
cells and tissues that is based on principles of subsidiarity and solidarity, many countries 
have installed (semi, or quasi) governmental organisations to regulate tissue and cell 
banking. The tasks of these organisations are among others, to prevent financial over- 
compensation or the commercialisation of tissue and cell grafts, and to safeguard the 
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interest of the general public from mishandling donations of human tissue and cell 
grafts (WHO Guiding Principles on human cell, tissue and organ transplantation).
The work of the tissue establishments in executing the four major processes as explained 
earlier in this chapter results in an economic value of the grafts.
CROSS-BORDER EXCHANGE, IMPORT AND EXPORT
A market is a physical or a virtual place where the demand and supply of goods or 
services meet to trade. In free markets, the economic reality is that given a high demand 
and a low supply of a certain product, the price of that product will undergo an upward 
pressure. However the tissue and cell “market” is not fully subject to these dynamics 
given the fact that these are not typical products and authorities often determine their 
price or the fee charged by the tissue establishment. Contrary to free markets for other 
goods, the flow of tissues and cells is controlled by authorities. In some countries, 
policies are in place to prevent tissues being the subject of free market forces in order to 
ensure that no profit is made from the donated material itself. Only in a few instances is 
a higher fee charged to international (including non-EU) recipients.
The cross-border distribution (within the EU), as well as import and export of tissues 
from/to third countries, are influenced by a number of factors (see also figure 2 below). 
One factor could be the introduction by some Member States of more stringent quality 
and safety requirements (than those laid down in the EU Directives), which may lead 
to the fact that a tissue establishment in one Member State does not necessarily meet 
the more stringent requirements in another Member State. An important obstacle for 
tissue establishments in freely distributing tissue grafts throughout the EU, relates to 
the different national implementations of EU legislation, and consequent differences 
in administrative and regulatory procedures which have to be overcome to get access 
to another Member State. EU legislation lays down only minimum requirements, and 
many Member States add a significant number of requirements (and procedures). An 
overview of these additional requirements is not available for the actors in the field 
(unless costly consultants can be paid for). It is therefore very difficult for a single tissue 
establishment in one Member State, in particular with limited resources, to address 
demands in other EU Member States. From this point of view, it may be considered that 
the European ‘market’ for tissues and cells is restricted.
Imports from third countries, specifically from the USA, seem to be needed to cover 
the needs of European patients. However, since most EU Member States do not have 
a sufficiency policy and/or do not collect data on cross-border distribution (within the 
EU) and import/export of tissues and cells from/to third countries, it is impossible 
to understand if these imports are absolutely needed or could be covered from other 
sources (e.g. EU tissue establishments). In some countries the import takes place on a 
structural basis.
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Compared to EU, US developed a completely different model. Donor recruitment is 
well organised and organ and tissue procurement organisations in USA are rewarded 
for tissue donor referrals, which results in a sufficient quantity of tissue. For US tissue 
establishments, Europe is an attractive market where they can distribute their surpluses 
and generate additional income. In particular musculoskeletal tissues and cornea are 
imported from the US.
Figure 2. Cross-border distribution, import and export
Source: Theo de By (2013)
Alliances between US tissue establishments and European partners have been created to 
ensure the continuity of the flow of tissues to Europe. These alliances also allow getting 
the necessary know-how to address (national) administrative procedures in EU Member 
States. As these US tissue establishments are usually larger, they also have resources 
to acquire insights into regulations and administration of different Member States, 
and hence facilitate access. Some US tissue establishments have assigned managers to 
facilitate distribution (in the US the term ‘sales’ is used) of their tissues in Europe. A few 
Member States report these imports to be important in order to address local shortages.
Some EU countries have organised their tissue banking structure in such a way that 
self- sufficiency is enabled. In some countries (IT, UK, NL) a mandatory allocation 
system is in place. This guarantees the supply to cover the national demand. In other 
countries, such as Germany (DE), Spain (ES) and France (FR), voluntary networks 
strive to achieve optimal allocation of available grafts.
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The situation of being able to satisfy the national need for tissue grafts, which is the result 
of this structure, prevents dependency on other countries. As we have seen over time, this 
dependency could interrupt the availability of tissue grafts for patients, e.g. in situations 
where import from areas with a high incidence of viral contamination is prohibited. Such 
was the case when an epidemic of SARS (Severe Acute Respiratory Syndrome) broke 
out in April 2003. The result of the epidemic was that tissue establishments outside the 
geographical area of contamination could not accept tissues from tissue establishments 
in that area. Moreover, donors from Europe, who had travelled in those areas, could (if 
they died after return) not be accepted as tissue donors in Europe. Safety criteria are also 
the reason why, for many years, the donor-acceptance criteria of tissue establishments 
forbid import of tissue originating from donors in the UK and Ireland (IE). The reason 
for this was the risk for variant Creutzfeldt-Jakob disease transmission. For example, IE 
does not procure from IE donors, nor does it accept UK donors. Therefore IE is strongly 
reliant on US import.
The factors mentioned above have a significant impact on the underlying discussion 
whether the EU should strive for self-sufficiency, and whether the exports to countries 
outside the EU could have (partly) compensated for the imports from the US.
IMPACT OF TAX AND VAT REGULATIONS
Increasingly, non-profit organisations active in the field of donation, banking and 
distribution of human tissue for transplantation, are confronted with contradictory 
policies between healthcare authorities and finance authorities.
In the EU, in line with the EU and national legislation and WHO and Council of 
Europe recommendations, health care authorities consider tissue banking as an activity 
which should take place in non-profit organisations. In some countries this principle 
is strictly enforced via different instruments, such as centrally made price decisions 
(e.g. by the Ministry of Health or other governmental bodies), and control measures 
(e.g. inspections/audits and border-control, etc.). Moreover, the non-profit character 
of tissue banking is comparable to that of other health services such as the provision of 
blood. If not exempted, then a zero VAT tariff would be compatible with the non-profit 
approach.
In EU treaties, and subsequent Directives with respect to Value Added Tax (VAT), human 
organs, blood and breast milk are exempted from being charged with VAT. Even though 
human tissues and cells are not mentioned, taking into account also the WHO guiding 
principles (where it is emphasised that the term ‘organ’ has to be interpreted widely and 
therefore include any type of human tissue), it is the authors’ view that tissues and cells 
should also be exempted from VAT. Several Member States used this globally accepted 
understanding when they transposed the provisions of the VAT Directive 2006/112/
EC into their national law and mentioned concretely tissues and cells for therapeutic 
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purpose as to be exempted from VAT to avoid any misinterpretation of the “exemptions 
for certain activities in the public interest” and to clarify the meaning of the written 
words “organs, blood and milk” (Article 132 (1)d of Council Directive 2006/112/EC of 
28 November 2006 on the common system of value added tax).
Recently, finance authorities in some national regions and EU countries have considered 
that human tissues should be subject to VAT. VAT charging Member States include DE, 
IT, ES and PT, while for example NL has a 0% VAT. Charging tax on human tissue 
may conflict with the principles in the EU Directive and also seems contradictory to 
the interpretation by these same finance authorities in the past. Besides decisions of tax 
authorities to charge VAT, it has been reported by some non-profit organisations that 
tax authorities charge them for profits and first national finance courts confirmed such 
decisions with the argument, that fair competition to commercial companies that could 
offer comparable activities would be harmed.
In parallel, local and national health authorities request from tissue establishments to 
continue to strive for and to stay close to state-of the-art methods (e.g. for screening 
and processing methods with the aim of further developed safety for patients) and to do 
clinical studies and research to bring evidence of such activities. The financial burden 
of such requests from health authorities can only be financed by making surpluses in 
advance or finding other resources. Taxes on these surpluses directly limit the cash ability 
of tissue establishments and their capacity to fulfil the above mentioned requests from 
health authorities.
In conclusion, according to declarations of tissue bankers as provided in the context 
of this study, the application of VAT seems to be against the principle of non- 
commercialisation of the human body as laid down in the EU Charter of Fundamental 
Rights. Currently, various interpretations of the VAT Directive 2006/112/EC within the 
EU create inequality between regions or countries, with tissue establishments required 
to charge VAT, while others do not. This inequality may disrupt the level playing field, 
putting in difficulty those who have to charge taxes to the end-user. At the same time, 
end-users, usually non-profit hospitals, are confronted with higher costs. This may give 
the general public the impression that altruistically donated tissues are commercialised, 
which in turn could potentially harm future willingness to donate organs and tissues.
CONCLUDING REMARKS AND SUMMARY HORIZONTAL ASPECTS
• The set-up of a tissue establishment requires equipment, know-how and appropriate 
facilities. These call for significant investment, in particular to build clean-rooms 
offering the environmental conditions to safely process tissues and cells, as required 
by EU-law. Building a high-grade clean-room (grade A in B) at least costs €250,000, 
and more regularly require amounts of over €1 million.
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• The consequent operational costs of tissue establishments are defined along four 
major activities needed to transform a tissue from a donor into a therapy for a 
recipient:
• Donor procurement: to identify a donor, obtaining consent, verification of 
suitability to donate and obtain the tissues or cells.
• Testing: to identify and avoid the risk of transmitting diseases
• Processing and storage: to transform the procured tissue/cell into a substance ready 
to be applied as treatment
• Distribution: to ship the final graft towards the clinician or hospital where the 
tissue/cell will be applied on a patient.
• The relative importance of each of these activities varies between the 3 sectors and 
along tissue type. E.g., for bone marrow transplants (HPC) processing and storage 
is relatively limited, but a reliable and fast distribution mechanism is of utmost 
importance.
• General overhead costs, such as management, or the need for a 24/7 presence, can 
add significantly to the budget. The high discard rates for quality reasons, like for 
heart valves, and the often short shelf-lives, like for corneas, add further challenges 
and significant costs. The stock of transplantable tissues should be high enough to 
cover direct demand, but low enough to prevent expiration, this is a challenge in 
itself.
• The surveys performed within this study indicate a limited cost-awareness on the 
real costs made by tissue establishments. The legal structure and funding model of 
the tissue establishment may play a role when it comes to this, in particular where 
tissue establishments are hosted in public hospitals, or where funding is based on 
charity.
• This limited cost-awareness is also reflected by the high variability in prices/fees 
charged for tissue and cells over the EU. These prices are often fixed at national 
level, and do not necessarily reflect costs, but rather reflect a national policy like 
ensuring self-sufficiency or avoiding commercialization of the human body. They 
do not really take account of the real cost or the volumes needed to cover all costs 
and come to a financial break-even.
• All these factors led to the conclusion that there is no real single EU market for 
tissues and cells, which is the reason why the authors prefer to title this study rather 
as an ‘economic landscape’.
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• Four funding models can be seen for tissue establishments in the EU. Tissue 
establishments can either have (1) a public model, with all costs carried by a 
public budget and the eventual tissue/cell provided without charge to the users. 
Alternatively, (2) public, (3) non-profit or (4) for-profit tissue establishments do 
recover their costs by charging a fee to the users. The (3) non-profit and (4) for- profit 
tissue establishments do also aim to obtain a financial surplus for investments, for 
building a reserve or for obtaining a profit in case of (4). Public tissue establishments 
can usually rely on public budgets or on charity to make investments.
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REPLACEMENT TISSUES
This chapter starts with a description of the field of replacement tissues, followed by the 
organisational structures and collaborations; it provides current and future perspectives 
and conclusions on the most common replacement tissues: cardiovascular, ocular, 
musculoskeletal tissue and skin.
FIELD DESCRIPTION (INCLUDING ECONOMIC ASPECTS)
Tissue grafts that replace a recipient’s existing tissue(s) in order to take over the 
functionality of damaged tissue are generally referred to as replacement tissues. In the 
large majority of cases, such tissue grafts are obtained from a donor who is different from 
the recipient, through an allogeneic donation. Although the donor and recipient can, 
in some cases, be the same person (autologous use), this chapter focuses on allogeneic 
donation.
Replacement tissues are mostly procured after death, but can also be donated by living 
donors (e.g. femoral heads removed during primary hip replacement). They consist of a 
wide variety of types. In this chapter the focus will be on the tissues that are used most 
commonly:
• cardiovascular tissue
• ocular tissue
• musculoskeletal tissue
• skin
Besides these, many other tissues can be transplanted, such as pancreatic islets, amnion, 
fascia and nerves, but the numbers donated and transplanted are much lower compared to 
the four categories listed above. Composite tissues such as hands or faces are transplanted 
on very rare occasions and are not addressed in this chapter. The procurement and 
transplantation of organs is beyond the scope of this study.
The substances, processes and therapies described below are largely established practice 
in the tissue sector. However, these substances, processes and therapies are subject to 
continuous innovations in processing or clinical application, some of which might 
lead to a classification as Advanced Therapy Medicinal Products (ATMPs). In these 
cases, the products are not only subject to the tissues and cell legislation for the 
donation, procurement and testing steps but also to the pharmaceutical legislation 
(ATMP Regulation) for all subsequent steps in the process. The legal classification 
and the different legal requirements fall outside the remit of this study, but for tissue 
establishments that are active in those fields, the economic implications are important.
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This chapter describes the different types of replacement tissue grafts and tissue 
establishments for replacement tissues and mentions ATMPS where they may, in the 
future, have a significant impact on the demand, and therefore the economic landscape, 
for a particular tissue as a starting material for ATMP manufacture.
Cardiovascular tissues
Cardiovascular tissues include heart valves (pulmonary and aortic), conduits, arterial 
vessels (in different forms), veins and pericardium.
Clinical application
Surgical heart valve replacement is an effective treatment for patients with damaged heart 
valves. The first clinical reports on the transplantation of cardiovascular tissue date back 
to 1962. While artificial heart valves were still in development and industrial engineering 
failures emerged, the human tissue allograft turned out to be an alternative for those 
patients suffering from severe and irreparable regurgitation, congenital heart diseases or 
endocarditis. For replacement of the damaged valve, current options include a prosthetic 
(synthetic) valve or a biological valve (of human or animal origin). As innovation has led 
to better artificial heart valves with fewer disadvantages and the availability of human 
hearts has decreased, the surgical use of human donor heart valves has declined and 
is now important for two main indications: children and adolescents suffering from 
congenital heart defects and patients suffering from endocarditis (TRIP Annual Report 
2012, Biovigilance). Transplantation of human heart valves requires specific surgical 
skills, which not all thoracic surgeons have acquired during their training.
The use of vascular tissue in surgery also developed in the 20th century. Autografts and 
allografts, as well as artificial vessels, are used for repairing and replacing damaged or 
defective vessels. Vascular allografts are used to repair or replace large and medium- 
sized arteries or veins. They are used in cardiovascular, reconstructive and solid-organ 
transplantation surgery. Vascular allografts are sometimes used to create a shunt to 
enable access for dialysis (Inston, 2015). For transplant purposes, mostly arterial vessels 
and conduits are used. They are indicated for aortic disease that leads to slackening of 
the vessel wall (aneurism) and in patients who suffer from vascular infection or infected 
synthetic blood vessel prostheses.
Patches are prepared from the pulmonary artery or aortic artery and are used for 
reconstructions of congenital malformations in paediatric cardiac surgery.
Recently, development of endovascular stent-grafts has reduced reliance on conventional 
grafts to replace diseased arteries and it is likely that this trend will continue in the 
future. Aortic grafts are recently also used as a biological matrix for extensive airway 
reconstruction (Martinod et al, 2013).
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Pericardium is a membrane tissue that can be used for cardiovascular anastomosis, dental 
and ocular replacement procedures (Fehily et al, 2012).
Activity level in the EU
In 2012 in the European Union, a total of 77 cardiovascular tissue establishments were 
active. In 2012, Member States reported the donation of 1,974 hearts, processing of 
3890 heart valves and discard of 1008 heart valves, resulting in 2,882 heart valves issued 
for transplantation.
Table 1. Volumes of heart valves
Donation Recovered Tissues 
available 
1-1-2012
Processed Discarded Total 
Import
Total 
Export
AT
BE 274 549 170 549 12 188
BG
HR 19 9 12 31 10 1
CY
CZ 53 90 407 72 42
DK
EE
FI 231
FR 326 368 494 272 196 76 1
DE 296 141 277 124 128
EL
HU 20 14 14 6
IE
IT 231 366 364
LV
LT
LU
MT
NL 220 452 47
PL 179 358 145 230 78 5
PT 22 54 75 10 35
RO
SK 11 15 15
SI 1 1
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Donation Recovered Tissues 
available 
1-1-2012
Processed Discarded Total 
Import
Total 
Export
ES 192 350 350 102 65
SE 150 323 323 136
UK 985 814 931 267 37 37
Total 1,974 3,719 2,272 3,890 1,008 242 343
Source: EUROCET 2012, Economic landscape survey NCATC (2015), data from 2012
The import and export is the total of cross-border distribution and to/from third non-
EU countries.
Besides valves, depending on the demand, and the ‘defined graft-range’ of the tissue 
establishment, several other vascular and non-vascular tissues can be procured from a 
single donor.
Procurement, processing and storage of cardiovascular tissues
Donations of cardiovascular tissues originate from three different sources:
• Organ donors, where the heart is not suitable for heart transplantation;
• Domino donors, i.e. living recipients of transplanted hearts where the removed 
heart can provide transplantable tissues;
• Deceased non-organ donors, from whom multiple tissues can be removed.
For the procurement of heart valves, the complete human heart is procured and 
subsequently the heart valve establishment performs dissection and preparation of heart 
valve grafts. The valves used for transplantation are the pulmonary and the aortic valve. 
Besides valves, depending on the demand, and the ‘defined graft-range’ of the tissue 
establishment, several other vascular and non-vascular tissues can be procured from a 
single donor.
Processing of cardiovascular tissues takes place in cleanrooms which are often Grade 
A in a Grade B background. Minimum requirement is Grade A in Grade D. Valves 
are prepared from the heart and macroscopically evaluated (e.g. measured, tested for 
function, examined for defects). The valves are temporarily stored in a mixture of 
antibiotics and cryopreserved in a container with medium that contains cryoprotectant. 
Vessels are similarly treated (Fehily et al, 2012).
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Cardiovascular tissues are cryopreserved and stored in liquid or vapour phase nitrogen. 
This preservation technique has enabled the storage of donated cardiovascular allografts 
in heart valve establishments for years in order to create a stock of different sizes.
Pericardium can be freeze-dried before storage.
Heart valves are matched between donor and recipient based on type and size. In general, 
pulmonary valves are in much higher demand compared with aortic valves. This has 
partly to do with a specific technique for the treatment of congenital valve abnormalities 
called the Ross operation in which pulmonary allografts are needed. Small size valves for 
newborns are rare and require donation by infants that die young. Larger sizes also have 
a limited availability.
Cost structure
Three cardiovascular tissue establishments provided a breakdown of costs over different 
activities for this study, including staffing dedicated to these processes, such as costs for 
donor procurement, additional testing, processing, and distribution. Unlike the removal 
of an eye, or a cornea from an eye, a cardiectomy requires a small operation team.
The differences in cost structure of these three cardiovascular tissue establishments (TEs) 
find their origin in the way they organise their processes. TE 1 receives the donor hearts 
free of charge from organ donation teams or from organ donor organisations.
Costs of the surgical removal of the heart (cardiectomy) are therefore not invoiced. TE 
3 has outsourced the donor screening to a commercial laboratory. The different aspects 
contributing to the costs of cardiovascular tissue banking are elaborated below.
Table 2. Cost divisions in cardiovascular tissue establishments
TE 1 TE 2 TE 3
Donor procurement 2% 15% 23%
Testing 14% 2% 30%
Processing 70% 75% 47%
Distribution 14% 7% Not specified*
Total 100% 99% 100%
Source: Survey to cardiovascular tissue establishments (2014), data from 2012
*Distribution costs of TE 3 are separately charged to the requesting hospital
The cost of procurement of cardiovascular tissue is mainly dependent on the donor 
source (organ donors, domino donors or non-organ donors).
176
Chapter 10
An important factor, negatively contributing to the cost/benefit ratio, is the high discard 
rate of retrieved donor hearts. This high discard rate finds its origin in the morphology 
of the donor hearts as well as in the incidence of contamination of the tissue when it 
arrives in the tissue establishment. As a result, discard rates for reasons of morphology of 
44% and microbiology up to 9.7% have been reported (De By, May 2013). One tissue 
establishment reported a total of 68% and 70% discard rate respectively for 2012 and 
2013 (Heart Valve Bank Rotterdam, Annual Report 2013).
Another important factor to take into account is the cost of donor operations, specifically 
those in non-organ donors with cardiac arrest. To enable these donations a well-trained 
team and accompanying logistics must be available.
The cryopreservation method enables cardiovascular tissue establishments to extend 
shelf life over many years. However, to safeguard preservation in the cryo-containers, 
the levels of liquid nitrogen must be constantly monitored and kept on a level sufficient 
to keep the temperature of the tissue grafts at an adequate level. Other costs relate to the 
maintenance and daily operations of clean room facilities.
The costs for retrieval, transport, materials and initial testing for all procured hearts must 
be calculated into the fee of the limited number of eventual grafts for transplantation.
A final aspect to be mentioned relates to financial liquidity: the relatively long shelf-life 
for cardiovascular grafts means that, at least for some (less frequently used) outlier graft 
sizes, it may take several years before the costs can be recuperated by a fee. In some 
instances, tissues have to be discarded after the shelf life expiration date.
Fee structure
The table below reflects the fees that cardiovascular tissue establishments charge to local 
recipient hospitals. It may be the case that different fees are charged to different hospitals 
as opposed to its ‘own’ hospital, where the tissue establishment is located, in the same 
country, or other countries. Where the costs of tissue establishments are compensated 
by the public health system, no fees are charged to hospitals, e.g. in Italy and in France. 
When tissues are distributed to other Member States, the fees in the table apply.
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Table 3. Fee of cardiovascular grafts
Fee charged to local recipient hospitals
Country Heart- valves Conduits Arteries Aortic 
bifurcations
Veins Peri- cardium Po patch
Belgium 3,895 2,269 2,647 2,647
Germany 3,500
Italy CVB 1 2,800
Italy CVB 2 2,800 1,200 1,200 1,200
Italy CVB 3 3,200 1,750 1,250 2,300 8
Netherlands 5,230 2,820 1920
Poland CVB 1 2,250 160
Poland CVB 2 1,823 939 944
Poland CVB 3 1,900
Portugal 1,925 1,405 1,405
Spain CVB 1 0
Spain CVB 2 3,300
Spain CVB 3 940
Spain CVB 4 1,336 1,336 1,336 1,336 1,336
UK 3,691 2,541 2,541 1,452
Average fee 2,573 1,974 1,767 1,871 1,314 371 1,686
Source: Survey to cardiovascular tissue establishments (2014), data from 2012
The table shows a remarkable difference in the fees charged to local hospitals. The one 
cardiovascular tissue establishment that does not charge anything nevertheless incurs 
costs; this can be an indication that the hospital management may have chosen not 
to work with cost-centres. It also has to be mentioned that this cardiovascular tissue 
establishment processes only three heart valves per year; the quantitative costs are thus a 
minimal part of the total university hospital budget.
It needs to be noted that in the Netherlands, as for corneas, the fees charged to the local 
and national hospitals cover more than just the processing in the tissue establishments; 
it includes overhead charges of the National Transplant Foundation, and other costs.
The difference in pricing between the cardiovascular tissue establishments has several 
causes:
• The fee to the end user is often determined by outside parties (authorities, insurance) 
and not based on calculations in which all costs are integrated into a price or fee that 
covers the real costs.
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• A systematic difference in organisational embedding. Some tissue establishments 
are “stand alone”, meaning that they are responsible for balancing the costs and 
the revenues. Others are part of a larger structure, usually a (university) hospital, in 
which this larger structure carries (part of ) the costs.
• Fee differences may also occur due to differences in the level of salaries and of other 
costs in the EU countries.
Fees determined by the tissue establishment itself are higher than those determined by a 
Ministry of Health or by a regional government though this is not to imply that in those 
cases, fees are too high. As explained elsewhere in this report, the economics of tissue 
banking are complex and depend on many factors.
Cross-border exchange and import/export of cardiovascular tissue
Cardiovascular tissues are occasionally exchanged between EU Member States. In some 
countries, specifically with ‘opting in’ donation systems, there is a shortage of donations 
(or procurements) rather than a shortage of donors. Organising permission and consent 
for the donation requires additional efforts, and always entails the possibility of a refusal 
to donate by the next of kin. To cover the shortage, tissues are distributed from other 
Member States and imported from the USA.
In the experience of the tissue establishments there are several hurdles to be overcome 
when tissues are to be distributed cross-border to other EU Member States.
• Verifying that tissues, selected for cross-border distribution or export, are not needed 
for national patients. Such a system is present in some Member States (like NL and 
IT), but lacking in most.
• Complying with (often unclear) additional donor selection and testing criteria in the 
country of destination or importing country, other than required in the exporting 
country.
• Complying with administrative and regulatory requirements, in particular when 
tissues are to be distributed to Germany, where there is the greatest demand.1
• Complying with criteria requires extended knowledge, sometimes about 
pharmaceutical regulations for those countries such as Germany where tissues 
are classified as medicinal products. Such knowledge isn’t available in most tissue 
establishments, and only those who can afford to pay consultancy fees to supporting 
experts, can – after going through an approval process that may take several years - 
achieve compliance with the criteria and regulations of some countries.
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• Differences in price or fee structure and of reimbursement systems.
• Differences in VAT rates, if applicable.
Many of the alliances mentioned earlier aim to create mutual support between tissue 
establishments financially (sharing the costs of regulatory consultants, for example) 
and also by sharing expertise. Such alliances include: BISlife (NL)-TSF (now Banco 
de Tejidos) (ES)-Homograftlabor DHZB; and EHB (BE) with the Homograftlabor in 
Zagreb (HR) (see also page 215 for international alliances).
Ocular tissues
Ocular tissues include corneas and sclera. The cornea is the clear anterior part of the 
eyeball which permits light to enter into the eye. A corneal transplant is indicated when 
eyesight is decreased due to corneal disease and provided that other parts of the eye are 
functional. The sclera is the outermost part of the eyeball and is partly visible as the 
whites of the eyes.
Clinical application
The most common indications for corneal transplant are opacity, deformation or scarring 
following infection or injury of the cornea. Often a transplant is the only available 
option for improving eyesight in these patients. In a small sub-group of patients the 
matching of HLA type between donor and recipient is indicated when the recipient 
has an atopic constitution or had previous rejection of a cornea graft. A large number 
of cornea donors need to be HLA typed in order to identify a suitable match a single 
patient because of the low probability of finding a match. Sometimes the HLA typing 
costs can be shared with the organ transplantation organisation in the case of an organ 
and tissue donor.
The affected cornea is (partly) replaced by the cornea of a deceased donor. Two types 
of corneal transplant techniques are used: penetrating and lamellar keratoplasty. In 
penetrating keratoplasty (PKP) the full thickness of the cornea is replaced by a donor 
cornea. There are some disadvantages of the PKP technique such as graft rejection, 
slow healing and irregular astigmatism. In lamellar keratoplasty (LKP) only the affected 
layer is replaced. Lamellar keratoplasty is subdivided according to the replaced layer, 
anterior or posterior. The disadvantages described for PKP are fewer. But the lamellar 
technique requires specific skills of the technician in the TE or the surgeon. Besides that, 
additional investments have to be made in devices to assist the cutting of the lamellas. 
The preparation of the lamellas can either be done in the operating theatre or at the 
cornea TEs (pre-cut lamella).
Donor sclera is used in reconstructive surgery of eyes and eyelids. Sclera can be preserved 
and stored for several years.
180
Chapter 10
Activity level in the EU
In Europe, in 2012, 141 corneal tissue establishments were active.
The table below shows the recovering of 40,185 corneas. From these, 30,428 corneas 
were distributed.
Table 4. Volumes of corneas
Donors Recovered Distributed 
in own MS
Distributed 
to other MS
Exported 
to third 
country
Received 
from other 
MS
Import 
from third 
country
AT* 200 NA 188 3 0 0 0
BE 413 973 906 0 0 45 0
BG 73 145 119 0 0 0 0
HR 178 374 133 0 0 1 53
CY 0 0 0 0 0 0 0
CZ 502 998 676 46 81 0 0
DK* 202 NA 356 0 207 23 0
EE 42 48 46 0 0 0 0
FI 134 273 NA 0 0 4 0
FR** 9,893 9,918 4,372 145 0 0 0
DE NA 8,435 5,458 405* 68* 188 0
EL NA NA NA NA NA NA NA
HU 287 302 536 0 0 0 0
IE*** 0 0 NA 0 0 0 175
IT 7,529 15,071 6,575 400* 178* 12 0
LV 13 26 NA 0 0 0 0
LT 29 58 53 0 0 0 0
LU*** 2 0 0 0 0 0 0
MT NA NA NA NA NA NA NA
NL 1,635 3,239 2,603 291 43 1* 0
PL 559 1,104 855 0 0 0 0
PT 448 905 NA 0 0 136 0
RO 48 48 NA 0 0 89 0
SK 99 186 118 0 0 0 0
SI 56* 146 110 0 0 0 0
ES 2,735 4,808 2,743 10 0 70 0
SE 516 859 829 21* 0 0 0
UK 3,031* 7,040 3,752 0 0 74 615
Total 37,059 40,185 30,428 1,321 577 643 841
Sources: EUROCET 2012 unless stated otherwise:
*The European Eye Bank Association, EEBA Directory, Twenty-Second Edition, January 2014;
**Agence de la Biomédecine, Rapport Annuel 2012
*** Data by IE NCATC. No procurement in IE due to vCJD disease
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Procurement, processing and storage of ocular tissues
Ocular tissues are obtained from deceased donors. Retrieval of ocular tissue is performed 
in the mortuary, in the hospital or at home. For cornea and sclera the complete eyeball is 
procured. For corneas only, the corneal disc can be removed at the donor procurement 
site; processing is done in ocular tissue establishments (Bredehorn-Mayr et al, 2009).
The preservation of the (living) endothelial cells is significant in cornea banking. If the 
corneal disc has not been removed at the procurement site, the eyeball is washed and in 
the cleanroom the cornea is removed. After evaluation and decontamination, the cornea 
is stored in preservation media. Preventing contamination is extremely important and 
antibiotics are used and microbiological cultures taken. Storage in organ culture medium 
is preferred for the endothelial cells as these will be more vital and there is more time 
for obtaining the results of donor testing and of microbiological cultures and, where 
relevant, HLA typing (Fehily et al, 2012). Some cornea banks distribute pre-cut lamellar 
cornea for LKP. The cornea is cut with a microkeratome by hand. New laser technics 
however can also be used and even enable cutting multiple lamellas from one cornea.
The shelf life of corneas is limited to four weeks for storage in organ culture medium at 
30-37oC. When stored under hypothermic conditions cornea’s can be stored up to 14 
days (Wilhelmus et al 1995), though in practice tissue establishments usually store grafts 
up to 5 days as endothelial cells will decrease in viability during storage. After evaluation 
of cell quality and quantity, the grafts can be released for transplantation. For reasons 
of quality, storing corneas in culture medium at body temperature is the most common 
technique applied in Europe, contrary to the US where cold storage is the standard 
method.
Sclera are stored separately in 70% ethanol. Distribution may be in segments of 10x15 
mm, in quadrants or complete sclera (TRIP Annual Report, Biovigilance, 2012; Haase- 
Kromwijk et al, 2007; Rijneveld, 2010).
Cost structure
In an additional survey, performed in the context of this study, three cornea tissue 
establishments (TEs) provided a breakdown of the costs of the major processes, while 
one cornea establishment could provide its processing costs. They have calculated the 
cost division per process (note: all TEs reported that donor procurement includes a 
+40% discard rate). In this overview, while cornea TE1 had specified its costs in great 
detail, cornea TE 2 has not separated processing costs from distribution costs.
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Table 5. Cost division in cornea tissue establishments
TE 1 TE 2 TE 3
Donor procurement 24% 25% 30%
Testing 22% 10% 8%
Processing 30% 65% 38%
Distribution 24% NA 23%
Total 100% 100% 99%
Source: Survey to cornea tissue establishments (2014), data from 2012
One of the cornea tissue establishments indicated that the total costs couldn’t be 
recovered from the income; the difference is covered by fundraising. The other two 
tissue establishments indicated that National Health Insurance compensated for most 
of the costs. An example mentioned elsewhere is the investments in the Lions Cornea 
Banks (Germany), which are mainly provided by the Lions service clubs.
An important cost factor in these calculations, recognized by all cornea tissue 
establishments, is the high discard rate of donor corneas (Bredehorn et al, 2009). Reports 
show that the discard rate can reach levels of over 50% (BIS Foundation, Annual Report 
2007). This discard rate has several causes and is a challenge to address. One of the main 
reasons is that many suitable donors are of older age, and, the older the eye, the higher 
the rate of idiopathic endothelial cell loss. This can however only be diagnosed in the 
tissue establishment after completion of procurement. Thus, many donated corneas do 
not fulfil the minimum cell count per mm2 of 2 000-2 500 according to the criteria of 
the European Eye Bank Association and have to be discarded.
Sundmacher and Reinhard (2009) reported that, to provide 300 transplantable grafts, 
an annual budget of almost €600 000 is needed to achieve a break-even between 
expenses and revenues (Sundmacher and Reinhard, 2009). The fixed expenses include 
a minimum of two technicians and two MDs on call to cover a 24/7 service. In the 
study of Sundmacher and Reinhard, 600 corneas had to be recovered to provide 300 
transplantable grafts to hospitals. To cover the total costs of €600 000, each distributed 
cornea would cost around €2 000. If the number of distributed grafts were higher than 
the necessary 300, the economy of scale could cause a favourable effect on the fee charged 
to the recipient hospitals, or to the health insurance responsible for reimbursement.
In our survey organized within the context of this report, two tissue establishments that 
indicated distribution of over 1 000 corneal grafts per year, processing cost per graft are 
shown to be lower as compared to those which processed fewer than 1 000 grafts per 
year. A decrease in number of corneas processed would mean that such a cornea tissue 
establishment would have to find financial support to cover the expenses, increase the 
price charged per cornea or else reduce its service level, which may lead to being unable 
to address donor calls or other service cut-backs.
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The table below shows the correlation between the number of distributed grafts and the 
processing costs of four cornea tissue establishments that could provide data with respect 
to their processing costs. It demonstrates the effect of the economy of scale.
Table 6. Number of corneal grafts and cost
Number of distributed grafts Processing costs per graft in €
Cornea TE 1 59 825
Cornea TE 2 989 643
Cornea TE 3 1386 471
Cornea TE 4 2702 315
Source: Survey to cornea tissue establishments (2014), data from 2012
The cost for a cornea also differs per preservation technique. The use of the preservation 
method should have no influence on the costs of procurement, testing, or distribution.
However there are large differences in costs when it comes to comparison of the two 
storage methods. When using the organ culture method, there’s need for a clean room 
environment in which establishments usually process under a class A cabinet with 
a background of class B. Moreover, the need to operate an incubator, the necessary 
change of medium before transportation and the regular microbiology tests of that 
medium contribute to additional costs. It can therefore be assumed that the culturing 
method generates more costs than the alternative ‘cold storage’ method. For cold storage 
industrially provided closed systems are available, negating the need for clean rooms. 
This can be a cost-effective solution where economic resources are limited
On the other hand, the culture medium method has a significant positive impact on 
discard rates due to the longer shelf life, thus contributing to the number of transplantable 
grafts and a better balance between costs and revenues. Overall, most European cornea 
tissue establishments have chosen to apply this preservation method based on quality 
arguments. This method enables evaluation of the quality of the cells, the presence of 
micro-organisms in the culture, as well as extended possibilities to screen donor material 
for the presence of transmittable diseases and viruses.
Fee structure
Table 7 reflects the fees TEs charge for different tissue grafts to local end-users. Different 
fees may be charged to hospitals outside the region. Again, different fees may be invoiced 
to hospitals in another EU country or to countries outside the EU.
184
Chapter 10
Table 7. Fee of ocular and amnion tissues to local end-users
Cornea PKP Cornea 
emergency
Anterior cornea 
lamella
DMEK2 Sclera Amnion
AT 1901 1901 2480 2319 479 210
BE 1349 1349 95 1092
BG 500*
CZ 790 790 1160 1160 790 190
DK 2078 2480 2078 429
DE 1875 1875 1875 1875 560 560
HU 250
IE 2988 2988 2988 2988 523 497
IT 3465* 875* 3130* 3130* 300 500
NL 2250* 2250* 2250* 2250* 100* 400*
PL 663* 840*
PT 671
RO
SK
SI
ES 1030* 1670* 825* 464* 203*
SE 1235 1235 107
UK 738
Minimum 250 790 825 1160 95 190
Maximum 3465 2988 3130 3130 2078 1092
Average 1420 1659 2003 2287 567 453
Source: Survey to cornea tissue establishments (2014), data from 2012; Economic landscape survey 
NCATC (2015), data from 2012
The difference in pricing, as shown in the table, leads to the following observations:
• Fees for all types of ocular tissue vary remarkably from one TE to another. For 
PKP corneas the range is €250-3465. Though this may partly be explained by 
differences in the technique used. When considering the differences in degree to 
which real costs are taken into account for price-setting as well as the difference in 
healthcare wages in the responding EU-countries, some of these fees include more 
than the costs of tissue establishment processes. In the Netherlands, for example, 
the fee includes the costs of HLA-typing of the recipient, but most importantly it 
must cover the overhead of the National Transplant Foundation and the imbalance 
between costs and income of several tissue establishments.
• The differences in fees, specifically for those tissue establishments that have the 
freedom to determine the fee to the end-user, may be explained from the point 
of ‘critical mass’. The greater the number of distributed tissue grafts, the better 
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that fixed costs, such as infrastructure and personnel, can be covered by income 
(Reinhard and Sundmacher, 2009). As mentioned, the break-even point would be 
expected at 300 transplantable corneas.
• Emergency corneas are grafts which are in the tissue establishment to be allocated 
in urgent cases (rather than scheduled operations) in which the patient may lose 
an eye if he/she doesn’t receive a graft. These emergency cases often occur at night 
or during weekends. Most cornea establishments have a small stock that is ready 
and prepared (to save time) for immediate shipping. Usually, the quality of these 
emergency corneas is lower than grafts for elective operations when it comes to the 
number of viable cells.
• The fee of sclera, which are in fact a by-product from cornea processing, varies from 
€95 to €2078. In some countries, sclera are considered to be a medicinal product 
(e.g. in Germany), the registration of which requires intensive legal- administrative 
application processes, but the observed differences cannot solely be explained from 
that point of view.
• While sclera are procured from deceased donors, amniotic membranes are donated 
by living donors. They serve the same purpose in ophthalmology surgery, namely 
providing a natural support to the eye globe that can easily be sutured. It may be 
expected that the cost structure for obtaining and processing amnion membranes 
are quite different from the collection of sclera. The observed differences in fees can 
otherwise not be explained.
Authorities and health insurance organisations may influence the fee for the end-user. 
Table 8 provides an overview of legal status and fees in which the decision-makers are 
listed per EU country. Given the fact that only 15 out of 60 cornea TEs responded 
to the questionnaire for this research, no conclusions can be drawn concerning the 
correlation between legal status, the determination of the fee and the fee to the end-user.
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Table 8. Fee determination of cornea
Legal status of 
organisation
Determination of fee by Fee of cornea PKP
Hungary Private foundation TE itself and insurance 250
Czech Republic University Hospital Insurance 790
Italy Private Foundation TE itself 1100
Sweden University Hospital Regional Council 1140
Belgium University Hospital Government 1349
Spain National Health TE itself 1425
Germany, TE 1 University Hospital Hospital 1850
Germany, TE 2 Private foundation TE itself 1900
Germany, TE 3 University Hospital TE itself 2000
Austria University Hospital Hospital 1901
Denmark University Hospital TE itself 2078
Ireland* National Health TE itself 2988
Netherlands TE 1 Private Foundation Insurance 2250
Netherlands TE 2 Private Foundation Insurance 2250
Source: Survey to cornea tissue establishments (2014), data from 2012
* Ireland imports all corneas from the US (because of vCJD in Ireland and the UK)
Cross-border exchange, and import/export of corneas
For cornea TEs, the international exchange shows different dynamics of cross-border 
distribution and import/export. In some Member States there is a surplus and corneal 
grafts are distributed to other Member States or exported, while in other countries there 
is a shortage and numerous grafts are ordered from other Member States or imported. 
Imports are mostly from the USA.
Table 9 shows that there is only one tissue establishment (in Hungary) that clearly 
indicates that there is no donor shortage. One cornea tissue establishment from Germany 
remarked that there shouldn’t be a donor shortage if donor referral and procurement were 
well organised. One tissue establishment from Germany reported an estimated national 
shortage of 5 000 corneas per year. One indicator for measuring a donor shortage is 
whether there is a waiting list for cornea recipients. Such a waiting list could also report 
the average and maximum waiting time for patients to receive a transplant.
Clearly, there is a donor shortage in different EU countries. Several respondents (BE, 
DE) reported that in the absence of such waiting lists, it is hard to determine the real 
level of this shortage.
The table below shows the exchange of tissue grafts, as reported by 14 responding tissue 
establishments. The reporting cornea TEs distributed 919 grafts to other EU countries, 
and exported 367 to third countries. All in all, more corneas were imported (772) from 
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outside the EU than exported (367) to these third countries. Greece has 5 ocular tissue 
establishments but as shown in the table, no data is available on number of donors, 
distribution and import and export. The donated cornea from donors in Luxembourg 
are processed and stored in another Member State.
Table 9. Cross-border distribution, import, export and shortages of cornea
Shortage of 
donors
Cross- 
border
from MS
Cross- 
border
to MS
Import 
from third 
country
Export 
to third 
country
Countries
Austria yes 1 11
Belgium yes 45
Czech Republic 47 78
Denmark 300 23 207 from USA
Germany TE 1 5,000
Germany TE 2
Germany TE 3 yes 188 405 68 from USA
Hungary no 80 to RO
Ireland 160 from USA
Italy 12 400 178
Netherlands yes 1 291 43
Portugal yes 136
Spain 100 70 10
Sweden 150 35 to DK
Total >5,550 431 919 772 367
Source: Survey to cornea tissue establishments (2014), data from 2012
At the same time, the table also shows that there are substantial imports from outside the 
EU. The reporting cornea tissue establishments purchased 772 grafts from the United 
States; in this survey this represents a large part of the distributed volume reported.
The export to countries outside the EU may be, partly, explained by the fact that during 
European holiday periods (e.g. Christmas–New Year) there is a reduced activity in 
ophthalmology clinics. As the preserved corneas in the tissue establishments have a short 
expiration period of about four weeks, corneas may expire if they are not transplanted. 
Corneas, which would otherwise expire, are therefore offered to countries that do not 
observe the same holiday periods. Often, these corneal grafts are offered at reduced fees.
Some EU countries have organised their tissue banking structure in such a way that 
self- sufficiency is enabled. In some countries (IT, UK, NL) a mandatory allocation 
system is in place. This guarantees the supply to cover the national demand. In other 
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countries, such as Germany, Spain and France, voluntary networks strive to achieve 
optimal allocation of available grafts.
Musculoskeletal tissues
Musculoskeletal tissues include bone and related soft tissue such as tendons and 
ligaments.
Clinical application
The need for bone grafts is determined by a number of medical indications:
• To substitute the loss of a patient’s own bone caused by trauma
• To replace a patient’s resected bone or joint because of malignancy
• To fortify the host’s bone mass to enable the placement of an artificial joint, usually 
in re-operations of the (replaced) hip or acetabulum
• To fortify the spine after trauma, for correction of spinal defects caused by congenital 
disease (scoliosis, lordosis), or severe wear of the vertebrae for other reasons
• To reconstruct dental or maxillofacial bone loss, and to support artificial dental 
implants by filling the cavity around the implant-base with demineralized bone 
powder or gel.
The main indications for tendons and ligaments are injuries, such as tearing, of the 
patient’s own tendon, usually the patella or Achilles tendon. Typically in the case of 
a revision of a previous reconstruction with an autologous tendon (Anterior Cruciate 
Ligament (ACL) and Posterior Cruciate Ligament (PCL) reconstruction with the 
patients’ own hamstring or other hemi tendon), allografts are needed (Robertson and 
Nutton, 2006). Other musculoskeletal tissues include cartilage, fascia and menisci 
from deceased donors. In exceptional cases a graft coming from a donor can replace a 
ruptured meniscus.
Chondrocytes are mainly used in autologous settings. This treatment involves in vitro 
culturing of cartilage cells after a harvesting procedure; the cultured cartilage cells are 
transplanted in a second procedure. The cartilage cells adhere to the bone surface and 
start forming new cartilage. The in vitro growing of cartilage is a sophisticated, recently 
developed technique (Bugbee et al, 2015). This cultured cartilage can be classified as 
ATMP; it was the first authorised product under this regulation.
Demineralized Bone Matrix (DBM) is produced from cortical bone. Cortical 
bone is harder than the above-mentioned cancellous chips, which, because of their 
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open structure, allow faster ingrowth of the host bone. Thus, cortical bone is less 
in demand for orthopaedic surgery. DBM is frequently used in dental applications, 
specifically to support the base of implants in the mandibular or in the upper jaw. 
Tissue establishments have developed DBM into several products, such as bone-gel with 
glycerol or hyaluronic acid, also called hydrogel, bone-flex, bone-putty etc. Bone-gel is 
often used for implantation along spinal fusion devices. The osteo-induction, caused 
by the DBM, results in a more rapid bone growth in the recipient the spinal implant/
the spine will obtain stability more rapidly. By removing the minerals from the cortical 
bone, the tissue becomes osteo- inductive, rather than osteo-conductive. The absence of 
minerals exposes the endogenous growth hormones which then stimulate the host bone 
to grow into the DBM. Since the removal of minerals causes the loss of weight bearing 
capacity of the bone structure, DBM is not suitable for grafting in recipient sites that 
need weight-bearing capacities. DBM is used as bone filler in cavities that need fast 
restoration.
During the last 10 years there is a clear trend of combining, in a package, CE-marked 
orthopaedic hardware, such as surgical instruments and/or industrially produced 
implants with bone tissue. The combination of tissue and hardware is offered to the 
surgeons to increase the efficiency of their operations. By making use of innovative 
technologies, musculoskeletal tissue can be combined with antibiotics. The argument 
for this approach is that it can prevent or eliminate the contamination of bone tissue, 
respectively prophylactic (in trauma patients with high risk for infection) or in patients 
who undergo a re-operation because of the failure of an industrial or of a tissue implant.
In the past, combinations of bone tissue grafts with growth factors, bone morphogenetic 
proteins (BMPs), have been seen. Although this combination has not resulted in 
successful clinical application, it may be expected that in the future, new combinations 
of bone and cells, and/or pharmaceuticals, aimed at stimulating bone healing, will be 
introduced.
Activity level in the EU
In 2012 there were 400 authorised musculoskeletal tissue establishments within the EU. 
There are several types of bone tissue establishment. Hospitals and orthopaedic centres 
often operate a bone tissue establishment to provide the required donor bone from their 
own patients. There are tissue establishments that focus on living bone donation and 
those that focus on processing deceased donor bone and other musculoskeletal tissues. 
Other tissue establishments focus on import of musculoskeletal tissue and/or storage 
and distribution.
Table 10 shows an overview over donation and distribution of musculoskeletal tissues. 
Though the number of living donors (of femoral heads) is 8 times as high as the number 
of deceased donations, the yield of tissue grafts coming from living donations is limited 
as compared to deceased donations. Depending on the number and size of donated 
bone tissues from a deceased donor, these can be cut and shaped into many units 
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of transplantable grafts. Specifically when grinded into small particles of DBM, the 
number of units can reach 100 or more. 87% of the distribution of musculoskeletal 
tissues processed by EU based tissue establishments takes place in the own Member 
State. In addition musculoskeletal tissue is imported with a quarter of all tissues coming 
from third countries. The import from third countries, outside the EU, is about ten 
times as high as the cross border exchange between Member States, inside the EU.
Table 10. Donation, distribution, import and export of musculoskeletal tissue
Deceased 
Donors
Living 
Donors
Total 
Distri- 
buted
Distributed 
in own MS
Cross- border 
to other MS
Exported 
to third 
country
Cross- 
border 
from other 
MS
Import 
from third 
country
BE 192 5595 14653 14243 275 1 135
BG 137
CZ 121 111 3344 3344
DE* 21372 64358 64358 144373 41648
EE 3 27 98 102 4
FR 60 31310 30130 1184 3796
HR 75 165 156 156
HU 20 458 623 623
IT 304 3540 16824 16824
LV 18 0
LT 4 82 67 67
LU 2
NL 128 36649 10027 19977 6645 257 110
PL 242 123 9657
PT 28 20 121 121 91
RO 10 127 89 89
ES 672 1451 14630 13731 900 1
SE 3 1893 1201 1164 58
SK 309 102 294 127 167
UK 28851 38384 2452 11985
Total 4326 35076 222925 193490 21603 153470 5106 53879
Source: EUROCET 2012. Please note that total numbers don’t add up as not all countries reported
*The total distribution in Germany has been interpreted as “Distributed in own Member State”. The import 
and export from third countries refer to a relation of one single tissue establishment.
Procurement, processing and storage of musculoskeletal tissues
Bone is obtained both from deceased and from living donors, who may donate a femoral 
head at hip replacement surgery. The femoral heads donated during hip replacement 
can only be used for non – structural purposes due to the brittleness of the bone (TRIP 
Annual Report 2012, Biovigilance).
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It must be collected aseptically into a suitable container and frozen. The donor must 
have been screened for mandatory markers using traditional serological tests plus either a 
repeat test 180 days after donation (unless Nucleic Acid testing (NAT) for the mandated 
markers was performed at donation). Testing for bacterial and fungal contamination 
must also be performed on samples taken from the tissue itself.
Surgically removed femoral heads are usually provided to the clinical user without 
further processing.
A significantly larger quantity of bone, and range of bone types, can be procured from 
deceased tissue donors. It can be processed to prepare a wide range of shaped bone 
allografts (e.g. ground bone, cubes, demineralised bone paste and putty etc.). From 50- 
300 units of bone/tendon can be prepared from one donation (Gillan et al, 2014). Often 
the bone donation is part of a multiple tissue donation including other musculoskeletal 
tissues, such as tendons and meniscus, and also other tissues such as skin and heart 
valves. The processing of bone is performed in a clean room suite to GMP standards, 
usually Grade A. The bone is then terminally sterilised using irradiation.
Procurement of musculoskeletal tissues requires a surgical approach. Preventing 
contamination is one of the main challenges. Cleaning, disinfecting and working in a local 
sterile field is necessary for procuring the grafts. Culturing samples for microbiological 
contaminants is an important step in guaranteeing the safety of the bone. Procurement 
of musculoskeletal tissues therefore usually takes place in an operating theatre (OR), 
particularly in those programmes where the tissue is not subsequently terminally 
sterilised. Depending of the number of grafts taken, an operation on a deceased donor 
may take up to three hours or more in which the OR cannot be used for other purposes. 
Some tissue establishments have therefore invested in dedicated operation theatres at 
their site, while others use the hospital facilities outside working hours.
Processing of bone may consist of several steps depending of the type of material and the 
use of the grafts. In general the following steps are applied (Veen, 1994):
a. Cleaning and removal of debris
b. Washing or rinsing to remove debris and bacteria
c. Cutting and shaping
d. Disinfection with different kind of disinfectants or by heating
e. End sterilisation by Gamma or E beam radiation
f. Freeze drying or freezing for storage.
While cleaning and washing with desinfective agents (processing steps a and b) are 
aimed at reducing the level of micro-organisms, the techniques used in the process 
steps d and e, are intended to remove or destroy all living micro-organisms. In order to 
achieve elimination of micro-organisms, the following sterilization and decontamination 
methods can be applied by musculoskeletal tissue establishments (Veen 1994):
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• Heat-sterilization
• Gas-sterilization
• Gamma-irradiation
• Ethanol
• Beta-propiolactone (Lo Grippo et al, 1956)
• Merthiolate (Arde, 1956)
Some musculoskeletal tissues (e.g. femoral heads from living donors) are frozen directly 
after procurement and distributed after microbiological cultures and donor tests are 
confirmed negative.
Decalcification (demineralization) of cortical bone is widely used to remove the 
nonorganic matrix and expose the organic matrix, with subsequent release of 
osteoinductive growth factors. This kind of bone implant stimulates renewing of bone 
and is primarily used where bone is implanted in a site that does not have bone mass, 
e.g. in dental implantation.
Bone can be cut and shaped into a large number of forms and sizes. Some of the most 
commonly used musculoskeletal tissue grafts are: femoral heads (from living and 
from deceased donors); cancellous chips, patella tendon whole, and patella tendon 
or hemi patella tendon); proximal tibia or distal femur frozen, cortical struts or rings 
demineralized bone powder and osseous gel (putty).
Cost structure
Depending on the donor source (living or deceased), the cost structure of bone banking 
varies considerably. The response to the survey into cost structures of musculoskeletal 
tissue establishments didn’t result in any information, either because the tissue 
establishments didn’t have the required data, or they didn’t want to provide it. Only 
one reliable source was available (table 11). Depending on factors such as organisation 
of the procurement teams, the distance to the donor site, the required virology and 
microbiology testing regiment, the method of processing, the costs of a post-mortem 
donation can reach a level of around €5000 in some tissue establishments, while other 
tissue establishments may be able to carry out these tasks at more reduced cost levels. 
The procurement of a femoral head from a living donor occurs additional costs such as 
swabbing, microbiology testing, packaging, labelling and transportation to the tissue 
establishment. Depending on organisational factors the total costs are a few €100.
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The following division of processes and related costs can be recognized.
Table 11. Cost division in a musculoskeletal tissue establishment
Post mortem donors Living donors
Donor procurement 16.20% 39.00%
Testing 4.30% 49.20%
Processing 42.00% 0.00%
Distribution 37.50% 11.80%
Total 100% 100%
Source: BIS Foundation Annual Financial Report 2008 and Netherlands Bone Bank Foundation 2008. 
Percentages based on financially audited costs of 111 deceased donors and 1145 femoral heads.
Survey to musculoskeletal tissue establishments (2014)
Procurement from living donors
As a femoral head is removed from the donor to place an artificial implant, there are 
only costs of the surgical recovery procedure (which takes place anyway, despite of 
the donation). After training and instruction of the staff, donor screening of medical 
suitability is executed in the hospital. The orthopaedic surgeon signs the screening form. 
Packaging of the graft is done in the operating room. Some tissue establishments offer 
compensation for administration and packaging. The fees, known to the authors, vary 
from €40 to €70 per donated femoral head. Additionally, there are transport costs, 
depending on distance from the tissue establishment, and of transport circumstances 
(cooled, frozen or otherwise).
Procurement from deceased donors
Deceased tissue donors can be organ or non-organ donors. In both cases, there is a 
limit with respect to the time during which musculoskeletal tissues can be removed 
after cardiac arrest. In case of a donor referral, a team with on average three trained 
professionals (MDs and/or technicians) travels to the donor site and carries out the 
donor operation. In this process, a variety of costs are incurred:
Compared to other tissue procurements (cornea, skin) the costs of musculoskeletal tissue 
donations are much higher. This is caused by the higher quantity of team members, 
more sterile materials for packaging of the tissues, a larger instrument set and a
multitude of microbiology swabs for the procured tissues. A 24/7 on-call service, 
executing an initial screening, requires many elements to be organised including:
• A well trained donor team which is on stand-by
• Instruments and sterile materials to operate and package the tissues
• Stock of tubes/swabs for virology and microbiology testing
• Travel to the donor site and back
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• Using the OR of the donor hospital or dedicated OR from Tissue establishment
• Carrying out the donor operation. The time depends on the circumstances (waiting 
for organ donation to finish y/n) and experience of the operating team.
• Administration of donor clinical details and operating report
• Transport costs, depending on distance from the tissue establishment, and of 
transport circumstances (cooled, frozen or otherwise)
• Virology and bacteriology testing. Virology testing is done with the post mortem 
blood (preferably also with the pre-mortem blood) of the donor. Bacteriology as 
well as virology tests are carried out by contracted laboratories, which are certified 
for these tests;
Donor detection and family interviews is organised in different ways throughout the EU 
Member States. In some Members States there are no costs reported for such activities, 
which may be related to an opting-out system, while in other Member States these 
services are part of the organ network structure and no costs are forwarded to the tissue 
establishments. In some countries hospitals have dedicated officers for donor recognition 
and in-house coordination of procedures.
Since bone donation comes with a large number of contra-indications, and to avoid 
procurements resulting in discards, thorough donor selection (before starting the 
procurement) is of utmost importance to avoid unnecessary costs. Discard rates of 
over 1.3% have been reported (EUROCET 2013). These discards are caused e.g. by 
contra- indications of the donor, by virology and microbiology results as well as by the 
morphology of the donated tissue.
Further processing and distribution
• Cutting the bones and tendons into shapes and sizes matching with the expected 
demand from surgeons.
• Processing of the bone. The costs are dependent on the method which is chosen, and 
which leads from almost no costs (when the bone is not cut, not macroscopically 
cleaned, e.g. by removing cartilage) to hundreds of euros per bone piece if intensive 
cleaning, cutting and processing is applied. Depending on the (terminal) sterilization 
method, and whether tissues are cryopreserved or freeze-dried, the processing costs 
can be higher or lower.
• Without processing, grafts are released after negative virology and bacteriology tests 
and approval of the donor’s medical screening.
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• Cleaning of the bone by removing attachments such as cartilage, sawing and soaking 
in an antiseptic such as alcohol. Usually irradiation afterwards.
• Sterilisation by means of irradiation.
• Cleaning by means of critical CO2 method, irradiation afterwards.
• Freeze drying or freezing, packaging and labelling.
• Storage and administration.
• Distribution.
Additional cost factors to consider relate to the maintenance and daily operations of 
clean room facilities. The freeze-drying and cryo-preservation methods enable tissue 
establishments to extend shelf life over many years. However, to safeguard preservation 
in the cryo-containers, the levels of liquid nitrogen must be constantly monitored and 
kept on a level sufficient to keep the temperature of the tissue grafts at an adequate level.
In the case of musculoskeletal tissue establishments it is a challenge for the management 
to balance demand and supply. Because of the fact that grafts are applied in a great 
variety of specific interventions, depending on the different shapes and forms into which 
they have been processed. Management should be aware of the demand in such medical-
specialist areas such as orthopaedic surgery, traumatology, neurosurgery, maxillofacial 
surgery and plastic surgery. The difficulty for the tissue establishment management is 
to optimize and process the donations in such a way that the demand is completely 
covered, while stock size is adequately kept and expiration of grafts is prevented.
Fee structure
The fee determination for musculoskeletal tissues reflects the relationship between the 
legal status of the organisation, determination of the fee and the fee charged to local 
end-users. As explained elsewhere in this chapter and in this report, the economics of 
tissue banking are complex and depend on many factors. This is one of the reasons for 
the observed differences in fees. On top of the factors already mentioned, the fee charged 
to the end-users may be influenced by specific situations such as the mix between living 
and deceased donations in a particular tissue establishment (the latter usually being 
more expensive than the first).
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Table 12. Fee determination of musculoskeletal tissues
Country Legal status of organisation Determination of fee by Fee in € charged to local 
hospitals
Cancellous 
chips 30cc
Achilles 
tendons
Belgium 1 Part of private hospital National insurance authority
Belgium 2 Part of university hospital National insurance authority 340
Bulgaria Not for profit shareholder company Tissue establishment 400 500
France Part of university hospital Public body
Germany 1 Part of university hospital Not applicable: the grafts 
are free for all the patients, 
tissue establishment receive 
lump sum by social insurance 
company directly, income is 
independent from production
Germany 2* Not for profit shareholder company Tissue establishment 350 750
Greece For profit shareholder company Public body (not CA)
Hungary Independent public foundation Public body (not CA)
Italy Not for profit shareholder company Competent authority 893 1200
Netherlands For profit shareholder company National insurance authority 485 1466
Spain 1 Part of public blood bank Regional health authority 695 1200
Spain 2 Part of public blood bank Regional health authority 440 486
UK 1 Part of national health hospital Tissue establishment
UK 2 Part of national health hospital Tissue establishment
Average fee 515 934
Source: Survey to musculoskeletal tissue establishments (2014)
The not-for profit shareholder company is a legal entity in some EU Member States. Usually the shares are 
owned by other not for profit institutions such as universities..
By distributing DBM, tissue establishments are able to reduce the surplus cortical 
bone stock, while addressing clinical needs, thus generating additional income for their 
organisations.
Cross-border exchange and import /export of musculoskeletal tissue
Only a small number of musculoskeletal tissue establishments responded to the survey 
conducted as part of this study and hence the information with respect to donor shortage 
and import-export provides a limited view on the economic landscape of musculoskeletal 
tissues in Europe. Table 13 shows a 25% import from third countries, while two US 
tissue establishments are responsible for about half of these imports (table 21); it may be 
expected that the relative share of imports from third countries will increase over time.
Many distributors of orthopaedic instruments and other hardware companies, which 
have qualified as tissue establishments, do import from different US tissue establishments.
Such companies advertise allografts on the websites or in catalogues. This observation 
was reason for the researchers to look at US imports.
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Table 13. Import, export and reported shortages of musculoskeletal tissues
Country Donor 
shortage 
L/D*
Cross- 
border to 
EU
Cross- 
border
From EU
Import from 
third country
Export 
to third 
country
Countries
Belgium 1 No answer No Yes No No FR
Belgium 2 No No No No No
Bulgaria No Yes Yes No Yes NL DE IT EL 
and Turkey
France Yes Yes No No No Not specified
Germany 1 No No No No No
Germany 2 No Yes Yes Not specified
Greece 50/50 Yes? Yes ES and US
Hungary No Yes Yes No No Not specified
Italy No Yes Yes UK DE
Netherlands 200/10 Yes Yes No Yes UK AT and 
Turkey
Spain 1 No No Yes No No Not specified
Spain 2 No No No No No
UK 1 No No No No No
UK 2 No No No Yes No US
Source: Survey to musculoskeletal tissue establishments (2014)
*L = living donors, D = deceased donors
All over the European Union musculoskeletal tissue grafts are imported from the US. 
There are two major reasons for the import of these tissue grafts:
• There is a shortage of tissue donors in the EU, compared to the demand in different 
EU Member States. EU Tissue establishments, through alliances with US tissue 
establishments, but also orthopaedic companies registered as tissue establishments, 
strive to cover the shortage.
• Many tissue establishments in the US have a surplus of tissue grafts. The possibility 
to export tissues to other countries enables them to reduce their surplus stock while 
obtaining a better financial coverage of the costs they incurred to recover and process 
the donations or increase their profits if they work on a ‘for-profit’ basis.
For the purpose of this study, two US (non-profit) tissue establishments have been 
willing to provide data with respect to their export to the EU in 2012 and 2013.
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Table 14. Export of musculoskeletal tissue from US to EU in units
US TE 1 US TE 2 Total
2012 2013 2012 2013 2012 2013
Bone tissue 4,857 5,572 2,894 2,806* 7,751 8,378
Soft tissue 813 1,070 38 52 851 1,122
DBM 12,156 12,265 1,333 2,318 13,489 14,583
Total 17,826 18,907 4,265 5,176 22,091 24,083
Source: Survey to musculoskeletal tissue establishments (2014)
*US TE 2 indicated that, because of a change in regulations in Italy, there has been a temporary decrease. 
In 2014 the level of bone tissue export to the EU was 4,286
This table reflects the increase (by 9%) of the number of musculoskeletal tissue grafts 
imported in the EU from 2012 to 2013. Both organisations reported an intention to 
strive for further growth. The table gives a breakdown of three different categories of 
tissue grafts:
• Bone. Unfortunately no particular information was received for a more detailed 
overview of categories (chips, struts, intercalary etc.). The US sources confirmed 
that more than 50% of the bone tissues were cancellous chips, since this specific 
graft is mainly used for hip revisions.
• Soft tissue. This includes primarily patella and Achilles tendons. In recent years an 
increase of tendon grafting has been observed in sports medicine (Leys et al, 2012; 
Persson et al, 2014).
• DBM (demineralized bone matrix). The result of the research for the report into the 
exchange of musculoskeletal tissue shows a mixed picture. Looking at the substantial 
import form the United States, it would be possible to conclude that there are 
general and specific shortages in the EU. General shortages refer to the number of 
donors for replacement tissues. Specific shortages refer to ‘products’ such as DBM, 
which are in general not produced by European tissue establishments. Clearly, also 
in the area of distribution of bone tissue grafts, the dependency of the supply from 
the United States (25% and growing, in relation to the total number of allografts 
distributed (tables 13 and 14) is noted.
199
Economic landscapes of human tissues and cells for clinical application in the EU. Replacement Tissues
10
Skin grafts
Clinical application
Skin tissue grafts are mostly used to cover chronic wounds or burn wounds. Skin consists 
of a thin outer layer called epidermis, and a thick inner layer called dermis. The benefit 
of a skin graft is that it forms a natural layer (as opposed to bandages) over the exposed 
tissue of the recipient. The term ‘biological bandage’ is often applied to skin grafting.
Thus, donor skin prevents the recipient from drying out, but skin grafts also protect 
the patient against the ingress of microbes. Additionally, human donor skin can form a 
scaffold for the recipient’s newly generated autologous skin. Autologous skin is harvested 
and applied in one procedure and used for limited covering. Large burn wounds are 
covered with allografts.
In second degree burn wounds a significant reduction in pain can be achieved very soon 
after grafting of the donor skin. In the first instance the donor skin is adherent and 
remains in place like a supple scab. In general, a very rapid high-grade epithelialization 
takes place under the skin grafts, after which the dried-out scab comes loose.
Both in second and in third degree burn wounds, the donor skin can be perforated 
(meshed) before being grafted. The advantage is that a larger surface of the recipient can 
be covered. In third degree burn wounds, after operative removal of the necrotic tissue, 
the wound is, if possible, covered with an autograft. This graft can then be covered 
with donor skin (so-called sandwich graft). This provides a covering for the areas of the 
wound left exposed by the distribution of the autograft. Donor skin also promotes rapid 
epithelialization (Verween et al, 2012).
The standard treatment of burn wounds by applying (donor) skin does not often lead 
to acceptable functional and cosmetic outcomes and leads to development of scar tissue 
and skin contractions. By growing skin cells (keratinocytes) in vitro to be applied with 
a meshed split skin graft, the burn will heal faster with less scarring. Although a well- 
established process in many tissue establishments, this is now classified as an ATMP 
with significant cost implications associated with achieving marketing authorisation as 
a medicine.
In chronic wounds as well as in burn wounds, glycerol-preserved donor skin has 
a cleansing and granulation-promoting effect on the wound bed. Significant pain 
reduction is an important side effect. Once the donor skin adheres to the wound bed, 
the latter is suitable for auto grafting.
Other clinical applications of skin grafting are reconstructive and cosmetic plastic 
surgery.
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Activity level in the EU
In 2012 there were 57 authorised skin tissue establishments within the EU. Table 15 
shows an overview of donation and distribution of skin tissues.
Based on the EUROCET 2013 report, 80% of the distribution would take place in 
the own Member State. Unfortunately the 2013 EUROCET report has no data with 
respect to distribution activities from the Netherlands. In an interview the Euro Skin 
Bank indicated that for distribution in the own Member State about 20-25 donations 
per annum would be necessary. This means that more than 90% of the donor tissue, 
equivalent to about 1 500 000 cm2, from the Netherlands is distributed to other Member 
States and to third countries. In the same interview it was stated that procured skin from 
all donations in Bulgaria is processed in the Netherlands and from there distributed by 
the Euro Skin Bank (Interview 2014).
Table 15. Skin graft donations, distribution, import and export
Donations Total 
Distributed
Distributed 
in own MS
Cross- 
border to 
other MS
Export 
to third 
country
Cross- 
border from 
other MS
Import 
from third 
country
BE 106 198427 198427
BG 166
CZ 44 926 1019
DE 26 35500 2
FI 32 0
FR 370 295905
HR 8 1250
HU 4 0
IT 339 845017 845347 330
LV 0 0
LT 0 0
LU 0 0
NL 495 0 8099 1952
PL 39 65513 65513
PT 1 9193 10067 74
RO 4 500 500
ES 94 214711 214691 20
SE 83 0 0
SK 3 19310 19319
UK 0 1225 1225
Total 1822 1684252 1353864 9144 1952 1225
Source: EUROCET 2012. Please note that total numbers don’t add up as not all countries reported.
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Procurement, processing and storage of skin
Deceased donor skin grafts are procured after shaving, washing, disinfecting and 
oiling the skin of the back, side and legs up to 24 hours after death. With an electric 
dermatome, a layer of 0.2 to 0.8 mm can be removed. Samples should be uniform of 
thickness and preferably have large dimensions, suitable for treating patients with major 
burns. Procurement takes place in mortuaries or operating theatres. If musculoskeletal 
tissue is also donated, it is preferred that skin is procured first.
The retrieved skin is placed in transport medium (e.g. glycerol solution) and transported 
in refrigerated containers to the tissue establishment for processing. Alternatively, skin 
can be placed on sterile gauze soaked with saline solution.
Skin from living donors after abdominoplasty operation is procured to obtain full 
thickness skin grafts for the production of de-epidermilised dermis. The tissue, complete 
with adipose layer, is stored in sterile containers for transport to the tissue establishment.
The processing of skin takes place in cleanrooms. Every skin tissue establishment uses 
specific graft processes, according to standard operating procedures and mandatory 
regulations, and depending whether sterilised or non-sterilised grafts are processed.
Fresh skin grafts and skin for cryopreservation are processed immediately to maintain 
cell viability (Leung 2009). After receipt, the skin is decontaminated and processed into 
fresh, glycerol-preserved, cryopreserved or freeze dried allografts. Glycerol preservation, 
a method in which the skin is preserved in glycerol. As glycerol has virucidal and 
bactericidal characteristics, the skin can be processed in a laminar flow cabinet (Grade 
A) placed in a Grade D cleanroom. By using the glycerol method, the skin matrix is 
kept intact while cells are not viable. With cryopreservation all cells for the donor skin 
are kept viable. To apply this method of conservation, processing must take place in a 
Grade A flow cabinet placed in a Grade D clean room. When skin cells are preserved by 
using cryopreservation, their function is maintained after grafting on the recipient. A 
disadvantage is that the recipient may undergo an immunological reaction and reject the 
allogeneic skin. Both glycerol preserved skin and cryopreserved skin are only temporary 
grafts; the final closure of the wound always takes place with autologous skin.
Freeze dried and glycerol-preserved skin can be stored at room temperature. Glycerol- 
preserved skin is a non-viable skin-graft that is considered a safe product due to 
the antibacterial/antiviral properties of high concentrations of glycerol and is less 
immunogenic than cryopreserved skin. It is used in partial thickness burns and other 
types of skin loss, or within the sandwich grafting technique, in which meshed human 
skin allograft is used as an overlay over widely meshed autograft (Vloemans et al, 2002).
Fresh skin has a safety risk, as donor screening and microbiological testing is mostly 
not completed. Therefore most physicians prefer cryopreserved skin to fresh skin. 
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Also the ease of storage and availability is an advantage of cryopreserved skin. 
Cryoprotectants such as glycerol or dimethylsulfoxide are used to maintain cell viability 
during cryopreservation. Despite this procedure, cell viability is negatively affected by 
cryopreservation in comparison with fresh skin.
Depending on the recipient’s wound site, allogenic donor skin can be grafted as “full 
thickness” as well as “split-thickness”. A full thickness grafts consists of the entire 
epidermis and a dermal component of variable thickness if the entire thickness of the 
dermis is included (Wax et al, 2015). The interaction of the autologous dermal and 
epidermal cells ensures a secure secretion of chemokines, growth factors and cytokines 
into a non- healing wound bed. Wound reactivation and re-epithelialization occurs 
through the direct secretion and cover of the wound bed (A-skin, Amsterdam). A split- 
thickness skin graft (STSG) is a skin graft including the epidermis and part of the 
dermis (Barret-Nerin et al, 2004).
By making openings (meshing) in the graft, the recipient cells are able to “bridge” the 
gaps toward the allogeneic graft. Thus, the wound site heals by re-epithelialisation from 
the dermis and surrounding skin and requires dressings.
For many decades, skin banks have also cultured autologous keratinocytes for burned 
patients. An autologous skin biopsy is taken and cells are cultured during some weeks to 
form skin sheets. These are often grafted together with allogeneic skin on burn wounds 
and chronic wounds. They are not rejected and stimulate the wound bed to provide 
faster healing and definitive coverage of the wound with less scars and contractions.
This method has advantages and disadvantages. The advantages are that, specifically in 
autologous grafts, the immunological reaction of the recipient is avoided. When used 
as allograft, cultured skin may function as temporary dressing releasing growth factors 
that can stimulate wound healing. When skin culturing could be done on a large scale, 
the necessity to recover skin from deceased donors would disappear. The consequent 
advantage would be that the extended logistics to maintain a 24/7 donor recovery team 
and associated costs would become obsolete.
The disadvantage of the autologous skin culture techniques is the time lapse between the 
start of the culturing process and the final results, which can be at least several days. In 
urgent situations, such as third degree burn wounds, cultured skin can’t bring immediate 
relief. The second disadvantage is that the laminar flow cabinet (Grade A), in which the 
culturing (both autologous and allogeneic) takes place, must be placed in a clean room 
Grade B. The investment and maintenance costs may be 60% higher than when a Grade 
D background is applied (like for deceased donor skin processing). However, many 
skin banks anyhow process cryopreserved skin in a grade A/B environment. Also the 
maintenance costs of a Grade B clean room are considerably higher.
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Although a well-established process in many tissue establishments, skin culture techniques 
are now sometimes classified as an advanced therapy medicinal product (ATMP). The 
classification of these two products as ATMPS implies significantly higher costs due to 
investment in obtaining a marketing authorisation as an ATMP (Pirnay et al., 2013).
Cost structure
For the purpose of this study, two skin TEs were investigated in depth: Human Cell and 
Tissue establishment, Queen Astrid Military Hospital, Brussels, Belgium, and the Euro 
Skin Bank, part of the Euro Tissue Bank Foundation in Beverwijk, The Netherlands.
Euro Skin Bank is the larger. Annually, 400-500 donors are reported to this foundation, 
providing about 1 700 000 cm2 of skin. Most of these donors originate from the 
Netherlands. The Human Cell and Tissue Establishment Queen Astrid Military Hospital 
reports about 100 donors annually, while its distribution is around 200 000 cm2.
No specific data were available with respect to the four cost categories: Donation, testing 
and screening, processing and distribution. Information which was provided during the 
interviews for this research learned that the costs of virology tests are often shared with 
the tissue establishments that procure corneas and/or the heart from the same donor.
Procurement costs are estimated to be 33%, and processing costs are estimated to be 
about 50% of the costs (source: Euro Skin Bank).
To enable post mortem donations a well-trained team and accompanying logistics must 
be available. Each donation generates expenses for logistics, salary costs for procurement 
personnel, virology testing etc. Specifically at a post mortem skin donation it is important 
to procure sufficient cm2 skin to cover those costs by the distribution of allografts after 
processing; For example the Euro Skin Bank indicated that they strive for 4000 cm2 per 
donor to make the donation feasible.
The need for a clean room environment in which establishments usually process takes 
place under a class A cabinet with a background of class B.
The cryopreservation method is used by some skin tissue establishments, while a glycerol 
preservation method is used in others. Both methods guarantee a shelf life of several 
years. However, the investment in hardware for cryo-preservation and to safeguard 
preservation, the levels of liquid nitrogen must be constantly monitored and kept on a 
level sufficient to keep the temperature of the tissue grafts at an adequate level.
The culturing of skin requires surgical procurement techniques from the living donor. 
After a culturing process which takes place under class A clean room conditions, and 
which may take several weeks, the cultured cells are placed into the wound bed of 
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the recipient. Again, this takes place under class A conditions. Although calculations 
couldn’t be provided, this entire process results in higher costs per cm2 than other skin 
grafting methods.
Fee structure
From the interviews for this research, it was reported that the following fees for glycerol 
preserved skin to the end-user per cm2 were applicable in 2014: Belgium EUR 1.39; 
Netherlands EUR 1.20 (when exported, e.g. to Belgium, the fee is adjusted to the local 
price in Belgium: EUR 1.39).
Cross-border exchange and import /export of musculoskeletal tissue
Since distribution of tissue grafts is done all over Europe, the Euro Skin Bank developed 
and maintains several donor sites over the continent. Thus, the organisation strives for a 
balance between national and international activities. In 2012 a total of 1 125 000 cm2 
was distributed by the Euro Skin Bank, of which 11% was used nationally, 71% was 
sent to other Member States and 18% was exported to third countries.
Of all tissues distributed, only 13 units of cultured skin were produced and transplanted 
(TRIP Annual Report 2012).
Research for this report provided little information about the need for donor skin in 
the EU Member States. The table below shows the national need in five Member States.
Table 16. Need for donor skin in EU Member States
Year cm2/year cm2 per 106 inhabitants
Belgium 2011 221,040 0.02
Croatia 2012 295,905 0.06
France 2012 2,960,000 0.04
Netherlands 2012 123,750 0.008
Poland 2012 601,000 0.01
Source: Economic landscape survey NCATC (2015), data over 2012
The number of tissue donors in the Netherlands is more than sufficient to cover the 
demand (495 in the year 2012, with an estimated yield of 1,980,000 cm2). The low 
volumes of distributed skin in the Netherlands is due to the fact that, compared to other 
Member States, there are relatively few severe burns in that country.
Amniotic membrane
The amniotic membrane or amnion is one of the foetal membranes and is used for 
various applications in ophthalmic surgery as well as for chronic ulcers, skin burns 
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and other skin wounds. Amnion can be used fresh (Adds et al, 2001) but is mainly 
cryopreserved or freeze dried and stored (TRIP Annual Report, 2012, Biovigilance;).
Within the EU there were 18 authorised tissue establishments for procurement, 
processing and distributing amnion, often linked to a cornea tissue establishment.
Pancreatic Islets
Langerhans’ islets beta cells can be prepared from donor pancreas. These cells are 
injected into the liver of a patient suffering from diabetes; the beta cells will synthesise 
insulin. At this point the procedure is only indicated for patients with type 1 diabetes 
who have severe complications. In the future, it can be extended to patients with fewer 
complications.
In order to produce grafts composed of these cells, human donor Langerhans’ islets are 
provided by organ donor centres. Since the recipients are mostly in need of a kidney 
transplant as well, islet cell donation and transplantation is often considered to be part 
of the organ transplant network. The processing of grafts, however, is part of the tissue 
banking framework from a regulatory point of view. After receiving a pancreas in the 
tissue establishment, grafts with selected size, composition and function are produced.
The biological properties of beta cell grafts should be characterized and adjusted to the 
metabolic and immunological status of the recipient. This type of graft should increase 
the efficacy of accompanying measures aiming at graft survival and/or metabolic 
correction (Gaba et al, 2012).
The supply of Langerhans’ islets to use for human beta cell grafting is insufficient. To 
produce a graft which matches the recipient’s requirements, at least one organ is needed. 
Cases of up to 5 organs being used to process one beta cell graft have been reported (Qi 
et al, 2009).
From the economic landscape survey to NCATC (2015), Poland reported 13 pancreas 
donations and 10 transplantations of beta cells in the year 2012. In 2012 there were 8 
authorized pancreatic islet tissue establishments in the EU.
Other tissues and cells
A variety of tissues and cells can be categorised in this group, including adipose tissue, 
nerves and hepatocytes. Autologous adipose tissue is sometimes used in plastic and 
cosmetic surgery, and was identified as a source of pluripotent stem cells (up to now 
only in experimental therapy (TRIP Annual Report, 2012).
Nerve tissue can be transplanted when nerves are damaged by trauma or resection and 
to reduce neuropathic pain. Preferably autologous tissue is used but this is not always 
possible. In those cases an allogeneic nerve graft can be transplanted. Nerve tissue can be 
radiated, freeze-dried or cryopreserved (Nunley et al, 1996; Houston, 2001).
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The grafting of hepatocytes has barely left the stage of clinical experiment (Guha et al, 
2000). No hepatocyte implantations were reported in the EU as part of the research 
survey. The donor tissue for hepatocyte grafts origins from the liver. The liver is recovered 
in organ donation procedures. In some European centres, the liver is provided to a US-
based firm (Cytonet), which processes these livers into hepatocyte grafts.
ORGANISATION OF THE SECTOR
Tissue establishments are organised in a variety of different legal structures. The table 
below contains an overview of the total number of tissue establishments per tissue group 
and a division in public and private establishments for replacement tissues.
The majority of tissue establishments are (part of ) public organisational structures or 
‘private’ foundations that operate on a non-profit basis. Hospital-based tissue banks can 
be categorised as public or as private, depending on whether they are part of a publicly 
or privately funded hospital. Supply of tissue by for-profit, shareholder-oriented banks 
also occurs in Europe, although not on the scale that is practiced in the US.
Initiated by surgeons in need of certain tissues, many tissue establishments are hospital 
based and associated with the surgical department they supply. The majority (about 
75%) of the 653 banks focus on one type of tissue (e.g. skin, bone), or one category of 
surgeons (e.g. ophthalmologists who need corneas and amnions). Most of the single- 
tissue banks are hospital-based bone banks where femoral heads are stored. The size of 
these single-tissue establishments is small (50-250 donations per annum) and the tissue 
they handle is often only distributed in the own hospital and sometimes to hospitals in 
the region. The cost for these activities is usually difficult to distinguish from the budget 
of the hospital in which they are located. Given the similarity of most of the processes, 
sometimes tissue banks are part of the local or national blood establishments.
Over time, some of these single-tissue establishments have developed into larger 
independent establishments handling a higher volume of donations. These 
establishments supply tissue to many hospitals on a supra-regional or national level, and 
may also exchange or export material internationally. Examples of these are the FBOV 
(Fondazione Banca degli Occhi del Veneto Onlus - Veneto Eye Bank Foundation) (>2 
000 donations a year) and Euro Skin Bank in the Netherlands (>80% of skin distributed 
internationally).
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Public and private tissue establishments
In the common law, a public organisation is an organisation that is directly or indirectly 
legally related to a governmental body, such as a ministry or a ministerial agency. For 
tissue establishments, the distinction between public and private tissue establishments 
is a gross one.
In the survey to tissue establishments as part of this research, tissue establishments 
indicated that they were either:
• Part of a public (university) hospital
• (Part of ) a national health organisation
• For profit shareholder company
• Not for profit shareholder company
• Independent private foundation
• (Part of ) a private hospital
From the 27 responding tissue establishments 12 (44%) reported they are part of a 
university hospital, being a public body, while 5 (19%) belonged to a national health 
organisation. 10 tissue establishments (37%) indicated that they are a private foundation. 
The Implementation survey, carried out in 2011, demonstrated that from 461 tissue 
establishments concentrating on replacement tissue activities, 299 (65%) is considered 
as a public establishment.
Table 18. Status of EU tissue establishments
Source: European Commission Implementation Survey (2013), data 2011
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Multi-tissue establishments are in most cases active in the procurement of tissues from 
deceased donors, and are usually stand-alone, i.e. independent of the surgical units in 
the hospitals. Given the source of the tissues, some of the multi-tissue establishments are 
associated with pathology departments. Examples of large multi-tissue establishments 
include the FBTV (Fondazione Banca dei Tessuti di Treviso) in Treviso, Italy; BST Blood 
and Tissue bank in Barcelona, Spain; DIZG in Berlin, Germany and the NHSBT Tissue 
Services in Liverpool, UK.
Associations and foundations of replacement tissue establishments
Given the scattered landscape in Europe with many small establishments that operate 
locally and a small number of large (multi-tissue) establishments, collaborations are 
important in this sector. These collaborations find their origin in the limited availability 
of tissues on the one hand and the regular need for matching/characterisation to find 
grafts that meet the needs of specific recipients on the other hand. The following sections 
include an overview of the associations active in the field of replacement tissue banking, 
the international alliances between tissue establishments in EU Member States and 
between tissue establishments in the EU and organisations in relevant third countries.
Associations
Two main associations are active in replacement tissue banking. These are the European 
Eye Bank Association (EEBA) and the European Association of Tissue Banks (EATB). 
Both associations have been active for over two decades and concentrate their efforts 
on sharing of information to support endeavours to improve the quality and quantity 
of tissue donation and tissue banking. The EATB has been actively involved in the 
development of Good Tissue Practices; a set of GMP (good manufacturing practices) 
adapted to the specific needs of the different replacement tissue sectors. Both associations 
hold annual congresses to provide a forum for scientific, ethical and clinical discussions 
relating to tissue banking and to provide a forum for presentation of research and 
collaborative working. The associations contribute to formal consultations and seek to 
actively involve their members in all their activities.
Another organisation, the Foundation of European Tissue Banks (SEGB), was founded 
in Germany when new national legislation, based on the EU Tissue Directives, was 
introduced. The aim is to assist tissue establishments in Germany and in Europe with 
fulfilling legal criteria, by supporting projects focused on the improvement of quality, 
and to increase the number of tissue donors in Germany and elsewhere in Europe. The 
Foundation organises meetings focused on specific aspects of tissue banking, mainly of 
cardiovascular tissue establishments, as well as on the advancement of tissue donation in 
forensic medicine institutions.
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National alliances between tissue establishments
In order to cover the need on a national level, cooperation between tissue establishments 
is an important tool to ensure allocation and best use of donor tissue, which is available 
in one tissue establishment, to hospitals in the regional working area of another tissue 
establishment. Such networks exist in one form or another in Belgium, France, Germany, 
Italy, Spain, The Netherlands and the UK. In some Member States, such as Italy and the 
Netherlands, there are regulatory requirements to ensure that tissue grafts originating 
from national donors are allocated to recipients from that Member State before export 
is allowed.
In the Netherlands, two large tissue establishments, BISLIFE and the Euro Tissue 
Bank have agreed to share with other tissue establishments all information with 
respect to multi-tissue donors. The donation and procurement teams for skin, corneas, 
cardio- vascular and musculoskeletal tissue are complementary, and procedures are 
synchronized. Test results for different tissues that are recovered from the same donor, 
are shared. The evaluation methods of test results and the process to interpret outcomes 
takes place through consensus between the participating organisations and the tissue 
establishments, that will carry out the processing of the different procured tissue types. 
Such shared efforts therefore have a direct cost-reducing impact.
In Germany, there are two active national networks in the field of cornea banking. 
One consists of a group of Lions Cornea Banks, which exchange tissues on request. 
This network is, as the name suggests, supported by regional Lions Service Clubs. The 
Lions have a specific focus on blindness and usually express their support by financial 
donations that enable the cornea establishments to purchase capital investment goods 
such as incubators or laminar flow cabinets. The other network consists of a group of 
cornea establishments that operate under the umbrella of the Deutsches Gesellschaft 
für Gewebetransplantation (DGfG) (German Society for Tissue Transplantation). 
This society finances, partly or entirely, mainly cornea establishments, and strives for 
standardising processing methods and quality management. By optimal allocation of the 
available tissue graft within the network of 15 tissue establishments, the use of available 
tissue grafts is optimised for specific patient groups and maximised in order to prevent 
expiration of grafts in stock.
International alliances between tissue establishments
Mainly for reasons of balancing the supply and demand in different countries, some 
larger tissue establishments have created alliances to provide tissue to one another, 
across borders within EU, but also with non-EU countries. These alliances include the 
following:
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BISLIFE (NL) and Musculoskeletal Transplant Foundation (MTF, USA)
The cooperation is based on an agreement that came into effect at the inception of both 
foundations in 1989. The agreement has been renewed from time to time. Initially, 
BISLIFE (then BIS Foundation) distributed MTF bone and soft tissue (tendons) 
whenever BISLIFE couldn’t provide tissues from their national donors.
Since 2010, the agreement includes processing of bone tissue from two-thirds of the 
deceased donors in the Netherlands at MTF’s facility in the USA. After processing, the 
grafts are sent back and are distributed by BISLIFE (until 2010, BISLIFE had a similar 
processing agreement with Osteotech Inc. in the USA). Since MTF has distributors 
and marketing experts focused on different European countries, the agreement with 
BISLIFE limits distribution by BISLIFE to the BENELUX countries.
Euro Tissue Bank (NL) and the Tissue Bank of the University Hospital Brno (CZ) 
The Euro Tissue Bank receives donor skin from different sources in Europe. One of these 
sources is the Tissue Bank of the University Hospital Brno. Donor skin is recovered in 
the Czech Republic. After medical screening of the donor and negative test results, the 
skin is processed at the Euro Skin Bank (part of the Euro Tissue Bank) in the Netherlands 
and distributed to different EU Member States and to third countries whenever the 
stock assigned for use in European hospitals allows.
Euro Tissue Bank (NL) and Tissue Bank Bulgaria (TBB, BG)
One other source for skin donation is the TBB. Donor skin is recovered in Bulgaria, 
though tested in the Dutch national blood bank Sanquin. After medical screening of 
the donor and negative test results, the skin is processed at the Euro Skin Bank and 
distributed to different EU Member States and to third countries whenever the stock 
assigned for use in European Hospitals allows.
Euro Tissue Bank (NL) and Banc de Sang I Teixits Barcelona (BST, ES)
As with TBB (above, under 3) donor skin is recovered in Catalunya and processed in 
Euro Tissue Bank’s facility in the Netherlands. After processing, the tissue grafts are 
distributed to different EU Member States and to third countries whenever the stock 
assigned for European hospitals allows.
European Cell and Tissue Bank (ECTB, AT) and European Medical Contract Manufactu-
ring (EMCM, NL)
EMCM uses a process, which uses critical CO2 to remove all soft tissue blood and bone 
marrow bone tissue, reducing viruses or other micro-organisms to the sterility assurance 
level of log 10-6.
The ECTB sends bone tissue from femoral heads of living donors to EMCM’s facility in 
the Netherlands. After processing, the tissue is sent back to ECTB in Austria. Superfluous 
tissue, not needed for Austrian recipients, is distributed in other EU Member States. 
This distribution is always done within the regulatory limits of the respective countries.
212
Chapter 10
Tissue Bank Osteocentre Bulgaria (TBOCBG4, BG) and Deutsche Institut für Zellen und 
Gewebeersatz (DIZG, DE)
Bone tissue of deceased donors is recovered in Bulgaria and processed at the DIZG in 
Germany. Tissue grafts are distributed in Germany, while the fulfilment of need for 
tissue in Bulgaria is guaranteed.
BISLIFE (NL) and Banc de Sanq I Teixits Barcelona (BST, ES)
Since the early 1990s, BISLIFE has functioned as the distributor for cardiovascular 
tissues of de Banc de Sang í Teixits in Sant Boi (near Barcelona). Tissue grafts are imported 
mainly into the Netherlands and Germany.
In 2015, the relationship was extended to the processing of bone tissue. Donor tissue 
from the Netherlands is shipped to BST for processing, after which the tissue is returned 
to BISLIFE for distribution in Europe.
BISLIFE (NL) and DIZG (DE)
Bone tissue of deceased donors is recovered in the Netherlands, one third is shipped to 
DIZG and, after processing, distributed by DIZG mainly in Germany.
DIZG (DE) and MTF (US)
DIZG is a full subsidiary of MTF through Biocon Corporation, its controlling affiliate. 
DIZG and MTF exchange (patented) knowledge on processing techniques for processing 
of tissue including bone and dermis and MTF provides DIZG with base material with 
the help of US procurement partners.
European Homograft Bank (EHB, BE)
The European Homograft Bank (EHB) is a non-profit association according to the 
laws of Belgium. The association operates a cardiovascular tissue establishment, and has 
international members throughout the EU. The members provide donor tissues to the 
bank. In return they receive processed tissue grafts. The EHB has been instrumental in 
setting up a cardiovascular tissue establishment in Zagreb (HR) which uses the same 
methods as the EHB Brussels facility.
University Tissue Bank Leuven (BE) and France
The University Tissue Bank has a regular contact with French tissue banks in which 
demand and supply are balanced in case there are shortages in either Member State.
Tutogen Medical GmbH (DE) and RTI (USA)
Tutogen Medical GmbH is a subsidiary of RTI (formerly Regeneration Technologies 
International). The acquisition took place in 2008. It is known that in the past, Tutogen 
processed donor bone tissues procured in Estonia, Latvia, Czech Republic, Hungary and 
Slovakia. In 2012 Tutogen terminated import from tissues from deceased donors from 
Ukraine. Tutogen distributes the final tissues to Europe and exports them to the USA.
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Tutogen and TBB (BG)
TBB provides bone tissue to Tutogen. TBB declares that these donations take place 
according to the legislative rules and regulations of Bulgaria. No other relations are 
known.
This list includes some well-known alliances in the sector, but is not exhaustive.
FUTURE PERSPECTIVES IN REPLACEMENT TISSUES
Cardiovascular tissues
Although a few years old, the surveys regarding the use of cardiovascular tissue allografts 
show no increasing trend in the number of implantations (Foundation of European 
Tissue Banks, directories of European Cardiovascular Tissue Banks, 2012, 2013). 
Several meetings of cardiovascular tissue bank experts discussed these trends and their 
probable causes (consensus meeting 2011). Our recent surveys confirm this finding. The 
reasons are three:
• The improvement of mechanical (industrially produced) valves and bio- prostheses;
• The limited availability of cardiovascular allografts has lead surgeons to use 
alternatives;
• The so called Ross operation, in which the own pulmonary valve of the congenital 
heart disease patient is placed in the aortic position and a pulmonary allograft is 
placed in the place of the relocated pulmonary graft of the patient, is considered to 
be extremely difficult. Given the alternatives, residents seem to be less commonly 
trained to perform the Ross operation. As a result, the use of human valves is 
reduced.
Alternatives for allograft transplantations are improving, their availability is increasing 
compared to allografts, and fewer surgeons are trained to apply the complicated 
transplant procedures; as such it is expected that the number of cardiovascular graft 
transplants will remain low (1 to 2% of all valve replacements) and even diminish in 
the coming years. However, there is a continuing demand for human valves for young 
children to avoid multiple replacement operations as the child grows.
There is a trend to research the possibilities and the long-term effect of decellularisation 
of homograft valves. The theory is that decellularisation diminishes the immune response 
of the tissue recipient and would allow the colonisation and growth of host tissue on 
the graft in vivo. Decellularisation is so far undertaken by a small number of tissue 
establishments and might be a development that can add to the success of cardiovascular 
tissue in the future. Long-time results are not yet known but a number of clinical studies 
are underway and some results are promising (Da Costa et al, 2010).
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Cardiovascular tissue can be decellularised and cultured with autologous stem cells to 
create tissue engineered valves. There is currently no authorised ATMP product of this 
kind on the market but if one were to be developed and approved it might have a 
significant impact on the need for cryopreserved heart valves, possibly replacing them 
entirely at some time in the future (De Jonge, 2013).
In conclusion, it is expected that the use of traditional human cardiovascular tissue 
allografts will slowly decrease over the next 5 years. Yet the application of homografts 
will not entirely disappear, especially not for young patients. Research into methods for 
decellularisation and tissue engineering of both heart valves and vessels may result in 
grafts with a better recipient compatibility and extended survival as compared to those 
preserved with traditional methods, and therewith into a new increase of demand.
Ocular tissues
Given the ageing population in the EU, there will be a gradual increase in the demand 
for corneal tissue. No innovative scientific developments seem to be promising short 
term alternatives.
What can be observed, however, is the increase of the use of lamellar tissue grafts. 
These grafting procedures, contrary to the traditional penetrating keratoplasties (PKPs), 
reduce surgical scarring and the complications of immunological reaction. It is expected 
that the number of anterior lamellar implants will, because of poor long-term results, 
be considerably reduced, or almost disappear. At the same time, the posterior lamellar 
implants are not only replacing the performance of PKPs, they also enable treatment 
of patients that were not suitable for PKP, and thus increase the demand for cornea 
donations and grafts.
One side effect for the tissue establishments of these shifts is an increase in costs. The 
equipment to process a cornea into a lamellar graft, and the instruments used, are 
still in development. Demands for greater precision using new techniques will require 
investments at tissue establishments.
A more recent addition to the options to treat corneal damage (especially with limbal 
deficiencies in cases of burns to the eye), comprises the culturing of limbal stem cells 
into cell sheets that can be transplanted into the damaged limbal region of the eye. Rama 
et al. reported long-term corneal regeneration using autologous cultivated limbal stem 
cells (CLET). They showed that permanent restoration and a renewal of the corneal 
epithelium were achieved in 76.6% of 107 damaged eyes (Rama et al, 2010). Many 
centres are providing these cells with good results in the hospital and TE setting (EEBA 
2015), while one such technique has been authorized as ATMP in 2015 (Holoclar, see 
also EMA 2015).
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Musculoskeletal tissues
With the increased possibilities presented by alliances between several tissue 
establishments in the European Union to complement each other’s activities and to 
increase efficiency by making use of investments made, one would expect an increase in 
the exchange of processed bone grafts within the EU.
These European alliances though, will have to be able to compete with other EU tissue 
establishments, which have, in their turn, an existing alliance with one or more tissue 
establishments in the United States. As the latter make use of orthopaedic distributing 
firms and sales representatives in their working areas, they will certainly remain a very 
important factor for providing musculoskeletal tissues in the EU.
As the exchange and distribution by the aforementioned organisations increases, 
a reduction in the number of local or regional bone tissue establishments may be 
expected, as these cannot cope with the increased needs for investment such as in GMP-
level facilities, quality management, software development, training of employees and 
innovation. Performance under a critical mass of an estimated 150 post-mortem, or 
1,000 living (femoral head), donations per year is no longer sustainable5. As a result, the 
number of tissue establishments is likely to decrease.
In the next 5 years, the quantity of exchanged and distributed musculoskeletal tissues 
is expected to grow. Tissue establishments continue to demonstrate the superiority and 
safety of allografts over alternatives such as bovine bone products (Amini et al, 2012).
While technologies such as, for example, 3D printing of materials which could be equal, 
or better, than the present tissue grafts, have a long way to go before they can offer an 
affordable alternative for human tissue allografts, they do not present a viable alternative 
to tissue grafts in the short term. Specifically for tissue grafts such as tendons, there is no 
alternative to human tissue on the horizon.
What will be seen in the next five years is the increase of combinations of allografts and 
medical devices and pharmaceuticals (such bone tissue impregnated with antibiotics or 
growth factors).
Skin
In a five-year forward looking assessment of the present techniques, it is expected 
that skin grafts will remain the first choice for patients with burn wounds and other 
dermatological diseases which require skin grafting. Yet, there will be a shift toward 
autologous skin culturing either as an alternative, but mostly in addition to grafting of 
allografts. In the next 5-10 years, it is likely that grafts of autologous cells will be used to 
complement meshed allografts by placing cultured autologous grafts in the openings of 
the allografts. The use of dermis (as a decellularized skin graft), which enables enhanced 
return of the recipient’s epidermis at the wound site, is a trend that is already evident.
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Further increase in its application is to be expected.
CONCLUDING REMARKS AND SUMMARY REPLACEMENT TISSUES
Category Cardiovascular Ocular Musculoskeletal Dermatological
Indications Congenital, 
endocarditis, & 
alternative for 
mechanical valves
Idiopathic cell 
loss, cut- & burn- 
accidents
Bone loss, trauma, 
cancer, tear & break 
of tendons
Burns, reconstructive 
surgery
Tissue types Heart valves (vascular 
graft)
Cornea (Sclera) Bone  Demineralised 
Bone Matrix (DBM) 
Tendons
Skin grafts
Donors Deceased Deceased Deceased + Living Deceased
Main costs Much discard Much discard, easy 
expiry
High procurement 
costs with high 
yield for DD, end- 
irradiation reduces 
processing costs
Easy procurement, 
some storage cost
Average price/fee 
(min-max) reported 
by sample of TEs
2600€ 
(950€-5250€) for a 
heart valve
1420€ 
(250€-3500€) for a 
cornea graft
520€ 
(340€-900€) for a 
30CC cancellous chip
1.2-1.4€ per cm2 skin
Tissue establishments 77, small scale, 
mainly public
141, small scale, 
mainly public
386, half are private, 
from local to large 
international scale
57, mainly local and 
public, few large 
international player
Import, export and 
cross-border exchange
I/+, E/- 
Informal networks 
for cross- border 
exchange
I/+, E/+ 
Informal networks for 
import/export
I/ +++, E/ -
International 
partnerships
I/ -  E/ - 
Some international 
partnerships
Replacement tissues allow to replace some damaged tissues and therewith their 
biological functions. The majority of EU tissue establishments focus on four categories 
of replacement tissues: cardiovascular, musculoskeletal, ocular and skin.
In addition there are 181 tissue establishments authorized to process other tissue grafts 
like amniotic membrane or pancreatic islets, and 166 to process multiple tissue types.
Price comparisons for the different types of replacement tissues reveal strong difference 
between Member States. These differences do not reflect real costs made, but rather 
are a consequence of different factors including the price-setting process, policy 
objectives (non-commercialisation, self-sufficiency), the relative high presence of public 
tissue establishments, limited cost-awareness and intra-EU differences in salaries and 
purchasing power.
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The absence of a single EU ‘market’ for tissues and cells is in particular true for the 
replacement tissue sector and driven by some additional thresholds at national borders:
• Several Member States have set-up prior authorization schemes for export  and 
(outward) cross-border exchange, in order to ensure local supply and self- sufficiency.
• Many Member States require additional national requirements on safety and 
quality including donor screening, testing or processing (in addition to EU legal 
requirements). These are not always clear for tissue establishments.
• Some Member States apply national legal frameworks for pharmaceuticals or 
medical devices on replacement tissues, which can for example lead to the need for 
prior administrative authorizations to supply tissues to that Member State.
• Administrative procedures in different Member States are to be addressed in 
different languages.
• Fees are set at different levels by different national authorities, often reflecting a 
more general policy objective (non-commercialisation, self-sufficiency).
• Some Member States recently changed VAT taxation policies for tissues and cells 
distributed within their borders, which impacts the fees to be charged.
All these factors hinder a free distribution of grafts across borders of EU Member 
States. Also, only few Member States have an overview of the distribution and cross-
border exchange of different tissue grafts. More importantly, these thresholds also lead 
to situations where surpluses in some EU Member States exist in parallel to shortages 
in other EU Member States. Eventually, clinicians/surgeons cannot access the optimal 
replacement tissue graft matched to their patients’ individual needs.
• Overcoming these thresholds at the border, and supplying tissues to multiple 
countries, requires dedicated regulatory know-how, which is expensive and usually 
not available for small-scale, public-funded tissue establishments with limited 
resources. This prevents many EU tissue establishments from supplying hospitals/
clinicians in a larger area and from growing their activities. This puts an important 
limitation to their development as, for reasons of efficiency a larger scale of activities 
might be increasingly needed to obtain economies of scale, and eventually to break-
even or remain profitable.
• Over time, a few larger tissue establishments in the EU have built alliances cross 
borders to overcome these barriers. Several of them are described in the report. 
These agreements allow for more efficient procurement, processing or distribution.
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In addition, some US-based tissue establishments seem to be able to overcome that 
barrier as well. They are usually private and well-funded, sometimes even through public 
listing on the financial markets, and therewith can acquire the resources and know-
how to overcome these barriers and supply multiple EU countries. High quantities of 
surplus musculoskeletal tissues, some corneal grafts and specific sizes of heart valves, are 
exported to, and distributed into Europe. They often do this by building partnerships 
with or acquiring major EU- based tissue establishments to do so. This can raise some 
competitive challenges for the local/smaller-scale establishments. It also brings a need to 
verify equivalency of safety and quality of the imported substances and to reflect on EU 
self-sufficiency and dependency on imports.
• Exports out of the EU to third countries seem to be limited. It mainly concerns 
cornea grafts, which have a limited shelf life and are therefore rather exported than 
expired, usually during seasonal holiday periods in the EU.
• When it comes to the long term continuity of individual tissue establishments in 
Europe, there are signs that, given the fact that many of them are small entities, there 
may be a consolidation or shake-out of tissue establishments in the next five years. 
It is expected that not all of the small entities will be able to continue processing 
and supplying a critical mass of tissues large enough to cover the increasing costs of 
regulatory quality requirements, and many of  them may therefore not be able to 
survive.
• A strengthened collaboration between Member State authorities to facilitate 
cross- border exchange of tissues within the EU might therefore be a key factor 
for success for the future of many EU based (replacement) tissue establishments. 
The fragmented availability of activity data and the need for a common vision on 
optimal demand and supply for replacement tissues at EU level are priorities to be 
addressed.
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ABSTRACT
Introduction: In the past 50 years, human cardiovascular tissue allografts, also called 
homografts, have been implanted into patients with different valvular diseases1,2,5,6-13,15. 
The use of these allografts and the number of cardiovascular tissue banks and their 
respective techniques increased3,4.We conducted a survey to establish the quantity of 
allografts processed, and issued by, European tissue banks. The survey also included the 
collection of other relevant statistics.
Materials and Methods: In 2011, the Foundation of European Tissue Banks collected 
data from 19 different cardiovascular tissue banks in 11 European countries. 
Results From 2007 to2010 the  data show a decrease in the number of hearts received, 
from 1700 to 1640 in 18 tissue banks; the average number of hearts received for 
cardiovascular tissue processing decreased from 113 to 91. The number of heart valves 
issued for transplantation increased from 1272 in 2007 to 1486 in 2010. The average 
rate of discard because of microbiological contamination was 20.7%, while 4.2% of the 
grafts were not used because of positive serology. Half of the tissue banks issued arterial 
grafts, while 3 banks also issued veins and pericardium.. An overview of decontamination 
methods shows considerable methodological differences between 17 cardiovascular 
tissue banks.
Conclusions: From the experience in Europe, it can be concluded that cardiovascular 
tissue banks have an established place in the domain of cardiovascular surgery. The 
statistics show fluctuating data concerning the demand for human cardiovascular 
allografts and methodological questions. There is room for growth and improvement 
with respect to validation of decontamination methods.
Keywords: Cardiovascular Tissue, Tissue Donor, Tissue Bank, Homograft, Ross 
Operation, Discard Rate, Microbiology, Contamination, Decontamination, Serology, 
Validation.
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INTRODUCTION
In the early 1960s Ross and Barratt-Boyes introduced the use of human allograft cardiac 
heart valves, or homografts, into clinical practice1,2. In 2012 the 50th anniversary of the first 
so-called Ross operation was celebrated. The Ross operation encompasses implantation 
of a pulmonary autograft in the aortic position, while an allograft is transplanted in the 
pulmonary position. Ever since, there has been a need to store available donor grafts, so 
that they can be prepared, stored in a tissue bank, and used for implantation, either in 
elective or in emergency patients. 
From the end of the sixties and into the eighties tissue banks were founded all over 
Europe3. In the same period studies about the techniques and successes of homograft 
implantation in larger series of patients were published, followed in the nineties by 
studies which covered more than a decade4-14. Because, over time, they were the only 
successful biological heart valve prostheses beside the mechanical ones, the results were 
very satisfactory. 
The advantages were clear: a low rate of thromboembolic events, thus avoiding a lifetime 
of anticoagulation therapy. In addition, their hemodynamic properties were superior to 
those of mechanical valves, especially those available in the early 1960s and 1970s.
As time went by, it became clear that the availability and cardiectomy techniques to 
obtain cardiovascular tissues were a problem as suitable donors were recipients of heart 
transplants, organ donors whose hearts were not accepted, or donors who were autopsied 
and their relatives had agreed to their tissues being used15.
In the last 20 years, the European cardiovascular tissue banks have invested a great 
deal of finances and effort in improving the safety and quality of their tissue banking 
methods and facilities. Issues such as donor selection, validation of testing methods, the 
improvement of sterility systems and clean rooms were addressed. Regulations based on 
Directives16 of the European Union became law in all member states.
The Foundation of European Tissue Banks initiated a survey to obtain an assessment 
and quantification of the situation in the field of cardiovascular tissue banks, after 
implementation of the European Directives into national legislation. This study presents 
the results of that survey.
MATERIALS AND METHODS
In 2011, questionnaires were sent out to 30 cardiovascular tissue banks, 18 of which 
completed and returned them. One cardiovascular tissue bank had started its activities 
in early 2011; hence no data could be reported as yet. Three additional questionnaires 
were received after the statistical analysis was closed, and these data are not included. 
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The data received were accumulated and statistically stratified. Ranges and means were 
calculated and tabulated giving insight into the level of activities of these cardiovascular 
tissue banks. Percentages of detected positive serology were assembled, and a break-
down of microbiological contamination as the reason for discarding tissue should yield 
information on the reasons for tissues being discarded during the process.
Ethical approval was waived given the observational and retrospective design of the 
study. No data from individual donors and patients were used in this study.
RESULTS
The statistics in Table 1 are based on the assumption that every heart received in the 
cardiovascular tissue banks provided two grafts. Out of 18 tissue banks, 11 had registered 
the number of donor reports rather than the hearts actually received in the bank. In 
these 11 tissue banks, 67% of the donors reported resulted in the receipt of a heart in 
the bank. Table 1 shows that from the total of 1640 hearts received by 18 tissue banks in 
2010, only 46.9% provided suitable grafts; hence the discard rate is 53.1%. 
The cardiovascular tissue banks show a considerable difference in their activities: while 
in 2010 the highest number of grafts received was 262, the smallest bank processed only 
17 grafts. When it comes to issuing grafts, similar differences are observed. As shown 
in Table 2, the number of grafts issued ranges from 4 to 243. The statistics in Table 2 
confirm that the demand for pulmonary grafts is about twice as high as the demand for 
aortic valves: 67% of all grafts issued were pulmonary valves.
The data provided by the 18 cardiovascular banks show that, in 2010, exporting of 
tissues to other countries was done by 7 banks, with the proportion varying from 1% to 
72% of the annual number of processed grafts.
Table 3 provides insight into the information with respect to donors. The average donor 
age ranges from 40 (in 2007) to 42 in 2010. Fifty-seven percent of the hearts originated 
from organ donors of whom the heart could not be transplanted, 28% from non-organ 
donors (those who become donors after an extended period of cardiac arrest, and are thus 
unsuitable as organ donors) and 15% were retrieved from so called “domino donors”. 
Domino donors are people who undergo a heart transplantation, and whose native heart 
may still have valves that are transplantable as tissue grafts.
The criteria for the time between cardiac arrest and cardiectomy, as observed by the 
tissue banks in this study, ranged from 2 to 48 hours. In reality, the average time until 
cardiectomy was between 8 hours in 2007, and 11 hours in 2010. After receipt in the 
tissue bank, the valvular grafts are excised from the heart and decontaminated. Also 
here, the criteria differed greatly between the banks and the time varied from 18 hours 
to 72 hours, while the average number of hours in practice was 24.
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Table 4 shows the reasons for discarding donor tissue. In 2010, 45.3% of the tissue 
grafts had to be discarded. In many cases there was more than one reason for not 
accepting the heart, or its tissue grafts, for transplantation. In 32.7% of the cases the 
reason for discard was that there were contraindications for transplantation of the tissue 
in the donor’s medical history. During processing 35.8% of the cardiovascular tissue 
was found to be unsuitable because of its morphology. In 17.65% and 4.2% of the 
cases, respectively, microbiology or serology test results were a reason not to accept the 
grafts for transplantation. Technical and unknown reasons were responsible for 7.3% 
and 7.8%, respectively, of the discards. 
Table 5 gives an overview of decontamination methods in 17 cardiovascular tissue 
banks. Substantial differences can be observed in the number of hours during which 
the tissue banks culture the tissue to detect and/or eliminate micro-organisms; the range 
is 5-72 hrs. Also, the temperature under which incubation takes place shows a large 
variety: from 4o C to 37o C. The banks use 25 different antibiotics in many different 
concentrations. 
In Table 6 a breakdown of other tissues provided by the banks in this study shows that 
pericardium, arteries and veins are processed alongside valvular allografts.
DISCUSSION
The level of activity in cardiovascular tissue banks is determined by the numbers of 
donors. This study shows that the range of donor hearts received in 18 banks varied 
from 1640 in 2010 to 1700 in 2007. 
As the number of hearts received represents only 67% of the number of donors referred, 
it may be worthwhile to analyze the reasons why the hearts of 33% of the reported donors 
were eventually not allocated to the tissue bank. By eliminating factors preventing the 
donation from materializing, banks would be able to increase their activity.
On the other hand the statistics document that in 2010 45.3% were not suitable for 
transplantation and had to be discarded. Better donor screening beforehand, and a more 
effective process from cardiectomy to excision and for decontamination in the bank are 
three factors which could decrease this high number of discards.
This study shows in statistics what cardiovascular tissue bankers have known for a long 
time, that the demand for pulmonary valves is about twice as high as the demand for 
aortic valves: 66% of all grafts are pulmonary valves. 
Although this study does not extend to the use of grafts, the literature shows that for 
many centers the pulmonary valve is the allograft of choice in congenital as well as in 
acquired cardiac diseases11.
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The activity of the banks varies from processing less than 20 to 262 donor hearts in 
2010. One has to wonder about the routine capabilities of personnel as well as about the 
optimal use of the investment and costs of maintenance of a class A laboratory. 
The donor age (Table 3) has gradually increased from an average of 40 in 2007 to 42 
years in 2010. As the average age in the European population increases, the donor age 
increases accordingly. 
Some cardiovascular tissue banks receive hearts from organ donors only. The reason is 
twofold: 
1. some authorities forbid the use of non-organ donors; 
2. to set up a cardiectomy team on a 24/365 basis requires additional organizational 
constraints and investments which some banks wish to avoid. 
Most cardiovascular tissue banks strive to increase the volume of available tissue. The 
dependency on the receipt of organ donor and domino donor hearts brings them into a 
vulnerable position. The need for additional cardiovascular grafts could be compensated 
by an effort to set up a non-organ donor program.
The discard because of morphology can hardly be avoided. However, the differences 
in decontamination methods, use of antibiotics and their concentrations, as well as 
temperature should be a subject to cause concern in the cardiovascular tissue banks 
participating in this study. 
In 2010, a conference of these tissue bankers and their microbiologists was organized by 
the Foundation of European Tissue Banks. Substructuring and validation methods were 
exchanged, and some arguments were proven to be right. 
At that conference, and from the questionnaire in this study, no adverse events were 
reported by any of the participating tissue banks.
While most of the cardiovascular tissue banks in this study concentrate on the processing 
and distribution of the “classic” homograft heart valves, nine banks showed activities 
with respect to processing tissues such as arteries, veins and pericardium. Table 6 clearly 
shows an increase in the distribution of arterial grafts. Correspondence with different 
tissue bank representatives revealed that the demand for arterial grafts is growing 
throughout Europe. While veins are used in access surgery (shunts), pericardium serves 
as patching material to bridge larger gaps of deficient tissue during cardiothoracic 
operations. The numbers of these tissues issued over the period 2007-2010 also show a 
considerable increase.
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CONCLUSIONS
For the first time since the start of the clinical use of human allogeneic heart valves, data 
from a number of European cardiovascular tissue banks could be accumulated. Statistics 
with respect to numbers, discard and use of cardiovascular tissue provide insight into 
the magnitude of their activities as well as into some of the parameters they use. First of 
all, looking at the number of tissue grafts issued for transplantation, one can conclude 
that the demand for tissues has not decreased during the period of 4 years encompassed 
in this study. Apparently the demand increased by 16.8%, from 1272 to 1486, over a 
4-year period. 
The results show that cardiovascular tissue bank activities have remained relatively stable 
over the years, though the number of donors has somewhat decreased (3.5%).
While the demand for pulmonary grafts still increased from 810 to 981 (21.1%), only 
505 aortic grafts were issued in 2010. What happens with all the aortic grafts which are 
not issued is a logistical as well as an ethical question. 
In order to cope with the persistently high demand for pulmonary grafts and arteries, 
those cardiovascular tissue banks which do not retrieve hearts from non-organ donors 
should seriously consider initiating such a donor program.
Although not clinically proven, studies show that stem cell techniques may eventually 
contribute to the quality and availability of human heart valves, yet none of the 
cardiovascular tissue banks indicated that they are in any way involved in stem cell 
research.
The differences in accepted time lapses from death to cardiectomy, and from cardiectomy 
until excision of the valves and further processing find their origin in view-points with 
respect to quality and safety. A consensus between the tissue banks contributing to this 
study should be based on data with respect to the potential loss of tissue quality starting 
at cardiac arrest and measured over time.
As there are very large methodological differences with respect to microbiology testing, 
incubation and decontamination of cardiovascular tissue between the 17 contributing 
tissue banks, there is a necessity to validate procedures and room for improvement17-19.
This survey shows an increased demand for other tissues, which may be worth further 
exploration. After all, where alternatives seem to fail or are absent, it is the task of tissue 
banks to satisfy the clinical demand for tissue grafts.
228
Chapter 11
REFERENCES
1. Ross DN. Homograft replacement of the aortic valve. Lancet 1962;2:487.
2. Barratt-Boyes BG, Lowe JB, Cole DS, Kelly DT. Homograft replacement for aortic valve disease. 
Thorax 1969;20:489.
3. Parker R. An international survey of allograft banks. Cardiac Valve Allografts, Science and Practice. 
Darmstadt: Steinkopf, New York: Springer, 1997; 5-9.
4. Clarke DR, Campbell ON, Hayward AR, Bishop DA. Degeneration of aortic valve allograft in young 
recipients. J Thorac Cardiovasc Surg 1993;105:934-42.
5. Yankah AC, Pasic M, Klose H, Siniawski H, Weng Y, Hetzer R. Homograft reconstruction of the aortic 
root for endocarditis with periannular abscess: a 17-year study. Eur J Cardiothorac Surg 2005;28:69-75.
6. Willems TP, van Herwerden LA, Steyerberg EW, et al. Subcoronary implantation or aortic root 
replacement for human tissue valves: sufficient data to prefer either technique? Ann Thorac surg 1995; 
60: 83-S86.
7. Musci M, Weng Y, Amiri A, et al. Homograft aortic root replacement in native or prosthetic active 
infective endocarditis: 20-year single center experience. J Thorac Cardiovasc Surg 2010; 139: 665-73.
8. Bekkers, JA, Klieverik LM, Raap GB, et al. Re-operations for aortic allograft root failure: experience 
from a 21-year single-center prospective follow-up study. Eur J Cardiothoracic Surg. 2011;40: 35-42.
9. Mokhles MM, van de Woestijne PC, de Jong PL, et al. Clinical outcome and health-related quality of 
life after right-ventricular-outflow-tract reconstruction with an allograft conduit. Eur J Cardiothoracic 
Surg. 2011; 40:571-8 
10. Parker R, Randev R, Wain WH, Ross DN. Storage of heart valve allografts in glycerol with subsequent 
antibiotic sterilisation. Thorax 1978; 33: 638–645.
11. O’ Brien, MF, Stafford G, Gardfner M, et al. The viable preserved allograft aortic valve. Journal of 
Cardiac Surgery 1987; 2 (Suppl): 153-167.
12. Carr-White GS, Kilner PJ, Hon JK et al. Incidence, location, pathology and significance of pulmonary 
homograft stenosis after the Ross operation. Circulation 2001;104:116-120.
13. Yankah, CA, Yacoub, MH, Hetzer, R. Cardiac Valve Allografts, Science and Practice. Darmstadt: 
Steinkopf, New York: Springer, 1997.
14.  Barrat-Boyes BG. Aortic allograft valve implantation: freehand or root replacement? J Card Surg 
1994; 9: 196-197.
15. Jashari R, Goffin Y, Vanderkelen A, et al. European Homograft Bank: Twenty years of cardiovascular tissue 
banking and collaboration with transplant coordination in Europe. Transplant Proc 2010; 42: 183-9
16. EU Directives 2004/23/EC, 2006/17/EC and 2006/84/EC 
17. Jashari, R, Vanhoeck B, Fan Y, Improving the cardiectomy at the European Homograft Bank (EHB). 
The Postmortem Donation of Cardiovascular Tissues, Forschungsergebnisse aus dem Institut für 
Rechtsmedizin der Universität Hamburg, Band 21, 105-08.
18. Contamination of human cardiovascular tissues. Origin, treatment and literature. Petit P, de By 
TMMH, The Postmortem Donation of Cardiovascular Tissues, Forschungsergebnisse aus dem Institut 
für Rechtsmedizin der Universität Hamburg, Band 21, 109-134.
19. Bactericidal effects of superoxide solution (SOS); proof of principle. Van den Bogaerdt AJ, Petit P, van 
Wijk M, Bogers AJ. The Postmortem Donation of Cardiovascular Tissues, Forschungsergebnisse aus 
dem Institut für Rechtsmedizin der Universität Hamburg, Band 21, 139-40.
229
Cardiovascular Tissue Banking in Europe
11
TABLES
Table 1. General statistics
2007 2008 2009 2010
Number of banks providing data 16 17 18 18
Number of countries 8 8 9 10
Number of hearts received 1700 1685 1663 1640
% of grafts issued for grafting 39.3 45 46.8 46.9
Average number of hearts received 113 120 111 91
Range of hearts received 10-312 4-334 9-307 17-262
Table 2. Heart valves issued per year
2007 2008 2009 2010
Aortic valves 462 508 514 505
Pulmonary valves 810 953 938 981
Mean number of aortic valves issued 36 34 34 34
Mean number of pulmonary valves issued 62 73 59 61
Range of aortic valves issued 4-95 10-84 5-85 4-79
Range of pulmonary valves issued 16-184 15-226 7-223 17-243
Table 3. Donor information
2007 2008 2009 2010
Mean age (yrs) 40 40 41 42
Death to cardiectomy criterion range in hrs.
Death to cardiectomy in reality, range in hrs
2-48 2-48 2-48 2-48
3-18 4-16 4-14 5-18
Death to cardiectomy, average hrs in reality 8 8 7 11
Death to excision criterion range in hours
Death to excision in bank in reality, range
24-72 24-72 24-72 24-72
12-44 13-45 17-42 18-43
Death to excision, average hours in reality 24 24 24 24
Table 4. Heart valve discards in 2010, average % of all cardiovascular banks
Heart valve discards in 2010, average % of all cardiovascular banks
Not selected because of: % of received hearts
Medical history 32.7
Serology 4.2
Microbiology Bacteria 10.7
Multi resistant bacteria 0.4
Fungi 3.2
Not specified 0.1
Suspected 0.35
Total microbiology 5.9
Morphology 35.8
Technical 7.3
Other or unknown reasons 7.8
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Table 5. Different decontamination methods in 17 European cardiovascular tissue banks
Valve bank Antibiotics Antibiotics: 
concentration
Duration 
of culture
Temperature mg/L Medium
Barcelona, BST Cefoxitin 240µg/mL 24hrs 5ºC (2-8ºC) 240
Vancomycin 50µg/mL 50
Polymyxin B 120µg/mL 120
Clindamycin 
(Lyncomicin)
100µg/mL 100
Amphotericin B 5µg/mL 5
Barcelona, TSF Penicillin 50 U / ml 24 hrs 5o C (+/- 
3oC)
50 U
Vancomycin 50 µgr /ml 50
Streptomycin 50µgr /ml 50
Amphotericin B 10µgr /ml 10
in medium 500 ml 
RPMI
 w/o L-glutamine RPMI
Bad Oeynhausen Mefoxitin 0.024% (m/V) 18-24 hrs 6o C 240
Lincocin 0.012% (m/V) 120
Colistin 0.0099% (m/V) 99
Vancomycin 0.005% (m/V 50
Berlin Amikacin 1.2mg/2ml Syringe 18-24 hrs 5o C (+/- 3o 
C)
Metrodinazol 1.2mg/2ml,
Flucytosin 3.0mg/2ml,,
Vancomycin 1.2mg/2ml,,
Ciprofloxacin 1.2mg/2ml,,
Bristol Amphotericin 0.05mg/ml 21-24 hrs 22o C 50
Ciprofloxacin 0.20mg/ml 200
Vancomycin 0.05mg/ml 50
Gentamicin 4.00mg/ml 4000
in Hanks’ BSS HANKS
Brussels Lincocin 120µg/ml 48 hrs 4o C 120
Vancocin 50µg/ml 50
Polymixine B 124µg/ml 124
in medium 199 M199
Cracow Gentamicin 100mg/ml 24 hrs 4° C 100 RPMI
Vancomycin 50 mg/ml 50
Clindamycin 120 mg/ml 120
Colistin 100 mg/ml 100
Ampicilin + Sulbactam 200 mg/ml 200
Amphotericin B 25 mg/ml 25
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Valve bank Antibiotics Antibiotics: 
concentration
Duration 
of culture
Temperature mg/L Medium
London Cefuroxime 250ug/ml 24 hours 37oC 250
Gentamicin 80ug/ml 80
Ciprofloxacin 200ug/ml 200
Vancomycin 500ug/ml 500
Colistin 1000 IU/ml 1000 UI
Amphotericin 100ug/ml 100
Linz Amphotericin B 125 µg/ml 24 +/- 2 
hrs
 + 4° C 125 RPMI
Gentamicin 600 µg/ml 600
Metronidazol 600 µg/ml 600
Ciprofloxacin 150 µg/ml 150
Vancomycin 600 µg/ml 600
Lund Amphotericin 250ug/ml 24 hours 5oC (+/- 3o 
C)
250
Ketokonazol 100ug/ml 100
Colistin 200ug/ml 200
Vancomycin 500ug/ml 500
Gentamicin 500ug/ml 500
Milano Polimyxine B sulphate 100 µg/ml  in 
RPMI1640 medium
24 hours 4°C 100
Vancomycin 50 µg/ml i n 
RPMI1640 medium
50
Cefoxitin or 
Cefotaxime 
240 µg/ml  in 
RPMI1640 medium
240
Lincomycin 120 µg/ml  in 
RPMI1640 medium
120
Oxford Amikacin 1g/L 18-24 hrs 20 - 30o C 1000 M199
Cefuroxime 500mg/L 500
Vancomycin 1g/L 1000
Timentin 3.2g/L 3200
Polymixin B 10,000,000iu/L
Nystatin 1440,000iu/L
Paris Vancomycin 500mg/L 18/24 h 4°C 500
Gentamicin 320mg/L 320
Clindamycin 600mg/L 600
In RPMI medium RPMI
Prague Amikacin 0.1 mg/ml 24 hrs 20 - 30° C 100
Ampicilin + Sulbactam 0.2 + 0.1 mg/ml 200+100
Cefoperazon 0.2 mg/ml 200
Fluconazol 0.1 mg/ml 100
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Valve bank Antibiotics Antibiotics: 
concentration
Duration 
of culture
Temperature mg/L Medium
Amphotericin B 0.1  
for NHBD
0.1 100
in medium 199  
Rotterdam Amikacin (as sulphate) 0.6 mg/mL 5-6 hours 37oC 600
Vancomycin 0.6 mg/mL 600
Ciprofloxacin (as 
lactate)
0.15 mg/mL 150
Metronidazole 0.6 mg/mL 600
Flucytosine 1.5 mg/mL 1500
Treviso Vancomycin 100 mg/ml di 
medium RPMI 
1640
72 hrs  + 4° C 100 RPMI
Polimyxine   100 mg/ml (= 1 Mio mIU/ml) di medium RPMI 
1640
100
Ceftazidima 240 mg/ml di medium RPMI 
1640 
240
Lincomycin  120 mg/ml di 
medium RPMI 
1640
120
Warsaw Tazocin (Piperacillin/
Tazobactam)
0.5 mg/ml 24 hrs 20o C (+/- 2o 
C)
500
Gentamicin 0.05 mg/ml 50
Nystatin 2 500 j./ml
Vancomycin 0.5 mg/ml 50
Table 6. Other tissues issued
Other tissues issued 2007 2008 2009 2010
Pericardium banks 3 3 3 3
in % of all banks 19% 18% 17% 17%
tissues 39 50 54 81
Arteries banks 7 7 7 9
In % of all banks 44% 41% 39% 50%
tissues 307 305 423 481
Veins banks 3 3 3 4
in % of all banks 19% 19% 17% 22%
tissues 245 229 314 286
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ABSTRACT
Objectives: Surgeons needing human cardiovascular tissue for implantation in their 
patients, are confronted with cardiovascular tissue banks using different methods to 
identify and decontaminate micro- organisms. To elucidate these differences, we 
compared the quality of processing methods in 20 tissue banks and 1 reference laboratory. 
We did this to validate the results for accepting or rejecting tissue. We included the 
decontamination methods used and the influence of antibiotic cocktails and residues 
with results and controls. The minor details of the processes were not included.
Methods: To compare the outcomes of microbiology testing and decontamination 
methods of heart valve allografts in cardiovascular tissue banks, an international 
quality round was norganised. Twenty cardiovascular tissue banks participated in this 
quality round. The quality round method was validated first and consisted of sending 
purposely contaminated human heart valve tissue samples with known micro-organisms 
to the participants. The participants identified the micro-organisms using their local 
decontamination methods.
Results: Seventeen of the 20 participants correctly identified the micro-organisms 
organisms; if these samples were heart valves to be released for implantation, 3 of the 20 
participants would have decided to accept their result for release. Decontamination was 
shown not to be effective in 13 tissue banks because of growth of the organisms after 
decontamination. Articles in the literature revealed that antibiotics are effective at 36°C 
and not, or less so, at 2–8°C. The decontamination procedure, if it is validated, will 
ensure that the tissue contains no known micro-organisms.
Conclusions: This study demonstrates that the method of sending contaminated tissues 
and assessing the results of the microbiological cultures is an effective way of validating 
the processes of tissue banks. Only when harmonization, based on validated methods, 
has been achieved, will surgeons be able to fully rely on the methods used and have 
confidence in the consistent sterility of the tissue grafts. Tissue banks should validate 
their methods so that all stakeholders can trust the outcomes.
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INTRODUCTION
Since the founding of the heart valve bank at the National Heart Hospital in London1, 
the practice bywhich cardiovascular tissue banks receive cardiac human donor organs 
and tissues from deceased orliving donors has persisted for more than 50 years2,3. The 
demand from cardiac surgeons for safe tissue grafts of consistent quality for implantation 
in their patients, has been the impetus for continuity among cardiovasculartissue 
banks. Whereas graft quality in general is guaranteed by directives and legislation4, 
the processingmethods of tissue banks often differ considerably. Such is the case in 
cardiovascular tissue bankprocesses5.
In short, the practical tissue banking process is as follows: The donor source of the 
received cardiac tissuesis screened for transmittable diseases and contraindications for 
using these tissues for implantationinto human recipients6. When no contraindications 
are present, the tissues are treated and tested formicrobiological sterility, processed and 
stored (with a final sterility control) until needed fortransplantation. 
Subsequently, implantation of tissue grafts takes place in the operating theatres of 
the recipients’ hospitals. In each of the processes, there is a risk that microbiological 
contamination may occur7. The idea for a quality round, whereby cardiovascular tissue 
banks compare results of microbiological tests during their tissue processing procedures, 
finds its origins in the fact that microbiological decontamination protocols in European 
tissue banks differ significantly, partly due to differences in endemic microflora and 
patented processes. Even when these methods have been validated, the results may 
differ8.
Organising quality rounds, in which standardised samples are sent to different 
laboratories for testing and resulting comparisons, is an accepted method to measure 
the quality of the outcomes9,10.
This study provides an inventory of methods of 20 participating cardiovascular tissue 
banks worldwide, most of which are in Europe. In this way, the entire process related to 
microbiological decontamination is checked. Additionally, the purpose of the study is 
to demonstrate the possibility of executing quality rounds comparing the differences in 
methods used by tissue banks.
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METHODS
Validation of the Quality Round method
Sending the same contaminated heart valves to tissue banks, following their standard 
procedures of testing, decontamination and control and comparing these results with 
those from other tissue banks and the reference laboratory is a proven method to validate 
all procedures of all participating banks. Validation of the quality round method took 
place in 2 stages of testing.
The first validation test took place in January 2014. The Centraalbureau voor 
Schimmelcultures of the Royal Netherlands Academy of Sciences validated the method 
for the quality and transport of freeze-dried bacteriological samples.
These freeze-dried samples were sent to 7 different European cardiovascular tissue banks 
and to 1 reference microbiology laboratory, all of which scored above average11.
The results and organisational findings from the two validation tests were used to 
improve and finalise the protocol for the quality round with donated Human Tissue, as 
described in the ‘Quality round with donated human tissue’ section below.
Quality round with donated human tissue
In September 2015, the third quality round was executed. Donated tissues, consisting of 
6 cardiac valvular homografts, were received from one of the participating cardiovascular 
tissue banks [The donated tissue was made available according to the provisions of the 
law of the Federal Republic of Austria:
Bundesgesetz über die Festlegung von Qualitäts- und Sicherheitsstandards für die 
Gewinnung, Verarbeitung, Lagerung und Verteilung von menschlichen Zellen und 
Geweben zur Verwendung beim Menschen (Gewebesicherheitsgesetz-GSG) StF: 
BGBl. I Nr. 49/2008 (NR: GP XXIII RV 261 AB 343 S. 40. BR:AB 7823 S. 751.) 
and StF: BGBl. Nr. 1/1957 (NR: GP VIII AB 164 S. 22. BR: S. 121.)]. These grafts 
were washed to remove any residues of antibiotics, and post-wash sterility testing was 
performed. Subsequently, these tissues were cut into 2 sets of 20 samples to be sent to 
the participating laboratories and 2 sets of 2 samples for the reference laboratory. The 2 
x 22 samples were contaminated and marked as follows:
• Tissue sample A (22): Escherichia coli (Ec) and Enterococcus faecalis (Enco).
• Tissue sample B (22): Due to insufficient stock, 50% of the tissue banks received 
tissues inoculated with coagulase-negative Staphylococcus and Streptococcus 
anginosus, and 50% of the tissue banks received tissues inoculated with coagulase-
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negative Staphylococcus, Escherichia coli (Ec) and Streptococcus anginosus (Sa) 
(Table 1).
The strains were isolated from the donated cardiac tissue, cultured and checked twice by 
a reference laboratory.
After contamination, the samples were packed in a sterile containe with saline. Samples 
were then packed and dispatched to
the participating tissue banks according to the European Directives (94/55/EC) for 
Transportation of Biomaterials.
Logistics
Transportation temperatures were validated at 3 different levels by the reference 
laboratory: 32°C, refrigerated at 6°C and at room temperature +20°C. In September 
2015, the samples were sent to the 20 participating tissue banks. They were sent midweek 
to avoid weekend delays. The time between contamination and delivery at the address of 
the tissue banks was within 24 h. The start of the investigations, i.e. the culturing of the 
samples, occurred 6 h to 168 h after delivery. There were no differences in the culture 
results between those that were started early and those that were started late.
Instructions for the laboratories on how to process the samples were given on an insert. 
After the specimens were received, they were processed and tested in accordance with 
the procedures of the individual tissue banks. All results were sent back to the reference 
centre and were received by December 2015. Tissue banks described the essentials of 
their processing: which antibiotic cocktail they used, how long they incubated the tissue, 
at which temperature and if they rinsed or neutralized the antibiotics and checked to see 
whether any residuals were left.
Reference laboratory
For sample A, the reference laboratory correctly identified both micro-organisms— 
Enterococcus faecalis and the Escherichia coli. For 50% of Sample B, coagulase-negative 
Staphylococcus was identified, while in the other 50% of the samples, Streptococcus 
anginosus , coagulase-negative Staphylococcus and Escherichia coli was correctly ientified. 
The reference laboratory isolated the S. anginosus from only 1 out of the 2 samples 
tested. Therefore, S. anginosus was excluded from the score.
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RESULTS
The results of all the 20 participating cardiovascular tissue banks were collated (Table 1): 
Seventeen tissue banks scored tissue sample A correctly. Three tissue banks either missed 
the Enterococcus (2) or the E coli (1).
Seventeen tissue banks scored tissue sample B correctly. Two tissue banks missed the 
coagulase-negative Staphylococcus and 1 bank received a sample contaminated with 
Enterococcus, probably due to cross-contamination with Sample A. All tissue banks 
used a cocktail of 3 to 6 different antibiotics to decontaminate the tissue. The antibiotic 
cocktails that were in use are as follows: 17 tissue banks used vancomycin, 11 used 
gentamicin and 10 tissue banks used antifungal drugs (mainly amphotericin or nystatin).
Specific anaerobic coverage (such as metronidazole, cefoxitin, sulbactam and tazobactam) 
was used by 11 tissue banks; 9 tissue banks did not cover anaerobic micro-organisms. 
Similarly, 10 banks did not cover fungi (Table 1, column 4) and 2 banks did not cover 
enterococci (which was one of the contaminants in the trial).
The goal of the decontamination protocol that the tissue banks use is to disinfect the 
tissue by immersion and incubation in mixture of the aforementioned antibiotics. Most 
(60%) contain vancomycin and aminoglycoside (Table 1, column 4). The tissues were 
incubated for a minimum of 6 h in 1 bank, and a maximum of 48 h in 4 banks. All 
other banks used time periods between 6 and 48 h (Table 1, column 5). Sixteen tissue 
banks immersed the tissue during decontamination at a temperature of 2°C to 8°C, 
and 4 tissue banks decontaminated the samples at room temperature or 37°C (see Table 
2). Of these last 4 tissue banks, 2 had a negative culture after decontamination. As 
can be seen in Table 2, only 7 tissue banks had a negative microbiological culture after 
decontamination with antibiotics.
Five tissue banks found only 1 of the 2 samples to be negative (4 times in Sample B). 
Seven tissue banks found the last-sterility-check culture to be negative, but only 3 tissue 
banks would release the tissue for implantation; the other 4 rejected the tissue. All other 
tissue banks (13) would reject the tissues. So, most tissue banks discarded the tissue, 
whatever the results of their controls.
Only 6 tissue banks rinsed the tissue or neutralized the tissue to get rid of antibiotic 
residues after decontamination. They did not indicate whether they tested the tissue for 
antibiotic residues and/or whether their methods were validated.
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Table 2. Temperature of decontamination and post-antibiotic growth
Temp. (°C) Number of banks Negative/total tissuesa No. of tissues accepted or rejected
2-8 16 14/32 = 44% 3 accepted and 29 rejected
20-30 3 3/6 = 50% 2 accepted and 4 rejected
=36-37 ? 1 2/2 = 100% 2 accepted
aEach Tissue Bank cultured 2 tissues: A and B. 20 Tissue Banks cultured together 20 tissues
DISCUSSION
Decontamination of cardiovascular allografts is a step in the tissue banking process aimed 
at eliminating microorganisms from the donor or contamination from cardiectomy 
team members. Thus, this step in the process contributes to the safety of the allograft 
required by the implanting surgeon.
In this study, decontamination was shown not to be effective in 13 tissue banks because 
of growth after decontamination. The literature revealed that antibiotics are effective 
at 36°C6,12,13 and not, or less so, at 2°C to 8°C. If microbes were found and identified, 
almost all tissue banks would reject the tissues, even when micro- organisms were not 
isolated from the tissue after decontamination. If a sample was already positive for 
micro-organisms at the first control, which is mostly the transport fluid, it would be 
rejected anyway.14
However, tissue banks do proceed the entire process because cultures usually become 
available several days after processing. This means considerable work with associated 
additional costs.
The reason why tissue banks, using a validated method, reject tissue that is negative for 
micro-organisms in the final control, is probably the risk of sampling error. Samples 
taken during processing consist of a biopsy from the valve and fluid samples from the 
irrigating and immersion solutions used to decontaminate and rinse the valves. The 
more fluid and tissue they check, the more reliable are the results. A second reason 
to reject could be the methods of culturing, which should be up-to-date according to 
microbiological quality handbooks for clinical specimens. Comparing the sampling and 
culturing methods could be a subject for the next quality round. Those tissue banks that 
would still deviate after a second quality round need to seriously consider a change in 
their procedures in this regard.
One-hundred percent sterilisation would only be achieved by applying rigorous 
methods, such as radiation or heat- sterilisation. However, the use of such methods 
would damage the valve tissue and make cardiovascular grafts unfit for implantation. 
The decontamination procedure, if it is validated, would ensure that the tissue contained 
no known micro-organisms. If there were no other contra-indications, the tissue could 
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be used for implantation. There are no recent reports of recipients of donated tissues 
developing infections due to the transplants they received, although 1 study showed that 
9.5% of the cultures taken from thawed valves just before implantation were positive for 
bacteria15 but no adverse reactions were found in recipients. An infection in recipients 
who receive bone tissue or corneal transplants is also rare.
It is advisable to validate procedures and methods by always taking cultures from 
homografts at the time of  implantation or during a specific period of time. Most tissue 
banks use extremely high concentrations of antibiotics for decontamination, much higher 
than those used in clinical situations. After decontamination, the tissues should ideally 
be rinsed, or even better, the residual antibiotics on the tissues should be neutralised. 
If not, the presence of antibiotics can induce bacteriostasis of micro-organisms, which 
will lead to false-negative results in all the tested samples [16, 17]. Perhaps even worse, 
there is a risk that the antibiotics can cause severe allergic or toxic reactions in tissue 
recipients [18, 19]. There were no current studies that reported on this issue and how 
serious the clinical consequences may be. There is a risk that recipients who have an 
allergy to specific antibiotics could develop allergic reactions after transplantation as a 
result of extremely high concentrations of antibiotics in the tissues [20, 17]. Because 
recipients are treated with antibiotics prophylactically, it would be difficult to prove, and 
there are no known recent clinical reports of a reaction caused by an antibiotic residue 
on the tissue allograft. Rinsing of grafts is standard practice in most tissue banks as well 
as clinically before implantation.
Also, residues of dimethyl sulphoxide, a cryoprotective fluid used for valve preservation, 
can cause renal and hepatic dysfunction and cardiovascular complications locally [21]. 
Soquet et al. describe the acute rejection of a cryopreserved arterial homograft of 
unknown origin that could be caused by the residual contents of antibiotics, dimethyl 
sulphoxide or damaged tissue proteins [22].
Many antibiotics (such as beta-lactam) do not work better in higher concentrations. On 
the contrary, the higher the dosage, the more toxic their effects may be on the recipient; 
the effect on graft survival is unknown.
Antibiotic cocktails disturb the intrinsic properties of tissues, enzymatic activities and 
immunological events. The presence of antibiotic lipids has been described in skin, 
cornea and amniotic membranes [17]. Furthermore, most antibiotics need multiplying 
micro-organisms to eliminate them, and cell replication does not happen at 4°C. If the 
tissue is immersed at a temperature of 4°C, the antibiotics will only be absorbed by the 
tissue, giving a false negative result in the post-antibiotic incubation tissue culture.
However, after weeks of incubation, the tissue might contain a slow-growing microbial 
population that could cause a chronic problem at the implantation site of the tissue 
recipient [12]. It is recommended that one use a temperature that allows bacteria to 
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grow well (36° C) and then use the antibiotic cocktail at a low clinical dose for only 6 h, 
because immersion for more than 6 h does not provide better results [8, 16].
The use of antibiotics means that there is an obligation to rinse the tissue after the 
decontamination procedure. The European and the US Pharmacopoeias recommend 
eliminating from samples any factor that may interfere with microbial growth during 
sterility testing [18]. As was shown previously, there are a number of ways to achieve 
this goal [23, 24].
Limitations
Cardiovascular tissue banks use concentrations of antibiotics that differ considerably 
in composition and concentration. An earlier survey showed that concentrations of, 
e.g. vancomycin vary from 50 mg/ml to 1000 mg/ml and of gentamicin from 50 mg/
ml to 4000 mg/ml, which is up to 400 times more than what is clinically used in 
patients [5]. The composition and concentration of antibiotics contribute to the level 
of toxic effect on the tissue cells. So, one question that remains unanswered in this 
study is the influence of these different concentrations of antibiotics on structural and 
biomechanical properties of the tissue matrix and of the valve leaflets. Although this 
unanswered question is a limitation of this study, the study of biomechanics requires a 
different group of specialists.
CONCLUSIONS
A surgeon who wishes to implant a cardiovascular tissue graft from a reliable source is 
confronted with cardiovascular tissue banks that have their own, often locally validated, 
methods of tissue sampling and processing and their own regimens for decontamination 
of antibiotics [8]. In addition, at this time, no consistent, quality parameter for 
microbiological decontamination exists. By using quality rounds to validate the practices 
of the various cardiovascular tissue banks, we can identify those cardiovascular tissue 
banks whose tissue processing methods (nontoxic) deviate from appropriate standards. 
Quality rounds will identify where the processing methods used are insufficient and 
need to be changed in conjunction with an agreed minimal protocol, accepted by 
the entire tissue bank community, for validation of sampling and testing, taking into 
consideration all of the different parameters used in those tissue banks.
In the first trial with the freeze-dried tissues, the microbiological culture results of the 
tissue banks were assessed and the scores were above average. However, there was some 
room for improvement [12]. In this study, the entire processing chains of 20 participating 
tissue banks were evaluated, including the antibiotic decontamination regimens, tissue 
rinsing methods, postantibiotic incubation (if any) and the sampling technique.
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This method of sending contaminated tissues to be processed by the tissue bank 
according to local standard procedures and testing them pre- and post-decontamination, 
and assessing the microbiological culture results, is an effective way of validating the 
processes of the participating tissue banks. It also demonstrates that the majority of 
tissue banks, 17 of 20, can save costs and manpower if they rely totally on the outcomes 
of their own procedures.
By repeating this method over time, it may be expected that the differences in 
processing, the interpretation of the results and, finally, the decision to release tissues for 
transplantation may be harmonized by the individual tissue banks [25].
Before harmonization has been achieved, surgeons must be aware of the techniques 
applied in the cardiovascular tissue bank that provides the allografts they use, especially 
when a graft comes from a supplier whose methods are unknown. Sampling at 
implantation is advised.
To prevent discarding scarce allografts, tissue banks should alter their procedures such 
that they rely on their own method of decontamination and not reject grafts if a non-
specified micro-organisms, which could be neutralized, is found.
Specifically, this argument gains additional weight when the decontamination method 
has been validated.
Differences between methods used by tissue banks may lead to incorrect outcomes 
of microbiological testing. Only when harmonization and validation of methods are 
achieved will surgeons and colleagues from cardiovascular tissue banks be able to rely 
fully on one another’s methods and have confidence in the consistent sterility of the 
tissue grafts and uniform quality criteria in the event that tissues for implanting are 
exchanged across borders.
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ABSTRACT
Purpose: The European Blood Alliance (EBA) Tissue and Cells annual benchmarking 
exercise identified that in 2014 the heart valve (HV) discard rate in tissue establishments 
(TEs) run by EBA members was between 19% and 65%. Given this significant discard 
rate a decision was taken to carry out a worldwide data-gathering exercise to assess the 
processing methodology in different TEs. 
Method: In collaboration with the Foundation of European TEs a questionnaire asking 
for the details on HV processing was sent to TEs worldwide. Nineteen questionnaires 
were received back from 15 European TEs and 4 non-European TEs. 
Results: The data provided confirmed a significant discard rate of HVs with 43-50% of 
aortic valves and 20-32% of pulmonary valves being discarded in 2015. The causes of 
HV discard varied, with microbiology contamination, anatomical and medical reasons 
being the main causes. 
Conclusion: This data-gathering exercise highlighted significant variations in practice 
in different TEs including how donor suitability is assessed, critical timings for heart 
retrieval and processing, heart rinsing, HV decontamination protocols and methods 
of microbiological testing. To reduce the discard rates, there are several aspects of HV 
banking that could be validated and standardised. Here we report the findings of this 
data-gathering exercise. We consider this a first step that will help lead to standardising 
HV banking. 
Key Words: Heart valves, Discard, Microbiology, Transplantation
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INTRODUCTION
The European Blood Alliance (EBA) Tissue and Cells Working Group (T&C WG) 
carries out an annual benchmarking exercise. The results of the 2014 EBA T&C WG 
benchmarking exercise identified that within the EBA TEs that provided data for 
2014, there was a HV discard rate ranging from 19% to 65% with a median of 41% 
(unpublished data, dr. S Zahra).
HVs are precious resources that may be life-saving [1] and which may be in short supply 
in a number of countries. It was therefore felt important to gather further information 
to establish the causes of HV discard in the different TEs. Furthermore many tissue 
banking and processing methodologies are not based on hard evidence. It was therefore 
felt important to try to gather as much information as possible about HV banking 
practice around the world. To this end a detailed data-gathering exercise to map the 
process of HV banking was carried out in May 2016, with the aim of improving practices 
that could be shared with all TEs. 
In order to maximise the number of participating TEs the EBA T&C WG carried out 
this data-gathering exercise in collaboration with the Foundation of European TEs.
METHOD
A detailed questionnaire covering all aspects of HV banking was developed which 
included questions on types of donors (live, multi-organ and tissue-only donors), age 
of donors, how donor assessment is carried out, details of retrieval, donor testing, tissue 
transport and HV processing. Each TE was also requested to provide data on the number 
of donors, number of HVs discarded and reason for discard. 
The questionnaire was sent out at the end of August 2016 to TEs in 15 European 
countries and an additional 11 countries world-wide. There was a very good response 
rate of 73% with 15 European and 4 non-European TEs returning results. The responses 
received were anonymised. 
RESULTS
HV Donors
From the responses received all 19 TEs retrieved HVs from multi-organ donors (MODs). 
Of these 19, 15 also retrieved HVs from tissue-only donors (TODs) and 8 TEs also 
retrieved HVs from live donors (LDs) (the latter are patients undergoing a domino-
donor operation during a heart transplant).
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The number of HV donors in each TE is shown in figure 1. The TEs vary significantly 
in size, ranging from as few as 6 donors in 2015 to a maximum of 320 donors in the 
same year. The majority of HV donors are MODs, followed by TODs and a smaller 
number of LDs.
Donor Age Limit for HV Donation
The upper age limit for HV donation varied from as low as 40 years for both aortic 
valves (AVs) and pulmonary valves (PVs) in one TE, to a cut off of 70 years for both AVs 
and PVs in two TEs, with the rest of the TEs having a cut off of 60 years or 65 years for 
AVs and/or PVs. HVs were not collected from donors above these age limits from any 
of the TEs that took part in this survey.
Proportion of HVs Discarded
The TEs reported a significant discard rate (for all reasons) of both AVs and PVs, with a 
median discard rate for AVs of 43% from TODs and 50% from MODs and a median 
discard rate for PVs of 32% from TODs and 20% from MODs.
Causes of HV Discard
The main causes (data not shown) of HV discard included microbiological contamination 
(i.e. bacterial and/or fungal contamination – variable type of contaminants are 
identified from the skin, airway, gastrointestinal tract or the environment, including 
Coagulase Negative Staphylococci, Streptococci, E. Coli and Pseudomonas amongst others), 
anatomical abnormalities and medical deferrals. Other less frequent causes of discard 
included damage at retrieval, damage at dissection, blood borne virus (BBV) positivity 
and other miscellaneous causes.
The discard rate due to microbiological (bacterial and/or fungal) contamination of HVs 
from TOD and HVs from MOD in the same TE has been compared – Figure 2. While 
the microbiological contamination rate is higher in TOD in TEs C, H, I, N and O, the 
reverse is true in TEs A, B, L, M and R with no difference in TE G; caution is however 
required in interpreting this data as some TEs are very small with very few donors in a 
given year (refer to Figure 1) so that results could easily vary from one year to another. 
Donor Suitability Assessment
The TEs were asked to provide information as to whether potential tissue donor 
suitability is assessed pre- or post-donation. Not all TEs provided information for this 
part of the questionnaire. Of the 13 TEs that did provide information, 12 carried out 
some form of pre-donation assessment. One TE did not perform detailed pre-donation 
assessment relying instead on Blood Borne Virus testing and post-mortem results to 
confirm suitability of the donor.
The TEs were asked whether they would routinely go through the donor medical notes, 
contact the donor family doctor and obtain post-mortem results as part of the donor 
suitability assessment. Not all the TEs provided responses for these questions, however 
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of the responses received, 8 TEs reviewed the medical notes while 4 did not; 7 TEs 
contacted the donor family doctor while 5 did not and 10 TEs reviewed the post-
mortem results while 1 did not. 
Blood Borne Virus Testing
All TEs carried out testing for BBVs although there was variation between the different 
TEs – Table 1.
Heart Retrieval for Valve Donation
The TEs indicated that heart retrieval for HV donation from MODs was always carried 
out (or supervised) by a medical doctor in a hospital theatre, in almost all cases at the 
end of other organ retrieval. 
On the other hand heart retrieval from TODs was carried out by varying groups of staff 
including doctors, nurses and/or laboratory staff; a doctor was involved in the retrieval 
process in the majority of TEs although in one TE the heart was retrieved by a team of 
trained nursing and laboratory staff and in another TE heart retrieval was carried out 
by trained laboratory staff only. In both organisations a responsible medical doctor was 
on call and could be consulted 24/7. When the donor was a TOD, the heart tended to 
be retrieved as the first or one of the first tissues during the tissue retrieval process by 
almost all TEs.
The venue for tissue retrieval from TODs varied and included mortuaries, hospital 
theatres, undertakers, and also dedicated tissue retrieval suites. In this data-gathering 
exercise there was no correlation between the venue used for tissue retrieval and the 
discard rate secondary to microbiological contamination (data not shown).
Heart retrieval from MODs took place as part of the organ donation process and as 
such was done very soon after the time of cardiac arrest/cross-clamp. This was different 
to heart retrieval from TODs. In the case of TODs retrieval tended to take place several 
hours after the time of cardiac arrest with different TEs having different criteria for 
acceptable time limits - Table 2. From the information provided there was no clear 
correlation between the retrieval timings and the rate of microbiological discard rate.
Ten TEs rinsed the heart at retrieval, six did not, while one TE had a variable practice, 
rinsing the heart from LDs but not from MODs. The rate of discard secondary to 
microbiological contamination was similar between TEs that rinsed the heart at retrieval 
(microbiological discard rate 2-23%) and those that did not (microbiological discard 
rate 0-20%), although there was a trend for a lower microbiological discard rate for TEs 
that did not rinse the heart at retrieval.
HV Processing
Practice varied as regards how quickly after retrieval the HVs were processed: six TEs 
processed the HVs immediately, seven TEs had a 24 hour cut off and the rest had a 
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variable longer cut off for HV processing up to a maximum of 72 hours. All TEs indicated 
that the time cut off indicated for HV processing was the maximum acceptable, with 
the HVs being processed as quickly as possible.  The microbiological discard rate for the 
three groups was broadly similar with no significant difference: 0-25% (TEs processing 
the HVs immediately), 0-20% (TEs processing the HVs within 24 hours) and 3-23% 
(TEs processing HVs beyond 24 hours).
HV Decontamination
All the TEs decontaminated HVs, however practice was very variable. The antibiotic 
cocktails used varied significantly; combinations of 2, 3, 4 or even 5 antibiotics were 
used and most but not all included antifungals (data not shown).
The protocol followed during HV decontamination also varied significantly. The 
majority of TEs carried out decontamination at 4°C, five TEs decontaminated at room 
temperature and only two TEs carried out decontamination at 37°C – Table 3.
The duration of antibiotic decontamination was also very variable, from as short as 6 
hours in some TEs to a maximum of 48 hours in other TEs. 
Fourteen of the TEs rinsed the HVs after decontamination while five did not. This 
aspect of HV decontamination was subject to a detailed separate analysis. 
Microbiological Testing During HV Processing
The samples taken and the culture methods used to detect microbiological contamination 
of the HVs varied significantly between different TEs – Table 4. 
All TEs took a tissue sample for culture, eleven cultured the transport fluid, less then 
half cultured a sample of the rinse fluid, and fewer still took swabs, or cultured a sample 
of the cryoprotectant or the antibiotic solution.
The culture techniques used were very variable, varying from culturing in TSB (Tryptic 
Soy Broth; a nutritious medium for detecting aerobic bacteria) and Thioglycolate (a 
broth suitable to detect anaerobic/facultative anaerobic bacteria) for 2 weeks at room 
temperature or 32°C, to culturing in Medium 199 (a medium that is considered 
unsuitable to identify the presence of contaminants) for 18 hours only at 4-7°C, and a 
significant variation in between.
Only 8 of the 19 TEs cultured the HVs for the presence of tuberculosis (TB). The 
duration of TB culture varied significantly from as short as 40-48 hours (one TE), to 2 
weeks (one TE), 2 months (five TEs) and one TE culturing for TB for 3 months.
Ten TEs carried out environmental monitoring during HV processing while nine did 
not. 
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DISCUSSION
This data-gathering exercise was an excellent collaborative venture between EBA T&C 
WG and the Foundation of European Tissue Banks (FETB). Despite the level of 
detail requested in the questionnaire, there was an excellent response, indicating that 
individuals involved in HV banking were keen to examine the process being followed.
The upper age limit for HV donation varied significantly in the different TEs. When the 
donor age limit was compared to the individual TE’s discard rate for anatomical reasons 
and medical reasons there was no correlation (data not shown). The TEs with the lowest 
and the highest age limits did not have a significantly different discard rate for either 
anatomical or medical reasons. The TE with the lowest age cut off for HV donation may 
wish to consider increasing the age cut off used if there is an unmet clinical demand. 
Clinical feedback on the suitability of HVs from older donors is required; this may allow 
the donor age limit to be safely increased.
Not all TEs provided information on the type of donor assessment carried out. Some 
TEs were in fact not responsible for the pre-donation part of the process. From the 
data provided all but one of the TEs indicated that there was an assessment of donor 
suitability done prior to proceeding with tissue retrieval. Further detailed comparisons 
of the type/level of detail of pre-donation donor assessment that is carried out is required 
to establish whether this has a significant impact on HV discard rate. 
The detail of post-donation donor assessment also varied between the different TEs, 
with some TEs reviewing the medical notes and contacting the donor family doctor and 
practically all TEs indicating that they also reviewed the post-mortem results. Only one 
TE indicated that rather than carrying out a detailed donor history they relied on BBV 
testing and post-mortem results to establish suitability of potential HV donors.
What is unclear from the information available is whether there was any difference in HV 
safety assessment between TEs that carried out very detailed potential donor assessment 
and those TEs that carried out a less detailed one, in particular if post-mortem results 
were routinely reviewed. Further information as regards any serious adverse events/
reactions in recipients is needed to establish whether the level of donor assessment detail 
that is carried out has an impact on product safety.
Further it is unclear whether the acceptance criteria between different TEs varied. It 
is quite possible that some TEs may be declining donors and/or discarding HVs that 
may be accepted by other TEs. Certainly it would be important to try and compare 
acceptance criteria between different TEs with the aim of standardising them. This will 
require further detailed work.
From the data provided the main reasons leading to HV discard included microbiological 
(bacterial and/or fungal) contamination, medical reasons and anatomical reasons. It 
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would be important to try to establish whether the medical and anatomical reasons 
leading to HV discard are being applied uniformly by all TEs. It would also be important 
to investigate further the microbiological contamination discards to establish whether 
the HV banking process can be amended to reduce the rate of such contamination. 
Harmonisation of the procurement and dissection techniques used, as well as the 
training of personnel, together with regular audit of the testing laboratories that TEs 
work with would help to decrease the discard rate of donated HVs by ensuring good 
uniform practice in all aspects of HV banking. This is subject to a separate study.
It is of note that only 7 of the 19 TEs reported HV discards secondary to BBV positivity 
in 2015 (data not shown). This may reflect either a higher prevalence of BBV positivity 
in the general donor population or a less detailed pre-donation donor assessment by 
these TEs. The latter certainly seems to be the case for at least one TE where 46% of all 
discards were due to BBV positivity – when contacted, TE D indicated that only a brief 
donor history was taken prior to tissue retrieval, relying instead on BBV testing and 
post-mortem results to assess suitability of the donated HVs. Further information, in 
particular the presence or absence of serious adverse events and/or reactions in recipients, 
is required to assess whether such practice impacts on donation safety or not; the risk of 
accepting “higher-risk” HV donors by TEs carrying out a less detailed donor assessment 
needs to be considered in the setting of the possibility of false negative results when 
relying mainly on BBV testing results [2-4].
All TEs carried out BBV testing although different TEs used different assays. NAT 
(nucleic acid test) testing for HIV, Hepatitis B and Hepatitis C was carried out by most 
but not all TEs, and all except one non-European TE tested for anti-HBc antibodies. 
Lack of information in this data-gathering exercise about the potential rate of serious 
adverse events/reaction (particularly as regards transplant transmitted infection rate) 
from the different TEs means that we cannot comment on the suitability or otherwise 
of the different testing regimes, although the risk of a transplant transmitted infection 
should be reduced by NAT testing as the window period is significantly reduced [5].
The staff responsible for carrying out heart retrieval for HV donation varied. 
Unsurprisingly, heart retrieval from MODs always included medical staff, however 
when the heart was being retrieved from a TOD, then the staff carrying out the retrieval 
included a varying combination of doctors, nurses and/or laboratory staff with one 
TE successfully carrying out retrieval using trained laboratory staff under medical 
supervision. There did not appear to be any correlation between the rate of HV discards 
and the type of retrieval team employed.
The order of heart retrieval varied between the different types of donors, with the 
heart often being the last organ to be retrieved from MODs, but the first or one of 
the first from TODs. It was of note that while most TEs had a higher microbiological 
contamination rate of HVs from TODs, this was not true in all cases (Figure 2). Further 
information is required to be able to reach definite conclusions about this as there were 
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too many variables: venue of retrieval; the length of time after circulatory arrest that 
tissue retrieval took place and the order of retrieval are all likely to have impacted the 
HV contamination rate. This level of detail was not part of this survey.
It is well documented that after cardiac arrest organs and tissue may be contaminated 
by endogenous organisms due to the transmigration of organisms from within the body 
[6], although this has been refuted by more recent literature [7]. The length of time 
between circulatory arrest and tissue retrieval of HV was not an issue for MODs as 
heart retrieval took place soon after cross-clamp or circulatory arrest as part of the organ 
retrieval process. However when HVs were being retrieved from a TOD, then retrieval 
took place at varying time points after the time of cardiac arrest. There was significant 
variation in the acceptable time limits that different TEs applied. There were too many 
variables that might have influenced the microbiological contamination rate of HVs to 
be able to draw definite conclusions from this data-gathering exercise, although there 
was a trend that the TE with the longest warm ischaemic time (12 hours after cardiac 
arrest) had one of the highest microbiological contamination rates of HVs, suggesting 
that cooling the donor body as soon as possible is important [8, 9].
Several of the TEs did not rinse the heart at the time of retrieval. The numbers in this 
data-gathering exercise are too small to reach definite conclusions, however there was 
a trend for a lower microbiological contamination rate of HVs in the TEs that did not 
rinse the heart at retrieval, something worth exploring further. Heart rinsing at the time 
of retrieval is carried out to remove any contaminants already present at the time of 
heart retrieval and also to remove any blood clots as the latter are thought to provide a 
good medium for bacterial growth[10]; however it is possible that the technique used 
for heart rinsing may have had an adverse impact on microbiological contamination.
Antibiotic decontamination protocols in use to decontaminate HVs varied significantly 
between the different TEs both in this data-gathering exercise and as previously reported 
by other authors [11-15]. The antibiotic cocktails used, the temperature at which 
decontamination was carried out and the lengths of time HVs were kept in antibiotics 
varied widely between different TEs. In the absence of further information as regards 
the presence or not of serious adverse events in recipients due to the presence of residual 
antibiotics it is impossible to comment whether the different protocols used were all 
equally effective in ensuring the microbiological safety of the HVs. This needs to be 
investigated further to try and establish best practice as regards HV decontamination.
The number and type of cultures taken and the culturing methods used also varied 
significantly between different TEs. It is highly likely that such different techniques would 
have led to different sensitivity in detecting contamination. Hence a low microbiological 
contamination rate quoted by some TEs could be due to a low sensitivity in identifying 
contamination rather than a genuinely low contamination rate [16]. Caution therefore 
needs to be exercised when interpreting the rate of microbiological contamination 
in isolation without attention to the numerous variables that may be influencing 
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that figure, including the potential of false negative culture results due to antibiotic 
treatment given to the donor in the hours prior to death and also the antibiotics used to 
decontaminate the HVs during processing [17, 18]. This requires further, more detailed 
work. It is important for individual TEs to be sure that the samples taken and the 
culture techniques used are sufficiently sensitive (using enriched culture media) to detect 
clinically significant contamination. 
It is worth noting that only eight of the nineteen TEs cultured for Tuberculosis (TB). 
Further the length of culture for TB varied significantly between TEs. This is something 
that should be relatively straightforward to standardise. Testing HV donors for the 
presence of undiagnosed TB is important [19]. Culturing for TB for 40 hours or even 2 
weeks is considered insufficient. Longer culture duration is required using tissue samples 
in specific culture media that has been shown to be suitable for the identification of 
the presence of TB. Expert microbiological opinion should be sought to ensure that 
TB cultures are done using appropriate culture media that is incubated for a sufficient 
length of time.
Further only just over half of the TEs carried out environmental monitoring during 
HV processing. The TEs that carried out environmental monitoring indicated 
that the environmental monitoring results were taken into account when deciding 
whether a particular HV would be released for transplant or not. Without carrying 
out environmental monitoring during HV processing it is impossible to assess whether 
the GMP (good manufacturing practice) environment has been maintained as required 
during the processing, leading to concerns re product safety [16].
CONCLUSIONS
This data-gathering exercise has highlighted that HV retrieval and processing are very 
variable with significant differences in processes between different TEs. There is a 
significant discard rate of HVs and many aspects of HV banking can and should be 
standardised through further collaborative work between TEs.
One weakness of this data-gathering exercise is the lack of information on the serious 
adverse events and/or reaction rates in recipients from the different TEs. Tissue vigilance 
should be encouraged by all TEs and clinicians to enhance the quality of the information 
available.
There are many aspects of HV banking that can be investigated further with the aim of 
validating and standardising practice. The main findings of this data-gathering exercise 
highlighted the significant variation in practice throughout the HV banking process 
- from the selection of the donor right through to storing the final product. All these 
factors need to be evaluated in a systematic manner to establish best practice. Following 
on from this initial exercise we also looked in greater detail at the microbiological testing 
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and decontamination protocols used by different TEs during HV banking. As a result we 
organised a HV Quality Round in 2017 as a first step in establishing an External Quality 
Assessment Scheme for HV banking, focusing in particular on the microbiological 
aspects of HV banking. The results of this Quality Round will be discussed in a separate 
publication.
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Figures
Figure 1. Donor numbers in the diff erent TEs in 2015.
Figure 2. Comparing the rate of microbiological contamination of HVs from MOD donors and TOD in 
individual TEs that bank HVs from both types of donors.
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Tables and Captions
Table 1. Details of blood borne virus testing carried out.
Testing Number of TEs
Hepatitis B
HBsAg 19/19
anti-HBc 18/19*
anti-HBs 6/19
anti-HBe/HBeAg 1/19
NAT 16/19
Hepatitis C
anti-HCV 19/19
NAT 16/19
HIV
Ag/Ab test 16/19
anti-HIV 3/19
NAT 16/19
Syphilis Antibody assay 18/19
HTLV Anti-HTLV I/II 13/19
*non-European TB
Table 2. Retrieval timings for HV donation from tissue-only donors.
TE Code Retrieval Timings
TOD Microbiology Discard 
rate: (Total No. retrieved) % 
discarded
Donor refrigerated Donor not-refrigerated
B < 6hrs < 6hrs (7) 0%
G < 4hrs - up to 24hrs n/a (1) 0%
C < 6hrs - up to 24hrs 12hrs (36) 33%
R < 6hrs – up to 24hrs 15hrs (2) 0%
O < 6hrs – up to 24hrs n/a (196) 18%
A, I < 6hrs - up to 48hrs 12hrs (25) 8%, (132) 12%
Q < 6hrs – up to 48hrs 24hrs (1) 0%
D,M < 6hrs – up to 48hrs n/a (53) 0%, (2) 0%
L < 10hrs - up to 24hrs 13hrs (4) 0%
N < 12hrs - up to 24hrs 15hrs (73) 25%
H up to 24hrs 15hrs (16) 19%
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Table 3. Temperature of antibiotic decontamination.
TE Code Temperature of 
Decontamination
Percentage HV Microbiology loss 
TOD+MOD+LD 
B, C, D, F, H, I, J, K, L, O, P, S 4°C 5, 25, 0, 0, 11, 8, 20, 11, 3, 13, 5, 2% 
E, G, M, Q, R 22°C 3, 0, 3, 6, 1% 
A, N 37°C 13%, 23% 
Table 4. Microbiological samples taken during HV processing.
TE Code Tissue 
Sample
Rinse 
Fluid
Transport 
Fluid
Swabs Cryoprotectant Antibiotic 
Soln.
Percentage HV 
Microbiology loss 
TOD+MOD+LD
A Yes Yes Yes No Yes Yes 13%
B Yes Yes Yes No Yes No 5%
C Yes Yes Yes No No No 25%
D Yes No No No No No 0
E Yes No No No No No 3%
F Yes No No No Yes No 0
G Yes No No No Yes No 0
H Yes Yes Yes No Yes No 11%
I Yes No No Yes No No 8%
J Yes No Yes Yes Yes Yes 20%
K Yes Yes Yes Yes No No 11%
L Yes No Yes No No Yes 3%
M Yes Yes No No No No 3%
N Yes Yes Yes No Yes No 23%
O Yes No Yes No No No 13%
P Yes No Yes No No No 5%
R Yes Yes Yes No No No 1%
S Yes No No No No No 2%
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ABSTRACT
Purpose: The performance of many laboratories can be evaluated by participation in 
external quality assessment (EQA) schemes. EQA allows for comparison of a laboratory’s 
performance with a source outside the laboratory - either a peer group of laboratories or 
a reference laboratory.
Such EQA schemes do not exist in tissue banking despite the fact that Tissue 
Establishments (TE) perform very complex procedures. This paper describes the first 
ever EQA scheme in the field specifically assessing microbiological aspects in heart valve 
(HV) banking.
Methods: Twenty-two TEs participated. Three HV tissue samples were sent to each 
participating TE - two contaminated with non-pathogenic micro-organisms and a third 
negative control. The aims were to isolate and identify the micro-organisms present and 
then to successfully decontaminate the HV tissue using the routine standard operating 
procedures of the TE.
Results: Eight of the TEs were able to isolate and identify all contaminating micro-
organisms present and of these, five also successfully decontaminated the tissue; thirteen 
TEs failed to establish the identity of one or more of the contaminants; five TEs appear 
to have introduced contamination during the processing or testing of the tissue; and 
eight failed to successfully decontaminate the HV tissue.
Conclusion: This initiative provides TEs with an international benchmark for tissue 
product microbiology testing. It has identified significant variation in practice and in 
the ability of different TEs to identify the presence of contamination. There is now work 
ongoing with the aim of setting up a regular EQA scheme for HV banking.
Key Words: heart valves, banking, transplantation, microbiology, contamination
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INTRODUCTION
For the cardio-thoracic surgical community, organ and tissue donation and 
transplantation are an important aspect of medical care. Donated tissues are regularly 
transplanted each year, providing life-saving (e.g. HVs, arterial grafts) and life-enhancing 
(e.g. veins, pericardium) treatment for thousands of patients [1].
Previous work by this group in 2016 identified significant differences in the methods 
used by TEs around the world in all aspects of HV banking, from donor selection and 
testing, tissue processing, and HV handling before implantation. It is unclear whether 
such variations in methodology are materially important to the safety and clinical 
effectiveness of the HVs.
It was therefore decided to investigate in more detail microbiological aspects of HV 
banking, including the microbiology testing and decontamination protocols used.
The method used to send out HV tissue purposefully contaminated with micro-organisms 
to different TEs around the world for them to isolate and identify the contaminating 
micro-organisms is based on the previously validated and published work of two of the 
authors (2,3).
METHODS
Thirty TEs from around the world were contacted, of which 25 (21 European, 4 Non-
European) participated. HV tissue for this project was sourced from the European 
Homograft Bank (EHB) in Brussels. All donations were anonymised and had the 
necessary consent. All HVs used were confirmed to be sterile on microbiological culture. 
The HVs were cut into strips to ensure sufficient HV tissue for all participating TEs, and 
split up into three separate groups, sample A, sample B and sample C (see later). 
Sample A was contaminated with Sphingomonas paucimobilis (Gram negative rod); sample 
B was the sterile negative control; and sample C was contaminated with Roseomonas 
mucosa (Gram negative coccobacilli) and Staphylococcus hominis (Gram positive cocci).
Three separate HV tissue samples were prepared for each TE, one each from sample A, B 
and C. The preparation of the samples was done at the EHB, using a clean room facility. 
The samples were packed in compliance with the European Directives for transportation 
of biomaterials (94/55EC). Two lots of samples were concurrently also sent to reference 
microbiology laboratories (one in Edinburgh and one in Rotterdam) as independent 
confirmation of the isolation and identification of the contaminating micro-organisms. 
The technique used was based on a previously published method that had been validated 
for different levels of contamination (high, medium and low), the transport medium 
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used, temperature of storage (room temperature) and transport duration (1 to 14 days) 
[2, 3].
The samples were sent out by registered delivery using a courier company that 
guaranteed delivery within 24 hours for European destinations and within 72 hours for 
non-European destinations. All participating TEs were asked to contribute a nominal 
charge to help cover the transport costs. The time of the organisers and equipment was 
provided free of charge.
Results were assessed against 4 microbiological criteria relevant in tissue banking: 
sampling methods, correct isolation and identification of micro-organisms, culture 
methods and decontamination protocols. Any deviations from these principles will be 
discussed.
RESULTS
Receipt of samples
Delivery of most samples was delayed, with only 2 samples being delivered within 24 
hours within Europe, and a longer delay for the non-European samples, the maximum 
delay being 6 days. Four of the TEs also reported some damage and leakage of one or 
more of the sample tubes delivered. Of the 26 samples sent out, 24 were safely delivered 
to 23 TEs (one TE requested 2 sets of samples), whilst two samples were never received 
(held up at customs).
Most TEs managed to process the samples as soon as they were received. However four 
TEs delayed processing the samples by 3 days, and three delayed processing by five, 
ten and twenty-three days delay respectively for operational reasons. Twenty-two TEs 
completed the exercise and returned their results.
Microbiology reference laboratory results and interpretation
Sample A
The reference laboratory in Rotterdam received the tissue samples within 24-36 hours 
and processed them immediately. Using Bactec and then subculture onto plate culture 
media they were able to successfully isolate and identify the Sphingomonas paucimobilis, 
however on repeat sampling after 72 hours and again after 2 weeks, there was no growth 
of the micro-organism. The micro-organisms were still identifiable by Gram stain. This 
laboratory also tested the sample for the presence of antibiotics and found it to be 
positive.
The reference laboratory in Edinburgh received the tissue samples after 48 hours. Using 
chocolate and blood agar culture techniques they were not able to culture, isolate and 
identify the Sphingomonas paucimobilis. On reviewing these results it was concluded 
that the presence of antibiotics in sample A was interfering with the growth of the 
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Sphingomonas paucimobilis so that an acceptable result for Sample A would be either “no 
growth” or identification of the Sphingomonas paucimobilis.
Sample B
Both microbiology reference laboratories confirmed that this was a sterile sample. This 
sample was confirmed as a suitable negative control for this project.
Sample C
Both microbiology reference laboratories confirmed the presence of both Roseomonas 
mucosa and Staphylococcus hominis.
The Rotterdam microbiology laboratory again checked for the presence of antibiotics, 
and while there were antibiotics present in this sample they were not interfering with the 
growth of either of the two contaminating micro-organisms. This sample was therefore 
suitable for this project.
Results of participating TEs
The number and type of culture samples taken to look for potential contamination pre- 
and post-decontamination varies between the different TEs.
A summary of the pre-decontamination samples taken for culture by the 22 different 
TEs is shown in Table 1a. At the pre-decontamination stage most (n=19) TEs take 
tissue biopsies for culture; often (n=12) combined with a transport-fluid sample or other 
sample (swab/antibiotic cocktail (n=2)). Six TEs take only tissue biopsies and 1 TE 
samples only transport fluid. Two TEs do not routinely take any pre-decontamination 
samples.
Table 1b summarises the culture samples taken post-decontamination by the different 
TEs. Such samples serve as a final check for the potential presence of contamination. 
Twenty TEs sample the cryoprotectant in which the HVs are preserved, and 15 combine 
that with tissue biopsies; one TE takes a tissue biopsy and sample of the antibiotic 
cocktail and one TE only samples the antibiotic cocktail.
Pre-decontamination culture results
A summary of the pre-decontamination culture results from the individual TEs is 
presented anonymously in Table 2 - each TE is represented by a number assigned 
randomly. Table 2 provides details where the result returned by the TE is not the 
expected result i.e. TEs that appear to have contaminated their samples and TEs that 
did not manage to isolate and identify the micro-organisms present.
Decontamination protocols used 
The antibiotic cocktails used and the temperature and duration of decontamination 
varies significantly between different TEs, with no two TEs using the same protocol. A 
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summary is provided in Table 3. It is worth noting that all TEs use antibiotic cocktails 
consisting of at least 3 different antibiotics from different antibiotic classes.
Post-decontamination microbiology culture results of participating TEs
Having decontaminated the HVs using their standard protocol, the TEs were asked to 
repeat microbiology culture of the HVs to check whether the HVs had been successfully 
decontaminated.
All TEs reported “no growth” post-decontamination of the HVs in sample A and sample 
B. Only twelve TEs reported “no growth” post-decontamination of the HVs in sample 
C. One TE (4) did not carry out post-decontamination testing of sample C due to 
the level of bioburden detected on the pre-decontamination cultures for this sample, 
which led to automatic discard of this HV. Eight TEs reported positive cultures post-
decontamination i.e. failed to successfully decontaminate the HV tissue – please refer 
to Table 4.
Culture media used by participating TEs
The participating TEs were asked to provide details of the culture media used to isolate 
any contamination that may be present. There is significant variation in the type of 
media used and also in the protocols used when culturing tissue samples by the different 
TEs. Table 5 provides a summary of the ability of the different culture media used by 
the different TEs in isolating the different types of micro-organisms that may be present. 
All TEs use culture techniques that are able to isolate aerobic and anaerobic bacteria 
present, although 12 TEs use culture techniques that would not support the growth 
of fastidious or nutritionally-deficient micro-organisms. Nine TEs do not use culture 
techniques that are able to identify the presence of fungi.
DISCUSSION
Both the data-gathering exercise in 2016 carried out by the same group on HV banking, 
and this EQA in 2017, have been met with enthusiasm by TEs around the world with the 
number wishing to participate and eventually participating exceeding our expectations.
The courier company chosen to deliver the samples to the TEs unfortunately failed to 
live up to their guarantees of delivery of samples. However, from the results reported, 
the delay in sample delivery does not appear to have adversely affected the ability of TEs 
to correctly isolate and identify the micro-organisms present even when the sample was 
not processed until day 23 (TE 5) after preparation. The TEs reporting damage to the 
sample tubes did not have an issue with contamination – in fact none of the TEs who 
appear to have contaminated their samples reported any damage to their sample tubes. 
Sampling error (i.e. failure to identify contamination that is present) in tissue banking is 
high (approximately 50%) if testing for the presence of contamination is done through 
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swabs and tissue biopsies only [4-6]. The sensitivity for isolating a contamination that 
is present can be increased to >90% if samples of the filtered transport fluid are also 
tested as well as a tissue biopsy [7, 8]. Most TEs in fact do sample both tissue biopsies 
and transport fluid. However this is not true of all TEs. In this EQA 6 TEs only tested 
tissue biposies, while one TE does not routinely take any pre-decontamination samples 
for culture. When deciding whether a particular HV is safe for clinical use or not it 
is important to be aware of whether there was any evidence of contamination on the 
tissue prior to attempting decontamination and the ID of such contaminating micro-
organisms. HVs that have evidence of significant degrees of contamination particularly 
if contamination is with highly virulent micro-organisms that may be difficult to 
eradicate with antibiotics should be discarded irrespective of the culture results in the 
post-decontamination stage. There are a number of publications which underline the 
risk of false negative culture results (i.e. HV still contaminated with undetected micro-
organisms) post-decontamination of tissue products when the pre-decontamination 
culture results are not taken into account [9-11]. 
In the post-decontamination stage, as a final sterility test of the HV tissue, most TEs 
take a sample of the cryoprotectant (DMSO) to check for the potential presence of 
contamination. DMSO has a toxic effect on micro-organisms and may therefore 
interfere with the successful isolation of contamination present leading to false negative 
culture results similar to the [12] effect of antibiotics, unless cultures are prolonged (2 
weeks) and in validated antibiotic-neutralizing media. In order to minimise the risk 
of such false negative culture results in the post-decontamination stage it is important 
to include other samples besides the cryoprotectant when checking the sterility of the 
product, including tissue biopsies and rinsing fluid.
In this EQA potential contamination of the HV tissue from the donor or during 
the retrieval process are not relevant as the HV tissue used was known to be sterile 
and was “processed” in a controlled clean room environment before being artificially 
contaminated. In view of this, if a TE has reported the presence of micro-organisms 
other than the ones used to purposefully contaminate the HV tissue as part of this EQA, 
then these micro-organisms must have been introduced either during the HV processing 
by the individual TE or during sample culturing by the microbiological laboratory. 
From information provided in the previous data-gathering exercise that was carried out 
in 2016, TEs indicated that they process HVs in a grade A environment with either 
a grade B or grade C background (i.e. in controlled environments with laminar flow; 
refer to Eudralex Volume 4, Annex 1) [13]. This means that the risk of contamination 
during HV processing by the TE is low and usually by skin-flora from the operators, 
although cross contamination remains possible. On the other hand, contamination of 
the culture samples in the microbiology laboratory, either from the personnel or from 
the environment, is more likely. Microbiology laboratories may use open environments 
and non-sterile benches; the technicians processing the samples work in uncontrolled 
environments (e.g. near water taps), with no laminar flow or air-particle monitoring 
[14-17]. 
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Sample A was contaminated with Sphingomonas paucimobilis. However it was 
retrospectively identified that in sample A there were residues of antibiotics that were 
interfering with the growth of the micro-organisms and even potentially killing the 
Sphingomonas. In view of this, this micro-organism could only be isolated if sample 
culture was carried out within 24 hours of the tissue samples being prepared, although 
the Gram negative rods could be identified microscopically for several days later and 
while these Gram negative rods weren’t formally identified it is felt likely that they were 
the same micro-organism rather than a new contaminant. This means that cultures from 
sample A taken more than 24 hours after the samples were prepared would likely result 
in a negative culture result, as demonstrated and confirmed by the two microbiology 
reference laboratories.  Any bacteria other than Sphingomonas isolated by the TEs at 
more than 24 hours from sample preparation must be a contaminant introduced by the 
TE or the microbiology testing laboratory.
Of the three TEs reporting a positive culture result for sample A, none of them reported 
damage to the sample tubes during transport. One of these 3 TEs reported the presence 
of a Gram negative rod (likely the Sphingomonas) but did not proceed to identify it. This 
was a correct result (cultured at <24 hours), and not a contaminant as the TE thought, 
and therefore considered a correct result for the purposes of this EQA, although ideally 
the micro-organism should have been fully identified. One TE reported the presence of 
a Bacillus species; the source of this contamination is likely to be Bacillus spores found 
in the environmental air; this type of contamination is most likely to have taken place in 
the microbiology laboratory. The third TE reported the presence of Staphylococcus cohnii, 
a skin commensal mostly found on the lower limbs, that is likely to have originated from 
the personnel handling the specimens, with the microbiology laboratory being the most 
likely source.
None of the TEs checked for the presence of antibiotics, which raises concern about the 
possibility of false negative culture results. Many donors will have received antibiotics 
before death which can lead to false negative culture results, unless the samples are 
cultured within a few hours in a blood culture medium that contains toxin and antibiotic 
neutralising resins. However most TEs rinse their tissue several times to remove any 
antibiotics that may be present, although most TEs have not confirmed or validated the 
effectivness of removing or neutralizing the antibiotics using this method.
Sample B was a negative control sample, also confirmed by both reference microbiology 
laboratories. Therefore any bacteria isolated in this sample would be a contaminant 
introduced either by the TE or the microbiology laboratory. Twenty of the 22 TEs 
reported “no growth” for this sample, while the remaining two TEs reported positive 
culture results: one TE (11) identified the presence of Staphylococcus hominis. This same 
TE reported “no growth” for sample C (which contained Staphylococcus hominis) leading 
to the possibility that this TE may have swapped their culture samples. The second 
TE reported the presence of Propionibacterium acnes, a skin commensal which may 
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have been introduced as a contaminant either by the TE or the medical microbiology 
laboratory.
Sample C was contaminated with Roseomonas mucosa and Staphylococcus hominis, also 
confirmed by both reference microbiology laboratories. Eight TEs isolated and correctly 
identified both contaminating micro-organisms (although one TE did not fully identify 
the Staphylococcus hominis, reporting the presence of coagulase negative Staphylococci 
(CNS) instead), these samples being processed between 48 and 552 hours after the 
samples were initially prepared.
A further seven TEs identified only the Roseomonas spp in their culture; these samples 
were processed between 48 and 192 hours after they were initially prepared (16 48 
hours; 20 & 21 72 hours; 1, 12 & 18 144 hours; 15 192 hours). A possible reason 
for these TEs not identifying the Staphylococcus hominis could be heavy Roseomonas 
growth (reddish colonies) on the culture plates, which would make recognition of the 
Staphylococci hominis (small yellow-orange colonies) difficult. 
One TE correctly identified the presence of the Roseomonas spp in sample C but also 
reported the presence of Bacillus pumilis; the only likely source of this contaminat 
are spores from the environmental air, most likely from the diagnostic microbiology 
laboratory. The presence of the Bacillus pumilis and Roseomonas are likely to have made 
identifying the Staphylococcus hominis also present difficult.
One TE reported the presence of Staphylococcus schleiferi for sample C; this is either a 
wrong identification or a contaminant from the microbiology laboratory given it is not 
a common CNS.
One TE reported the presence of Staphylococcus hominis together with Stenotrophomonas 
maltophilia for sample C. The latter could either be a wrong identification or possibly 
a contaminant, most likely introduced by the medical microbiology laboratory, as this 
micro-organism is normally found in water systems and the microbiology laboratory is 
the only site during HV processing where there would be direct contact with a water 
system.
Four TEs reported “no growth” for sample C – one of these four does not routinely 
carry out pre-decontamination tissue cultures (although did culture the samples sent for 
the purposes of this EQA) and two of the TEs probably use media that are insufficient 
to identify all potential contaminants. The fourth TE may has swapped sample C with 
sample B, explaining their return of “no growth” for this sample (see earlier).
When considering the decontamination protocols used, the different TEs used very 
variable protocols with variable antibiotic cocktails at variable temperatures for variable 
lengths of time. The important question is whether the antibiotic cocktail used is likely 
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to be effective against the skin, mucosal and environmental contaminants that are likely 
to be present on HVs. 
In order to have effective antibiotic decontamination of HVs, the antibiotic cocktail 
used needs to have broad effectiveness against aerobic and anaerobic bacterial and fungal 
micro-organisms. 
The concentrations of antibiotics used by the different TEs varies significantly. When 
compared to the doses normally used clinically to treat patients, all TEs are using very 
high concentrations of antibiotics. Only three TEs use antibiotic concentrations that 
do not exceed the dose used in clinical patients (i.e. the therapeutic dose) by three-fold. 
The smallest antibiotic doses used by five of the TEs is around 10-times a therapeutic 
dose and the remaining 17 TEs use antibiotic doses that are more than 20-times higher 
than therapeutic doses, in some cases up to more than 50-times higher. Such doses are 
very difficult to rinse or neutralise leading to concerns about potential false negative 
culture results after antibiotic decontamination and may have toxic effects on the tissue, 
something that is a concern for all antibiotics, but is a particular concern when using 
Aminoglycosides and Amphotericin [18] at high doses. 
The temperature at which decontamination is carried out also varies between different 
TEs (4°C, room temperature or 37°C). Bacteria that grow on humans, both commensal 
and pathogenic micro-organisms, are “mesophilic” i.e. they grow best at a temperature of 
20 to 40°C. Below 20°C such micro-organisms grow much slower, their enzymes cannot 
mediate chemical reactions, so that eventually the viscosity of the cell-interior brings 
all activity to a halt. All human bacteria (and human cells) slow down and eventually 
die at low temperatures. Most bacteria do not grow at all, or minimally so, at 4°C 
which means that betalactam antibiotics (all penicillins and cephalosporines) cannot be 
effective at low decontamination temperatures [19]. Even protein-attacking antibiotics 
are only effective against growing bacteria when protein synthesis is taking place and not 
at low temperatures. Any static/cidal effect on the micro-organisms at low temperatures 
therefore is not being caused by the antibiotics but by the temperature/medium and 
other factors in the liquid that the HVs are in.
The length of time the HVs are left in the antibiotic cocktail for decontamination also 
varies between the different TEs. Killing of bacteria is mostly done within the first hour 
of contact with antibiotics at 35°C with no additional benefit beyond 6 hours at this 
temperature [20]. This temperature has been shown to lead to a 100% antibiotic cidal 
effect for several antibiotic cocktails; this is not the case for decontamination carried out 
at 4°C (10)
Post-decontamination, 13 TEs reported negative cultures, while 8 TEs reported 
persistently positive cultures with the same micro-organisms that had been present in 
the pre-decontamination cultures. The most likely cause for persistent growth after 
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antibiotic decontamination is the lack of antibiotic activity at the low temperatures used 
during decontamination by seven of the TEs.
A further identified reason for failure of decontamination is that Roseomonas is resistant 
to Cephalosporins, Piperacillin/Tazobactam and Polymyxin/Colistin. Five of the 8 TEs 
that failed to successfully decontaminate the HVs use only Polymyxin or Polymyxin in 
combination with a cephalosporin. Further one TE left the HVs in antibiotics for only 
5 hours (at 37°C); this is possibly too short a period to be fully effective against slow 
growing and slimy bacteria in tissue.
Finally consideration needs to be given to the potential of residual antibiotics leading 
to false negative post-decontamination culture results. Hence the importance of proper 
rinsing or neutralisation [21] before carrying out repeat tissue culture.
When selecting the media used to culture tissue samples TEs need to ensure that the 
media will be able to isolate all potentially contaminating micro-organisms, including 
aerobic, anaerobic and also fungal contaminants. Fastidious bacteria are common on 
skin, mucosa and in the environment: for example Corynebacteria and Propionibacterium 
from the skin, Stenotrophomonas from the environment and Neisseria and Streptococci 
from the mucosa amongst others. In order to isolate such potential contaminants it is 
necessary to use enriched media (such as blood culture media). Enriched media are also 
required in order to be able to successfully isolate many streptococci and other mucosal 
inhabitants as well as non-fermenting Gram negative bacteria from the environment 
(Pseudomonas-like). A different medium needs to be added to allow growth of anaerobes 
(an oxygen free medium with extra iron). Blood culture-media is also able to neutralise 
toxins and antibiotics that may be present [22, 23] so that growth of micro-organisms 
may be possible even when antibiotics are present in the tissue (although this still needs 
to be validated). 
Contamination from the air, especially by spores, is very common. Since many such 
spores are fungal, culture at a lower (20°C) temperature is required to isolate such micro-
organisms. When looking for potential contamination of HVs it is therefore important 
to use media that supports fungal growth to ensure no contamination of the tissue 
occurs during processing. 
Table 5 provides a summary of the suitability or otherwise of the culture media used by 
the TEs in isolating the different types of potentially contaminating micro-organisms. 
As can be seen from this table more than 50% of the TEs do not use culture media that 
would allow the isolation of fastidious bacteria or fungi. This would particularly be a 
concern if the antibiotic cocktail used for decontamination did not provide sufficient 
broad coverage that is effective against all types of micro-organisms, including against 
potential fungal contaminants. On the other hand there are reports of positive bacterial 
results post-implantation without resultant clinical infection [24, 25], suggesting that 
low numbers of commensals (but not environmental micro-organisms and spores) that 
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may be present on HVs are not necessarily detrimental to the recipient, although it is 
impossible to confirm this in a research trial, since avoidance of infection transmission 
remains the aim.
An important question to consider is whether culturing at temperatures other then 
30-37°C is necessary or not. Only fungi and bacteria that survive at human body 
temperature (30-35°C) can be pathogenic. At temperatures <30°C some micro-organisms 
die straight away. However there remains a concern that toxins and spores from such 
micro-organisms can cause problems in the recipient, leading to the conclusion that 
TEs should aim to identify any potential contaminants that may be present to be able 
to minimise the risk to recipients as much as possible. 
One weakness of this work is that hardly any TE carry out recipient follow-up. It is 
important to establish whether the reported differences in the decontamination 
procedures used are leading to clinical problems or not. 
CONCLUSIONS
This was an excellent collaborative initiative following on from our previous data-gathering 
exercise on HV banking. There is evidence of significant differences in practice between 
different TEs. While a number of TEs were able to successfully isolate and identify all 
contaminating micro-organisms present and then successfully decontaminate the HV 
tissue, a fair number of TEs failed to isolate and identify one or more of the contaminants 
due to the use of culture media that do not support all types of potential contaminants 
that may be present or invalid identification of the micro-organisms. Further some TEs, 
or their microbiology laboratories, appear to have introduced contamination during 
their processing or testing of their samples. Also, a number of TEs were unable to fully 
decontaminate the HV tissue, likely due to insufficient antibiotic cover and/or the 
incubation temperature at which decontamination was carried out; and none of the TEs 
checked for the residual presence of antibiotics.
Following on from this initiative we now aim to work towards establishing a regular 
External Quality Assessment scheme for HV banking, and potentially other tissue 
products, with the aim of standardising tissue banking and improving the clinical safety 
of tissue products.
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Tables and Captions
Table 1a. Summary of the pre-decontamination samples taken by TEs for culture
Number of TEs Tissue biopsy Transport fluid Antibiotic
cocktail
Swabs No samples 
taken
11 + +
1 + + +
1 + +
6 +
1 +
2 +
Total : 22 19 13 1 1 2
Table 1b. Summary of the post-decontamination samples taken by TEs for culture (final check for potential 
of contamination)
Number of TEs Tissue biopsy Cryoprotectant Antibiotic cocktail Rinsing fluid
12 + +
2 + + +
1 + + +
1 + +
2 +
2 + +
1 + +
1 +
Total: 22 16 20 5 3
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Table 2. Summary of culture results submitted by the participating TEs.
TE
code
Wrong/ 
insufficient 
results
No. TEs 
with 
correct
results
No pre-
decontamination
sampling
Insufficient
Media
Other potential 
cause
Sample A 20*
Contamination 2 Bacillus spp Possible air 
contamination ML**
10 Staph.cohnii TE or ML** 
contamination
Sample B 20***
Contamination 11 Staph.hominis Cross contamination 
or sample B and C 
switched
10 Propionibact.acne TE or ML** 
contamination 
Sample C 8****
No growth 2 No growth +
11 No growth +
13 No growth +
28 No growth unknown
Only one 
micro-organism 
identified
14 Roseomonas spp Possible ML** error
16 Roseomonas spp Possible ML** error
1 Roseomonas spp Possible ML** error
21 Roseomonas muc Possible ML** error
20 Roseomonas muc Possible ML** error
12 Roseomonas gilardi Possible ML** error
23 Roseomonas spp Possible ML** error
One micro-
organism 
identified + 
contamination
3 Roseomonas spp+
Bacillus pumilis
Possible air 
contamination ML**
4 Staph.hominis +
Stenotrophomonas
Possible 
environmental 
contamination ML**
Contamination 10 Staph.schleiferi Possible false identity 
ML**
TE - Tissue Establishment; No.- Number; ML - Microbiology laboratory
*1 TE correctly identified the presence of non-fermemtative Gram-negative rods in sample A but did 
not fully identify this micro-organism, the other 19 TEs reported “no growth” for sample A; 1 TE (13), 
concerned that they had been unable to identify any micro-organisms in the samples, also carried out a 
Gram stain of the samples (Gram stain not being part of their normal protocol) – the Gram stain identified 
the presence of Gram negative bacilli in the sample. TE 13 reported that the samples had been received after 
six days and the tube of sample A was leaking.
**ML - probable error (e.g. not recognised Staph. hominis amongst the Roseomonas) or contamination of the 
culture samples occurred in the diagnostic medical microbiology laboratory 
***20 TBs reported “no growth” including TE 13 which again carried out a Gram stain of the samples 
(Gram stain not being part of their normal protocol), the Gram stain being negative on this sample i.e. no 
micro-organisms present. 
****8 TEs identified both the Roseomonas and the Staph hominis; TE 13 again carried out a Gram stain on 
the sample (Gram stain not being part of their normal protocol) – the Gram stain confirmed the presence 
of micro-organisms.
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Table 5. Summary of ability of culture media used to identify different types of micro-organisms 
TE* code Gram +ve bacteria Gram –ve bacteria Anaerobes Fungi
Robustǂ Fastidiousǂ Robustǂ Fastidiousǂ
1 + + + + + +
2 + + + + + +
3 + - + - + +
4 + - + - + +
5 + + + + + -
6 + - + - + +
7 + - + - + +
8 + + + + + -
9 + - + - + +
10 + - + - + -
11 - - + - + -
12 + - + - + +
13 + - + - + +
14 + + + + + -
15 + - + - + +
16 + - + - + -
17 + + + + + +
18 + + + + + +
19 + + + + + -
20 + - + - + -
21 + + + + + -
22 + + + + + +
Total 21+/1- 10+/12- 22+ 10+/12- 22+ 13+/9-
*TE – Tissue Establishment
ǂRobust vs Fastidious micro-organisms: robust micro-organisms are ones that are able to grown on general 
media without needing the additon of special nutritional supplements or conditions, as different to 
fastidious micro-organisms.
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Differences in applied methods and their outcomes can be determined in different areas 
of cardiac surgery. By comparing the identified differences, cardiac surgery centres and 
cardiovascular tissue establishments can gain insight into the quality of their activities 
and clinical outcomes. To this end, various registries and databases in which data from 
many international centres are collected and shared, are used. When the comparison 
provides a negative result, for example showing a higher morbidity, more frequent 
infectious infections or indicates shortages of cardiovascular allografts, there will be 
room for improvement. By periodic benchmarking of their outcomes and analysing 
the results, the individual centers can concentrate on the elimination of identified areas 
for improvement. As a result, the outcomes improved and the differences with other 
organisations are minimised or eliminated. In this way they arrive at the best possible 
‘best practices’.
Benchmarking of outcomes in cardio-thoracic surgery at European level
In Chapter 2 we presented a survey of literature concerning the influence of registry data 
on the outcomes of heart surgery. The hypothesis was that there are hundreds of studies 
that claim that the registries investigated contribute to quality improvement, but that 
the causal relationship is often not demonstrated.
Numerous publications conclude that a reduction in morbidity and mortality in the 
clinical units of the participants is demonstrated. However, studies demonstrating 
the direct causal link between the use of cardio-thoracic surgery-oriented registers 
and improvement of clinical hospital outcomes are extremely scarce. In this study, we 
wanted to analyse the causal relationship between the use of cardio-thoracic surgery-
oriented registers and improvement of clinical outcomes. In a systematic literature 
review, publications were selected that demonstrate the use of registry data to obtain 
consolidated quality improvements. After analysing 2990 scientific publications, 6 studies 
filled the inclusion criteria. The selected studies acknowledged that benchmarking of 
data with registries was used for targeted and methodologically organised improvement 
in cardio-thoracic departments. Combined with the impact of the applied methods 
on healthcare, their results show quantifiable improved local results over time. An eye-
catching observation is that the United States has a big lead over Europe. This leads to 
the conclusion that Europe has some catching up to do.
Benchmarking in the field of therapy through support hearts.
Chapters 3 and 4 show the state of affairs with regard to the use of “Mechanical 
Circulatory Support” or MCS  in centres participating in the EUROMACS Registry. The 
implanted devices provide mechanical support for the heart, and, as a result the blood 
circulation, in the long term. MCS is often used for patients who are at risk of dying on 
the waiting list for heart transplantation (“bridge to transplant”) or, as an alternative, 
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for patients with end-stage heart failure who are not eligible for a heart transplant. The 
second EUROMACS report, presented in Chapter 4, shows that most devices are used 
to support the function of the left ventricle of the heart: 2646 implants. In this situation 
they are referred to as “Left Ventricular Assist Devices, LVADs”. In addition to this, 114 
Right Ventricular Assist Devices (RVADs) were implanted to support the right ventricle; 
81 to support both ventricles (BiVAD); and 31 as “total artificial heart” (TAH) implants. 
In 36% of the patients an MCS device was implanted to assess whether the patient 
would be eligible for a heart transplant (“bridge-to-candidacy”). This was immediately 
apparent in 28% of patients with heart failure (“bridge-to-transplant”). There are two 
forms of pump technology that are used in support hearts: pumps that pulsate and 
pumps that rotate continuously. In this study, the ratio was 68 (3%) and 2214 (97%), 
respectively. Furthermore, it was found that the total population of patients consisted of 
18% women and 82% men. This is important for further research as shown in chapter 6.
For those who do not qualify for heart transplantation, generally or due to age and/
or additional illnesses, an artificial heart is permanently implanted as a last resort 
(“destination therapy”): 16%. In this category, most patients were older than 65 years.
The development of the mechanical support therapy for circulation is relatively new. 
Although the devices have undergone technical improvements in recent years, the therapy 
frequently results in serious complications: in the first 3 months after implantation, 
647 serious complications were reported and 1404 after more than 3 months from 
implantation. Infections (41.2%) are the most common serious complications of 
therapy, followed by bleeding (21%) and malfunction of the supporting heart, often 
due to thrombosis (22%) and neurological incidents (15%).
In the second EUROMACS report we also looked at the long-term results of MCS and 
the long-term clinical results. We only observed the results of “mainstream” devices with 
continuously rotating pumps. The survival of 2268 adult patients (older than 17 years) 
with an average follow-up time of 379 days was 86% after 30 days, 66% after 1 year, 
53% after 2 years; and 42% after 3 years.
The report provides a breakdown of those survival rates by age, stage of heart failure 
(INTERMACS level) and therapy strategy (bridge to transplant, destination therapy 
etc.).
It was of great importance to investigate the chance of competing outcomes. In the 
case of supporting heart therapy this means that the frequency of heart transplantation 
influences survival with an MCS device. At the end of the first 6-month period, 5.4% of 
the observed population (n = 2044) were transplanted and 27.4% had died. In 65.2% 
of patients, the device still functioned after 6 months, while the heart of 1.5% of this 
group recovered so that the assist device could be explanted. Chapter 7 focuses on the 
latter phenomenon.
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The importance of these analyses is that heart failure programs participating in the 
EUROMACS registry, as well as programmes that do not participate, can compare their 
outcomes with accumulated European results. With this second report we have created a 
benchmark for therapy with MCS in Europe. Furthermore, we benchmarked the results 
with those of the American registry, INTERMACS. This showed that considerable 
differences in results could be observed. The 3-year survival of patients with an LVAD 
and of patients with a BiVAD was 44% and 21% respectively in the EUROMACS 
database and 58% and 40% in that of INTERMACS. If the European outcomes are 
real and not biased by the different types of patients, non-compliance of the provided 
data, and/or differences in definitions between Europe and the United States, then 
the causes of the poorer outcomes in Europe should be further investigated. Possibly, 
the differences in patient categories, the extent of illnesses and additional disorders, in 
addition to specific selection criteria and other therapeutic applications, contributed to 
the observed differences.
These differences are also observed in Chapter 4 in which data regarding MCS therapy 
in children are analysed. The use of MCS in children differs from adults in that 36% of 
the implanted devices are pulsating. In children younger than 10 years the number of 
implanted pulsating devices is 84%. This is due to the limited range of suitable devices 
for small children; there is only one supplier, other than the mainstream manufacturers 
who only make rotating pumps, which also produce small sizes.
One of the most striking differences with the situation on the American continent (in 
this case the United States and Canada) is the waiting time for children with heart 
failure on a donor heart for transplantation. The North American data, collected in 
the Pedimacs Report, where almost 50% of the children could undergo a transplant 
within 6 months, was only 33% in Europe. The competitive outcomes, however, show 
a more favourable picture for European patients with regard to death: 15% after 1 year 
and 17% after 2 years. These percentages are relatively low and give good prospects for 
assistive heart therapy in Europe. In both the Pedimacs and in the EUROMACS report, 
neurological complications were the main cause of death 30% versus 24%.
With this study we have been able to create a benchmark for child heart specialists. This 
report provides a first insight into the results of supporting heart therapy in children in 
Europe. As with the adults, the Benchmark with data from the Pedimacs report raises 
possible differences with regard to treatment methods. These questions, like those asked 
in the report on the results of adults with supporting hearts, should be the subject of 
further studies.
In Chapter 5 we added the data of the EUROMACS registry to those from the 
International Society for Heart and Lung Transplantation Mechanical Circulatory 
Support (IMACS) registry database. In the report, data from 14,062 patients from 
different parts of the world are accumulated and analysed. The 1- and 2-year survival of 
all patients was 80% and 70% respectively. The 3-year survival of patients with an LVAD 
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equipped with a continuously rotating pump was 61%, which is better than the results 
reported in the second EUROMACS report, but also better than those in the seventh 
INTERMACS report. For the first time, a comparison was also made between MCS 
with pulsating and MCS with continuously rotating devices. Although the pulsating 
devices represent only a relatively small amount of the total number of implants (3%), 
the survival compared to continuously rotating devices over the 3-year term was better: 
79.6% versus 62.4%. An important finding in the analysis we did for the IMACS report 
is that kidney function was measured 2 days before implantation of an MCS device. 
Patients undergoing dialysis had higher preoperative urea and creatinine levels and 
higher premature death. As in the EUROMACS cohort, bleeding and infection were 
the most important major complications of therapy.
With regard to the IMACS registry, the conclusion is justified that the data, partly due 
to its quantity, is an important benchmark for analyses of outcomes of MCS therapy on 
an international level.
In Chapter 6 we present a study of the differences in results of LVAD devices in men 
and women, using data from the EUROMACS database. 151 (15.6%) of the patients 
studied were female and 815 (84.4%) male. Moreover, although heart failure is more 
frequent in women than in men, the likelihood of being treated with an assist device is 
lower. This study attempts to identify the factors that influence the survival of women 
and men. In doing so, we looked at factors that play a preoperative role and at the other 
hand at what influences outcomes peri- and post-operatively. It is also striking that in 
the selection of patients who are eligible for an LVAD, women are later in time eligible 
for implantation as compared to men. This is despite the fact that in the final selection, 
heart failure is more advanced in women than in men.
During the peri-operative period, it appeared that women, after implantation of an 
LVAD, required more frequent support of the right ventricle. It is possible that the size 
of the assist device and the type play a role here. At the time of the study, there was 
only one manufacturer offering a smaller LVAD in terms of size. However, this type is 
associated with thrombosis formation. Postoperatively, women also stayed in intensive 
care for longer than men, while the ventilation period was longer too. An analysis of peri-
operative and long-term outcomes has shown that the number of serious complications 
such as bleeding, arrhythmia and right heart failure was greater in numbers than in men. 
Also, the mortality rate for women undergoing LVAD implantation is 7.7% higher 
after 1 year than in men (24.5% and 16.8% respectively) and 7.3% higher after 2 years 
(32.1% and 26.8%).
The number of publications regarding differences in selection and treatment by gender 
when applying MCS therapy is still very limited. This study has provided a benchmark 
that contributes to the insight that it is necessary to further investigate the causes of 
the observed differences. Moreover, the clear timing and practical consequences for the 
clinical application of MCS therapy in women must be included.
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In Chapter 7 we investigate patients whose MCS device has been explanted after 
adequate recovery of the heart muscle and, if so, what the long-term outcomes are. Data 
from the EUROMACS registry were also used for this study. 49 patients were identified 
in the registry with the LVAD successfully removed. As explantation, in addition to 
heart transplantation and death, is an end point in EUROMACS, the follow-up data 
after explantation are unfortunately not in EUROMACS. That is why the practitioners 
of the patients concerned were approached with a questionnaire. This questionnaire 
had a response rate of 57% (28 patients, 17.9% female) and provided information on 
primary outcomes as well as relevant clinical data after explantation. The long-term 
outcomes of the investigated patient group were excellent with 92% 4-year survival 
with no major complications and or little need for renewed LVAD implantation or heart 
transplantation. This study is one of the first studies to show results at a European level 
based on data from multiple centers, for patients of whom the LVAD has been removed. 
As such, the data is a reference for necessary future studies. It is recommended that in 
new follow-up studies, the clinical data should continue to be recorded even after the 
MCS device has been explanted and, moreover, to add biological and pathological data 
to the database.
In Chapter 8 we present a comparison between patients who have undergone surgery 
on the tricuspid valve during the implantation of an LVAD. In patients with heart 
failure, in which the left ventricle should be supported with an assist device, leakage 
of the tricuspid valve is more frequent, current guidelines recommend that surgery be 
performed on the tricuspid valve when an LVAD is implanted. As there is hardly any 
good clinical literature on this, we have performed an extensive analysis using data from 
the EUROMACS database and show that such an intervention does not necessarily lead 
to significantly better results in the short or longer term. A good selection of patients with 
leakage of the tricuspid valve may possibly give better results. Prospective, randomized 
studies are required for this.
Benchmarking in the field of tissue transplants, organizational forms, costs 
and quality
Chapters 9 and 10 form part of a wide-ranging study for the European Commission 
into applications for the clinical use of human tissues in the European Union. The 
selected chapters relate to economic and organisational aspects of processes that aim to 
acquire, process, preserve and distribute human tissues for transplantation.
The studies that are presented give an overview of tissues that are used in various 
specialties as a replacement for a diseased tissue in the patient with the aim of taking 
over the original function of the diseased tissue.
In order to be able to make a non-donated post-mortem human tissue available to a 
surgeon for implantation in a patient, investments in people and resources must be 
294
Chapter 15
made. Chapter 10 explains which aspects play a role in setting up a process aimed at 
making human tissues available for transplantation. Since the European Directives in 
the field of quality and safety of human tissues came into force, investments in clean 
rooms have become necessary. The conditions in those clean rooms are comparable 
to similar units in pharmaceutical production companies. In addition to the costs of 
the cleanrooms, there are costs that are accumulated in the process from donation to 
transplantation. Chapter 10 shows that process. Ultimately, the total of investment and 
processing costs is spread over the tissues to be distributed. The different ways of passing 
on costs, if not from a public or private organisational setting, leads to the obstacles 
identified in Chapter 11 in achieving a balance between supply and demand.
For use in cardiac surgery we have focused on human heart valves, also known as 
homografts, and on other tissues that are transplanted in cardiac surgery to replace the 
recipient’s own tissue such as arteries, veins and pericardium. Important findings with 
regard to factors that obstruct a sufficient supply of donor tissue for use in cardiac surgery 
in a number of European countries are presented in Chapter 10. In those countries 
where explicit permission (opting-in) for donation is required, the additional effort that 
is required to obtain permission from relatives of the donor is a further obstacle in 
obtaining sufficient heart valve and other tissues. A better exchange could take place at 
European level so that the supply of human implants is better balanced with the demand 
from the clinics. The obstacles identified are summarised as follows: giving priority to 
national patient recipients over those from other European countries; differences in 
donor selection criteria; deviating virological and microbiological test regimes; divergent 
legislation; and costs of the process included in the price of the tissue be passed on. 
When determining the costs and charging them to the receiving hospital, the question 
is whether the tissue establishment that receives, processes and distributes the tissue is 
a public or private organisation. It can also play a role in this if the tissue establishment 
is part of another (public law) hospital, an independent foundation or an organisation 
financed with shareholder capital.
The report from the European Commission takes stock of the figures from 2012 and 
2013, showing no increasing trend in availability or in the number of implantations of 
cardiovascular tissues. One of the causes is the aforementioned obstructing factors for 
obtaining suitable grafts. On the other hand, more industrially produced valves and bio-
prostheses are produced, using bovine or porcine tissues. By innovating the production 
methods, those bio-prostheses are getting better and better.
Our conclusion is that there is a decreasing trend in the use of cardiovascular donor 
tissues, but that there will always be a - albeit lower - demand. For the long term, 
we expect better long-term results due to the application of new techniques such as 
decellulating heart valves before implantation.
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Benchmarking methods and outcomes of cardiovascular tissue 
establishments
In Chapter 11 we present detailed findings from a study of 18 different cardiovascular 
tissue institutions. These institutions received an average of 1672 donor hearts per year 
(range 1640-1700). On average, 709 usable heart valves were preserved from those 
donor hearts. The number of distributed valves differs greatly per tissue establishment: 
from a minimum of 4 to a maximum of 79 aortic valves and from 17 to 243 for 
pulmonary valves per year. The reasons for these differences are largely due to divergent 
selection criteria in these institutions. The application of those criteria leads to much 
higher rejection rates than we believe is necessary. Very large methodological differences 
in decontamination of heart valves raise the question of the substantiation of those 
methods and demonstrate the need for standardisation of these methods.
Chapter 12 is the first step towards the need to validate decontamination methods, as 
found in Chapter 11. The starting point for this quality round, in which microbiological 
methods and their results are examined in tissue establishments, is that cardiac surgeons 
must be able to trust that the methods used are effective and that tissue grafts are sterile. 
The participating institutions, 19 of which are situated in the European Union, and one 
in Singapore, each received 2 pieces of tissue that we had contaminated with our known 
micro-organisms. The task of the participants was to identify and decontaminate those 
micro-organisms with the locally used method. Then it had to be tested whether the 
tissues were free of micro-organisms and to indicate whether the institution in question 
would release the tissue, if it were to be a heart valve, for implantation.
This study shows in detail the large differences between both the nature and concentration 
of antibiotics used, as well as a wide spread in the temperature used (20° C to 30° C) 
and whether or not antibiotics were washed out after the decontamination procedure.
Ultimately, the decontamination method in 13 tissue establishments was not effective 
enough to perform adequate decontamination. Moreover, it could be established that 
many unnecessary process steps were carried out. 17 tissue establishments could save 
costs by applying a more logical design of their processes.
The exercise by means of a quality round in this study is in fact a benchmarking tool that 
makes best practices visible. This study also demonstrates once again that harmonisation 
of methods is necessary to prevent the loss of scarce tissue. If a stage can be reached in 
which tissue establishments can rely on each other’s methods, exchange at European 
level can be optimised.
The research presented in Chapter 13 is in line with that of Chapter 12. Where Chapter 
12 relates to the outcomes of microbiological research and decontamination methods 
of micro-organisms, Chapter 13 focuses on mapping factors that lead to the rejection 
of donated hearts or tissues of hearts. The research among 15 European and 4 non-
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European organisations showed that all 19 cardiovascular tissue establishments accept 
multi-organ donors. 4 limit themselves to these and do not accept other donors. Most 
other (15) also accept donor hearts from deceased people who are only tissue donors. 
So-called domino hearts, which are hearts of patients undergoing a heart transplant, and 
whose sick heart sometimes still has one or more good heart valves, were accepted by 8 
institutions. Another factor that influences the quantity of donated tissues is the upper 
age limit set on donors. This varies from 40 years to 70 years. We also saw great variation 
in the anamnestic study, in which 4 respondents indicated that the medical history is 
never examined, 7 did not contact the GP more closely and 1 establishment does not 
use pathology data.
Striking differences were noted in other important quality-determining processes, 
such as donor cooling, accepted post-mortem time and virological tests. Again, the 
decontamination methods and the temperatures used in them were found to be different 
and correlation with rejection rates was observed.
The conclusions of the research presented in Chapter 13 into the factors that play a role 
in rejecting hearts and tissues encouraged us to organise a quality round again.
In Chapter 14 we report the findings of the second quality round in which the 
microbiological methods used in cardiovascular tissue settings are examined in more 
detail than before. 25 organisations were involved in the survey (21 of them from 
Europe). 3 contaminated tissue samples were sent to each participating institution. Two 
of the samples (sample A and sample C) were infected with micro-organisms known to 
us. The third sample (sample B) was sterile and intended as a control for negative testing. 
20 of the 22 institutions tested sample A correctly and only 8 tested sample C correctly. 
In the sterile sample B, 2 institutions still found micro-organisms; an evaluation showed 
that the cause is probably the result of cross-contamination and/or swapping of samples. 
Once again it was suspected that low decontamination temperatures are often ineffective, 
an analysis of the results of the institutions that proved unable to decontaminate sample 
C was sufficient. The low temperature (4° C to 22° C) was the cause of the failure.
The large variation found in donor selection criteria, working methods, decontamination 
methods and assessment criteria led us to initiate a recurring external objective quality 
assessment. Its purpose must lead to standardisation and improvement of the clinical 
quality of tissues for implantation.
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Future perspective
In many countries, national databases with data and outcomes of cardio-thoracic 
procedures are used to accumulate and compare data. This process is still ongoing in 
some countries. It is expected that in Europe the development of an instrument of 
benchmarking for hospitals and surgeons providing cardio-thoracic care will be realised 
in the coming years and play an important role in demonstrating quality. In addition, 
they must demonstrate that they are able to meet the justified expectation that they, 
as healthcare providers, can actually deliver, according to the definition: “quality of 
care is the degree to which health services for individuals and populations increase 
the likelihood of desired health outcomes and are consistent with current professional 
knowledge”. This is not exclusively limited to benchmarking based on numbers. Tools 
such as standardised feedback reports and collaborative groups in which differences in 
methods and results are frequently analysed and discussed at European level have proven 
to add to the improvement of outcomes. For the success of registries and the resulting 
improvement initiatives, the objectivity and good governance of the responsible 
organisation are of great importance. Additionally, adequate structural financing of costs 
must guarantee long-term maintenance of the registry.
In view of the growing population of heart failure patients worldwide, and taking 
into account that further innovations are being implemented, it is expected that the 
implantation of MCS devices will increase in the long term. In this thesis it is already 
suggested that further improvement of the results can be expected through early selection 
of patients who are eligible for an assist device.
Further developments and innovations in the field of support MCS devices are to 
be expected. The devices will become smaller, which is beneficial for children, young 
adults and women. Complications due to advancing technological innovation, such as 
minimal invasive or percutaneous implantations, and/or from full support to partial 
support will decrease unwanted complications. In addition to this, much can be gained 
by investigating which factors can improve the long-term outcomes for women. The 
largest number of complications occurs as a result of infections. Their occurrence is 
largely caused by the porte d’entrée that is formed by the external power supply of 
the support hearts. The first results of a fully implantable artificial heart were recently 
presented. The external power supply took place by means of induction. However, 
many problems still have to be solved before this technique can be used as standard. In 
particular, issues such as heat development affecting the skin and other organs of the 
patient are a point of attention.
Cardiac surgeons must be able to trust that human allogeneic tissue is available for 
transplantation and that it is also safe for the patient. As there is progressive insight 
within the European Union about the different methods used in the member states, 
the international allocation of cardiovascular grafts can be improved. The tissue 
establishments that collaborate in the international benchmarking project are looking 
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to eliminate factors that influence quality by setting up an affiliation with NEQAS 
(National External Quality Assessment Service) an independent, now international, 
consortium that focuses on improving test results in laboratories. Eventually the 
observed differences in outcomes will disappear and the certainty that the quality of the 
tests is reliable will increase.
The use of human heart valve tissue will generally decrease, for specific indications 
decellulated tissues will be preferred, although due to the high processing costs, no total 
substitution of traditionally processed heart valves can be expected.
Conclusion
This dissertation contributes to the knowledge of bridging negative differences in 
outcomes through analysis and providing methods for improvement. Benchmarking 
methods providing more detailed insight where there is specific room for improvement are 
presented. Literature research combined with analyses from registries and quality rounds 
shows how we can contribute to the knowledge about improving clinical outcomes and 
preventing complications. Reports and studies using the data from the EUROMACS 
database reflect the European state of affairs regarding the results of implantation of 
Mechanical Circulatory Support devices in adults and children. Moreover, these results 
can be compared with outcomes on a global level and it can be determined that adult 
mortality is higher. North American data on the course of supporting heart therapy in 
children show that although the chance of a heart transplant in Europe is smaller, the 
results in Europe show a longer survival on assist devices. Additionally, it was found 
that a comparison between the results of MCS therapy is worse in women compared 
to that of men. This observation does not only occur with MCS therapy and therefore 
deserves priority in further research. The long-term outcomes of patients whose own 
heart muscle could function independently after explantation of an assist device show 
that the results in those patients are very good. To better understand the factors that play 
a role, further research is also indicated for this group of patients. With the study of the 
effect of surgical correction of the tricuspid valve during the implantation of an LVAD, 
it has been shown that there is no significant improvement in results.
For the first time, Europe-wide insight has been provided into the landscape of human 
tissues for transplantation. Our contributions to the European Commission’s report 
show where there are bottlenecks in the quantity and quality of the processes that lead 
to the adequate availability of grafts at international level. This is an impetus for the 
European Commission to develop further policy.
Four studies that are in line with each other show which methods are used by tissue 
establishments in acquiring and processing cardiovascular tissues for transplantation. 
Areas for improvement were identified through consensus meetings and benchmarking. 
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Given the high participation rate of the organisations, it can be expected that best 
practices can be realised in the long term and with the help of external standards.
Finally, it is hoped that this thesis contributes to the work of cardiac surgeons and 
cardiologists who are responsible for the clinical care of patients.
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SUMMARY
Increasingly, health care providers must demonstrate that they are able to meet the 
justified expectation that they can actually deliver results of care according to the 
definition: “quality of care is the degree to which health services for individuals and 
populations increase the likelihood of desired health outcomes and are consistent with 
current professional knowledge”.
Measuring the outcomes of health services as such doesn’t provide adequate information 
about the quality of services of an individual provider. It’s when we compare the 
outcomes of that provider with those of other providers, offering similar services, that 
the results can be analysed in perspective. In this way best practises can be defined and 
the relative outcomes of an individual provider of (health) services can be determined. 
This process is called benchmarking. (Chapter 1)
In this thesis different benchmarking studies in the field of cardio-thoracic surgery are 
presented.
The instruments and platforms, used in these studies, in order to objectively assess 
outcomes are databases and registries. In addition professional societies and peer-
organisations play a key role in organising focus-meetings and workshops indicating the 
possible causes, and directions to solve the negative differences.
A systematic literature review (Chapter 2) of benchmarking studies showed that the 
causal relationship between the use of registries and increased quality could be proven. 
Benchmarking provided tangible evidence of measurable qualitative improvement of 
outcomes. All studies provided additional instruments to come to best practises. 
Heart failure is an important cause of morbidity and mortality. Ultimately, heart 
transplantation was -and perhaps is- the therapy of choice for heart failure patients. Since 
more than 2 decades, a technological innovation in the form of Mechanical Circulatory 
Support (MCS) in the form of blood-pumps has made it possible to support the heart, 
and therewith the blood circulation of these patients. Several studies about the use of 
MCS are presented in this thesis (Chapters 3-8). Since the common denominator of this 
thesis is the benchmarking of methods and outcomes, these studies provide benchmarks 
based on registry data, specifically of the European EUROMACS registry. 
Two studies (Chapters 3 and 4) provide reports on the application of MCS respectively 
in adult and in paediatric patients. The reports show the applied practises in the field 
of MCS by the accumulation of base-line data. Follow-up analyses analyse the factors 
contributing to short- and long-term outcomes. 
Such data have been made available on a global level too. One chapter (Chapter 5) of 
this thesis is a study of the International Society for Heart and Lung Transplantation 
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Registry for Mechanical Circulatory Support (IMACS Report), in which, besides data 
from EUROMACS, contributions of similar data from other parts of the world are 
brought together. The source of these data is mostly from the United States, while data 
from countries such as Canada, Japan, Singapore and Australia are integrated as well. 
The IMACS report offers multiple benchmarks with respect to device strategies, risk-
factors, adverse events and predictors for mortality.
A difference between female and male patients in terms of selection for as well as 
outcomes of MCS therapy was demonstrated as part of this thesis (Chapter 6). While 
heart failure is more frequent in women, only 15.6% of the patients in the EUROMACS 
database was female, and short- as well as long-term mortality appeared to be higher. 
One of the causes may be the limited availability of smaller devices (only 1 manufacturer 
offered smaller devices at the time of the study). The results of the study have provided a 
benchmark for future analysis of the differences in outcomes in female patients.
Another benchmark has been set in the paper (Chapter 7) about patients whose MCS 
device has been explanted after adequate recovery of the heart muscle, showing that 
weaning from an MCS device shows excellent results, and that only a minority of the 
patients suffer from a relapse or significant heart failure.
The EUROMACS registry enabled us to compare different strategies when it comes to 
patients with leakage of the tricuspid valve. While some studies underlined the necessity 
to repair the tricuspid valve during valve implantation. The study in this thesis (Chapter 
8) demonstrates that such an intervention doesn’t necessarily lead to better results, and 
that an improved patient selection may possibly give better results.
The transplantation of human tissues (allografts), focused on cardio-vascular allografts, 
comprises several chapters of this thesis (Chapters 9 and 10). First, a wide-range study, 
carried out for the European Commission, looks into the clinical use. Qualified as 
“replacement tissues” cardiovascular allografts are implanted in those patients with 
illnesses or malfunction of the heart-valves or arteries. The causes can be congenital or 
acquired, such as by infections or sepsis. 
To make replacement tissues available for transplantation they must be donated by a 
deceased donor. Contrary to organ donation, in which the short time between donation 
and transplantation is a qualitative factor, tissues can be stored for a longer period of 
time. This enables tissue establishments to evaluate the quality of the tissue in different 
ways. 
The presented studies give an insight in the different methods that are applied. Rates 
of donations and transplantations are quantified for countries in the EU, while cross-
border activities have been chartered. A breakdown of factors influencing the availability 
of sufficient grafts learns that in countries with an opting-in system, the additional 
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efforts to obtain permission for donation is threshold to overcome to get sufficient grafts 
to cover the clinical need. 
These studies also provide an economic evaluation into the costs, generated because of 
the necessary quality and safety requirements. Although donated for altruistic reasons, 
the processing and investment costs require compensation of the hospital, or the patient’s 
insurance once the graft is transplanted. 
Our conclusion is that there is a decreasing trend in the use of cardiovascular donor 
tissues, but that there will always be a - albeit lower - demand. For the long term, 
we expect better long-term results due to the application of new techniques such as 
decellularized heart valves before implantation.
Four chapters (Chapters 11-14) of this thesis consist of studies focusing on different 
methods used by tissue establishments and their outcomes. 
Contamination of the implanted tissue graft can lead to severe complications in the 
vulnerable recipient. In order to determine that no micro-organisms are transferred 
to the recipient, tests are carried out. In a first study (Chapter 12) we observed great 
differences in methods and results of the different tissue establishments in Europe and 
in third countries. And concluded that there was a need for an international standard.
A second study (Chapter 12) made a quantitative inventory of numbers of donations 
and transplantations as well of methods used in the processes from donation, excision, 
decontamination and storage. The observed differences triggered us to execute a “quality 
round” in which the tissue establishments were asked to determine which micro-
organisms could be found in samples that were purposely contaminated. From the 
20 participating establishments, 13 appeared to use methods that were insufficiently 
effective to perform adequate decontamination. Moreover, some methods could save a 
substantial level of costs if they would re-design their processes in a more logical way. 
The conclusion was that, in order to come to best practises, harmonisation of methods 
was, and is an necessity to enable exchange of grafts on a European level. Moreover, 
surgeons -in the interest of their patients- must be able to rely on the methods used. 
In an additional study (Chapter 13) we focused on mapping the factors that lead to the 
rejection donation of  heart or tissues of hearts from donors. This time, great differences 
were found in e.g. donor management, age limits and the acceptance of non-organ 
donors, thus limiting of the availability of tissues for transplant. The decontamination 
methods and the temperatures were again found to be different and correlation with 
rejection rates of potential donors was observed.
The last study (Chapter 14) reports the results of a 2nd quality round in tissue establishment 
in which from 21 European and 4 third countries participated. The instruction was 
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to identify micro-organisms in each of 3 samples. Repeatedly, some establishments 
provided incorrect results. What became clear though is that low temperatures of 4o C 
to 22 C° are inadequate to decontaminate, thus setting a standard and a benchmark for 
applied methodologies in cardiovascular tissue establishment.
In a future perspective (Chapter 16) we stated that the necessity to come to national 
and international European registries that provide adequate data for benchmarking is 
increasing. In order to demonstrate that health care providers can deliver the health 
outcomes that are desired by society, they must prove, by benchmarking and transparent 
publication of their outcomes, that their results and outcomes are consistent with current 
professional knowledge. As for patients who need MCS several factors will determine 
future results. One is the early selection of eligible patients, and another is that devices 
will become smaller, which will benefit women and children. A third is the development 
of peripherals such as apps that enable monitoring patients at a distance, on-line, that 
enable clinicians to detect adverse events in an early stage.
The tissue establishments that collaborate in the international benchmarking project are 
looking to eliminate factors that negatively influence quality by setting up an affiliation 
with NEQAS (National External Quality Assessment Service) an independent, now 
international, consortium that focuses on improving test results in laboratories. 
Eventually the observed differences in outcomes will disappear and the certainty that 
the quality of the tests is reliable will increase.
The use of human heart valve tissue will generally decrease, for specific indications 
decellularized tissues will be preferred, although due to the high processing costs, no 
total substitution of traditionally processed heart valves can be expected.
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SAMENVATTING
In toenemende mate moeten zorgverleners aantonen dat zij in staat zijn te voldoen 
aan de gerechtvaardigde verwachting dat zij daadwerkelijk resultaten van zorg kunnen 
leveren volgens de definitie: “kwaliteit van zorg is de mate waarin gezondheidsdiensten 
de kans op resultaten in overeenstemming met de huidige professionele kennis de 
gewenste gezondheid voor individuen en bevolkingsgroepen vergroten”.
Het meten van de resultaten van gezondheidsdiensten als zodanig biedt geen adequate 
informatie over de kwaliteit van de diensten van een individuele aanbieder. Het is 
wanneer we de resultaten van die aanbieder vergelijken met die van andere aanbieders 
die vergelijkbare diensten leveren, dat de resultaten in perspectief kunnen worden 
geanalyseerd. Op deze manier kunnen best practices worden gedefinieerd en kunnen de 
relatieve resultaten van een individuele aanbieder van (gezondheids-) diensten worden 
bepaald. Dit proces wordt benchmarking genoemd. (Hoofdstuk 1)
In dit proefschrift worden verschillende benchmarkingstudies op het gebied van cardio-
thoracale chirurgie gepresenteerd.
De instrumenten en platforms die in deze studies worden gebruikt om de resultaten 
objectief te beoordelen, zijn databases en registries. Daarnaast spelen professionele 
verenigingen en peer-organisaties een sleutelrol bij het organiseren van focusbijeenkomsten 
en workshops waarin de mogelijke oorzaken en oplossingsrichtingen voor de negatieve 
verschillen.
Een systematisch literatuuronderzoek (Hoofdstuk 2) van benchmarkingstudies toonde 
aan dat het causale verband tussen het gebruik van registries enerzijds en anderzijds een 
verhoogde kwaliteit kon worden aangetoond. Benchmarking leverde tastbaar bewijs op 
van meetbare kwalitatieve verbetering van de resultaten. Alle studies hebben aanvullende 
instrumenten opgeleverd om tot best practices te komen.
Hartfalen is een belangrijke oorzaak van morbiditeit en mortaliteit. Uiteindelijk was 
harttransplantatie de therapie bij uitstek voor patiënten met hartfalen. Sinds meer 
dan twee decennia heeft een technologische innovatie in de vorm van Mechanische 
Circulatory Support (MCS), in de vorm van steunharten, het mogelijk gemaakt om het 
hart en daarmee de bloedcirculatie van deze patiënten te ondersteunen. Verschillende 
studies over het gebruik van steunharten worden gepresenteerd in dit proefschrift 
(Hoofdstukken 3-8). Aangezien de gemeenschappelijke noemer van dit proefschrift de 
benchmarking van methoden en resultaten is, bieden deze studies benchmarks op basis 
van registry-gegevens, met name van het Europese EUROMACS-register.
Twee studies (hoofdstukken 3 en 4) geven rapporten over de toepassing van steunharten 
bij respectievelijk volwassen patiënten en kinderen. De rapporten tonen de toegepaste 
werkwijzen op het gebied van MCS door de accumulatie van gegevens m.b.t. 
310
Chapter 16
voorgeschiedenis en peri-operatieve gegevens. Door middel van follow-up analyses 
worden de factoren die bijdragen aan de resultaten op korte en lange termijn manifest.
Dergelijke gegevens zijn ook op mondiaal niveau beschikbaar gesteld. Een hoofdstuk 
(Hoofdstuk 5) van dit proefschrift is een studie van de International Society for Heart 
and Lung Transplantation Registry for Mechanical Circulatory Support (IMACS 
Report), waarin, naast gegevens van EUROMACS, bijdragen van vergelijkbare gegevens 
uit andere delen van de wereld worden samengebracht. De bron van deze gegevens is 
meestal afkomstig uit de Verenigde Staten, terwijl gegevens uit landen zoals Canada, 
Japan, Singapore en Australië ook zijn geïntegreerd. Het IMACS-rapport biedt meerdere 
benchmarks met betrekking tot implantaat strategieën, risicofactoren, ongewenste 
voorvallen en voorspellers voor mortaliteit.
Een verschil tussen vrouwelijke en mannelijke patiënten in termen van selectie voor, en 
uitkomsten van, steunhart-therapie werd aangetoond als onderdeel van dit proefschrift 
(Hoofdstuk 6). Hoewel hartfalen vaker voorkomt bij vrouwen, was slechts 15,6% van 
de patiënten in de EUROMACS-database vrouwelijk en bleek zowel de korte- als de 
lange termijn sterfte hoger te zijn. Een van de oorzaken kan de beperkte beschikbaarheid 
van kleinere apparaten zijn (slechts 1 fabrikant bood op het moment van het onderzoek 
kleinere apparaten aan). De resultaten van de studie hebben een benchmark opgeleverd 
voor toekomstige analyse van de verschillen in uitkomsten bij vrouwelijke patiënten.
In dit proefschrift (hoofdstuk 7) is een benchmark gezet voor patiënten bij wie het 
steunhart is geëxplanteerd na voldoende herstel van de hartspier, waaruit blijkt dat in 
dergelijke gevallen het verwijderen van een steunhart uitstekende resultaten oplevert en 
dat slechts een minderheid van de patiënten een terugval heeft of aanzienlijk hartfalen 
ontwikkelt.
Het EUROMACS-register stelde ons in staat om verschillende strategieën te vergelijken 
als het gaat om patiënten met lekkage van de tricuspidalisklep. Sommige studies 
onderstreepten de noodzaak om de tricuspidalisklep te repareren tijdens implantatie van 
een steunhart. De studie in dit proefschrift (hoofdstuk 8) laat zien dat een dergelijke 
interventie niet noodzakelijkerwijs tot betere resultaten leidt en dat een verbeterde 
selectie van patiënten mogelijk eerder betere resultaten oplevert.
De transplantatie van menselijke weefsels (allografts), gericht op cardiovasculaire allo-
transplantaten, omvat verschillende hoofdstukken van dit proefschrift (hoofdstukken 
9 en 10). Ten eerste wordt in een breed onderzoek, uitgevoerd voor de Europese 
Commissie, gekeken naar het klinische gebruik. Gekwalificeerd als “vervangingsweefsel” 
worden cardiovasculaire allografts geïmplanteerd bij patiënten met ziekten of storingen 
van de hartkleppen of slagaders. De oorzaken kunnen aangeboren of verworven zijn, 
zoals door infecties of sepsis.
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Om vervangende weefsels beschikbaar te maken voor transplantatie moeten ze worden 
gedoneerd door een overleden donor. In tegenstelling tot orgaandonatie, waarbij de 
korte tijd tussen donatie en transplantatie een kwalitatieve factor is, kunnen weefsels 
voor een langere periode worden bewaard. Hierdoor kunnen weefselinstellingen de 
kwaliteit van het weefsel op verschillende manieren evalueren.
De gepresenteerde studies geven inzicht in de verschillende methoden die worden 
toegepast. Tarieven van donaties en transplantaties worden gekwantificeerd voor landen 
in de EU, terwijl grensoverschrijdende activiteiten in kaart zijn gebracht. Een uitsplitsing 
van factoren die de beschikbaarheid van voldoende transplantaten beïnvloeden, leert 
dat in landen met een opting-in-systeem de extra inspanningen om toestemming voor 
donatie te krijgen een drempel zijn om te om voldoende transplantaten te krijgen 
teneinde de klinische behoefte te dekken.
Deze studies bieden ook een economische evaluatie van de kosten, gegenereerd vanwege 
de noodzakelijke kwaliteits- en veiligheidseisen. Hoewel gedoneerd om altruïstische 
redenen, vereisen de verwerkings- en investeringskosten een vergoeding van het 
ziekenhuis of de verzekering van de patiënt zodra het transplantaat is getransplanteerd.
Onze conclusie is dat er een dalende trend is in het gebruik van cardiovasculaire 
donorweefsels, maar dat er altijd een - zij het minder - vraag zal zijn. Voor de lange 
termijn verwachten we betere resultaten als gevolg van de toepassing van nieuwe 
technieken zoals het decelluleren van hartkleppen vóór implantatie.
Vier hoofdstukken (hoofdstuk 11-14) van dit proefschrift bestaan  uit studies die zich 
richten op verschillende methoden die worden gebruikt door weefselinstellingen en de 
resultaten daarvan.
Besmetting van het geïmplanteerde weefseltransplantaat kan leiden tot ernstige 
complicaties bij de kwetsbare ontvanger. Om te bepalen dat er geen micro-organismen 
op de ontvanger worden overgedragen, worden tests uitgevoerd. In een eerste studie 
(hoofdstuk 11) hebben we grote verschillen waargenomen in methoden en resultaten 
van de verschillende weefselinstellingen in Europa en in derde landen, en concludeerden 
dat er behoefte was aan een internationale standaard.
Een tweede studie (hoofdstuk 12) maakte een kwantitatieve inventaris van het aantal 
donaties en transplantaties en van methoden die worden gebruikt in de processen van 
donatie, excisie, decontaminatie en opslag. De waargenomen verschillen hebben ons 
ertoe aangezet een ‘kwaliteitsronde’ uit te voeren waarin de weefselinstellingen werd 
gevraagd om te bepalen welke micro-organismen konden worden gevonden in monsters 
die opzettelijk waren besmet. Van de 20 deelnemende instellingen bleken er 13 methoden 
te gebruiken die onvoldoende effectief waren om adequate decontaminatie uit te voeren. 
Bovendien zouden sommige weefselinstellingen een aanzienlijke hoeveelheid kosten 
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kunnen besparen als ze hun processen op een logischer manier zouden herontwerpen 
en inrichten.
De conclusie was dat, om tot best practises te komen, harmonisatie van methoden een 
noodzaak was en is om uitwisseling van allografts op Europees niveau mogelijk te maken. 
Bovendien moeten chirurgen - in het belang van hun patiënten - kunnen vertrouwen op 
de gebruikte methoden.
In een aanvullend onderzoek (hoofdstuk 13) hebben we ons gericht op het in kaart 
brengen van de factoren die leiden tot het niet accepteren van hart of hartweefsels van 
donoren. Deze keer werden grote verschillen gevonden in b.v. donormanagement, 
leeftijdsgrenzen en de acceptatie van niet-orgaandonoren, waardoor de beschikbaarheid 
van weefsels voor transplantatie wordt beperkt. De ontsmettingsmethoden en de 
temperaturen bleken opnieuw verschillend te zijn en correlatie met de reden waarom 
potentiële donoren werden afgewezen werd waargenomen.
De laatste studie (hoofdstuk 14) rapporteert de resultaten van een 2e kwaliteitsronde 
in weefselinstellingen waaraan 21 Europese en 4 derde landen hebben deelgenomen. 
De instructie was om micro-organismen in elk van de 3 monsters te identificeren. 
Herhaaldelijk leverden sommige vestigingen onjuiste resultaten op. Wat echter duidelijk 
werd, is dat lage temperaturen van 4° C- 22o C onvoldoende zijn om te ontsmetten, 
waardoor een norm en een benchmark wordt vastgesteld voor toegepaste methodologieën 
voor instellingen die cardiovasculair weefsel bewerken.
In een toekomstperspectief (hoofdstuk 15) hebben we gesteld dat de noodzaak om 
naar nationale en internationale Europese registries te komen die voldoende gegevens 
voor benchmarking verstrekken, toeneemt. Om aan te tonen dat zorgaanbieders de 
door de maatschappij gewenste gezondheidsresultaten kunnen leveren, moeten zij 
door benchmarking en transparante publicatie van hun resultaten aantonen dat die 
resultaten consistent zijn met de huidige professionele kennis. Wat betreft patiënten 
die een steunhart nodig hebben, zullen verschillende factoren de toekomstige resultaten 
bepalen. Een daarvan is de vroege selectie van in aanmerking komende patiënten, en een 
andere is dat apparaten kleiner zullen worden, wat vrouwen en kinderen ten goede zal 
komen. Een derde is de ontwikkeling van randapparatuur, zoals apps waarmee patiënten 
op afstand online kunnen worden gevolgd, waardoor artsen in een vroeg stadium 
bijwerkingen kunnen detecteren.
De weefselinstellingen die samenwerken in het internationale benchmarkproject 
proberen factoren te elimineren die de kwaliteit negatief beïnvloeden door een 
samenwerkingsverband op te zetten met NEQAS (National External Quality 
Assessment Service), een onafhankelijk, nu internationaal consortium dat zich richt op 
het verbeteren van testresultaten in laboratoria. Uiteindelijk zullen de waargenomen 
verschillen in uitkomsten verdwijnen en zal de zekerheid dat de kwaliteit van de testen 
betrouwbaar is toenemen.
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Het gebruik van menselijk hartklepweefsel zal in het algemeen afnemen, voor specifieke 
indicaties zullen gedecelluleerde weefsels de voorkeur hebben, hoewel vanwege de hoge 
verwerkingskosten geen totale vervanging van traditioneel bewerkte hartkleppen kan 
worden verwacht.
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Dit proefschrift, en in het bijzonder de studieresultaten die in de verschillende 
hoofdstukken zijn opgenomen, is het resultaat van samenwerking met veel mensen 
in de medische wereld en daarbuiten. Ik wil graag iedereen bedanken die met mij de 
inspanningen hebben geleverd om de resultaten van ons werk te kunnen publiceren. 
Zonder hen zou dit proefschrift niet to stand zijn gekomen. Ik hoop dat ze tevreden zijn 
met het resultaat. Een aantal mensen wil ik in het bijzonder bedanken.
In de eerste plaats mijn promotor, Prof. dr. Ad Bogers. Beste Ad, onze samenwerking 
gaat decennialang terug. Een van mijn vroegste herinneringen is de overdracht van 
de verantwoordelijkheden voor de toenmalige Rotterdamse hartkleppenbank van je 
voorganger aan jou. Het gebeurde in een etablissement aan de Zweth, hetgeen, naar jouw 
verbazing, destijds de gebruikelijk locatie was voor besprekingen over de samenwerking 
met betrekking tot  het preserveren van hartkleppen. Na jouw aantreden werden de 
bijeenkomsten zakelijker en effectiever. Ik zal jouw diplomatieke optreden rond de 
grote financiële verschillen tussen het Erasmus MC en Stichting BIS niet licht vergeten. 
In die periode werd de Rotterdamse hartkleppenbank de grootste van Europa en de 
in Rotterdam gehanteerde methodes werden overgenomen door Europese collega’s. 
Je steunde toen mijn initiatief om de internationaal waargenomen verschillen in 
preservatietechnieken bespreekbaar te maken in zgn. consensus meetings. De presentatie 
en onderbouwing van de verschillende werkwijzen was het begin van benchmarking dat 
nu het onderwerp is van dit proefschrift. 
Na mijn vertrek bij Stichting BIS zette ik dit werk voort en met jouw steun kon ik 
resultaten gaan publiceren. Ik ben je dankbaar dat je mij de mogelijkheid hebt geboden 
om mijn publicaties in dit proefschrift te presenteren.
Mijn copromotor dr. Kadir Caliskan. Beste Kadir, sinds onze eerste ontmoeting in 
Praag, in 2012, hebben wij samen gestalte kunnen geven aan de verder opbouw van de 
EUROMACS database. Daaruit zijn mooie studies voortgekomen en ik verwacht dat er 
nog zeker een aantal zal volgen. Dankzij jou heeft de reikwijdte van het onderzoek met 
onze data internationaal ingang gevonden onder cardiologen op het gebied van hartfalen. 
Recent hebben we weer initiatieven ontwikkeld die uiteindelijk zullen bijdragen aan 
inzichten die leiden tot verbetering van de klinische resultaten in de cardiologie en in 
de hartchirurgie. Ik zie uit naar onze verder samenwerking. Jij bent degene geweest die 
mij heeft gestimuleerd om te werken aan “een kroon op mijn werk” zoals je het noemde. 
Die kroon is gemaakt en ligt hier nu ingekaft voor de lezer om te aanschouwen. Ik ben 
je veel dank verschuldigd. 
Prof. dr. Mark Hazekamp. Beste Mark, mijn (her)aantreden in Leiden, eind jaren 80, 
viel ongeveer samen met jouw begin als thoraxchirurg. Het gebruik van homografts, in 
het bijzonder in kinderen met aangeboren hart(klep)-afwijkingen bracht ons op elkaars 
pad. We werkten ook samen om te proberen de continuïteit van de congenital database 
te waarborgen. Hopelijk zal dat uiteindelijk een positief resultaat hebben. Dank voor de 
samenwerking en voor je bereidheid om plaats te nemen in de kleine commissie.
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Prof. dr. Bart Meyns, beste Bart, vanuit je positie als lid van de EACTS EUROMACS 
Committee, en sinds 2017 als voorzitter, heb je mij gesteund bij het tot stand brengen 
van onderzoek en samenwerking tussen de verschillende Europese ziekenhuizen die 
steunharten implanteren. Je nuchtere aanpak heeft ervoor gezorgd dat de registry groeit 
en, ook dat ook degenen die aanvankelijk kritisch over EUROMACS waren, zich hebben 
aangesloten. Hartelijk dank voor dit alles en in het bijzonder ook voor je bereidheid om 
plaats te nemen in de kleine commissie.
Prof. dr. Hanneke Takkenberg, beste Hanneke, De Rotterdamse Hartkleppenbank 
opende op 24 augustus 1988 en niet lang daarna leerde ik je kennen als onderzoekster 
in het vakgebied van de homografts. Jouw analyses werden hoog gewaardeerd en jouw 
aanwezigheid en presentaties tijdens de consensus meetings hebben mij gesteund in mijn 
pogingen d.m.v. benchmarking de verschillende werkwijzen en de resultaten daarvan 
kritisch te vergelijken. Ik waardeer je huidige werkzaamheden bijzonder en ben vereerd 
dat je in de kleine commissie hebt willen plaatsnemen.
Prof. dr. Örjan Friberg, dear Örjan, our joint efforts to develop the EACTS Adult 
Cardiac Database into a benchmarking tool that is accepted all over Europe as an 
instrument to improve outcomes seem to have some success. Since many can learn from 
the achievements from you and your colleagues from Swedeheart, I hope to continue 
our cooperation even after you step down as chair of the ACD task force. It is an honor 
for me that  you’re a member of my PhD committee.
Prof. dr. Kitty Jager, ongeveer 25 jaar geleden leerden we elkaar kennen toen we met 
gezamenlijk werkten aan de verbetering van de orgaan- en weefseldonatie procedures in 
Nederland. Nadat je BIS verliet ben je onderzoek gaan doen op het gebied van de renale 
informatica en renale epidemiologie. Daarbij maak je gebruik van verschillende Europese 
registers die inzicht geven in incidentie en behandeling van eindstadia van nierziekten 
bij kinderen en adolescenten. In het gebruik van registries zie ik een overeenkomst met 
een groot aantal studies in dit proefschrift, en bij het schrijven van hoofdstuk 2 kon ik 
gebruik maken van de bevinding van een onderzoek van een van jouw promovenda. Ik 
was vereerd en trots dat ik bij je inaugurele rede aanwezig mocht zijn, en ben je dankbaar 
dat je nu in mijn promotiecommissie hebt willen plaatsnemen.
Prof. dr. Domenico Pagano, dear Domenico, thank you for your willingness to be part 
of my PhD committee. I’m honored to have the visionary and initiator of the EACTS 
Quality Improvement Project (QUIP) as a member of my PhD committee. In one of 
your publications you quoted “If you want to go fast, go alone. If you want to go far, go 
together”. Bringing this in practice, you have created a great ACD team that is able to 
realise the EACTS’s quality improvement goals. I’m happy to be part of it.
Prof. dr. Osama Soliman. Beste Osama, de risk score die jij ontwikkelde op basis van 
EUROMACS data heeft de trend gezet naar verder onderzoek in de samenhang tussen 
LVAD implantatie en rechter-hart falen. In de nabije toekomst kunnen we hopelijk 
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de EuroEchoVAD studie op de rit zetten om de invloed van de LVAD op de rechter-
hart functie te visualiseren en inzichten te verkrijgen die uiteindelijk de patiënten met 
hartfalen ten goede komen. Hartelijk dank dat je in mijn grote commissie hebt willen 
plaatsnemen.
Egbert Ottevanger. Beste Eg, eigenlijk ben je al 40 jaar mijn paranymf, vanaf de tijd dat 
we bij Eurotransplant werkten en waar we naast ons werk menige goodwill reis hebben 
ondernomen. Daarna, terwijl jij wetenschappelijk onderzoek deed en ik bij de Nationale 
Ziekenhuisraad werkte, produceerden we jaarverslagen met Appleworks op de Apple 
IIc, waarbij jij de genius was en ik de productie medewerker. Ik heb toen veel van je 
geleerd. Door de tijd heen zijn we dicht bij elkaar gebleven en het doet me genoegen 
dat we ook in 2020 nog steeds samen leuke (startups) en aanverwante projecten doen. 
Ik heb bewondering voor je doorzettingsvermogen in slechte tijden en ik ben blij dat je 
nog steeds mijn paranymf en vriend bent en hopelijk nog lang blijft.
Arlinke Bokhorst. Beste Arlinke, de psycholoog die rond jouw indiensttreding, destijds 
bij BIS, de compatibiliteit van onze karakters onderzocht waarschuwde ons dat ons 
wederzijdse ondernemerszin en enthousiasme om de organisatie verder uit te bouwen 
ons té positief zou kunnen beïnvloeden. Dat is ook regelmatig gebeurd, en we hebben 
ons inderdaad vaak moeten beheersen om niet teveel tegelijk te willen doen. Samen 
hebben we véél initiatieven ontplooit en heel veel projecten tot een goed einde gebracht. 
Ook de interne organisatie stond door onze inspanningen op hoog niveau. Jij en je 
medische staf zorgden ervoor dat onze reputatie internationaal een voorbeeld vormden 
voor vele collega-organisaties. Ook als je ziek was stond werkte je, alsof er niets aan de 
hand was, door ter wille van de doelen die we hadden gesteld, chapeau! Ik ben je heel 
veel dank verschuldigd voor alles wat je deed om onze samenwerking en onze organisatie 
te doen welslagen. Ik ben er trots op dat je mijn paranymf wil zijn.
Pieter Petit. Beste Pieter, dankzij de goede samenwerking met jou heb ik de draad 
m.b.t. de consensus meetings en het benchmarken van decontaminatie methoden en 
technieken weer op kunnen pakken. Zo zijn we beiden aan onze vierde (of vijfde?) 
carrière begonnen. Ik had je in het verleden aan het werk gezien tijdens de onderzoeken 
die je deed met de artsen bij BIS. Dat resulteerde steevast in een proefschrift en promotie 
van die mannen waarin het detecteren van micro-organismen en het onschadelijk 
maken daarvan voor de recipiënten van transplantaten het centrale onderwerp was. En 
uiteindelijk heb je zelf ook een promotiefeest gegeven. Nu heb ik zelf mogen ervaren 
hoe systematisch je te werk gaat bij de opzet van zo’n onderzoek, en ik dank het aan jou 
dat ik de studies naar methoden in cardiovasculaire weefselbanken die zijn opgenomen 
in dit proefschrift heb kunnen publiceren.
Prof. dr. Roland Hetzer in the 1990s we were able to develop a homograft laboratory 
to cover the needs of the Deutsches Herzzentrum Berlin and, in a European setting, to 
address the demand for safe grafts from yourself and from your international colleagues. 
Your initiative to found the European Foundation of Tissue Banks, and giving me 
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the opportunity to become director, enabled me to further develop the scheme of 
benchmarking methodologies in cardiovascular tissue banking. Additionally, this led to 
your invitation to me to become director of EUROMACS as well. Again, this appointment 
enabled me to make another important step in my career. Both organisations appeared 
to be an excellent basis for the analysis of data and for the publication of the results. I 
regret that we disagreed about the best move for EUROMACS, nevertheless I wish to 
express my gratitude to you. I have great respect for your lifetime achievements.
Here, I also wish to thank my late friend, Norbert Franz. Norbert and I enjoyed a true 
European friendship that started in the 1970s when Norbert was working at Station 
37B at the Medizinische Hochschule Hannover. Later, in the interest of the DHZB 
and BIS Foundation we cooperated to influence the decision making of the German 
legislators with respect to organ donor and tissue legislation. The connection with Prof. 
Hetzer was established thanks to Norbert, and I owe it to Norbert that a good relation 
with the DHZB and BIS Foundation flourished during a great many years. We dearly 
miss you Norbert.
I am grateful to the chairmen and the committee members of EUROMACS who give 
great support and stimulate the work I do for the EACTS MCS registry: Prof. Jan 
Gummert, Prof. Bart Meyns, now member of the doctoral committee, as is dr. Kadir 
Caliskan, Prof. Paul Mohacsi, Prof. Steven Tsui, dr. Felix Schönrath, Prof. Daniel 
Zimpfer, dr. Michel Morshuis, Prof. Ivan Netuka, Prof. Pascal Leprince, Priv. Doz. 
Evgenij Potapov, Prof. André Vincentelli, Prof. Finn Gustafsson, Prof. Gregorio 
Rábago, and Prof. Francesco Musumesci. 
Thomas Höhn and Mehran Moazami Goudarzi, it was a pleasure to work with you as 
co-directors of the Foundation of European Tissue Banks. Your matter-of-fact approach 
of the activities and position of the foundation has been of great help to me when 
striving to materialise the goals of the foundation. Several of the tissue-banking studies 
and publications have been made possible thanks to the fact that you created the right 
circumstances. Finally, we were able to terminate the foundation’s activities in an orderly 
manner. Mehran, I’m happy that our friendship survived the foundation.
Special thanks to Prof. dr. Rainer Sundmacher for the establishing our fruitful 
relationship which resulted in the cornea transplantation of many of your patients. 
In times of trouble you provided tremendous help when the Netherlands had an 
organisational problem. In your position of Director of the Augenklinik der Heinrich 
Heine Universität Düsseldorf you decided that the Lions Hornhautbank Nordrhein 
Westfalen would process the donated corneas from the Netherlands. Today, when one 
looks at the website of the Hornhautbank the enormity of that work is still visible in the 
statistics. Our good relation and the mutual trust also lead to the successful investment 
in research. We jointly worked to influence the Bundestag to draft legislation that 
guaranteed a good position for cornea transplantation activities. In the Ausschuss of the 
Bundesärztekammer we achieved to establish new guidelines, serious business, but we 
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also had great fun from time to time. Equally in the board of BIS Foundation in which 
you functioned a great many years. Thank you for your lasting friendship. 
Prof. dr. Thomas Reinhard, the studies that you did during your time at the HHU taught 
me that scientific sub-structuring of our work is of utmost importance. It was a pleasure 
to see subsequent publications coming from your pen. In Freiburg you continued to 
do so, moreover you’ve shaped the Klinik für Augenheilkunde to a leading clinic and 
foremost research unit in ophthalmology. With great interest I read your annual reports 
and I have great admiration for what you have achieved. Thank you for all you have 
done in the years we cooperated. 
Natalie Delesalle, Merci beaucoup de m’avoir inspiré. Votre exemple m’a incité à réaliser 
des études collaboratives nationales et européennes sur les contrôles microbiologiques 
des tissus et sur les contrôles qualité.
Patrick McBrayer has been instrumental to, and assisted me setting up, the allograft 
donation and transplantation programme under the auspices of BIS Foundation. Besides 
a successful working relationship, we became close friends, and we’re like brothers to one 
another. You honored me by being my best man. For more than 30 years we exchange 
almost daily literary preferences, film recommendations and great recipes. And…we 
continue to working together; the recipe to reach old age? Thank you Pat.
Martí Manyalic: from the first moment we met there was an understanding between us 
about the fact that we could join forces to create an international co-operation to jointly 
allocate tissue allografts to those clinicians who needed them for their patients. And we 
built up a network for that purpose. Also, we became brothers, had social get-togethers 
while at the same time we elaborated plans to improve the quality of our work. We 
organised successful multi-national projects, symposia and publications, the results of 
which were clear steps in the improvement processes of tissue establishments in Europe 
and in third countries. Moltes gràcies germà.
Boy van de Wiel, docent en vriend, je was en bent voor mij de guru van het inrichten 
van organisaties rondom processen. Jarenlang bracht ik de methoden die je doceerde 
aan Business School Nederland in praktijk. De gevolgen waren: Goede focus op de 
behoeften van de klanten, een lerende organisatie, goed gedefinieerde ruimte voor 
innovatie (20%) en goed georganiseerde processen om te komen tot strategie- en beleid, 
om maar een paar verworvenheden te noemen. Ik mis ons gezamenlijke golfwedstrijden 
en gezelligheid, hopelijk heb ik daar meer tijd voor na de Hora Est.
Prof. dr. José Luis Pomar, our mutual friend Martí introduced us some 30 years ago and 
we managed to extend the activities of the Criobarna cardio-vascular tissue bank while 
always maintaining -thanks to you and your co-workers- a high level of quality. In 2013, 
in your capacity of president of the EACTS, an additional dimension was added to our 
co-operation, when you and Pieter Kappetein decided to continue the EUROMACS 
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registry and my position as director under the auspices of the EACTS. Now that you’re 
chairman of the of the International Cooperation Committee of EACTS we have good 
reasons, not that we need any, to continue our friendship.
Prof. dr. Pieter Kappetein, heel veel dank voor het vertrouwen dat je in me hebt gesteld 
door de overname van EUROMACS waaraan ik hiervoor refereerde. Door de vrijheid 
die je mij gunde om de registry verder te ontwikkelen zijn we nu in staat om veel 
wetenschappelijke output te genereren. Daarenboven heb je het als secretary general 
van de EACTS mogelijk gemaakt om een nieuw platform te creëren waarin jouw 
vakgenoten, zowel degenen die implantaties van steunharten bij volwassenen, alsook die 
bij kinderen, implanteren, kunnen samenkomen om op basis van data best practises na 
te streven. 
Mijn collega-promovendi dr. Rahat Muslem en Stan Antonides, ik dank voor jullie 
inbreng in de verschillende publicaties over respectievelijk benchmarking en van analyses 
met EUROMACS data. Ook ben ik Kevin Veen en Yunus Yalcin erkentelijk voor de 
goede samenwerking. Mijn dank betreft natuurlijk ook in het bijzonder dr. Sakir Akin 
die altijd enthousiast doorpakt en die zijn mateloze energie verdeelt tussen zijn gezin, 
de cardiologie en steeds weer nieuw onderzoek. Onze reis naar de Turkse VAD centra 
heeft onze vriendschap voor altijd beklonken. Dank je wel voor de opdracht in jouw 
proefschrift “Theo, you are the next”. Die opdracht is hiermee vervuld.
Mijn grote dank gaat vooral ook uit naar degenen die mij gedurende mijn carrière hebben 
gestimuleerd en gesteund. In de eerste plaats wil ik wijlen Henk Schippers en dr. Guido 
Persijn bedanken voor hun nooit aflatende steun en hun onvergetelijke bijdrage aan mijn 
carrière. Henk Schippers nam mij in 1974 bij Eurotransplant als werkstudent in dienst 
om -naar zijn voorbeeld- al tijdens de studie iets nuttigs te doen en geld te verdienen om 
te voorzien in mijn levensonderhoud. Later, toen Henk voorzitter werd van Stichting 
BIS was hij altijd, ook als het soms wat minder goed ging, positief stimulerend. Zijn 
raad “het bestuur zorgt voor jou, zorg jij goed voor je mensen” heb ik getracht in praktijk 
te brengen. Het is aan anderen te oordelen of dat ook is gelukt. Van Guido Persijn heb 
ik de grondbeginselen van het wetenschappelijk veldwerk geleerd. Voor zijn promotie 
onderzoek reden we stad en land af en haalden we, soms onaangekondigd (het was 
nog in het tijdperk van voor de AVG-wet), informatie uit statussen en archieven van 
bloedbanken voor de bewijsvoering dat 3 transfusies konden bijdragen aan een langere 
overleving van getransplanteerde nieren in de ontvangers. In zijn functie als bestuurder 
van Stichting BIS heb ik van Guido zeer gewaardeerde steun en advies mogen krijgen. 
Arnoud Slooff. Een betere adjunct en tegelijkertijd manager innovatie heb ik me 
niet kunnen denken. Je nam destijds een behoorlijk stuk werk van mijn schouders, je 
steunde me door dik en dun, maar was ook kritisch als dat nodig was. Ik ben je daar 
zeer erkentelijk voor.
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Mijn collega’s en teamgenoten bij Stichting BIS (helaas kan ik me niet alle namen 
herinneren waarvoor mijn verontschuldigingen): 
Alimieke Bol, Remmelt Veen, Nicole van Nierop (de beste secretaresse ooit), Ruud 
Deijkers, Eveline Abbekerk, Audrey Laven, Herman Kaptijn, Stephan Vehmeijer, 
Huibert Tjabbes, Heiman Wertheim, Hajo Bruining, Fieke Wijffels, Manon Hanekamp, 
Saskia Tuinstra, Gijs Patijn, Josien Wolterbeek, Carmen van der Pol, Arlette de 
Voogd, Igor van den Brand, en dan toch ook Jurriaan van den Brand, Crispijn van 
den Brand, Charlotte van Koesveld, Tim Bredehorn, Paul van der Eerden, Jan Willem 
Mazel, Pol Huysmans, Arno Starrenburg, Els Erich, Joris van der Putten, Charlotte 
Robertson, Annette Barkhof, Martijne van ’t Riet, Marit Maatman, Thirza Horn, Prof. 
Heiman Wertheim, Corné Otto, Hélène van Paridon, Jenneke Litjens, Ben Schmidt, 
Marnix de Roos, Els Janssens, Noor Holsboer, Stan Antoine Bel, Caroline Dorrepaal, 
Rijk Spijkerboer, Stan Vos, Leonard Corion, en Lieke Welling, ik dank jullie allemaal 
voor de goede samenwerking van destijds. Jullie hebben allemaal bijgedragen aan de 
kwaliteit van werken en aan de successen die we samen konden boeken.
Lieve kinderen, Esther, Felix en Frédérique, ik ben heel erg trots op wat jullie doen en 
wat jullie tot nu toe hebben bereikt en ik weet zeker dat jullie nog veel tot stand gaan 
brengen. Ik hou ontzettend veel van jullie. Het spijt me dat ik er niet altijd voor jullie 
was vanwege het werk dat ik deed.
Fijn dat jullie goede partners hebben in Jelle, Claire en Frank, en ik ben gelukkig 
vanwege het feit dat we allemaal samen met Salomon en Jonathan een grote familie 
vormen. 
Lieve Marie-Thérèse, ik heb het met jou wel heel erg goed getroffen. Je bent mooi en 
je hebt goede smaak, we hebben veel overeenkomstige belangstellingssferen, genieten 
daar samen veelvuldig van, we lachen veel en kunnen ook van mening verschillen. 
“Het is stil waar het nooit waait” is een wijsheid die je van je ouders hebt meegekregen. 
“We zijn een héél goed setje” zeggen we vaak. Voor de kinderen zette je jezelf, en nog 
steeds, met grote betrokkenheid in. Ik ben trots op jou vanwege je professionele instelling 
in het werk dat je doet en natuurlijk op je initiatief waardoor destijds Interplast Holland 
gestalte kon krijgen, en waarin je nog steeds veel van je eigen tijd investeert. Terecht 
werd je daarvoor geridderd. Veel geduld bracht je op gedurende de tijd dat ik achter, nee 
vóór, het computerscherm doorbracht om aan dit proefschrift en andere publicaties te 
werken. We hebben tijdens onze lange wandeltochten véél plannen ontwikkeld en zijn 
bezig die te realiseren. Dank je voor je liefde, ik hou ook veel van jou, en héél veel dank 
voor je steun tijdens mijn werk en ook voor alles dat ons leven zo prettig maakt.
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PhD Portfolio 
Name PhD student Theo M.M.H.de By
Erasmus MC department: Cardiothoracic Surgery
PhD period: 2010 – 2019 
Title thesis: International Benchmarking in Cardio-Thoracic 
Surgery. Mechanical Circulatory Support and Heart 
Valve Banking
Promotors: A.J.J.C. Bogers
Co-promotor: K. Caliskan
ACADEMIC EDUCATION
1975-1978 Bachelor of Science, Rijksuniversiteit Leiden, the 
Netherlands
1995-1997 Master of Business Administration, Business School 
Nederland, The Netherlands
1979 Hospital Sciences, Rijksuniversiteit Utrecht, the 
Netherlands
Oral presentations
Foundation of European Tissue Banks, Schiedam, the 
Netherlands
2010 1,2
Foundation of European Tissue Banks, Berlin, Germany 2011 1,2
6th World Congress on Tissue Banking, Barcelona, Spain 2011 1,2
The 1st Sino-German Summit Forum on Cardiac Surgery, 
Shanghai, China
2012 1,2
European Eye Bank Association, Freiburg Germany 2011 1,2
European Association of Tissue Banks, Hannover, Germany 2016 1,2
Portuguese and Brazilian Transplant Congress, Porto, Portugal 2016 1,2
European Association of Tissue Banks, Treviso, Italy 2017 1,2
European Association of Tissue Banks, Lund, Sweden 2014 1,2
European Association of Tissue Banks, Brussels, Belgium 2013 1,2
European Association of Tissue Banks, Barcelona, Spain 2012 1,2
International Society of Rotary Blood Pumps, Yokohama, Japan 2012 1,2
International Society of Rotary Blood Pumps, Split, Croatia 2015 1,2
European Society for Artificial Organs, Leuven, Belgium 2015 1,2
8e TRIP symposium Biovigilance, Utrecht, the Netherlands 2015 1,2
SFCTCV Annual Meeting, Nantes, France 2015 1,2
DGTHG, Freiburg, Germany 2014 1,2
DGTHG, Freiburg, Germany 2015 1,2
EUMS, Berlin, Germany 2018 1,2
ETS, Bern, Switzerland 2014 1,2
British Association of Tissue Banks, Oxford, England 2012 1,2
International Society of Heart and Lung Transplantation, San 
Diego, USA
2014 1,2
VIIIth Congress of the Czech Society for Cardiovascular 
Surgery, Brno, Czech Republic
2018 1,2
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EACTS Annual Meeting, Vienna, Austria 2013 1,2
EACTS Annual Meeting, Milan, Italy 2014 1,2
EACTS Annual Meeting, Amsterdam, the Netherlands 2015 1,2
EACTS Annual Meeting, Barcelona, Spain 2016 1,2
EACTS Annual Meeting, Vienna, Austria 2017 1,2
EACTS Annual Meeting, Milan, Italy 2018 1,2
Société Française de Chirurgie Thoracique et Cardio-
Vasculaire, Rennes, France
2019 1,2
International Society for Mechanical Circulatory Support, 
Bologna, Italy
2019 1,2
3rd EACTS Mechanical Circulatory Support Summit, Berlin, 
Germany
2018 1,2
4th EACTS Mechanical Circulatory Support Summit, Prague, 
Czech Republic
2019 1,2
Teaching
MCS workshop, Berlin, Germany 2013 0,6
MCS workshop, Berlin, Germany 2014 0,6
MCS workshop, Berlin, Germany 2015 0,6
MCS workshop, Berlin, Germany 2016 0,6
MCS workshop, Berlin, Germany 2017 0,6
MCS workshop, Berlin, Germany 2018 0,6
MCS workshop, Berlin, Germany 2019 0,6
VAD Coordinators Training Course Berlin 2015 0,6
VAD Coordinators Training Course Berlin 2016 0,6
VAD Coordinators Training Course Berlin 2017 0,6
DTI Training Course, Venice, Italy 2011 0,6
DTI Training Course, Barcelona, Spain 2012 0,6
International conferences
6th World Congress on Tissue Banking, Barcelona, Spain 2011 1,5
The 1st Sino-German Summit Forum on Cardiac Surgery, 
Shanghai, China
2012 1,5
European Association of Tissue Banks, Hannover, Germany 2016 1,5
8e TRIP symposium Biovigilance, Utrecht, the Netherlands 2015 1,5
European Association of Tissue Banks, Treviso, Italy 2017 1,5
European Association of Tissue Banks, Lund, Sweden 2014 1,5
European Association of Tissue Banks, Brussels, Belgium 2013 1,5
European Association of Tissue Banks, Barcelona, Spain 2012 1,5
British Association of Tissue Banks, Oxford, England 2012 1,5
European Training Symposium (ETS), Bern, Switzerland 2012 1,5
European Training Symposium (ETS) Bern, Switzerland 2014 1,5
DGTHG, Freiburg, Germany 2014 1,5
EUMS, Paris, France 2015 1,5
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EUMS, Paris, France 2016 1,5
EUMS, Bad Oeynhausen, Germany 2017 1,5
EUMS, Berlin, Germany 2018 1,5
EUMS, Paris, France 2018 1,5
EACTS Annual Meeting, Barcelona, Spain 2012 1,5
VIIIth Congress of the Czech Society for Cardiovascular 
Surgery, Brno, Czech Republic
2018 1,5
EACTS Annual Meeting, Vienna, Austria 2013 1,5
EACTS Annual Meeting, Milan, Italy 2014 1,5
EACTS Annual Meeting, Amsterdam, the Netherlands 2015 1,5
EACTS Annual Meeting, Barcelona, Spain 2016 1,5
EACTS Annual Meeting, Vienna, Austria 2017 1,5
EACTS Annual Meeting, Milan, Italy 2018 1,5
EACTS Annual Meeting, Lisbon, Portugal 2019 1,5
International Society of Heart and Lung Transplantation, 
Prague, Czech Republic
2012 1,5
International Society of Heart and Lung Transplantation, 
Montreal, Canada
2013 1,5
International Society of Heart and Lung Transplantation, San 
Diego, USA
2014 1,5
International Society of Heart and Lung Transplantation, Nice, 
France 
2015 1,5
International Society of Heart and Lung Transplantation, 
Washington D.C., USA
2016 1,5
International Society of Heart and Lung Transplantation, San 
Diego, USA
2017 1,5
International Society of Heart and Lung Transplantation, Nice, 
France
2018 1,5
International Society of Heart and Lung Transplantation, 
Orlando, USA
2019 1,5
Gordon Research Conference, Castelldefels, Spain 2019 1,5
International Society for Mechanical Circulatory Support, 
Bologna, Italy
2019 1,5
4th EACTS Mechanical Circulatory Support Summit, Prague, 
Czech Republic
2019 1,5
Total 102,3
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